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Zusammenfassung 
Der Tumorsuppressor p53 ist eines der am häufigsten mutierten Proteine in 
humanen Krebsarten und wird daher umfassend für seinen Nutzen in der 
Krebstherapie erforscht. Dies führte in China zur Markteinführung von Wildtyp-p53 
zur Therapie von Kopf-Hals-Karzinomen. 
p53 fungiert in der Zelle hauptsächlich als Transkriptionsfaktor und stimuliert eine 
Vielzahl von Genen, die im intrinsischen und extrinsischen Apoptosemechanismus 
involviert sind. In Krebszellen treten Mutationen normalerweise in der DNA-
Bindungsdomäne von p53 auf, wohingegen die Tetramerizationsdomäne (TD) des 
Tumorsuppressors intakt bleibt. Dies führt intrazellular zur Bildung von 
Heterotetrameren von Wildtyp-p53 und seiner mutierten Form, was die 
Transkriptionsaktivität erheblich beeinträchtigt und einen dominant negativen Effekt 
ergibt.  
Während transkriptionell aktives p53 als Gentherapeutikum genutzt wird, ist das 
therapeutische Potential für den Einsatz von mitochondrialem p53 noch nicht 
vollständig ermittelt. Wenn p53 zum Mitochondrium getargeted wird, interagiert es 
mit pro- und anti-apoptotischen Proteinen, die sich in der mitochondrialen 
Auβenmembran befinden. Für diese Interaktion reicht die monomere Form von p53 
aus, was bedeutet, dass es nicht durch mutiertes p53 inaktiviert werden kann.  
In dieser Arbeit wurde die Funktion von mitochondrialem p53 charakterisiert, indem 
es zu verschiedenen mitochondrialen Kompartimenten getargeted wurde: der 
mitochondrialen Auβenmembran, der Innenmembran und der Matrix. Es konnte 
nachgewiesen werden, dass mitochondriale Targeting Sequenzen (MTS) in der 
mitochondrialen Auβenmembran optimal für eine p53-spezifische Aktivierung 
geeignet sind. Auch konnte gezeigt werden, dass als minimalste Domäne von p53 
die DNA-Bindungsdomäne (DBD) ausreicht, um Apoptose zu induzieren. Weitere 
Untersuchungen haben ergeben, dass das Vereinigen von p53 oder nur seiner DBD 
mit der MTS von Bcl-XL, eine Bcl-XL spezifische Apoptose hervorruft, während eine 
Vereinigung der Segmente mit Bak auf p53/Bak spezifische Apoptose 
zurückzuführen ist. Dies hebt hervor, dass mitochondriales Targeting von p53 stark 
von der benutzten MTS abhängig ist. Auβerdem haben in vitro-Studien gezeigt, dass 
die Bindung von p53 oder DBD an die MTS von Bcl-XL eine dominant negative 
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Inhibition überwinden kann, aber auβerstande ist dominant negative MDA-MB-468 
Tumore in einem orthotopischen Maus-Tumor-Model für das gewählte Dosisschema 
zu reduzieren.  
Die Thematik dieser Dissertation war die Entwicklung Apoptose-induzierender 
Proteine basierend auf p53 und seinen Bindungsdomänen, um eine modifizierte 
Version von p53 zu generieren. Der Schwerpunkt lag sowohl auf der Optimierung 
eines mitochondrial getargeten p53 für mögliche Krebstherapien als auch in der 
Neugestaltung der TD von p53, um den dominant negativen Effekt der 
Transkriptionsaktivität zu überwinden. Dafür wurde die Oligomerizationsdomäne von 
p53 mit der Coiled-Coil (CC) Domäne von BCR ersetzt, damit der dominant negative 
Effekt von mutiertem p53 ausgeschaltet wird. Experimente zeigen, dass das chimäre 
p53 (p53-CC) in den Nukleus transloziert, Gene transaktiviert und Apoptose in 
ähnlicher Form wie Wildtyp-p53 auslöst. In vitro- und in vivo-Studien haben gezeigt, 
dass im Gegensatz zu Wildtyp-p53, das neu generierte p53-CC nicht mit endogen 
mutiertem p53 interagiert und seine apoptotische Aktivität in Krebszellen, die 
dominant negatives mutiertes p53 enthalten, beibehält.  
Zusammenfassend liegt der Forschungsschwerpunkt dieser Dissertation in der 
Entwicklung neuartiger p53-Gentherapeutika, die das Potential haben derzeitige 
Einschränkungen einer Wildtyp-p53 Therapie zu überwinden.  
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Abstract 
The tumor suppressor p53 is one of the most frequently mutated proteins in human 
cancer and has been extensively targeted for cancer therapy. This resulted in wild 
type p53 gene therapeutic approval for the treatment of head and neck cancer in 
China. p53 mainly functions as a transcription factor and stimulates a variety of 
genes involved in the intrinsic and extrinsic apoptotic pathway by binding to p53 
responsive elements as a tetramer. In cancer cells, mutations in p53 typically occur 
in its DNA binding domain (DBD), while its tetramerization domain remains intact. 
Therefore, mutant p53 can heterotetramerize with wt p53 and abolish its 
transcriptional activity (dominant negative effect). 
While transcriptionally active wt p53 is used for gene therapy, mitochondrial p53 has 
not been fully exploited yet. Targeting p53 to the mitochondria causes a direct rapid 
apoptotic response by directly interacting with pro-and anti- apoptotic proteins at the 
mitochondrial outer membrane. Because the monomeric from is sufficient to interact 
with pro-and anti-apoptotic proteins, mitochondrial p53 is not affected by the 
dominant negative inactivation. To ensure mitochondrial targeting of p53, we 
targeted p53 to different mitochondrial compartments; mitochondrial outer 
membrane, inner membrane and matrix. We have demonstrated that MTSs from the 
mitochondrial outer membrane are optimal for p53-specific activation. In addition, we 
discovered the minimal domain of p53, its DNA binding domain (DBD), which is 
needed for apoptosis induction. Further studies have shown that fusing p53 or DBD 
to MTS from Bcl-XL causes p53/Bcl-XL specific apoptosis while fusing them to Bak 
results in p53/Bak specific apoptosis, emphasizing that mitochondrial targeting of 
p53 is highly dependent on the MTS used. Further, we have shown that DBD fused 
to the MTS from Bcl-XL can overcome dominant negative inhibition in vitro, but it 
was unable to shrink dominant negative MDA-MB-468 tumors in an orthotopic 
mouse model at one dosing regimen attempted.  
The main theme of this thesis was to design apoptotic proteins based on p53 
domains to create modified versions of p53. We focused mainly on optimizing 
mitochondrial targeting of p53 for cancer therapy but also redesigned the TD of p53 
to overcome the dominant negative effect. We substituted the oligomerization 
domain of p53 with the coiled-coil (CC) domain from BCR to bypass dominant 
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negative inhibition of mutant p53. Our chimeric p53 (p53-CC) can translocate into the 
nucleus, transactivate genes and cause apoptosis in a similar manner as wt p53. 
Unlike wt p53, p53-CC does not interact with endogenous mutant p53 and retains 
apoptotic activity in cancer cells harboring dominant negative mutant p53 in vitro and 
in vivo. In summary this dissertation focuses on new p53 gene therapeutics, with the 
potential to overcome current limitations with wt p53 therapy.  
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1. Introduction 
1.1 The p53 protein 
The tumor suppressor p53 is one of the most widely studied proteins. Over the last 
30 years it has been shown that p53 is involved in a wide network of signaling 
pathways that involves tumorgenesis, cellular senescence, metabolism and DNA 
damage preventing tumorgenesis (1). Since its discovery, p53 has been of great 
interest because it is mutated in almost 50% of all human cancers (2). Mutations in 
p53 are crucial for cancer development and therefore make it an interesting target for 
cancer therapy (3). 
 
1.2 Structure of wt p53  
The 393 amino acid p53 protein is encoded by the TP53 gene (4). It contains a N-
terminus, a DNA binding domain (DBD) and a C-terminal region as shown in figure 
1. The N-terminus consists of the transactivation domain (TA) and the proline rich 
domain (PRD) (4). The TA can be further divided into MDM2 binding domain (MBD) 
(5) and a nuclear export signal (E) (6). The C-terminus contains three nuclear 
localization signals (NLS)s (7), one nuclear export signal (E) (8) and the 
tetramerization domain (TD) as depicted in figure 1 (9). 
The TA is essential for either the transcriptional activity of p53 (10, 11) or for its 
degradation (12) depending on post-transcriptional modifications occurring in the TA. 
When no transcriptional modifications occur, p53 is ubiquitinated via MDM2 and 
MDMX and degraded via the ubiquitin-dependent proteasomal pathway (12). On the 
other hand, when Thr 18 is phosphorylated, the affinity of TAD for transcriptional 
cofactors such as p300/CBP and its various subdomains is highly increased and p53 
can exhibit its function as a transcription factor (13).  
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The PRD has a predominantly structural role (14). It allows for the TA to interact with 
transcription cofactors and components of the basal transcription machinery. The 
DBD, as the name implies, binds directly to DNA sequences and triggers gene 
transcription (15).  
The C-terminus undergoes various posttranslational modifications and can adopt 
different secondary structures. Modifications on this region play complex roles so 
that it can interact with numerous partner proteins (16). The three NLSs within the C-
terminus are important for localization to the nucleus where p53 exhibits its function 
as a transcription factor (7). Tetramer formation is essential for the majority of its 
transcriptional activity (17). The p53 tetramer is formed via a dimeric intermediate 
(18). Primary dimers are stabilized by an intermolecular β-sheet and helix-packing 
interactions. The hydrophobic helix interfaces of two such dimers form a tightly 
packed tetramer, which is highly thermodynamically stable (19).  
 
Figure 1: Structure of wt p53. The amino terminus contains the transactivation 
domain (TA), a nuclear export signal (E) and the MDM2 binding domain (M). The 
DNA binding domain (DBD) is between amino acids 94 and 294. The C-terminus 
consists of three nuclear localization signals (NLS) and the tetramerization domain 
(TD). 
 
1.3 Degradation of p53 
p53 is known as a transcription factor which inhibits tumor growth. It is capable of 
transactivating a variety of genes responsible for apoptosis, cell cycle arrest and 
DNA repair (20). Since p53 induces cell-cycle arrest and apoptosis, it has an 
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inhibitory effect on cellular growth. Therefore, p53 needs to be regulated so normal 
development can take place. The major regulator of p53 is the E3 ubiquitin ligase 
MDM2 (21). Even though other p53 E3 ligases have been discovered over the last 
couple of years, MDM2 still appears to be the physiological and primary E3 ligase 
regulating p53 (12). MDM2 and p53 form an autoregulatory feedback loop in which 
p53 transactivates MDM2 and influences its own degradation (22). p53 is degraded 
via different degradation pathways which all eventually result in polyubiquitination 
and eliminations by the 26S proteasome (Fig. 2) (23). In the nucleus, p53 binds 
directly to the MDM2 binding domain, monoubiquinates it and initiates nuclear export 
(24). Cytoplasmic mono-ubiquitinated p53 then gets polyubiquitinated by E4 factors 
(USE4B) or E4-like molecules (Cul4-DDB complex), and MDM2 is then sent to the 
proteasome for degradation (Fig. 2) (12). Additionally, other E-ligases (Pirh2) can 
facilitate polyubiquitination and proteasomal degradation of p53 with no involvement 
of MDM2 (25). Furthermore, it has been reported that MDM2 can form a heterodimer 
with another protein MDMX facilitating polyubiquitination and proteasomal 
degradation (Fig. 2) (26). MDMX and MDM2 show low amino acid sequence overlap 
but a nearly identical p53 binding domain located at their N-terminus and a C-
terminal RING domain (12). Heterodimer formation occurs through this RING 
domain. MDMX alone does not have significant E3 ligase activity, but has been 
shown to modulate p53 via modulation of its transcriptional activity (12, 27).  
The regulatory effect of MDM2 on p53 can also result in negative outcomes. The 
MDM2 gene is amplified or overexpressed in many human cancers, consequently 
inactivating p53. These cancers have been associated with poor prognosis (28). 
Therefore, the interaction of p53 and MDM2 provides an interesting target for cancer 
therapy.  
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Figure 2: Proteasomeal degradation pathway of wt p53: MDM2 monoubiquitinates 
p53 in the nucleus; cytoplasmic monoubiquitinated p53 can either get 
polyubiquitinated via MDM2 and E4 factors, E-like molecules, via other E-ligases, or 
via MDM2/MDMX heterodimers. Polyubiquitinated p53 is targeted to the proteasome 
and degraded into peptides.  
 
1.4 Regulation of gene transcription: cell cycle arrest or apoptosis? 
p53 positively and negatively regulates the expression of responsive genes. 
Depending on the severity of damage to the cell, p53 decides the fate of the cell. p53 
response elements (REs) are located within a few thousand nucleotides upstream or 
downstream from the transcription start site (29). It has been shown that binding 
affinity of p53 for its specific REs differs dramatically. Growth arrest-related genes 
have high affinity sites for p53 whereas proapoptotic genes are mostly associated 
with low affinity sites (30). Additionally, some REs exist in open occupied states 
while others do not (31). Since recognition of elements in Mdm2 and p21 promoters 
depend on non-B-DNA conformation, conformation of the DNA may also be 
important (32). Taken together these findings suggest that not all targeted genes are 
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equally responsive to p53 and that levels of p53 protein may determine which genes 
to turn on or off.  
Mild damage to a cell is often reparable. Basal or low levels of p53 usually turn on 
cell cycle genes. Additionally, p53 undergoes pro-arrest modifications by 
ubiquitination of the Lys 320. Pro-apoptotic cofactors such as Brn3a reduce the 
ability of p53 to transactivate pro-apoptotic Bax whereas stimulating transcription of 
p21, results in cell cycle arrest (33). Transient cell cycle arrest allows for sufficient 
time to repair DNA damage and re-entry into the normal cell cycle. 
When severe damage occurs, p53 levels rise dramatically and promote 
transactivation of pro-apoptotic genes due to pro-apoptotic posttranslational 
modification of the protein, such as acetylation of K120 (34), K320 (35) and 
phosphorylation of S46 in the p53 protein (36). DNA damage activates ASSP1 and 2 
which interact with DBD of p53 and activate pro-apoptotic Bax and PIG3 genes but 
do not promote transcription of pro-arrest genes such as p21 or regulatory genes 
such as Mdm2 (37). Another example is the crosstalk between p53 and the NF-KB 
subunit p52 leading to repression of the cell cycle activator p21 and activation of 
proapoptotic DR5 and PUMA resulting again in apoptosis (38).  
 
1.5 p53 activates the intrinsic and extrinsic apoptotic pathway 
Apoptosis proceeds through intrinsic and extrinsic pathways. p53 is capable of 
activating both apoptotic pathways. p53 induces genes encoding the transmembrane 
proteins FAS, DR5 and PERP (also called death receptors) which are essential for 
activating the extrinsic apoptotic pathway (Fig. 3) (39). Death receptors recruit 
adapter molecules such as FADD, which in turn, recruit procaspase-8 monomers. 
Dimerization and interchain cleavage of procaspase-8 facilitates the activation of 
caspase-8 (40). Caspase 8 then leads to cleavage of the inactive procaspase-3 
dimer and the inactive procaspase-7 dimer via intramolecular rearrangements 
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resulting in active caspase-3 and caspase-7 dimers leading to apoptosis (Fig. 3) 
(41). However, cross talk between intrinsic and extrinsic apoptotic pathway occurs 
via BID which is truncated to tBid via caspase-8 (42). 
The intrinsic apoptotic pathway occurs as a result of mitochondrial outer membrane 
permeabilization (MOMP) which releases various proteins from the mitochondrial 
intermembrane space such as cytochrome c (43). p53 targets a key subset of Bcl-2 
family genes BAX, NOXA and PUMA which once transcribed and translated into 
proteins promote cytochrome c release and facilitate caspase-9 activation (Fig. 3) 
(44). Binding of cytochrome c and apoptotic protease-activating factor 1 (APAF1) 
assembles into a heptameric, wheel-like structure known as the apoptosome. The 
apoptosome activates the initiator caspase-9, which then initiates the executioner 
apoptotic caspases, caspase-3 and caspase-7 (Fig. 3) (45). Additionally, 
mitochondrial release of second mitochondrial derived activator of caspase (SMAC) 
and OMI neutralize the caspase inhibitory function of X-linked inhibitor of apoptosis 
protein (XIAP). XIAP is known to bind and inactivate caspases (46). All of these 
processes contribute to DNA fragmentation and eventually apoptosis (47).  
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Figure 3: Transcriptional activity of wt p53: wt p53 translocates to the nucleus, forms 
a tetramer, binds to DNA and activates gene transactivation. Extrinsic pathway is 
facilitated via the death receptors Fas, Dr5 and PERP which trigger caspase-8 
induction resulting in apoptosis. The intrinsic pathway is initiated via Puma, Noxa 
and Bax resulting in MOMP, cytochrome c release, caspase-9, and eventually 
triggers apoptosis.  
 
1.6 Regulation of the intrinsic apoptotic pathway via the Bcl-2 
protein family 
In healthy cells, anti-apoptotic B cell lymphoma 2 (Bcl-2) family members form 
heterodimers with pro-apoptotic proteins resulting in their inactivation (48). However, 
when an apoptotic stimuli occurs such as DNA damage or ER stress, anti-apoptotic 
Bcl-2 proteins are released from the inhibitory complexes and homooligomerize 
resulting in MOMP (49). 
The Bcl-2 family members are localized on the outer surface of the mitochondrial 
outer membrane. As listed in table 1, the Bcl-2 family of proteins are divided into 
three groups based on the Bcl-2 homology (BH) domain (50); anti-apoptotic Bcl-2 
proteins such as Bcl-2, Bcl-w, Bcl-XL, A1 and Mcl-1 consists of four BH domains 
(BH1-4) and a transmembrane (TM) domain (51). The BH domain is responsible for 
their anti-apoptotic function while the TM domain is for the insertion into the 
mitochondrial outer membrane (51-53). Pro-apoptotic Bcl-2 proteins are divided into 
effectors and enhancers (50). The effectors are Bcl-2-associated X protein (Bax), 
Bcl-2 antagonist or killer (Bak) and Bcl-2-related ovarian killer protein (Bok) (54). 
They contain three BH domains (BH1-3) and the TM domain for membrane insertion 
(54, 55). Unlike other Bcl-2 proteins the pro-apoptotic enhancers BCL-2 antagonist of 
cell death (BAD), BH3-interacting domain death agonist (BID), BCL-2-interacting 
killer (BIK), BCL-2-interacting mediator of cell death (BIM), BCL-2-modifying factor 
(BMF), BCL-2 and adenovirus E1B 19 kDa protein-interacting protein 3(BNIP3), 
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hara-kiri (HRK), p53 upregulated modulator of apoptosis (PUMA) consist of only the 
BH3 domain and therefore do not insert themselves into the mitochondrial outer 
membrane (56).  
Class 
 
Members Structural domains 
Anti-apoptotic Bcl-2, Bcl-w, Bcl-XL, A1, 
Mcl-1 
BH1, BH2, BH3, BH4, TM 
Pro-apoptotic: effectors Bak, Bax, Bok BH1, BH2, BH3, TM 
Pro-apoptotic: enhancers BAD, BID, BIK, BIM, BMF, 
BNIP3, HRK, Puma 
BH3 
 
Table 1: Classification of the different Bcl-2 protein family members with 
representative members and structural domains.  
 
1.7 Transcriptional-independent activation of the intrinsic apoptotic 
pathway by p53 
Aside from transactivating Bax, NOXA and PUMA, p53 can also directly activate the 
intrinsic apoptotic pathway by translocating to the mitochondria upon severe stress 
signal induction such as radiation (57). Unlike other mitochondrial proteins, p53 does 
not contain a mitochondrial targeting signal. It has been hypothesized that nuclear 
p53 gets mono-ubiquitinated and exported into the cytoplasm. Cytoplasmic 
monoubiquitinated p53 is imported into the mitochondria via the herpes virus-
associated ubiquitin-specific protease (HAUSP) (58, 59). At the mitochondrial outer 
membrane p53 interacts directly with pro-and anti-apoptotic Bcl-2 family members 
(Fig. 4) (60-62). The DBD of p53 are essential for the electrostatic interaction with 
anti-apoptotic Bcl-XL and Bcl-2 and pro-apoptotic Bak (60, 61). The positively 
charged basic surface of the DBD interacts with the negatively charged BH4 domain 
and the loops between alpha 4/5 and 5/6 of Bcl-XL and Bcl-2 (61, 63, 64). The 
affinity of the positively charged DBD to bind pro-apoptotic Bak is 10 times less than 
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to Bcl-XL and Bcl-2 (61, 64, 65). The lower interaction is due to the differences in 
structure between Bcl-2, Bcl-XL and Bak. While Bcl-XL and Bcl-2 contain a very 
acidic protein surface and a BH4 domain, Bak does not have a very acidic protein 
surface nor a BH4 domain and therefore its binding affinity to the positively charged 
DBD of p53 is decreased. Bax on the other hand has been shown to be activated by 
p53, but no actual interaction has been detected yet (66). Since p53 has to directly 
bind to and sequester Bcl-XL and Bcl-2 to liberate Bak and Bax (60, 61), the affinity 
towards these proteins has to be higher than to Bak and Bax, while the pro-apoptotic 
Bcl-2 proteins Bak and Bax only need to be activated and can then form homo-
oligomers. Additionally, the higher affinity towards Bcl-2 and Bcl-XL suggests a 
sequential mechanism. First p53 binds to Bcl-2 and Bcl-XL and then it binds to Bak 
and Bax (65). Therefore, p53 is considered a super BH3-only protein because it acts 
as an enabler and as an activator of pro- and anti-apoptotic mitochondrial proteins 
(67). All of these functions eventually result in MOMP and activation of the intrinsic 
apoptotic pathway (65).  
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Figure 3: Mitochondrial p53 directly activates the intrinsic apoptotic pathway through 
a sequential mechanism: First mitochondrial p53 interacts with anti- (Bcl-XL) and 
then binds to pro- (Bak; Bax) Bcl-2 proteins. Bak or Bax form homo-oligomers 
causing MOMP and cytochrome c release, activation of caspase 9 and eventually 
apoptosis. 
 
1.8 p53 and its function in metabolism and cell growth 
Besides its well characterized functions of cell cycle arrest and apoptosis, p53 has a 
clear role in glycolysis, autophagy, cell survival and regulation of oxidative stress, 
invasion and motility, cellular senescence, angiogenesis, differentiation and bone 
remodeling (68). Unlike for transactivation of apoptotic genes where high 
concentrations of p53 are required, low levels of p53 have been shown to be 
essential for normal growth, development and metabolism (68).  
p53 has multiple functions in cellular metabolism. It is a negative regulator of 
glycolysis  and lowers gene expression of glucose transporters, inhibits NF-KB and 
represses the insulin receptor promoter (69). Additionally, TP53-induced glycolysis 
and apoptosis regulator (TIGAR) lowers the glycolysis rate and promotes the 
pentose phosphate pathway (70). On the other hand, p53 promotes the more 
efficient tricarboxylic acid (TCA) cycle by enhancing transcription of cytochrome c 
oxidase 2, subunit1 of complex IV and AIF (essential for complex I function) (71). 
Taken together the negative regulation of glycolysis and the promotion of the TCA 
cycle oppose the Warburg effect (aerobic glycolysis) which promotes cancer cells 
proliferation and is an additional proof for p53 tumor suppressor activity. Concerning 
oxidative stress, p53 has an ambivalent role. Under mild stress p53 plays an anti-
oxidative role. It promotes transcription of GPX1, MnSOD, ALDH4 and TPP53INP1 
all of which are antioxidant targets. Under severe stress, p53 promotes ROS which 
then triggers apoptosis through cytochrome c oxidation (69, 72).  
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1.9 Negative activity of p53  
Besides the functions of p53 that prevent tumorgenesis (DNA-repair, cell cycle 
arrest, apoptosis and metabolism), the apoptotic function of p53 can also result in 
unfavorable outcome. p53-dependent apoptosis is the major contributor to radiation 
and chemotherapy induced sickness (68). Furthermore, the shortage of glucose and 
oxygen caused by ischemia results in p53 activation. This can cause stroke and 
myocardial infarct (73, 74). Finally, in neurodegenerative diseases, p53 causes cell 
death in neurons and therefore worsens Parkinson’s (75), Alzheimer’s (76) and 
Huntington’s (77) disease. Small molecules such as pifithrin α have therefore been 
developed which block p53-dependent transcriptional activity while protecting 
healthy cells from genotoxic stress caused by most chemotherapeutics. Pifithrin α 
can also protect neuronal cell death (78).  
 
1.10 Inactivation of p53 in cancer via mutations 
When p53 was discovered in 1979, it was first thought to be an oncogene. The 
observation that many tumors produce high levels of p53 while normal cells harbor 
low or undetectable levels suggested that this hypothesis was true. Ten years after 
its discovery, it was finally determined that p53 is a tumor suppressor (1). The first 
assumption of p53 being an oncogene is not surprising since p53 is mutated in 
around 50% of all tumors, and mutated p53 has oncogenic potential that differs 
completely from wild type activity. The mutations occurring in p53 are unique among 
tumor suppressors. While most tumor suppressors are inactivated by deletion or 
truncating mutations, TP53 is inactivated in 74% of cases by a single monoallelic 
missense mutation resulting in formation of a stable full length protein (79).  
Mutations in TP53 differ in their frequency depending on the type of cancer. In 
hematopoietic malignancies about 10% (80) and in breast cancer about 30% of p53 
shows mutations (81). However, in ovarian (82), colorectal (83) and head and neck 
(84) cancers, p53 is mutated 50% to 70% of the time. The majority of TP53 
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mutations take place in the DNA-binding domain of p53 (85, 86). The tetramerization 
domain of p53 is usually not mutated; therefore mutated p53 can form 
heteroteramers with wt p53 and inactivate wt p53 function: this is referred to as the 
dominant negative effect (87-89). Additionally, p53 mutants can also inactivate p53 
family members p63 and p73, which are usually not mutated in human cancer (90, 
91).  
In general, TP53 mutations can be classified as conformational and DNA contact 
mutations. Conformational mutations either cause local (R249S; G245S) or global 
(R175H; R282W) disruptions of the protein structure (79). DNA contact mutants 
obliterate p53 binding to specific DNA-sequences and therefore abolish its 
transcriptional activity (92). Additionally, these contact mutants cause dominant 
negative inhibition and are responsible for new oncogenic functions such as drug-
resistance, survival and metastasis. The mechanism of mutant p53 function is 
multifaceted: binding to DNA, altering gene expression, binding to transcription 
factors to enhance or prevent their function, or interacting with proteins to alter their 
function directly (93).  
 
Figure 5: Frequency of TP53 mutations with the most frequent mutations outlined in 
the DBD. Line length indicates the number of mutations (79). 
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1.11 p53 therapeutics 
Targeting p53 for cancer therapy is either achieved by directly reintroducing wt p53 
into cancer cells via gene therapy, activating p53 and its family members via small 
molecules and peptides, or using immunotherapy.  
 
1.11.1 p53 gene therapy 
The following paragraph is exerted from: Matissek KJ BR, Davis JR, Lim CS. 
Choosing Targets for Gene Therapy.  Targets for Gene Therapy 2011 July. 
“The first p53 based gene therapy in humans was conducted in 1996. This trial used 
a retroviral vector containing wild type p53 with an actin promoter for the treatment of 
non-small cell lung carcinoma. In this study three patients showed tumor regression 
and three other patients showed tumor growth stabilization (Roth et al. 1996). China 
was the first country which approved a p53 adenovirus for gene therapy, 
GendicineTM SiBiono, in combination with radiotherapy for head and neck squamous 
cell cancer in 2004 (Shi & Zheng 2009). GendicineTM is a recombinant serotype 5 
adenovirus with the E1 region replaced by the p53 expressing cassette (with a Rous 
sarcoma virus promoter). The adenovirus particles infect tumor target cells carrying 
therapeutic p53 (Peng 2005). Clinical trials for GendicineTM showed that in 
combination with radiation therapy it caused partial or complete tumor regression 
(Peng 2005; Xin 2006). There were also some clinical trials for GendicineTM in 
advanced liver cancer, lung cancer and other advanced solid tumors (Peng 2005). It 
should be kept in mind that China’s State Food and Drug Administration (SFDA) has 
different standards for the approval of a cancer drug compared to the U.S. FDA and 
the European Medicine Agency (EMA). GendicineTM was approved in China on the 
basis of tumor shrinkage. The U.S. FDA and the EMA require novel cancer drugs to 
extend the lifetime of the treated patients (Guo & Xin 2006). Another p53 product is 
GendicineTM from Shanghai SunwayBiotech, an oncolytic virus. GendicineTM was 
approved for the treatment of head and neck cancer in China in 2006 (Yu & Fang 
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2007). It is a replicative adenovirus 2/adenovirus 5 hybrid with deletion in E1B55K 
and E3B (Raty et al. 2008). This oncolytic virus was expected to infect and lyse 
cancer cells only and not affect normal cells (Guo et al. 2008). Even though clinical 
studies showed that it was not specific for cancer cells, it did, however, kill tumor 
cells preferentially (Garber 2006). Phase I/II trials showed little dose-limiting toxicity 
(Lockley et al. 2006) and the combination of GendicineTM with chemotherapy showed 
greater tumor shrinkage in patients with head and neck cancer, compared to 
chemotherapy alone. It should be kept in mind that like GendicineTM, OncorineTM was 
also approved by the SFDA based on objective response rate, not on survival 
(Garber 2006). Nevertheless, all the available data concerning p53 and its proven 
function as tumor suppressor qualifies it as an adjuvant treatment with radiotherapy 
or chemotherapy.” (20) 
 
1.11.2 Activating wt p53 
About 50% of all tumors retain wild-type p53 function that is inhibited by increased 
degradation or proteins that interact with p53. The most famous example is the cis-
imidazoline compound Nutlin-3a. It interacts with the p53 binding pocket of MDM2 
and consequently disrupts the p53-MDM2 interaction resulting in p53 activation and 
tumor shrinkage (94). On the other hand, the small molecule RITA (reactivation of 
p53 and induction of tumor cell apoptosis) binds directly to p53, preventing MDM2 
binding and promoting a strong apoptotic effect on tumors (95). 
Furthermore, several siRNA approaches have been investigated for wt p53 
activation. The viral E6 protein from the human papilloma virus binds and targets p53 
for inactivation and degradation. SiRNA targeting of E6 inactivates E6 and triggers 
p53 mediated response (96). SiRNA targeting of MDM2 can also stabilize and 
activate p53 (97).  
Another way to stabilize wt p53 is through post transcriptional modifications. 
Acetylated p53 is more stable and cannot be degraded via the MDM2 degradation 
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pathway. Therefore, inhibiting protein-deacetylating activities of proteins such as 
SirT1 and SirT2 (members of the sirtuin family) could stabilize p53. The small 
molecule inhibitor Tenovin-1 and its more water-soluble analog Tenovin-6 both 
prevent protein-deacetylating activities of SirT1 and SirT2 (98). 
 
1.11.3 Reactivating p53 mediated response in cancers with mutated p53 status 
The challenge in targeting mutant p53 is that it is a heterogeneous target because of 
the broad range of mutations occurring in human tumors. Drugs developed in the last 
couple of years mainly focused on reactivating specific variants of mutant p53 to 
achieve wt p53 like function. One such drug is the carbazole derivative PhiKa083, 
which binds only to the unstable Y220C mutant, raises its melting temperature and 
reactivates its function. The Y220C mutation accounts for 75000 patients per year 
(99). On the other hand contact and conformational mutants can both be rescued via 
an ellipticine derivate, 9-hydroxy-ellipticine, which induces G1 arrest and triggers G1 
phase-restricted apoptosis in a mutant p53-dependent manner (100).  
The small molecules PRIMA (p53 reactivation and induction of massive apoptosis) 
and MIRA (mutant p53-dependent induction of rapid apoptosis) both can reactivate 
mutant p53. PRIMA rescues DNA contact mutants and structural mutants by forming 
adducts with thiols in mutant p53 core domain. This covalent modification reactivates 
mutant p53 and induces apoptosis in tumor cells (101, 102). MIRA restores wt 
conformation and function of mutant p53 and is more potent than PRIMA (103). The 
maleimide group in MIRA reacts with thiol and amino groups in proteins and 
stabilizes the native fold of p53 (102, 103).  
Further, p53-mediated response in tumors containing mutated p53 can be activated 
not by restoring p53, but instead by its family member p73. In human cancers, p73 is 
usually not mutated. The small molecule RETRA (reactivation of transcriptional 
reporter activity) releases p73 from the inhibitory p73/p53mut complex which 
produces a p53-like tumor suppressor response. Therefore, RETRA increases p21 
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and PUMA transcription and eventually triggers a delay of tumor formation in 
xenograft tumor model (104).  
 
In summary, many different approaches have been used to target the p53 pathway 
for cancer therapy. However, all have critical disadvantages. When reintroducing wt 
p53 via gene therapy into cancer cells that harbor mutant p53, endogenous wt p53 
will face dominant negative inhibition and oncogenic gain of function of mutant p53. 
This is also the reason why small molecules such as Nutlin-3 that attempt to 
reactivate functional wt p53 could be indirectly inactivated by mutant p53. Therefore, 
this approach is only beneficial for patients with wt p53. Additionally, p53 is a very 
heterogeneous target, and some drugs such as PhiKa083 only work for a very small 
subset of patients. The function of all the drugs listed in this section is highly 
dependent on the p53 status of the cancer, which require personalized medicine in 
treating each cancer patient individually.  
We propose to target p53 directly to the mitochondria using an optimal mitochondrial 
targeting signal (MTS). Since p53 exhibits its rapid, direct apoptotic function at the 
mitochondria in its monomeric form, regardless of p53 status, we hypothesis that it 
will be effective under any circumstances.  
 
Therapeutic Mechanism of 
action 
Application 
dependent on 
p53 status 
Ref: 
gene GendicineTM Similar to 
endogenous wt p53 
wt p53, p53 null (20) 
OncorineTM Similar to 
endogenous wt p53 
wt p53, p53 null (20) 
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siRNA siRNA to E6 Inactivates E6; p53 
mediated apoptosis 
 
wt p53 (96) 
siRNA to 
MDM2 
Prevents p53 
degradation 
 
wt p53 (97) 
Small 
molecule 
Nutlin-3a Binds to MDM2; 
stabilizes 
wt p53 (94) 
RITA Binds to p53; 
stabilizes p53 
wt p53 (95) 
Tenovin-1 or 
6 
Inhibits p53 
deacetylation: 
stabilizes p53 
 
wt p53 (98) 
 
PhiKa 083 Binds to 
p53Y220Cmut; 
raises melting 
temperature 
 
p53Y220Cmut (99) 
Ellipticine 
derivate 
Induces G1 arrest; 
G1 restricted 
apoptosis 
 
p53mut (100) 
PRIMA Forms thiol adducts 
with p53mut core 
domain; stabilizes 
folding  
 
p53mut (101) 
MIRA Maleimide group 
reactivates thiols 
and amines in p53 
mut; stabilizes its 
folding 
 
p53mut (103) 
RETRA Releases p73 from 
inhibitory 
p73/p53mut 
complex 
p53mut (104) 
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Table 2: Summary of p53 therapeutics with their mechanism of action and p53 status 
 
1.12 Mitochondrial targeting of p53 for cancer therapy 
Wild type p53 has been used almost for a decade in cancer gene therapy. It was 
approved for the treatment of head and neck cancer in China under the trade name 
Gendacine® and Oncorine® (20). In the U.S., there are several clinical trials ongoing 
with wild-type p53 mostly in combination with other chemotherapeutics (105). All 
these gene therapy approaches have focused mainly on p53’s role as a transcription 
factor (20, 105, 106). Moll and colleagues have attempted targeting p53 to the 
mitochondria for cancer therapy but did not achieve clinical translation (107-109). For 
better understanding of mitochondrial targeting, we discuss the mitochondrial 
compartment in section 1.13.  
As mentioned before, p53 does not contain a mitochondrial targeting signal. Moll and 
colleagues suggested that MDM2 triggers monoubiquitination of p53 which results in 
nuclear export. Cytoplasmic monoubiquitinated p53 is imported into the 
mitochondrial via the herpes virus-associated ubiquitin-specific protease (58, 59). At 
the mitochondria p53 triggers the intrinsic apoptotic pathway by interacting with anti- 
(Bcl-XL, Mcl-1) and pro- (Bak, Bax) apoptotic Bcl-2 protein family members (57, 65, 
66, 110). At the mitochondrial outer membrane, p53 interacts first with anti-apoptotic 
Bcl-2 proteins by sequestering them. Then it activates pro-apoptotic Bak and Bax, 
triggers their homo-oligomerization, resulting in cytochrome c release, caspase 
activation and eventually apoptosis (65). 
In this thesis, we evaluated different mitochondrial targeting signals (MTS)s for their 
ability to induce p53-mediated apoptosis. The Moll group has already demonstrated 
that p53 can be targeted to the mitochondria via the MTS from the ornithine 
transcarbamylase (OTC) (58, 59). However, we have shown that OTC has internal 
toxicity and therefore identified non-toxic MTS from XL as optimal for mitochondrial 
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targeting. Further, we investigated if a p53 subdomain is sufficient to trigger 
apoptosis at the mitochondria through p53-specific interaction with anti-apoptotic Bcl-
XL and pro-apoptotic Bak. 
Mitochondrial p53 is superior to wild type p53 in three ways. First, mitochondrial p53 
directly interacts with pro-and anti-apoptotic proteins at the mitochondrial outer 
membrane and triggers the intrinsic apoptotic pathway. wt p53 usually acts as a 
transcription factor and needs to transactivate its targeted genes first. Therefore, 
mitochondrially targeted p53 causes a more rapid apoptotic response compared to 
wild type p53 (57, 107). Second, mitochondrial p53 solely induces apoptosis while wt 
p53 has the ability to transactivate genes involved in cell cycle arrest, DNA repair 
and metabolism which might not have a beneficial effect in cancer therapy. Third, 
transcriptional activity of p53 is highly dependent on tetramer formation (111, 112). In 
cancer cells, p53 mutations occur in the DNA binding domain of p53 while the 
tetramerization domain (TD) remains active forming wt/mut heterotetramers 
(described previously as dominant negative effect) (87-89). In contrast to tetrameric 
transcriptionally active p53, mitochondrial p53 is mostly monomeric and may be 
unaffected by dominant negative inhibition. Another approach to overcome dominant 
negative inhibition by mutant p53 is discussed in section 1.14. 
 
1.13 The mitochondrial compartment and its import machinery  
The mitochondria is known to be involved in the synthesis of ATP and in numerous 
other metabolic processes including biosynthesis of vitamin cofactors, amino acids, 
fatty acids, and iron- sulfur clusters (113, 114). Additionally, mitochondria are also 
known as the central regulator of the intrinsic apoptotic pathway (115, 116). The 
mitochondrion consists of an outer membrane surrounding an inner membrane and 
two aquosis compartments intermembrane space (IMS) and matrix (117). IMS 
harbors cytotoxic proteins such as cytochrome c and SMAC/diabolo while the matrix 
is essential for citric acid cycle and fatty acid-oxidation (118). Even though the 
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mitochondrion encloses their own genome (119, 120), most of the mitochondrial 
polypeptides are encoded in the nuclear genome (121). Mitochondrial proteins are 
synthesized in the cytosol and imported into the mitochondria (122). For proper 
translocation and membrane insertion of these proteins, the mitochondrial 
membranes contain specific machinery for mitochondrial import. The two 
mitochondrial membranes contain two major import receptors (123). The translocase 
of the outer mitochondrial membrane (TOM) complex is localized as the name 
implies in the mitochondrial membrane. It contains seven different subunits, the 
receptors Tom20, Tom22, Tom70; the channel-forming protein Tom40 and the small 
Tom proteins Tom5, Tom6, Tom7 (124-126). The Tom 20 receptor recognizes the 
mitochondrial targeting signal (MTS) of the mitochondrial protein, guides it to Tom22 
which than targets it to the translocase of the inner membrane (TIM) (127, 128). The 
TIM complex consists of two functional modules the membrane-integrated 
translocase unit (Tim23, Tim17, Tim50) and the presequence-translocase-assoiated 
import-motor complex (PAM complex) (129, 130). The ATP-powered PAM complex 
is a multiprotein complex consisting of mitochondrial heat-shock protein-70 
(mtHsp70) and its essential cofactors (130).  
There are two main classes of mitochondrial targeting signals, N-terminal 
presequences and tail-anchored sequences (131-133). Most of the matrix and some 
of the inner and intermembrane space proteins have the N-terminal presequences 
consisting of 10-30 amino acids which form an α- helix (134). One side of the helix 
has a hydrophobic surface and the other side is positively charged (135). The MTSs 
are recognized and imported by the TOM complex and the TIM complex. Once they 
reach the matrix, matrix-localized processing peptidase cleave the MTS from the 
remaining protein (136). Tail-anchored proteins are usually found on the 
mitochondrial outer membrane. They consist of a signal membrane insertion 
sequence at their C-terminus and display a large N-terminal portion to the cytosol 
(55, 137). Examples of tail-anchored proteins are the pro-and anti-apoptotic Bcl-2 
proteins such as Bcl-XL, MCl-1, Bcl-2, Bak and Bax to mention a few (133, 138).  
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1.14 Replacing TD of p53 to overcome dominant negative inhibition 
To avoid dominant negative inhibition by mutant p53, we substituted the TD of p53 
with an oligomerization domain of break point cluster region (Bcr) a 72 amino acid 
coiled-coil (CC) named p53-CC (139). Superficially, these two oligomerization 
domains might appear structurally different, but both contain a main α-helix that 
forms antiparallel dimers of dimers. One other group has replaced the TD with an 
oligomerization domain that forms parallel dimers of dimers (111, 140). However, 
their construct only showed marginal success, which might be due to the parallel 
tetramer formation of their p53 construct. We hypothesis that p53-CC will solely 
homotetramerize with itself while causing p53-dependent apoptosis in dominant 
negative breast cancer in vitro and in vivo. We plane on delivering mitochondrial 
targeted p53 and p53-CC by using adenoviral drug delivery. 
 
1.15 Adenoviral drug delivery 
Since p53 delivered by adenovirus is already approved as a drug and has been used 
in various clinical trials (141-144), we chose adenovirus for delivery as well. There 
are two major types of gene delivery vehicles: viral and non-viral vectors. Non-viral 
gene delivery is potentially a safer approach but limited due to inefficiency (145, 
146). Conversely, viral vectors allow efficient gene transfer with some safety risks 
(147). Two viral vectors are used in clinical trials; retrovirus  and adenovirus (144). 
Retrovirus has the advantage of having a permanent effect on the infected cells 
since the gene-load is inserted in the genome of the host cells. This advantage 
represents a double-edged sword: on one hand it is highly efficient but on the other 
hand it integrates randomly into the patient’s genome and can therefore cause 
additional malignancies (147). Since we do not need a permanent genomic change 
and only want to cause cancer cell apoptosis, we decided to proceed with adenoviral 
drug delivery which only has an immediate effect and therefore does not integrate 
into the host’s genome (148). The disadvantage of adenoviral drug delivery is the 
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development of antibodies against the virus (149). Since we are targeting a local 
tumor in breast cancer, intratumoral injections can be used for adenoviral gene 
therapy in vivo (150). Further hypothesis and specific aims will be introduced.  
 
1.16 Statement of objectives 
The long term objective of this project this project is to develop re-engineered p53 
constructs for effective treatment of cancer. 
Hypothesis I: Targeting p53 to the mitochondria using an optimal mitochondrial 
targeting signal (MTS) will achieve rapid and efficient apoptosis of cancer cells. 
Aim 1: Investigate an optimal mitochondrial targeting signal to facilitate p53 
compartmentalization to the mitochondria. 
Aim 2: Determine which subdomain of p53 is responsible for interacting with anti-
apoptotic Bcl-XL and pro-apoptotic Bak or Bax. 
Aim 3: Validate that designed constructs from Aim 1 and Aim 2 delivered using an 
adenovirus vector will eradicate or reduce breast cancer in an orthotopic breast 
cancer model. 
 
Hypothesis II: Replacing the tetramerization domain of wt p53 with the coiled-coil 
(CC) domain from Bcr (breakpoint cluster region) maintains similar transcribtional 
activity as wt p53 while escaping dominant negative inhibition of mutant p53. 
This project I was co-author on, with Abood Okal as the primary author. 
Aim 1: Validate that p53-CC will still retain the tumor suppressor activity of p53 and 
additionally preclude the formation of hetero-oligomers. 
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Aim 2: Demonstrate that designed constructs from Aim 1 delivered using an 
adenovirus vector will eradicate or reduce breast cancer in an orthotopic breast 
cancer model. 
Hypothesis and Aims will be discussed in chapter 2-6. Thereby hypothesis I 
represents mainly the foundation of this thesis with aims 1-3 decribed in chapter 2 
through 5. Hypothesis II is described in chapter 6. 
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2.1 Abstract 
Targeting the tumor suppressor p53 to the mitochondria triggers a rapid apoptotic 
response as efficiently as transcription-dependent p53.(1, 2) p53 forms a complex 
with the anti-apoptotic Bcl-XL, which leads to Bak and Bax oligomerization resulting 
in apoptosis via mitochondrial outer membrane permeabilization.(3, 4) Although p53 
performs its main role in the mitochondrial outer membrane it also interacts with 
different proteins in the mitochondrial inner membrane and matrix.(5, 6) To further 
investigate mitochondrial activity of p53, EGFP-p53 was fused to different 
mitochondrial targeting signals (MTSs) directing it to the mitochondrial outer 
membrane (“XL-MTS” from Bcl-XL; “TOM-MTS” from TOM20), the inner membrane 
(“CCO-MTS” from cytochrome c oxidase) or matrix (“OTC-MTS” from ornithine 
transcarbamylase). Fluorescence microscopy and a p53 reporter dual luciferase 
assay demonstrated that fusing MTSs to p53 increased mitochondrial localization 
and nuclear exclusion depending on which MTS was used. To examine if the MTSs 
initiate mitochondrial damage, we fused each individual MTS to EGFP (a non-toxic 
protein) as negative controls. We performed caspase-9, TUNEL, Annexin-V, and 7-
AAD apoptosis assays on T47D breast cancer cells transfected with mitochondrial 
constructs. Except for EGFP-XL, apoptotic potential was observed in all MTS-EGFP-
p53 and MTS-EGFP constructs. In addition, EGFP-p53-XL showed the greatest 
significant increase in programmed cell death compared to its non-toxic MTS control 
(EGFP-XL). The apoptotic mechanism for each construct was further investigated 
using pifithrin-α (an inhibitor of p53 transcriptional activity), pifithrin-μ (a small 
molecule that reduces binding of p53 to Bcl-2 and Bcl-XL), and over-expressing the 
anti-apoptotic Bcl-XL. Unlike the MTSs from TOM, CCO, and OTC, which showed 
different apoptotic mechanisms, we conclude that p53 fused to the MTS from Bcl-XL 
performs its apoptotic potential exclusively through p53/Bcl-XL specific pathway. 
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2.2 Introduction 
The tumor suppressor p53 stimulates a wide network of signals involved in DNA 
repair, cell cycle arrest, senescence and apoptosis.(7-9) Although most of these 
effects can be linked to its role as a transcription factor, recent work has clearly 
demonstrated that p53 can cause apoptosis through its transcription-independent 
mitochondrial pathway.(3, 10) A small but highly reproducible fraction of p53 
translocates to the mitochondria at the onset of p53-dependent apoptosis.(10) 
Translocation of p53 to the mitochondrial outer membrane triggers the release of 
cytochrome c and procaspase-3 activation. The DNA binding domain of p53 (DBD, 
residues 239-248) forms inhibitory complexes with anti-apoptotic Bcl-XL and Bcl-2 
proteins (Figure 1), which are located in the mitochondrial outer membrane.(11) This 
induces oligomerization of Bak and Bax allowing them to form supramolecular 
pores.(4, 12, 13) In addition, p53 activates, directly binds to, and induces 
oligomerization of Bak and Bax.(4, 13, 14) The formation of permeability transition 
pores causes outer membrane rupture and releases cytochrome c from the 
intramembranous space into the cytosol triggering apoptosis via the apoptosome 
formation (Figure 1).(15-17) In addition, targeting p53 to the mitochondria triggers 
apoptosis faster than the transcription-dependent nuclear pathway.(1, 2) In most 
cancer cells, p53 is not able to bind to Bcl-2 proteins due to missense mutations in 
the DBD of p53, demonstrating the importance of the DBD in mitochondrial 
apoptosis.(11)  
The therapeutic effect of pharmaceutical agents such as p53 may differ depending 
on their intracellular delivery (18). Precise compartmentalization and sub-
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compartmentalization of proteins are essential for their biological activity. The 
majority of endogenous mitochondrial p53 localizes to the outer surface of the 
mitochondria,(19) which occurs after either DNA damage or hypoxic stress.(10) A 
detailed mechanism on how p53 translocates into the mitochondria is still under 
investigation since it is a nuclear protein due to its nuclear localization signals.(20) A 
study has shown that Bad (Bcl-2 antagonist of cell death) physically interacts with 
cytoplasmic p53 directing it to the surface of the mitochondria.(21, 22) Moll has 
suggested that p53 is imported via mtHsp70 targeting the membranous 
compartments.(10) The interaction with mtHsp70 and Hsp60 is increased with the 
R72P polymorphism in p53 due to elevation in nuclear export of p53.(23) MDM2 
protein is responsible for the nuclear exclusion and ubiquitination of p53. The 
monoubiquitylated p53 is targeted to the mitochondria under stress, which disrupts 
the p53/MDM2 complex (24). 
Despite what is known, exogenous mitochondrial targeting of p53 is still under 
investigation. To improve apoptosis via the p53/Bcl-XL pathway, p53 was delivered 
to different mitochondrial compartments. In this study, p53 was fused to different 
mitochondrial targeting signals (MTSs) targeting the mitochondrial outer membrane 
[MTS from Bcl-XL and MTS from the translocase of the outer membrane (TOM 20)], 
inner membrane (MTS from cytochrome c oxidase subunit VIII) and matrix (MTS 
from ornithine transcarbamylase) (Figure 1). These MTSs (Table 1) are generally 
thought to form α-helices, and are important for their recognition by translocation 
machineries in the mitochondrial outer (TOM complex) and inner (TIM complex) 
membranes.(25-28) Since MTSs are mainly found on the amino terminus of 
mitochondrial proteins.(25) All MTSs used were cloned on the amino terminus 
except for XL, which is inherently found on the carboxy terminus.(29) XL targets the 
outer surface of the mitochondria(29-32) while TOM is inserted into the outer 
membrane;(29) CCO translocates the outer membrane and then becomes imbedded 
into the inner membrane(33, 34) while the OTC crosses both membranes and 
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translocates to the matrix.(3, 35) The purpose of this work is to determine the ideal 
MTS for p53 mitochondrial targeting to induce the intrinsic apoptotic pathway. 
 
Figure 1. The mitochondrial apoptotic pathway of p53. When p53 is targeted to the 
mitochondria, it interacts with anti-apoptotic Bcl-XL, enables Bax and Bak 
oligomerization, and activates the intrinsic apoptotic pathway. The apoptosome 
(cytochrome c, APAF-1 and caspase-9) is triggered, leading to apoptosis via 
activation of caspases-3, -6, and -7. The left side of the diagram indicates the 
mitochondrial signals (MTSs) used and the different subsections of the mitochondria 
targeted, including the outer membrane (“XL-MTS” from Bcl-XL; “TOM-MTS” from 
TOM20), the inner membrane (“CCO-MTS” from cytochrome c oxidase), and the 
matrix (“OTC-MTS” from ornithine transcarbamylase).   
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Protein Compartment MTS Sequence 
XL Outer Membrane RKGQERFNRWFLTGMTVAGVVLLGSLFSRK 
TOM Outer Membrane MVGRNSAIAAGVCGALFIGYCIYFDRKRRSDPN 
CCO Inner Membrane MSVLTPLLLRGLTGSARRLPVPRAKIHSL 
OTC Matrix MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQNKVQ 
 
Table 1. A list of the mitochondrial targeting signals used in this paper. TOM and XL 
target the mitochondrial outer membrane, CCO translocates to the mitochondrial 
inner membrane, and the OTC localizes to the mitochondrial matrix. 
 
2.3 Materials and Methods 
2.3.1 Plasmid Construction 
EGFP-p53 Plasmid (pEGFP-p53). The DNA encoding p53 was amplified through 
PCR from pCMV-p53 wt (a generous gift from Dr. S. J. Baker, Addgene, Cambridge, 
MA) using the primers 5-GCGCGCGCGCTCCGGAGCCATGGAGGAGCCGCAGT-
3 and 5- GCGCGCGCGCGGTACCTCAGTCTGAGTCAGGCCCTTCTGTC-3.  This 
was subcloned into the BspEI and KpnI restriction enzyme sites in pEGFP-C1 
(Clontech, Mountain View, CA).  
pOTC-EGFP-p53 Plasmid. An oligonucleotide encoding the mitochondrial targeting 
signal from OTC (including the Kozak region), 5- 
CCGGTCGCCACCATGCTGTTTAATCTGAGGATCCTGTTAAACAATGCAGCTTTT
AGAAATGGTCACAACTTCATGGTTCGAAATTTTCGGTGTGGACAACCACTACAA
AATAAAGTGCAGCGA-3 was annealed to its complementary strand.  This was then 
cloned at the amino terminus of EGFP-p53 at the AgeI site.  
pTOM-EGFP-p53 and pCCO-EGFP-p53 Plasmids. The OTC region from pOTC-
EGFP-p53 was replaced with annealed oligonucleotides encoding the mitochondrial 
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targeting signal from the TOM20 complex (TOM) at the AgeI site, 5-
GATCCCCGGTCGCCACCATGGTGGGTCGGAACAGCGCCATCGCCGCCGGTGT
ATGCGGGGCCCTTTTCATTGGGTACTGCATCTACTTCGACCGCAAAAGACGAAG
TGACCCCAACCGA-3 and its reverse complement, or with oligonucleotides 
encoding the mitochondrial targeting signal from the cytochrome c oxidase (CCO) at 
the AgeI site, 5- 
CCGGTCGCCACCATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAG
GCTCGGCCCGGCGGCTCCCAGTGCCGCGCGCCAAGATCCATTCGTTGA-3 and 
its reverse complement. 
pEGFP-p53-XL Plasmid. The mitochondrial signal from Bcl-XL was fused to the 
carboxy terminus of EGFP-p53 using the BamHI restriction site as follows. The XL 
oligonucleotide 5-
AGAAAGGGCCAGGAGAGATTCAACAGATGGTTCCTGACCGGCATGACCGTGGC
CGGCGTGGTGCTGCTGGGCAGCCTGTTCAGCAGAAAGTGA-3 was annealed to 
its complimentary strand (with BamHI sticky ends). The p53 stop codon was then 
mutated (TGA to TTA) in pEGFP-p53-XL using the primers 5-
GAAGGGCCTGACTCAGACTTAGGTACCGCGGGCCCGGGAT-3 and the reverse 
complement.  
pEGFP Constructs with MTSs. Plasmids encoding OTC-EGFP, TOM-EGFP, CCO-
EGFP, and EGFP-XL were constructed using the same oligonucleotides and 
restriction sites mentioned above but inserted in pEGFP-C1 instead of pEGFP-p53. 
MTS-EGFP-p53NLSmut. Mutations (K319T and K320T) in the nuclear localization 
signal (NLS) of p53 were introduced in all mitochondrial p53 constructs via 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) using the 
primers 5- CTCTCCCCAGCCAACGACGAAACCACTGG -3 and its reverse 
complement. 
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2.3.2 Cell Lines and Transient Transfections.  
1471.1 murine adenocarcinoma cells (gift of G. Hager, NCI, NIH), MCF-7 human 
breast adenocarcinoma cells (ATCC, Manassas, VA), and T47D human ductal 
breast epithelial tumor cells (ATCC) were grown as monolayers in DMEM (1471.1) or 
RPMI (MCF-7 and T47D) (Invitrogen, Carlsbad, CA), supplemented with 10% fetal 
bovine serum (Invitrogen), 1% penicillin-streptomycin-glutamine (Invitrogen), and 
0.1% gentamicin (Invitrogen). In addition, T47D and MCF-7 media was 
supplemented with 4 mg/L insulin (Sigma, St. Louis, MO). The cells were maintained 
in a 5% CO2 incubator at 37ºC. 7.5 × 10
4 cells for 1471.1 and 3.0 × 105 cells for 
MCF-7 and T47D were seeded in 6-well plates (Greiner Bio-One, Monroe, NC) or 2-
well live cell chambers (Nalgene Nunc, Rochester, NY). Transfections were carried 
out 24 hours after seeding using Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s recommendations. Unless otherwise indicated, 1 pmol DNA was 
transfected per well for all assays. 
 
2.3.3 Mitochondrial Staining, Microscopy, and Image Analysis.  
Prior to live-cell imaging and mitochondrial staining, media in live cell chambers was 
replaced with phenol red-free DMEM (Invitrogen) for 1471.1 cells or phenol red-free 
RPMI (Invitrogen) for T47D and MCF-7 cells containing 10% charcoal-stripped fetal 
bovine serum (CS-FBS, Invitrogen). Cells were incubated with 250 nM MitoTracker 
Red FM (Invitrogen) for 15 min at 37˚C and protected from light. Images were 
acquired as previously (36), using an Olympus IX71F fluorescence microscope 
(Scientific Instrument Company, Aurora, CO) with high-quality narrow band GFP 
filter (ex: HQ480/20 nm, me: HQ510/20 nm) and HQ: TRITC filter (ex: HQ545/30, 
me: HQ620/60) from Chroma Technology (Brattleboro, VT) with a 40X PlanApo oil 
immersion objective (NA 1.00) on an F-View Monochrome CCD camera. Images 
were analyzed for mitochondrial stain overlap with EGFP fusion constructs using 
Image software and the Jacopo plugin (37). Jacopo was used to generate the 
localization statistic [i.e., Pearson’s correlation coefficient (PCC) post Costs’ 
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automatic threshold algorithm] (38, 39), as we have done before (40). PCC 
evaluates correlation between pairs of individual pixels from EGFP and MitoTracker 
stained cells. The higher the PCC value the higher the correlation. For increased 
visual clarity of mitochondrial localization of the EGFP-fused constructs, spatial 
representations of pixel intensity correlation have been generated using 
Colocalization Color map (ImageJ).(41) Microscopy was repeated in triplicate (n=3) 
and 10 cells were analyzed for each construct. 
 
2.3.4 Luciferase Assay 
 All constructs (3.5 μg of DNA) were co-transfected with 3.5 μg of p53-Luc Cis-
Reporter (encoding for firefly luciferase, Agilent) in T47D and MCF-7 cells. To 
normalize for transfection efficiency, 0.35 μg of pRL-SV40 plasmid (encoding for 
renilla luciferase, gift from Dr. Philip Moos, University of Utah) was co-transfected. 
The Dual-Glo Luciferase Assay System (Promega, Madison, WI) was used to 
determine firefly luciferase activity and renilla luciferase per manufacturer's 
instructions. Luciferase activity was detected 24 hours after transfection using 
PlateLumino (Stratec Biomedical Systems, Birkenfeld, Germany). Firefly luciferase 
values were normalized for renilla luciferase. EGFP-p53 served as a positive control 
and EGFP as a negative control. The Dual-Glo Luciferase Assay was run three times 
independently, each in triplicate. 
 
2.3.4 Caspase-9 Assay 
T47D cells were probed 19 hours after transfection using CaspaLux®9-M2D2 kit 
(OncoImmunin, Inc., Gaithersburg, MD) per manufacturer’s recommendations. The 
cells were then suspended in flow cytometry buffer (OncoImmunin, Inc.) and 
analyzed via the FACSAria-II (BD-BioSciences, University of Utah Core Facility) 
utilizing 488 nm (for EGFP) and 563 nm (for cleaved caspase 9 substrate) lasers. 
FACSDiva software was used as an evaluation tool. Only EGFP transfected cells at 
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507 nm emission were analyzed. All constructs were gated at the same EGFP 
intensity levels to ensure equal expression of proteins. The samples were detected 
in the PE (phycoerythrin) channel with the 580 nm emission peak. Each construct 
was assayed three times (n=3).  
 
2.3.6 TUNEL Assay 
T47D cells were prepared 48 hours after transfection using In Situ Death Detection 
Kit, TMR red (Roche, Mannheim, Germany) per the company’s protocol. The kit, 
labels the DNA single strand breaks (TUNEL reaction) in apoptotic cells. The 
FACSAria-II was used to analyze the cells suspended in PBS (Invitrogen). The same 
FACS settings mentioned above with the caspase-9 assay were used. Only EGFP 
positive cells were analyzed for DNA segmentation. Each construct was analyzed 
three times (n=3).  
 
2.3.6 Annexin-V Assay 
At 48 hours post transfection, T47D cells were assayed for Annexin-V binding. The 
cells were suspended in 100 μl Annexin binding buffer (Invitrogen) and incubated 
with 5 μl Annexin-APC (Annexin-V conjugated to allophycocyanin, Invitrogen) for 15 
minutes. The incubated cells were then diluted in 400 μl Annexin binding buffer and 
analyzed using the FACSCanto-II (BD-BioSciences, University of Utah Core Facility) 
with FACSDiva software. EGFP was excited at 488 nm wavelength and detected at 
507 nm. APC was excited with 635 nm laser and detected at 660 nm. Analysis was 
based on EGFP positive cells. All constructs were gated at the same EGFP intensity 
levels. Each construct was tested three times (n=3). 
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2.3.7 7-AAD Assay 
T47D and MCF-7 cells were stained with 7-aminoactinomycin D (7-AAD, Invitrogen) 
according to manufacturer’s instructions 48 hours after transfection. The samples 
were analyzed using the FACSCanto-II (BD-BioSciences). Analyzed cells were 
gated for EGFP (as mentioned in Annexin-V assay). In addition, EGFP and 7-AAD 
were excited with the 488 nm laser.  EGFP and 7-AAD were detected at 507 nm and 
660 nm, respectively. Each construct was assayed three times (n=3). 
 
2.3.8 Rescue Experiment Using Pifithrin-α.  
Six hours after transfection, T47D cells were incubated with previously optimized 
concentration of 40 μM pifithrin-α (Cayman Chemical, Ann Arbor, MI) for 42 hours 
and compared to transfected cells without pifithrin-α. At the 48 hour time point, the 7-
AAD assay was performed as above.  
 
2.3.9 Rescue Experiment Using Pifithrin-μ 
Six hours after transfection, T47D cells were incubated with previously optimized 
concentration of 5 nM pifithrin-μ (Tocris Bioscience, Ellisville, MO) for 42 hours and 
compared to transfected cells without pifithrin-μ. At the 48 hour time point, the 7-AAD 
assay was performed as detailed above.  
 
2.3.10 Rescue Experiment Using Bcl-XL 
T47D Cells were co-transfected with 1 pmol of MTS constructs and 1 pmol of pBcl-
XL (Addgene). After 48 hours, cells were pelleted and assayed with 7-AAD as 
described above. 
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2.3.11 Statistical Analysis 
All experiments were repeated in triplicate (n=3). The data were presented as the 
mean ± standard error. Statistical differences between each MTS-EGFP-p53 and its 
MTS-EGFP were resolved via unpaired t-test using GraphPad Prism software. The 
MTS-EGFP controls were compared to EGFP by one-way ANOVA with Tukey’s post 
test. The degree of colocalization was analyzed using odds ratio with Pearson’s Chi-
square. A p value <0.05 was considered significant. 
 
2.4 Results 
2.4.1 Mitochondrial localization of MTS-EGFP-p53 
Mitochondrial targeting of all constructs was verified using fluorescence microscopy. 
Figure 2A shows representative 1471.1 cells, which are larger in size, spread well, 
and are generally easier to visualize versus T47D or MCF-7 cells. However, 
irrespective of the cell line, similar microscopy results were observed in T47D and 
MCF-7 cells (data not shown). To better illustrate the colocalization of the EGFP 
fused constructs, PCC values were generated and graphed for each construct 
(Figure 2B). PCC values range from +1 to -1; perfect correlation is represented by 
+1, anti-correlation by -1, and a PCC value of zero denotes random distribution (37). 
Following the example of Bolte and Cordelières, a PCC of 0.6 or greater will define 
colocalization or co-compartmentalization (Figure 2B) (37, 40). Fusing different 
MTSs to EGFP and p53 showed a high degree of colocalization with the 
mitochondria. EGFP-C1 served as negative control for colocalization analysis and as 
expected, there was no colocalization between EGFP alone and the mitochondria. 
EGFP and p53 tagged to TOM and XL targeted the mitochondria better than CCO-
EGFP-p53 and OTC-EGFP-p53. CCO and OTC were the “weakest” MTSs since 
there was some nuclear targeting of both CCO-EGFP-p53 and OTC-EGFP-p53. 
Therefore we mutated K319T and K320T in the nuclear localization signal (NLS) of 
p53 (20) which resulted in increased mitochondrial targeting for CCO-EGFP-p53 and 
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OTC-EGFP-p53. For easier visualization of colocalization among constructs, a 
spatial depiction of pixel overlap and intensity correlation are provided in the ‘Color 
Map’ column (Figure 2A). The Color Map spectrum moves from cold to warm colors 
as pixel correlation increases (41). 
 
2.4.2 Testing the transcriptional activity of MTS-EGFP-p53 
To demonstrate the lack of transcriptional activity of these p53 constructs, a p53 
reporter dual luciferase assay was performed in T47D (Figure 3A) and MCF-7 cells 
(Figure 3B). T47D cells contain a mutation in p53 (in the DBD which renders it 
inactive) that is also localized in the cytoplasm(42, 43) while MCF-7 cells express 
wild-type p53 mislocalized to the cytoplasm.(44) TOM and XL fused to EGFP-p53 
showed no nuclear activity in either cell lines. CCO-EGFP-p53 expressed similar 
transcriptional activity to EGFP-p53 (positive control) in T47D (Figure 3A) and 
significant activity in MCF-7 (Figure 3B) compared to the EGFP negative control. 
Introducing NLS mutations (K3319T and K320T) in CCO-EGFP-p53 resulted in 
major reduction of nuclear activity in both cell lines. OTC-EGFP-p53 showed low 
transcriptional activity in MCF-7 (Figure 3B) and a significant activation in T47D cells 
(Figure 3A). Surprisingly, introduction of NLS mutations into OTC-EGFP-p53 did not 
result in any changes in nuclear activity in either cell line (Figures 3A and B). 
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Figure 2. Colocalization of MTS constructs and MitoTracker Red mitochondrial stain 
in 1471.1 cells. A) Representative images of MTS-EGFP-p53, MTS-EGFP-p53 NLS 
mutation, MTS-EGFP and EGFP-C1 are shown in the left column with images of 
MitoTracker Red distribution in the middle column. The ‘EGFP’ and ‘MitoTracker’ 
columns have been false colored green and red, respectively. Enhanced 
visualization of colocalized pixels is rendered in the ‘Color Map’ column. Warm 
colors depict pixels with highly correlated intensity and spatial overlap while cool 
colors are indicative of anti- or random correlation (color bar for interpretation is 
shown below column). Corresponding PCC values are shown in the right column. 
White scale bars are all 10 μm. B) The degree of colocalization is represented by 
PCC following Costes’ approach. (38, 39) All constructs with values higher than 0.6 
are considered highly colocalized with mitochondrial stain MitoTracker Red. 
Statistical analysis was performed by using odds ratio with Pearson’s Chi-square. 
The adjusted odds ratio for PCC value of 0.6 were compared with each sample. 
*p<0.05, and **p<0.01 comparing odds ratio of lowest value for samples with odds 
ratio of 1 for PCC of 0.6. 
 
2.4.3 The effect of MTS-EGFP-p53 on early apoptosis (caspase-9)  
In this paper we focused on T47D cells because they are more resistant to apoptosis 
compared to MCF-7 (45). The apoptotic potential of p53 fused to different MTSs 
targeting the mitochondrial matrix, outer, and inner membranes was evaluated via 
caspase-9, TUNEL, Annexin-V and 7-AAD assays. Caspases are a group of 
proteolytic enzymes that are directly involved in apoptosis by cleaving proteins such 
as lamin and PARP. Its inactive form procaspase-9 is activated through cytochrome 
c release and APAF-1 which occurs after mitochondrial outer membrane disruption 
(known as the intrinsic apoptotic pathway).(46) Caspase-9 itself cleaves the peptide 
sequence LEHD, which was used in the caspase-9 assay to measure the intrinsic 
apoptotic pathway.(47) Only EGFP-p53-XL (p<0.05) and OTC-EGFP-p53 (p<0.05) 
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were significantly different from their corresponding MTS-EGFP controls as shown in 
figure 4.  
 
 
 
Figure 3. Luciferase assay: All MTS-EGFP-p53 and MTS-EGFP-p53 NLS mutation 
constructs were tested for their ability to activate a p53 reporter in A) T47D cells and 
B) MCF-7 cells. EGFP-p53 serves as a positive control and EGFP as a negative 
control. All constructs were corrected to EGFP-p53 control, which is set at 100%. 
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Statistical analysis was performed by using one-way ANOVA with Tukey’s post test. 
**p<0.005 and ***p<0.0005 compared to EGFP-p53. 
 
 
 
Figure 4. The activation of caspase-9 was analyzed 19 hours following transfection 
of T47D cells. All constructs were corrected to untreated control, which is set at 
100%. Statistical analysis was performed by using unpaired t-test. * p<0.05 for MTS-
EGFP-p53 compared to its MTS-EGFP. 
 
2.4.4 The effect of MTS-EGFP-p53 on DNA fragmentation 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was 
measured to detect DNA fragmentation by labeling the terminal end of nucleic acids. 
DNA fragmentation is a hallmark of apoptosis and is generated by caspase cleavage 
(48). Figure 5 illustrates that EGFP-p53-XL and CCO-EGFP-p53 are the only 
constructs that were statistically significant from their control MTS-EGFP. Constructs 
with mutations in the NLS of p53 did not differ from constructs without mutation (see 
the supporting information: S1). Staurosporine, which activates caspase-3/7 and 
leads to DNA fragmentation (45), served as a positive control. 
54 
 
 
 
 
 
 
 
Figure 5. T47D cells were tested 48 hours following transfection. DNA fragmentation 
was analyzed with the TUNEL assay. All constructs were corrected to staurosporine 
positive control, which is set at 100%. Statistical analysis was performed by unpaired 
t-test. * p<0.05 for MTS-EGFP-p53 compared to its MTS-EGFP.  
 
2.4.5 The effect of MTS-EGFP-p53 on plasma membrane 
The effects of the mitochondrial constructs were further explored by analyzing 
externalization of phosphatidylserine and cell membrane rupture. Annexin-V was 
used to detect the externalization of phosphatidylserine on the cell surface of 
apoptotic cells via flow cytometry.(49, 50) In the majority of healthy cells, the plasma 
membrane expresses phosphatidylserine on the cytosolic surface while in apoptotic 
cells, the phosphatidylserine is transported to the outer surface, which allows labeled 
Annexin-V to bind.(51) All MTS-EGFP-p53 constructs showed a significant effect on 
inducing apoptosis compared to their corresponding MTS-EGFP controls in T47D 
cells (Figure 6). In addition, EGFP-XL was the only construct that showed minimal 
activity similar to the non-toxic EGFP negative control (Figure 6). 
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To further validate the effect of mitochondrial p53 on late apoptosis, the 7-AAD 
assay was performed via flow cytometry (Figure 7). The 7-AAD fluorescent marker 
cannot stain the DNA in healthy cells due to inability to penetrate an intact cell 
membrane (52). However, it is able to stain the DNA in apoptotic and necrotic cells 
because of their disrupted membrane.(53) Similar to Annexin-V results, all 
mitochondrial p53 constructs showed significant 7-AAD intercalation with DNA 
compared to their MTS-EGFP controls (Figure 7A). In addition, EGFP-XL was the 
only construct that showed similar activity to EGFP alone (Figure 7A). In a cell line 
that is less resistant to apoptosis such as MCF-7 (45), EGFP-p53-XL is the only 
construct that was significantly different than its MTS-EGFP control (Figure 7B). In 
MCF-7 cells, there was no statistical difference between p53 fused to TOM, CCO or 
OTC and their respective MTS-EGFP controls (Figure 7B). Mutating the NLS of p53 
in MTS-EGFP-p53 had no effect on 7-AAD permeation in both cell lines except with 
CCO-EGFP-p53 in T47D (see the supporting information: S2). In addition, EGFP-XL 
showed no activity similar to EGFP alone in MCF-7 (Figure 7B). Similar to Annexin 
V, EGFP-XL was also the only construct with minimum activity as EGFP alone in 
T47D cells (Figure 7A). 
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Figure 6. Annexin-V assay was conducted in T47D cells 48 hours after transfection. 
Statistical analysis was performed by one-way ANOVA with Tukey’s post test. 
**p<0.005 and ***p<0.0005 comparing MTS-EGFP-p53 to their MTS-EGFP controls. 
The negative controls (MTS-EGFP) were compared to EGFP-C1 using one-way 
ANOVA with Tukey’s post test ##p<0.005. 
 
 
 
Figure 7. The 7-AAD assay was tested in (A) T47D and (B) MCF-7 cells 48 hours 
after transfection. Statistical analysis was performed by one-way ANOVA with 
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Tukey’s post test. * p<0.05, **p<0.005 comparing MTS-EGFP-p53 to their MTS-
EGFP controls. The controls (MTS-EGFP) were compared to EGFP-C1 using one-
way ANOVA with Tukey’s post test ##p<0.005. 
 
2.4.6 Investigating the apoptotic mechanism 
Apoptosis resulting from p53 transcriptional activity of our mitochondrial p53 
constructs was examined via a pifithrin-α rescue experiment. Pifithrin-α is a small 
molecule, which inhibits p53-mediated transcriptional activity (54, 55). The effect of 
pifithrin-α was measured in a 7-AAD assay (Figure 8A). As expected from the 
transcriptional activity data, the apoptotic effect of EGFP-p53 fused to either CCO or 
OTC was reduced significantly after pifithrin-α treatment. In addition, there was no 
impact on the apoptotic potential of EGFP-p53 fused to either XL or TOM (Figure 
8A). 
In order to investigate p53’s apoptotic mechanism in the mitochondria, pifithrin-μ was 
used in a rescue experiment in the 7-AAD assay. Pifithrin-μ is a compound that 
reduces the binding affinity of p53 to the anti-apoptotic proteins, Bcl-2 and Bcl-XL 
(56, 57). Pifithrin-μ had a significant impact on the apoptotic potential of p53 fused to 
both XL and OTC (Figure 8B). However, apoptosis caused by p53 fused to either 
TOM or CCO was not rescued by pifithrin-μ. In addition, all the MTS-EGFP controls 
were not altered in this rescue experiment (see the supporting information: S3A).  
The apoptotic mechanism was further explored by over-expression of the anti-
apoptotic protein, Bcl-XL. The cells were then analyzed in the 7-AAD assay via flow 
cytometry. Bcl-XL had a significant effect on reducing 7-AAD positive cells treated 
with EGFP-p53 fused to TOM, XL, and OTC (Figure 8C). Cells treated with EGFP-
p53-XL showed the most significant reduction in 7-AAD when co-transfected with 
Bcl-XL. Meanwhile, Bcl-XL had no effect on cells transfected with CCO-EGFP-p53. 
In addition, all the MTS-EGFP controls were not altered in this rescue experiment 
(see the supporting information: S3B). 
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Figure 8. Rescue experiments using (A) pifithrin-α, (B) pifithrin-μ, or (C) Bcl-XL. 7-
AAD assay was performed 48 hours after transfection in T47D cells. All constructs 
were fused to EGFP. Statistical analysis was performed by unpaired t-test. * p<0.05, 
**p<0.005, ***<0.0005 comparing treated (with pifithrin-α, pifithrin-μ, or Bcl-XL) to 
untreated (no drug or Bcl-XL added). 
 
2.5 Discussion 
The tumor suppressor p53 was targeted with different MTSs in order to investigate 
its optimal mitochondrially triggered apoptotic pathway. We hypothesized that it 
might be possible that sending any protein (even EGFP) to mitochondria could be 
“toxic” to cells by disruption of mitochondrial function. Fusing p53 to MTSs targeting 
the mitochondrial outer membrane, inner membrane, and matrix did indeed result in 
apoptosis. However, sending even EGFP to the mitochondrial matrix (OTC), the 
inner membrane (CCO), or the TOM complex (TOM) perturbed mitochondrial 
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stability as evidenced by the apoptotic assays. Only p53-XL was capable of inducing 
mitochondrial apoptosis exclusively via mitochondrial p53/Bcl-XL pathway. 
Directing EGFP to the matrix and inner membrane via OTC and CCO, respectively, 
resulted in late stage apoptosis. This shows that fusing EGFP to OTC or CCO has a 
toxic effect on the mitochondria. We speculate that sending EGFP to the 
mitochondrial matrix and inner membrane could cause an imbalance in the sensitive 
mitochondrial system due to import through mitochondrial membranes. On the other 
hand, targeting EGFP to the mitochondrial outer membrane using TOM and XL 
shows minimal toxicity with XL but significant toxicity with TOM. Since EGFP-XL is 
directed towards Bcl-XL (58) on the surface of the outer membrane (29-31), it is not 
expected to become imbedded into the mitochondrial membrane. Conversely, the 
TOM-EGFP may interfere with TOM20 involved in mitochondrial import machinery 
(18, 59). The TOM complex is responsible for importing proteins across the 
mitochondrial outer membrane. TOM20 is one of the receptor subunits in the TOM 
complex (60, 61). Perhaps fusing any protein to the MTS from TOM20 might affect 
the sensitive import mechanism.  
As p53 is a nuclear protein, the MTS fused to it will compete with the protein’s 
nuclear localization signals (NLSs). p53 contains three NLSs; the most active of 
them is located at residues 305-322 (20). The nuclear import of large proteins is 
dependent on the availability of a NLS (62-64). To prevent the nuclear targeting of 
our constructs, we introduced mutations (K319T and K320T) in the strongest NLS of 
p53.(20) Colocalization data and p53 transcriptional activity assay showed an 
increase in mitochondrial targeting and a decrease in p53 nuclear activity after the 
introduction of the NLS mutations in CCO-p53. According to our colocalization data, 
CCO-EGFP showed the lowest mitochondrial targeting compared to the other MTS-
EGFP (Figure 2). The weak mitochondrial CCO signal explains the high 
transcriptional activity when fused to p53 without NLS mutations (Figure 3). The 
strong NLS in p53 competes with the relatively weak MTS from CCO and shifts the 
distribution to the nucleus. After mutating the strong NLS, the CCO MTS was also in 
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competition with the other weak NLSs in p53 (20), which may explain why the CCO-
p53 NLS mutation still showed transcriptional activity (Figure 3). However, the 
mutations did not have any effect on the mitochondrial targeting or nuclear activity of 
the TOM, XL, and OTC constructs. EGFP-p53 fused to TOM and XL showed 
minimal nuclear p53 activity presumably due to their strong mitochondrial signals. 
Introducing NLS mutations to p53 fused to TOM or XL did not show any reduction on 
the already low transcriptional activity (Figure 3). On the other hand, OTC-p53 
showed significant p53 nuclear activity but was not reduced upon NLS mutation 
(Figure 3). 
In addition, the nuclear activity of MTS-p53 differed between MCF-7 and T47D. 
These differences might be due to variability in proteins involved with p53 
transcriptional activity, mitochondrial shuttling, or number of mitochondria in each cell 
line. In MCF-7, all MTS-p53 constructs (with or without NLS mutations) showed 
minimum transcriptional activity except for the CCO-p53, which had half the activity 
of wild type p53 (Figure 3B). However, in T47D cells all MTS-p53 constructs showed 
generally higher nuclear activity than in MCF-7, especially CCO-p53, which showed 
the same nuclear activity as wild type p53. CCO-p53 NLS mutation and OTC-p53 
(with and without NLS mutation) showed fifty percent transcriptional activity in T47D 
(Figure 3A).  
Even though the NLS mutations increased mitochondrial targeting of the CCO-p53 
construct, it did not have any effect on increasing the apoptotic potential. This was 
also the case for NLS mutations in all other constructs (see the supporting 
information: S1 and S2). CCO-p53 was significant compared to its CCO-EGFP 
control in TUNEL, Annexin-V, and 7-AAD assays. Since CCO-EGFP showed 
cytotoxicity, the increase in apoptosis when attached to p53 was likely due to nuclear 
p53 activity. This is reflected in our luciferase assay (Figure 3) and the rescue 
experiments with pifithrin-α, pifithrin-μ and Bcl-XL (Figure 8). The apoptotic activity of 
CCO-p53 was reduced in the pifithrin-α (an inhibitor of p53 transcriptional activity) 
rescue experiment. However, it was not rescued by either over-expression with the 
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anti-apoptotic Bcl-XL or incubation with pifithrin-μ (an inhibitor of p53 binding to Bcl-2 
and Bcl-XL) (56, 57). This demonstrates that CCO-p53 does not initiate p53/Bcl-XL 
specific apoptosis.  
OTC-p53 also showed transcriptional activity. In addition, OTC-p53 exhibited 
significant caspase-9 induction, and late stage apoptosis compared to its cytotoxic 
OTC-EGFP control. To examine if the increase of activity was due to nuclear or 
mitochondrial p53, the rescue experiments (with pifithrin-μ and Bcl-XL) were 
conducted and showed reduction in programmed cell death (Figure 8). This indicates 
that apoptosis was likely initiated through p53 binding to Bcl-XL and Bcl-2. In 
addition, the transcriptional activity data demonstrates that OTC-p53 has activity in 
both the nucleus (rescued by pifithrin-α) and the mitochondria (rescued by pifithrin-μ 
and Bcl-XL). Even though OTC directs p53 to the mitochondrial matrix, p53 is still 
able to interact with Bcl-XL and Bcl-2 proteins on the outer membrane. This could be 
due to cleavage of the MTS by endopeptidase, which enables p53 to target the outer 
membrane (3, 10). 
Instead of targeting the protein to the matrix then translocating it to the outer 
membrane, as was the case for OTC, we fused EGFP-p53 to TOM to directly target 
the outer membrane. Direct targeting of the outer membrane with TOM-p53 was able 
to initiate apoptosis (Annexin-V and 7-AAD) robustly compared to its TOM-EGFP 
control. Interestingly this increase in apoptosis was only rescued when Bcl-XL was 
co-transfected but not when pifithrin-α or pifithrin-μ were added (Figure 8). The 
pifithrin-α rescue experiment indicates that TOM-p53 has no transcriptional activity. 
We speculate that TOM-EGFP-p53 is binding to pro-apoptotic Bak and enhancing its 
oligomerization, which disrupts the mitochondrial outer membrane.(13, 14) Bcl-XL 
forms a heterodimer with Bak and prevents Bak homodimerization.(14, 65, 66) 
Therefore, when Bcl-XL is over-expressed, it competes with TOM-p53 in binding with 
Bak and hence reduces apoptosis. Since pifithrin-μ reduces the binding of p53 to 
anti-apoptotic Bcl-XL and Bcl-2 and has no effect on binding to Bak, it did not show 
reduction in programmed cell death for TOM-p53. 
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In an effort to directly target the p53/Bcl-XL pathway, we fused XL to EGFP-p53. 
Directing p53 to the mitochondria via XL showed significant caspase-9, TUNEL, 7-
AAD, and Annexin-V activity compared to its EGFP-XL control. This apoptotic 
response was not due to transcriptional activity of p53 as shown in the luciferase 
assay data (Figure 3) and the pifithrin-α rescue experiment (Figure 8A). However, 
the apoptotic response was due to p53/Bcl-XL pathway. To confirm this interaction, 
rescue experiments using pifithrin-μ and Bcl-XL were conducted and showed 
reduction in apoptosis (Figure 8B and C). In addition, the EGFP-XL control showed 
no toxicity compared to the other MTS-EGFP controls especially in MCF-7 cells 
(Figure 6 and 7). This data demonstrates that sending p53 to a specific protein (Bcl-
XL) in the mitochondrial outer membrane causes p53 specific apoptosis. Table 2 is a 
summary of the results and speculation from this work.  
MTS XL TOM CCO OTC 
Mitochondrial 
compartment 
Outer surface 
of outer 
membrane 
Outer 
membrane 
Inner 
membrane 
Matrix 
Relative MTS 
Strength* 
Strong Strong Weak Medium/Strong 
Intrinsic mito-
toxicity of MTS-
EGFP 
Non-toxic Toxic Toxic Toxic 
p53 apoptotic 
response  
Caspase-9, 
TUNEL, 
Annexin-V, 
and 7-AAD 
Annexin-V, 
and 7-AAD 
TUNEL, 
Annexin-V, and 
7-AAD 
Caspase-9, 
Annexin-V, and 7-
AAD 
Speculated 
apoptotic 
mechanism 
May interact 
with Bcl-XL 
May 
interact 
with Bak 
Transcriptional 
p53 
Transcriptional p53 
and may interact 
with Bcl-XL 
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Table 2. A summary of collected data and speculated mechanism. The table 
compares the four MTSs in mitochondrial localization, strength (*based on 
colocalization), mito-toxicity of MTS-EGFP, apoptotic response of MTS-p53 
compared to MTS-EGFP, and speculated apoptotic mechanism.  
 
In summary, efficiency in targeting the mitochondria depends on the strength of the 
MTS. In the case of targeting proteins containing relatively strong NLSs such as p53 
(residues 305-322) (20), mitochondrial targeting can best be achieved by using 
strong MTSs to counter the NLS. In this study, relatively weaker MTSs are not 
efficient enough to compete with the strong NLS in p53. In addition, protein targeting 
to the mitochondria disrupts the sensitive balance in the mitochondria, which initiates 
intrinsic apoptosis. Except for EGFP-XL, all mitochondrial constructs had apoptotic 
effects. We conclude that p53-XL was the most specific to p53/Bcl-XL mitochondrial 
pathway. Our data shows that not all mitochondrial targeting signals are optimal for 
mitochondrial induction of apoptosis with p53. In conclusion, specific binding of p53 
to mitochondrial Bcl-XL (and hence apoptotic activity) is best achieved by directly 
targeting p53 to Bcl-XL via the XL MTS. This work therefore provides a mechanistic 
explanation and provides additional speculation towards the understanding of 
mitochondrial p53 apoptosis. Our future goal is to employ the p53-XL construct as a 
therapeutic in vivo using viral delivery. Ultimately, p53-XL gene therapy is expected 
to be beneficial for other types of progressive cancers that currently have no 
effective therapy 
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2.6 Supporting Information  
 
Figure S1: T47D cells were tested 48 hours following transfection. DNA 
fragmentation was analyzed with the TUNEL assay. All constructs were corrected to 
staurosporine positive control, which is set at 100%. Statistical analysis comparing 
MTS-EGFP-p53 NLS mutation to MTS-EGFP-p53 was performed by unpaired t-test. 
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Figure S2. The 7-AAD assay was tested in (A) T47D and (B) MCF-7 cells 48 hours 
after transfection. Statistical analysis was performed by unpaired t-test. * p<0.05 for 
MTS-EGFP-p53 NLS mutation compared to its MTS-EGFP-p53. Except for CCO-
EGFP-p53 NLS mutation in T47D cells all constructs with NLS mutation were not 
statistically significant from constructs without mutations. The T47D data is 
consistent with luciferase assay (Figure 3A) and pifithrin-α rescue experiment (Figure 
8A). 
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3.1 Abstract 
The tumor suppressor p53 is one of the most studied proteins in human cancer (1-3). 
While nuclear p53 has been utilized for cancer gene therapy, mitochondrial targeting 
of p53 has not been fully exploited to date (4, 5). In response to cellular stress, p53 
translocates to the mitochondria and directly interacts with Bcl-2 family proteins 
including anti-apoptotic Bcl-XL and Bcl-2 and pro-apoptotic Bak and Bax (6). Anti-
apoptotic Bcl-XL forms inhibitory complexes with pro-apoptotic Bak and Bax 
preventing their homo-oligomerization (7). Upon translocation to the mitochondria, 
p53 binds to Bcl-XL, releases Bak and Bax from the inhibitory complex and 
enhances their homo-oligomerization (8). Bak and Bax homo-tetramer formation 
disrupts the mitochondrial outer membrane, releases anti-apoptotic factors such as 
cytochrome c and triggers a rapid apoptotic response mediated by caspase induction 
(9). It is still unclear if the MDM2 binding domain (MBD), the proline-rich domain 
(PRD) and/or DNA binding domain (DBD) of p53 are the domains responsible for 
interaction with Bcl-XL (10-17). The purpose of this work is to determine if a smaller 
functional domain of p53 is capable of inducing apoptosis similarly to full length p53. 
To explore this question, different domains of p53 (MBD, PRD, DBD) were fused to 
the mitochondrial targeting signal (MTS) from Bcl-XL to ensure Bcl-XL specific 
targeting (18). The designed constructs were tested for apoptotic activity (TUNEL, 
Annexin-V, and 7-AAD) in 3 different breast cancer cell lines (T47D, MCF-7, MDA-
MB-231), in a cervical cancer cell line (HeLa) and in non-small cell lung 
adenocarcinoma cells H1373. Our results indicate that DBD-XL (p53 DBD fused to 
the Bcl-XL MTS) reproduces (in T47D cells) or demonstrates increased apoptotic 
activity (in MCF-7, MDA-MB-231, and HeLa cells) compared to p53-XL (full length 
p53 fused to Bcl-XL MTS). Additionally, mitochondrial dependent apoptosis assays 
(TMRE, caspase-9), co-IP and over-expression of Bcl-XL in T47D cells suggest that 
DBD fused to XL MTS may bind to and inhibit Bcl-XL. Taken together, our data 
demonstrates for the first time that the DBD of p53 may be the minimally necessary 
domain for achieving apoptosis at the mitochondria in multiple cell lines. This work 
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highlights the role of small functional domains of p53 as a novel cancer biologic 
therapy. 
 
 
3.2 Introduction 
The tumor suppressor p53 is one of the most commonly mutated genes in all 
cancers (1-3). Although nuclear-mediated transcriptional activity has been 
extensively characterized, mitochondrial targeting of p53 has yet to be fully exploited 
as a therapeutic approach (4, 5). The main advantage of targeting p53 to the 
mitochondria is its ability to trigger a rapid apoptotic response, while in the nucleus 
p53 first has to form a tetramer, bind to DNA, and initiate transcription of various 
apoptotic genes. As a consequence of stress, p53 translocates to the mitochondria 
and initiates apoptosis through mitochondrial outer membrane permeabilization 
(MOMP) (6). Mitochondrial p53 directly interacts with anti- and pro-apoptotic 
members of the Bcl-2 family of proteins located in the mitochondrial outer 
membrane. In apoptosis resistant cells, the anti-apoptotic members, Bcl-XL, Bcl-2 
and Mcl-1 form heterodimers with pro-apoptotic proteins Bak and Bax, preventing 
apoptosis (7). To trigger MOMP, p53 binds to Bcl-XL, Bcl-2 and Mcl-1 and frees pro-
apoptotic Bak and Bax allowing them to oligomerize (8). Homo-tetramer formation of 
Bak and Bax in the mitochondrial outer membrane triggers the release of various 
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pro-apoptotic proteins such as cytochrome c. APAF-1 and cytochrome c form the 
apoptosome and activate caspase-9 that can initiate the caspase cascade resulting 
in programmed cell death (9).  
It is unclear which domains of p53 are directly responsible for triggering apoptosis at 
the mitochondria, presumably by interacting with anti-apoptotic Bcl-XL (11-15). The 
structure of p53 can be divided into amino terminus, DNA binding domain (DBD) and 
C-terminal region (Fig. 1A) (10). The amino terminus consists of the MDM2 binding 
domain (MBD) and the proline-rich domain (PRD). The C-terminal region encloses 
the tetramerization domain (TD) and three nuclear localization signals (NLS) (Fig. 
1A) (10). It has been reported that the DBD binds to anti-apoptotic Bcl-XL in the 
mitochondrial outer membrane and the PRD functions as an enhancer that improves 
this binding (11-13). However, the MBD has been also proposed as a binding partner 
for Bcl-XL which is enhanced by the PRD (14-17).  
To our knowledge, no one has attempted to target different domains of p53 to the 
mitochondria. Therefore, the purpose of this study is to determine if a smaller domain 
of p53 is capable of inducing apoptosis similar to full length p53 when targeted to the 
mitochondria. This will be achieved by fusing different domains of p53 (MBD, PRD, 
DBD, TD) to the mitochondrial targeting signal (MTS) from Bcl-XL (abbreviated XL) 
to ensure mitochondrial targeting (Fig. 1B) (18). This information will provide details 
on which domain is responsible for the rapid apoptotic response at the mitochondria. 
In addition to answering this mechanistic question, an overall goal is to decrease the 
size of the p53 construct for gene therapy purposes. 
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Figure 1: a: Schematic representation of wild type p53 (wt p53). The 393 amino 
acids of p53 are divided into amino terminus, DNA binding domain (DBD), and C-
terminal region. The MDM2 binding domain (MBD) and proline-rich domain (PRD) 
are located in the amino terminus. The tetramerization (TD) domain and the nuclear 
localization signals (NLSs) are located in the C-terminus. b: Schematic 
representation of the main experimental constructs and controls including the 
rational for design. p53-XL shows the structure of full length p53 with the enhanced 
green fluorescence protein EGFP on the amino terminus and the MTS from Bcl-XL 
(XL) on the C-terminus. All the other constructs contain various combinations of the 
different domains of p53, in addition to EGFP and XL. The negative control (E-XL) 
consists of only EGFP and XL.  
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3.3 Materials and Methods  
3.3.1 Cell Lines and Transient Transfections 
1471.1 murine adenocarcinoma cells (gift of G. Hager, NCI, NIH), T47D human 
ductal breast epithelial tumor cells (ATCC, Manassas, VA), MCF-7 human breast 
adenocarcinoma cells (ATCC) (18), MDA-MB-231 human breast adenocarcinoma 
cells (a generous gift from Dr. David Bearss, University of Utah), HeLa human 
epithelial cervical adenocarcinoma cells (ATCC), and H1373 human non-small lung 
carcinoma cells (a kind gift from Dr. Andrea Bild, University of Utah) were grown as 
monolayers in DMEM (1471.1) and RPMI (T47D, MCF-7, MDA-MB-231, HeLa, 
H1373) (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Invitrogen), 1% 
penicillin-streptomycin (Invitrogen), 1% glutamine (Invitrogen) and 0.1% gentamycin 
(Invitrogen). T47D and MCF-7 cells were additionally supplemented with 4 mg/L 
insulin (Sigma, St. Louis, MO). Cells were maintained in a 5% CO2 incubator at 
37ºC. 3.0 x 105 cells for T47D and MCF-7 cells, 1.0 x 105 cells for MDA-MB-231 and 
HeLa, 2.0 x 105 for H1373 were seeded in 6-well plates (Greiner Bio-One, Monroe, 
NC). Different amounts of cells were plated to account for varying cell growth rates in 
order to maximize transfection efficiency. Approximately 24 h after seeding, 
transfection was performed using 1 pmol of DNA per well and Lipofectamine 2000 
(Invitrogen) following the manufacturer’s recommendations.  
 
3.3.2 Plasmid Construction 
The main plasmids used in this work are depicted in Fig 1B. 
pEGFP-p53ΔC-XL (p53ΔC-XL): The DNA encoding p53ΔC (amino acids 1-322), a 
truncated version of wt p53 that lacks the C-terminus, was amplified via PCR with 
the primers 5’-GCGCGCGCGCTCCGGAATGGAGGAGCCGCAGTCA-3’ and 5’- 
GCGCGCGCGCGGTACCTCATGGTTTCTTCTTTGGCTGGGG-3’ using previously 
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subcloned pEGFP-p53 (18) as the template DNA. p53ΔC was cloned into pEGFP-XL 
(E-XL) (18) using BspEI and KpnI sites.  
pEGFP-DBD-XL (DBD-XL): The DNA encoding the DBD was amplified via PCR from 
pEGFP-p53-XL (p53-XL) (18) using 5’- 
CCGGGCCCGCGGTCCGGAACCTACCAGGGCAGCTACG-3’ and 5’- 
CCGGGCCCGCGGGGTACCTTTCTTGCGGAGATTCTCTTCCT and cloned into E-
XL (18) using BspEI and KpnI sites. 
pEGFP-PRD-DBD-XL (PRD-DBD-XL): The DNA encoding the PRD-DBD was 
amplified using PCR from p53-XL (18) with the primers 5’-
GCGCGCGCGCGGTACCGCTCCCAGAATGCCAGAGGC-3’ and 5’- 
GCGCGCGCGCGGATCCTTTCTTGCGGAGATTCTCTT and cloned into E-XL (18) 
at the KpnI and BamHI site. 
pEGFP-TD-XL (TD-XL): The DNA encoding the TD was amplified via PCR from 
previously subcloned p53-XL (18) using 5’-
GCGCGCGCGCGGGATCCGGCTGGATGGAGAATATTTCACCCTTCA-3’ and 5’-
GCGCGCGCGCGGGAtCCTCACCCAGCCTGGGCATCCTT-3’ and cloned into E-XL 
(18) at the BamHI site. 
pEGFP-MBD-PRD-XL (MBD-PRD-XL): Previously subcloned p53-XL (18) was 
mutated via site-directed mutagenesis using the QuikChange II XL Site directed 
Mutagenesis Kit (Agilent, Santa Clara, CA) using 5’ 
TCCCTTCCCAGAAAAGGTACCAGGGCAGCTACGGT-3’ and its reverse 
complement to introduce an additional KpnI site (mutations underlined). Then the 
DBD and C-terminus were digested out using KpnI. Additionally, a frame shift 
mutation was corrected (one base pair deletion) by mutating the cloned plasmid 
using 5’-
TCGAGCTATGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAACGGAATTCT
G-3’ and its complementary strand via site-directed mutagenesis.  
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pEGFP-PRD-XL (PRD-XL): MBD-PRD-XL was mutated via site-directed 
mutagenesis using 5’ 
TTCACTGAAGACCCAGGTCCATCCGGAGCTCCCAGAATGCCAGA-3’ and its 
complementary strand to introduce an additional BspEI site. The MBD was cut out 
with BspEI to create PRD-XL 
pEGFP-CC (E-CC): pEGFP-CC was subcloned as before (19). 
pBFP-Bcl-XL (BFP-Bcl-XL): Bcl-XL was digested out from pSFFV-neo-Bcl-XL (gift 
from Dr. S. Korsmeyer, Addgene, Cambridge, MA) with EcoRI and cloned into the 
EcoRI site of the pTagBFP-C vector (Evrogen, Moscow, Russia). A frame shift 
mutation was conducted (one base pair addition) by mutating the cloned plasmid 
using 5’- TCTCGAGCTCAAGCTTCGAATTCATTGGACAATGG-3’ and its 
complementary strand via site-directed mutagenesis. 
 
3.3.3 Mitochondrial Staining, Microscopy, and Image Analysis  
Before live-cell imaging and mitochondrial staining of transfected cells was 
performed, media in live cell chambers was replaced with phenol red-free DMEM 
(Invitrogen) for 1471.1 cells or phenol red-free RPMI (Invitrogen) for T47D and MCF-
7 cells containing 10% charcoal stripped fetal bovine serum (CS-FBS, Invitrogen). 
Cells were incubated with 150 nM MitoTracker Red FM (Invitrogen) for 15 min at 37 
°C and protected from light. As previously, images were acquired using an Olympus 
IX71F fluorescence microscope (Scientific Instrument Company, Aurora, CO) with 
high quality (HQ) narrow band GFP filter (ex, HQ480/20 nm; em, HQ510/20 nm) and 
HQ:TRITC filter (ex, HQ545/30; em, HQ620/60) from Chroma Technology 
(Brattleboro, VT) with a 40× PlanApo oil immersion objective (NA 1.00) on an F-View 
Monochrome CCD camera (19-21). 
ImageJ software and JACoP plugin was used to analyze images for mitochondrial 
stain overlap with EGFP fusion constructs (18, 22-24). As previously, JACoP was 
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used to generate the colocalization statistic [i.e., Pearson’s correlation coefficient 
(PCC) post Costes’ automatic threshold algorithm] (23-27). PCC evaluates 
correlation between pairs of individual pixels from EGFP and MitoTracker stained 
cells. The higher the PCC value, the higher the correlation. According to Costes a 
PCC value of 0.6 or greater determines colocalization between a cellular 
compartment and the designed protein (25). Spatial representations of pixel intensity 
correlation have been generated using Colocalization Color map (ImageJ) for 
increased visual clarity of mitochondrial localization of the EGFP-fused constructs 
(28). Microscopy was repeated in triplicate (n = 3), and 10 cells were analyzed for 
each construct. 
 
3.3.4 7- AAD Assay 
Transfected T47D, MCF-7, MDA-MB-231, HeLa and H1373 cells were pelleted and 
resuspended in 500 μL PBS (Invitrogen) containing 1 μM 7-aminoactinomycin D (7-
AAD) (Invitrogen) for 30 min prior to analysis following the recommended protocol 
from the manufacturer. The assay was performed 48 h after transfection for T47D 
(18), MCF-7 (18) and H1373 and 24 h after transfection for MDA-MB-231 and HeLa. 
Only EGFP positive cells were analyzed by using the FACS Canto-II (BD- 
BioSciences, University of Utah Core Facility) with FACS Diva software. EGFP and 
7-AAD were excited with the 488 nm laser, and were detected at 507 nm and 660 
nm, respectively. Independent transfections of each construct were tested three 
times (n=3). 
 
3.3.5 Annexin V Assay 
48 h after transfection, T47D cells were pelleted and resuspended in 400 μL of 
annexin-V binding buffer (Invitrogen) and incubated with 5 μL of annexin-APC 
(annexin-V conjugated to allophycocyanin, Invitrogen) for 15 min as before (18). 
Only transfected cells were analyzed as mentioned in 7-AAD assay. EGFP and APC 
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were excited at 488 nm and 635 nm wavelengths, respectively and detected at their 
corresponding 507 nm and 660 nm wavelengths. Independent transfections of each 
construct were tested three times (n=3).  
 
3.3.6 TUNEL Assay 
T47D cells were harvested 48 h after transfection. In situ Death Detection Kit, TMR 
red (Roche, Mannheim, Germany) was used following manufacturer’s 
recommendations as before (18, 24). Cells were resuspended in PBS (Invitrogen) 
and analyzed via the FACSAria-II (BD-Biosciences, University of Utah Core Facility). 
EGFP and TMR red were excited at 488 nm and 563 nm, respectively, and 
FACSDiva software was used to analyze the data.  Independent transfections of 
each construct were tested three times (n=3). 
 
3.3.7 Colony Forming Assay (CFA) 
Transfected T47D cells were harvested 24h post transfection and resuspended in 
RPMI (Invitrogen) at a concentration of 3.0 x 105 cells/mL. The Cytoselect® 96-well 
cell transformation assay (Cell Biolabs, San Diego, CA) was used following 
manufacturer’s recommendations. Equal amount of 1.2% Agar Solution, 2X 
DMEM/20% FBS media, and cell suspension (1:1:1) were mixed and 75 μL of the 
mixture was added to a 96-well plate containing a solidified base agar layer (50 μL of 
previously solidified1.2% Agar Solution), and allowed to solidify at 4ºC for 15 min. 
The following steps were performed according to the manufacture’s 
recommendations. A Spectra Max M2 plate reader (Molecular Devices, Sunnyvale, 
CA) was used to detect fluorescence using a 485/520 nm filter set. Independent 
transfections of each construct were tested three times (n=3). 
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3.3.8 TMRE Assay 
36 h after transfection T47D cells were incubated with 100 nM 
tetramethylrhodamineethylester (TMRE) (Invitrogen) for 30 min at 37ºC (29). T47D 
cells were pelleted and resuspended in 300 μL annexin-V binding buffer (1X) 
(Invitrogen). Only EGFP positive cells were analyzed by using the FACS Canto-II 
(BD- BioSciences, University of Utah Core Facility) with FACS Diva software. EGFP 
was excited with the 488 nm laser with emission filter 530/35 and TMRE was excited 
with the 561 nm laser with the emission filter 585/15. Mitochondrial depolarization 
(loss in TMRE intensity) correlates with an increase in MOMP. Independent 
transfections of each construct were tested three times (n=3).  
 
3.3.9 Caspase-9 Assay  
T47D cells were probed 48 h after transfection using SR FLICA Caspase-9 Assay Kit 
(Immunochemistry Technologies, Bloomington, MN) (30, 31). Cells were incubated 
with SR FLICA Caspase-9 reagent for 60 min per manufacturer’s recommendations, 
pelleted and resuspended in 300 µL 1X wash buffer (Immunochemistry 
Technologies). Only EGFP positive cells were analyzed by using the FACS Canto-II 
(BD- BioSciences, University of Utah Core Facility) with FACS Diva software. EGFP 
and FLICA were excited with the 488 nm (emission filter 530/35) and the 561 laser 
(emission filter 585/15), respectively. Independent transfections of each construct 
were tested three times (n=3). 
 
3.3.10 Co-Immunoprecipitation (Co-IP) 
Anti-GFP antibody (ab290, Abcam) was coupled to dynabeads using Dynabeads 
Antibody Coupling Kit (Invitrogen). 24 h post transfection, T47D cells were prepared 
using the Dynabeads Co-Immunoprecipitation Kit (Invitrogen). Cell pellets were lysed 
using extraction buffer B (1 x IP, 100 nM NaCl, 2 mM MgCl2, 1 mM DTT, 1% 
protease inhibitor). The lysate was incubated for 30 min at 4ºC with 1.5 mg of 
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dynabeads coupled with anti-GFP antibody, and co-IP was performed per the 
company’s protocol. The final protein complex was denatured and western blot was 
performed (19) by using Bcl-XL antibody (ab 2568, Abcam).  
 
3.3.11 Rescue Experiment using BFP-Bcl-XL 
T47D cells were co-transfected with 1 pmol of EGFP constructs and 1 pmol of BFP-
Bcl-XL (BFP tag is necessary for gating Bcl-XL transfected cells). 48 h after 
transfection the 7-AAD assay was performed as described above. FACSCanto-II 
(BioSciences, University of Utah Core Facility) and FACSDiva software were used 
for EGFP and BFP gating. Excitation was set at 488 nm, and detected at 507 nm 
and 660 nm for EGFP and 7-AAD, respectively. BFP was excited at 405 nm and 
detected at 457 nm. Independent transfections of each construct were tested three 
times (n=3). 
 
3.3.12 Statistical Analysis 
All experiments were conducted in a triplicate (n=3). Statistical significance was 
determined by one-way analysis of variance (ANOVA) with Tukey’s or Bonferroni’s 
post test as indicated in figure legends; Student t-test was used to analyze the 
rescue experiment data. The degree of colocalization was analyzed using odds ratio 
with Pearson’s Chi-square. A p value <0.05 was considered significant. 
 
3.4 Results  
3.4.1 Mitochondrial localization of single domain constructs 
Different domains of p53 (Fig. 1B) were fused to the MTS from Bcl-XL (abbreviated 
XL) (18) and tested for their mitochondrial localization. Mitochondrial targeting of 
these constructs (Fig. 1) was determined by fluorescence microscopy as previously 
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(18, 23, 24). Figure 2A illustrates representative 1471.1 cells, which are large in size, 
spread well, and are optimal for microscopy. However, similar microscopy results 
were observed in T47D cells (data not shown). Figure 2B shows colocalization of the 
EGFP fused constructs with mitochondria which were generated using Pearson’s 
correlation coefficient (PCC) following the example of Bolte and Cordeli res and 
graphed for each construct (22, 25, 26). PCC values range from +1 (perfect 
correlation) to -1 (anticorrelation), and a PCC value of zero represents random 
distribution (22). Costes et al. have shown that a PCC of 0.6 or greater defines 
colocalization, or co-compartmentalization (Figure 2B) (25). Figure 2 shows that all 
designed single domain constructs translocate into the mitochondria, as expected. 
EGFP served as negative control for colocalization analysis, and there was no 
colocalization between EGFP alone and the mitochondria. Even though p53 is a 
nuclear protein containing three nuclear localization signals (NLSs), the XL MTS is 
strong enough to overcome nuclear targeting and directs p53-XL to the mitochondria 
(Fig. 1 and ref. (18)).  
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Figure 2: Colocalization of EGFP constructs and MitoTracker Red mitochondrial 
stain in 1471.1 cells. (A) Representative images of MBD-XL, PRD-XL, DBD-XL, TD-
XL, p53-XL, E-XL and EGFP are shown in the left column with images of 
MitoTracker Red distribution in the middle column. The “EGFP” and “MitoTracker” 
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columns have been false colored green and red, respectively. Enhanced 
visualization of colocalized pixels is rendered in the “Color Map” column. Warm 
colors depict pixels with highly correlated intensity and spatial overlap while cool 
colors are indicative of anticorrelation or random correlation (color bar for 
interpretation is shown below column). Corresponding PCC values are shown in the 
right column. White scale bars are all 10 μm. (B) The degree of colocalization is 
represented by PCC following Costes’ approach. All constructs with values higher 
than 0.6 are considered highly colocalized with mitochondrial stain MitoTracker Red. 
Statistical analysis was performed by using odds ratio with Pearson’s Chi-square. 
The adjusted odds ratio for PCC value of 0.6 was compared with each sample. *p < 
0.05, and **p < 0.01comparing odds ratio of lowest value for samples with odds ratio 
of 1 for PCC of 0.6. 
 
3.4.2 Screening the mitochondrial activity of different p53 domains via 7-AAD 
To determine if a subdomain of p53 was capable of evoking a similar apoptotic 
activity as wild type p53, different domains of p53 (Fig. 1B) fused to XL and 
combinations of them were tested for apoptosis using the 7-AAD viability assay in 
T47D human breast cancer cells. 7-AAD is a late apoptosis/necrosis assay which 
allows for distinguishing between apoptotic/necrotic (ruptured plasma membrane) 
and healthy (intact plasma membrane) cells. If the plasma membrane is disrupted, 
the 7-AAD dye intercalates with nuclear DNA of apoptotic/necrotic cells (32, 33). 
Figure 3 demonstrates that all constructs containing DBD (PRD-DBD-XL, DBD-XL, 
and p53ΔC-XL) are statistically higher than the negative control E-XL. Additionally, 
these three constructs are not statistically different from p53-XL (positive control) 
indicating that all constructs containing the DBD show similar apoptotic potential to 
p53-XL (Fig. 3). Further, MBD-XL, MBD-PRD-XL, and PRD-XL are not statistically 
significant from the negative control E-XL suggesting no apoptotic activity (Fig. 3). 
Interestingly, TD-XL is statistically different from the negative controls but is also 
significantly lower than p53-XL (Fig. 3).  
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Data from figure 3 illustrate that there is no difference in activity between the single 
domains (MBD-, PRD-, DBD-, TD; 1st, 3rd, 5th, 6th bars, respectively) versus 
combinations of the domains (MBD-PRD, PRD-DBD, p53ΔC; 2nd, 4th, 7th bars, 
respectively) when fused to XL. Therefore, we proceeded with the single domain 
constructs (i.e. MBD-XL, PRD-XL, DBD-XL, and TD-XL) for the remaining 
experiments.  
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Figure 3: The 7-AAD assay was analyzed in T47D cells 48 h after transfection. 
Statistical analysis were conducted by one-way ANOVA with Tukey’s post test. ***p 
< 0.001. PRD-DBD-XL, DBD-XL, p53ΔC-XL and p53-XL were not statistically 
significant from each other. MBD-XL, MBD-PRD-XL, PRD-XL, and TD-XL are 
statistically significantly lower than p53-XL. 
 
3.4.3 Exploring the apoptotic potential of designed constructs  
To test the apoptotic potential of our designed single domain constructs (Fig. 1B), 
the externalization of phoshatidylserine on the cell surface of apoptotic cells was 
measured via annexin V staining 48 h after transfection (18, 34). DBD-XL showed a 
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significantly higher apoptotic response than p53-XL (Fig 4A). Additionally, both 
constructs were significantly higher than the negative control E-XL whereas MBD-
XL, PRD-XL and TD-XL were not statistically significant from the negative control 
(Fig 4A).  
Further, the fragmentation of nuclear DNA was measured utilizing terminal 
deoxynucleotidyl transferase dUTP labeling (TUNEL) which tags the terminal end of 
nucleic acids. DNA fragmentation occurs when a cell is undergoing apoptosis, and 
the cellular DNA is cleaved by caspases (35). The TUNEL assay was conducted 48 
h after transfection. Figure 4B shows that both p53-XL and DBD-XL have similar 
activities and are significantly higher than E-XL while MBD-XL, PRD-XL and TD-XL 
are not statistically different from the negative control.  
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Figure 4: (A) Apoptotic potential was tested in T47D cells 48 h after transfection via 
annexin V assay. Statistical analysis was performed using one-way ANOVA with 
Tukey’s post test with * p < 0.05. (B) Apoptotic potential was tested in T47D cells 48 
h after transfection via TUNEL-assay. Statistical analysis was performed using one-
way ANOVA with Tukey’s post test with * p < 0.05, *** p < 0.001. p53-XL and DBD-
XL were not statistically significant from each other. MBD-XL, PRD-XL, and TD-XL 
are statistically significantly lower than p53-XL. 
 
3.4.4 Testing the oncogenic potential 
To test the potential of designed constructs to inhibit the transforming ability of 
cancer cells, a colony forming assay was carried out in T47D cells eight days after 
treatment. As expected, p53-XL and DBD-XL showed significant decrease in 
transformative ability of T47D cells represented by fewer colonies (reduction in 
relative fluorescence units) compared to E-XL (Fig. 5). All the other small domain 
constructs failed to reduce cell proliferation similar to the negative control E-XL. 
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Figure 5: Transformative ability of T47D cells was determined 8 d after transfection 
of T47D cells via colony forming assay. Statistical analysis was accompanied using 
one-way ANOVA with Tukey’s post test *** p < 0.001. 
 
3.4.5 The ability of DBD-XL to induce late stage apoptosis is not cell line 
specific 
To ensure that the ability of DBD-XL to induce apoptosis is not cell line- or cancer 
cell type specific, a 7-AAD assay was conducted in breast cancer cells (MCF-7, 
MDA-MB-231), cervical adenocarcinoma cells (HeLa) and human non-small cell lung 
adenocarcinoma (H1373). T47D and MDA-MB-231 both express mutant p53, with 
the mutations restricted to the DBD (L194F in T47D (36) and R280L in MDA-MB-231 
(37)). These mutations reduce the activity of tumor suppressor activity substantially 
and cause these cells to be more resistant to apoptosis than MCF-7 and HeLa (38). 
Additionally, MCF-7 harbor mislocalized p53 in the cytoplasm (38), HeLa have 
endogenous wt p53 (39) and H1373 are p53 null (40). 
Since MDA-MB-231 and HeLa are highly proliferating cells, both cell lines were 
assayed 24 h after transfection while T47D, MCF-7 and H1373 cells were assayed 
48 h post transfection (optimal time points determined empirically). 
Interestingly, DBD-XL showed significantly higher apoptotic activity compared to 
p53-XL in MCF-7 (Fig. 6A), MDA-MB-231(Fig. 6B) and H1373 (Fig. 6D). In HeLa 
cells, DBD-XL (and PRD-XL) were both statistically significant from p53-XL (Fig. 5C). 
These results are consistent with the apoptosis data from T47D cells (Figs. 3, 4A, 
and 4B) and show that DBD-XL is capable of inducing late stage apoptosis in four 
cell lines which differ in their endogenous p53 status, similarly to p53-XL. 
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Figure 6: 7-AAD assay was conducted in (A) MCF-7, (B) MDA-MB-231, (C) HeLa 
and (D) H1373. Statistical analysis was performed using one-way ANOVA with 
Tukey’s post test ** p < 0.01 and *** p < 0.001. 
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3.4.6 The apoptotic activity of DBD-XL is triggered via the mitochondrial/ 
intrinsic pathway 
To determine that constructs-induced apoptotic effects are through the mitochondria 
TMRE and caspase-9 assays were performed. The DBD-XL was the only single 
domain construct that showed the same or higher apoptotic potential as p53-XL 
consistently in all tested cell lines. Therefore, we proceeded to investigate only the 
mechanism for DBD-XL compared to p53-XL for our further studies. 
To ensure that DBD-XL causes MOMP in the same manner as p53-XL, the TMRE 
assay (analogous to the JC-1 assay) was used (41). TMRE is a cell-permeant, 
cationic, red-orange fluorescent dye that rapidly accumulates in mitochondria of 
living cells due to the negative mitochondrial membrane potential (ΔΨm) of intact 
mitochondria compared to cytosol (29, 42, 43). Mitochondrial depolarization results 
in a loss of TMRE from mitochondria and a decrease in mitochondrial fluorescence 
intensity (FI) (42). The mitochondrial membrane permeabilization (loss of FI) was 
illustrated as %MOMP induction on the y-axis. DBD-XL and p53-XL have similar 
activity and are significantly higher than E-XL (Fig. 7A).  
Further the activation of caspase-9 was measured. Caspase-9 is only triggered 
through the intrinsic apoptotic pathway. Once cytochrome c is released from the 
mitochondria, caspase-9 is the first effector caspase downstream of cytochrome c 
(44). Caspase-9 itself cleaves the peptide sequence leucine-glutamic acid-histidine-
aspartic acid (LEHD) which is used in the caspase-9 assay to measure the intrinsic 
apoptotic pathway (45). DBD-XL and p53-XL show higher caspase-9 activation than 
E-XL (Fig. 7B). However, p53-XL triggers caspase-9 activation significantly more 
than DBD-XL (Fig. 7B). A proposed explanation for this effect will be explained 
further in the discussion.  
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Figure 7: (A) Mitochondrial depolarization correlates with an increase in MOMP (as 
measured by TMRE). T47D cells were transfected with mitochondrial constructs and 
assayed using TMRE 36 h post transfections. (B) The activation of caspase-9 was 
analyzed 48 h following transfection of T47D cells. Statistical analysis was performed 
by using one-way ANOVA with Bonferroni’s post test ** p < 0.01 and *** p < 0.001. 
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3.4.7 Investigating the apoptotic mechanism via co-IP and overexpression of 
Bcl-XL 
To explore the apoptotic mechanism of our constructs, a co-IP was conducted (Fig. 
8A). p53-XL, E-XL and E-CC (a negative control that does not contain the XL signal 
(19)) were transfected into T47D cells. T47D cells express the highest amount of 
endogenous Bcl-XL protein compared to MCF-7, MDA-MB-231 and HeLa (see the 
Supporting Information: S1). Approximately 24 h after transfection cells were lysed 
and incubated with anti-GFP antibody. A western blot was performed against EGFP 
(which is fused to all the constructs) and against Bcl-XL. Endogenous Bcl-XL (26 
kDa) was expected to co-immunoprecipitate with exogenous p53-XL (75 kDa) due to 
its ability to induce apoptosis, while Bcl-XL should not co-immunoprecipitate with the 
negative control E-XL. Surprisingly, Bcl-XL co-immunoprecipitated with E-XL (32 
kDa) just as p53-XL did (Fig. 8A, lane 1 and 2). To address if the binding is due to 
the mitochondrial targeting signal which was originally taken from the Bcl-XL protein, 
another negative control E-CC was used, which does not contain a MTS. EGFP (27 
kDa) could not be used as a negative control because it is too close in size to Bcl-XL 
(26 kDa) and would not be distinguishable on the gel. Bcl-XL did not co-
immunoprecipitate with E-CC (Fig 8A, lane 3) implying that the binding of E-XL to 
Bcl-XL was due to the XL mitochondrial targeting signal.  
To further explore the apoptotic mechanism of DBD-XL and p53-XL at the 
mitochondria, Bcl-XL was overexpressed in T47D cells. The apoptotic activity was 
measured by 7-AAD. Cells transfected with just p53-, DBD-, or E-XL were compared 
to cells cotransfected with either of these constructs and with BFP-Bcl-XL. It was 
expected that the apoptotic potential of the constructs that are undergoing apoptosis 
through the p53/Bcl-XL pathway would be rescued by Bcl-XL overexpression. 
Indeed, DBD-XL and p53-XL apoptotic activities were significantly reduced when 
BFP-Bcl-XL was cotransfected (Fig. 8B). However, E-XL was not rescued by 
cotransfection of BFP-Bcl-XL (Fig. 8B).  
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Figure 8: (A) Representative cropped western blot of protein complexes co-
immunoprecipitated using anti-GFP antibody. Lane 1, exogenous p53-XL (75 kDa) 
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which was transfected into T47D cells co-immunoprecipitates with endogenous Bcl-
XL (26 kDa). Lane 2, exogenous E-XL (32 kDa) co-immunoprecipitates with 
exogenous Bcl-XL (26 kDa). Lane 3 exogenous E-CC (35 kDa) fails to co-
immunoprecipitate with endogenous Bcl-XL. Unlabeled bands are nonspecific 
binding. (B) Rescue experiment using Bcl-XL. 7-AAD assay was conducted 48 h 
post transfection in T47D cells. Statistical analysis was tested via unpaired t-test ** p 
< 0.01 and *** p < 0.001. 
 
3.5 Discussion 
Our laboratory has previously shown that targeting p53 to anti-apoptotic Bcl-XL is 
best achieved by using the MTS from Bcl-XL (18). Additionally, we validated that the 
XL signal is the only MTS that has no inherent toxicity by itself since it is targeting 
the outer surface of the mitochondrial outer membrane (18). Mitochondrial targeting 
of proteins to this region does not disrupt the sensitive balance of the mitochondria 
as reported with other MTSs (46-49). As an approach to determine which domain of 
p53 is capable of inducing apoptosis similar to p53-XL, different domains of p53 
were fused to XL. To our knowledge, this is the first attempt to target different 
domains of p53 to the mitochondria.  
Here, we have shown that our designed constructs translocate to the mitochondria 
(Fig. 2) and that any construct that contains the DBD of p53 is capable of inducing 
apoptosis similar to wt p53 (Fig. 3). It has been suggested that a combination of 
different domains of p53 is necessary for its apoptotic function and interaction with 
Bcl-XL at the mitochondria (11-13). For instance, the PRD is thought to enhance the 
binding of p53 to Bcl-XL (17). However, our data (Fig. 3) clearly validates that the 
DBD region without the PRD region of p53 is sufficient to induce the full 
mitochondrial apoptotic function of p53. Even though the PRD was reported to 
enhance the binding of MBD and DBD to Bcl-XL, it did not have any effect on 
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increasing the apoptotic potential. Hence, individual domains of p53 (Fig.1B) instead 
of combinations of domains were used in the remaining apoptotic assays. 
Since the 7-AAD assay (Fig. 3) does not distinguish between apoptotic and necrotic 
cells, early apoptosis assays (annexin V and TUNEL) were conducted to verify that 
our designed constructs are causing cell death via apoptosis and not necrosis. 
Indeed, DBD-XL showed the same (Fig. 4B) or higher (Fig. 4A) apoptotic activity 
compared to p53-XL in human breast cancer cells (T47D). To further validate the 
tumor suppressor function of our constructs and their ability to inhibit proliferation, a 
colony forming assay was conducted. As expected, DBD-XL showed similar 
reduction in transformative ability as p53-XL in T47D breast carcinoma cells (Fig. 5). 
To ensure that the increase in apoptotic activity is not cell line, cancer type or p53 
status dependent, four different cancer cell lines (MCF-7, MDA-MB-231, HeLa, 
H1373) were tested. Surprisingly, DBD-XL induces late stage apoptosis significantly 
higher than p53-XL in all tested cell lines except T47D (Fig. 6). The p53/MDM2 
pathway might offer an explanation to why DBD-XL shows higher apoptotic activity 
compared to p53-XL. MDM2, an ubiquitin ligase (E3) binds to the MBD domain of 
p53 and helps to transfer ubiquitin from E2 to lysine residues on the carboxy 
terminus of p53. Ubiquinated p53 is dragged to the proteasome for degradation (50, 
51). DBD-XL may evade degradation by MDM2 since it lacks the MBD and C-
terminal domain, allowing for higher stability and consequently increased apoptotic 
activity. Hagn et al. showed that the amino acids of p53 responsible for interacting 
with Bcl-XL are located in the DBD of p53 (Gly117, Ser121, Cys176, His178, 
Asn239, Met243, Arg248, Gly279, and Arg280) and the contact sites on Bcl-XL are 
residues Ser18, Tyr22, Ser23, Gln26, and Ser28 in helix 1 and 2, Ile114 between 
helix 3 and 4, and Val155, Asp156, and Glu158 in helix 5 (11). Consequently, DBD-
XL contains the residues important for interaction with Bcl-XL while lacking the 
domains responsible for degradation. 
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Alternatively, the anti- oxidative role of p53 might offer an explanation to why p53-XL 
shows lower apoptotic activity compared to DBD-XL. In healthy cells, basal p53 
expression limits oxidative stress and promotes cell survival (52). p53 upregulates 
the expression of genes involved in the oxidative stress survival pathways such as 
GPX1 (53), SOD2 (53), ALDH4A1 (54), INP1 (55), TIGAR (56), Hi95 (57) and PA26 
(57). Even though all designed constructs translocate into the mitochondria (Fig 2), a 
small fraction could still enter the nucleus. Our previous publication shows that p53-
XL remains some residual transcriptional activity (18). Unlike p53-XL which contains 
full length p53, DBD-XL is not capable of transcribing genes because it lacks the TD 
to form the transcriptionally active tetrameric p53 and the PRD which enhances 
transcription of various genes. This could provide another explanation why DBD-XL 
(which does not activate gene expression) shows higher apoptosis than p53-XL 
(which could upregulate the expression of genes involved in preventing oxidative 
stress).  
Furthermore, the “mitochondrial priming theory” suggests that some cancer cells 
such as MCF-7 cells are inherently more sensitive to cytotoxic drugs than other cells 
(38, 58, 59). This response correlates with the sensitive balance of anti- and pro-
apoptotic Bcl-2 family members at the mitochondrial outer membrane (58, 59). It is 
known that T47D (60), MCF-7 (61, 62), MDA-MB-231 (62) and HeLa (61) express 
anti-apoptotic Bcl-XL. Therefore, we compared the expression levels of Bcl-XL in 
T47D (60), MCF-7 (61, 62), MDA-MB-231 (62) and HeLa (61) (see the Supporting 
Information: S1). Indeed, T47D cells had the highest expression level of Bcl-XL 
confirming that they are “less primed” and more resistant to apoptosis. 
Since the DBD-XL shows similar or higher apoptotic activity (measured by TUNEL, 
annexin V and 7-AAD) compared to p53-XL consistently in every tested cell line (Fig. 
3, 4, and 6), we wanted to examine if the effect on cell death is due to a 
mitochondrial dependent mechanism. DBD-XL triggers more caspase-9 activation 
than the negative control E-XL (Fig. 7B) but surprisingly less caspase-9 induction 
than p53-XL (Fig. 7B). Even though p53-XL caspase activity is higher, this is a 
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transient effect that is not reflected in the more “final” apoptotic assays (Fig. 3,4,6). 
Additionally, a certain threshold of caspase 9 activation achieved by DBD-XL may be 
sufficient to induce cell death. Furthermore, DBD-XL induces MOMP to the same 
extent as p53-XL, suggesting that DBD-XL dependent apoptosis occurs through the 
intrinsic apoptotic pathway and might be through a direct interaction with Bcl-XL (Fig 
7A). As described above, p53-XL could possibly be degraded via the proteasome. 
Once MDM-2, an ubiquitin ligase, binds to the MBD of p53, the C-terminal region of 
p53 becomes ubiquitinated and p53 is dragged into the proteasome for degradation 
(50, 51). This could explain why initially p53-XL causes more caspase-9 activation 
(Fig. 7A) but this difference in activity is not reflected in the more “final” apoptosis 
assays where DBD-XL shows even higher apoptosis activity compared to p53-XL 
(Fig. 6). 
In an effort to determine if the apoptotic potential of our designed constructs is due to 
their interaction with Bcl-XL or if it is independent of the p53/Bcl-XL pathway, we 
conducted a co-IP and a rescue experiment achieved by overexpressing Bcl-XL. 
Interestingly, Bcl-XL co-immunoprecipitated with the "negative control" E-XL in the 
same manner as p53-XL (Fig. 8A). We hypothesize that the interaction with Bcl-XL is 
independent of p53 and it is mainly due to the XL MTS which will directly target every 
protein that contains XL to Bcl-XL. To investigate this hypothesis, E-CC (a negative 
control lacking the XL signal) was created. As expected, E-CC did not bind to Bcl-XL 
(Fig.8A), confirming that the XL signal is responsible for the interaction with Bcl-XL. 
To prove indirectly that the apoptotic mechanism of p53- and DBD-XL are through 
direct interaction of p53 and DBD with Bcl-XL, a rescue experiment using 
overexpressed Bcl-XL was conducted. As expected the apoptotic activity of MBD-, 
PRD- and E-XL was not altered by Bcl-XL overexpression (see the Supporting 
Information: S2). However, DBD-XL, p53-XL (and even TD-XL) demonstrated 
reduction in apoptotic potential, further demonstrating the necessity of Bcl-XL for 
apoptosis initiation (Fig 8B, S2). Even though TD-XL showed significantly lower cell 
death compared to p53-XL, it was still significantly higher than the negative control 
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E-XL, and was still rescued by Bcl-XL (S2). It could be speculated that TD-XL binds 
to endogenous, mutant p53 through its TD and drags it to the mitochondria where it 
potentially interacts with Bcl-XL and triggers marginal apoptosis (63). Even though 
endogenous, mutant p53 is transcriptionally inactive in T47D cells due to the 
presence of the L194F mutation, this mutant p53 could still be active at the 
mitochondria, since the L194 residue is not involved in the interaction between p53 
and Bcl-XL (11). 
In summary, DBD-XL shows the same (T47D) or higher (MCF-7, MDA-MB-231, 
HeLa, H1373) apoptotic activity compared to p53-XL. Mechanistic studies suggest 
that DBD-XL may bind and trigger apoptosis similar to p53 through the Bcl-XL 
dependent pathway. Our data highlights that DBD (about half the size of full length 
p53) can be used instead of p53 for achieving apoptosis at the mitochondria when 
fused to the MTS from Bcl-XL. The benefit of decreasing the overall size of p53 by 
half while still maintaining full apoptotic activity allows for better drug delivery 
options. The next goal is to use DBD-XL as a therapeutic in vivo using adenoviral 
drug delivery. In conclusion, we show for the first time that DBD-XL can be used to 
trigger a potent, rapid apoptotic response in various cancer cell lines (including 
breast, cervical and lung carcinomas) with different p53 status, and is an alternative 
to wt p53 gene therapy. Importantly, the mechanism of DBD-XL-mediated apoptosis 
is distinctly different from conventional wild type p53 and represents a novel 
approach for cancer therapy. 
 
3.6 Supporting Information  
Additional figures depicting different endogenous expression levels of Bcl-XL can be 
found in Supplementary Figure 1. Rescue experiment including MBD-, PRD-, DBD-, 
TD-, p53- and E-XL can be found in Supplementary Figure 2.  
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S1 Expression levels of Bcl-XL in T47D, MCF-7, HeLa and MDA-MB231 determined 
by western blot.  
 
S2 Rescue experiment: T47D cells transfected either with or without Bcl-XL and 
MBD-XL, PRD-XL, DBD-XL, TD-XL, p53-XL and E-XL. 48 h post transfection 7-AAD 
assay was conducted. Statistical analysis was performed by using two-way ANOVA 
with Bonferroni’s post test; ** p < 0.01, *** p < 0.001.  
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4.1 Abstract 
p53 targeted to the mitochondria is the fastest and most direct pathway for executing 
p53 death signaling. The purpose of this work was to determine if mitochondrial 
targeting signals (MTSs) from pro-apoptotic Bak and Bax are capable of targeting 
p53 to the mitochondria and inducing rapid apoptosis. 
p53 and its DNA-binding domain (DBD) were fused to MTSs from Bak (p53-
BakMTS, DBD-BakMTS) or Bax (p53-BaxMTS, DBD-BaxMTS). Mitochondrial 
localization was tested via fluorescence microscopy in 1471.1 cells, and apoptosis 
was detected via 7-AAD in breast (T47D), non-small cell lung (H1373), ovarian 
(SKOV-3) and cervical (HeLa) cancer cells. To determine that apoptosis is via the 
intrinsic apoptotic pathway, TMRE and caspase-9 assays were conducted. Finally, 
the involvement of p53/Bak specific pathway was tested. 
MTSs from Bak and Bax are capable of targeting p53 to the mitochondria, and p53-
BakMTS and p53-BaxMTS cause apoptosis through the intrinsic apoptotic pathway. 
Additionally, p53-BakMTS, DBD-BakMTS, p53-BaxMTS and DBD-BaxMTS caused 
apoptosis in T47D, H1373, SKOV-3 and HeLa cells. The apoptotic mechanism of 
p53-BakMTS and DBD-BakMTS was Bak dependent.  
Our data demonstrates that p53-BakMTS (or BaxMTS) and DBD-BakMTS (or 
BaxMTS) cause apoptosis at the mitochondria and can be used as a potential gene 
therapeutic in cancer. 
 
4.2 Introduction  
The tumor suppressor p53 exhibits distinct functions at the cytoplasm, the nucleus 
and the mitochondria (1). Under normal conditions, the E3 ligase murine double 
minute 2 (MDM2) binds to the MDM2 binding domain (MBD) of p53 prompting 
polyubiquitination of terminal lysines on the C-terminus of p53, which marks p53 for 
proteasomal degradation (2). Upon stress induction, such as DNA damage or ER 
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stress, cytoplasmic p53 translocates either to the nucleus (3) or to the mitochondria 
(4). Three nuclear localization signals (NLS) in the C-terminus of p53 are responsible 
for p53 nuclear localization (5). In the nucleus, p53 forms a tetramer via its 
tetramerization domain (TD) (3) allowing its DNA binding domain (DBD) to bind to 
DNA activating various genes that are involved in apoptosis, DNA repair and cell 
cycle arrest (1). 
Although p53 does not contain a mitochondrial targeting signal (MTS), it can still 
translocate to the mitochondria. Machenko et al. postulated that MDM2 triggers 
dimer formation and mono-ubiquitination of cytoplasmic p53 resulting in 
mitochondrial import via herpes virus-associated ubiquitin-specific protease (6). At 
the mitochondrial outer membrane, p53 directly interacts with pro-apoptotic (Bak or 
Bax) (7, 8) and anti-apoptotic Bcl-2 family members (Bcl-XL, Bcl-2, Mcl-1, Bcl-w, and 
A1) (9-11) through a sequential mechanism first binding anti-apoptotic Bcl-2 proteins 
followed by binding to pro-apoptotic Bak (Fig. 1) or Bax (12). Activation of Bak (Fig. 
1) or Bax leads to homotetramer formation, which causes cytochrome c release from 
the intermembrane space (13). Binding of cytochrome c to APAF-1 stimulates the 
assembly of a hepameric, wheel-like structure known as the apoptosome (13). The 
apoptosome activates the initiator caspase-9 which initiates the executioner 
apoptotic caspase-3 and caspase-7 (Fig. 1) (14). Their proteolytic activity leads to 
nuclear fragmentation, chromatin condensation and cell shrinking, also known as 
programed cell death or apoptosis (4).  
In cancer cells, overexpression of Bcl-2, Bcl-XL and Mcl-1 correlates with more 
aggressive phenotypes and leads to chemotherapy resistance (15-17). Many agents 
have been identified to target the anti-apoptotic Bcl-2 family members such as 
navitoclax (inhibits Bcl-2, Bcl-XL, and Bcl-w) and ABT-199 (inhibits Bcl-2) (17). 
These therapeutics initiate apoptosis by neutralizing anti-apoptotic proteins at the 
mitochondria thus allowing the pro-apoptotic Bcl-2 family members Bak or Bax to 
homo-oligomerize leading to apoptosis (18). However, these inhibitors do not 
inactivate anti-apoptotic Mcl-1 (17). Overexpression of Mcl-1 is linked to reduced 
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response to chemotherapy and poor prognosis which limits the therapeutic options 
for navitoclax and ABT-199 (17). Mcl-1 (and to a certain extent Bcl-XL) is the main 
inhibitor of Bak (9, 19) while Bax is mainly inhibited by Bcl-2 and Bcl-w (20). Our 
approach is to directly activate pro- apoptotic Bak and Bax by targeting p53 to the 
mitochondria using Bak’s or Bax’s own MTSs (Fig. 2). Targeting p53 to the 
mitochondria executes the shortest apoptotic pathway for p53. wt p53 mostly 
translocates to the nucleus due to its NLS, forms a tetramer, binds to DNA, produces 
mRNA which then is then translated to proteins and after that these proteins need to 
translocate to their designated compartment. On the other hand mitochondrially 
targeted p53 directly interacts with pro- and anti- apoptotic proteins at the 
mitochondria resulting directly in apoptosis.  
The MTSs of Bak or Bax are located on the C-terminal hydrophobic regions of these 
proteins. The C-terminus contains the transmembrane domain (TM) and the C-
segment (CS) (21, 22). The C-terminus contains the transmembrane domain (TM) 
and the C-segment (CS) (21, 22). The Amino acid sequence of the MTSs from Bax 
are as follows GTPTWQTVTIFVAGVLTASLTIWKKMG and from Bak as follows 
GNGPILNVLVVLGVVLLGQFVVRRFFKS with italic representing the TM domain and 
underlined illustrating the CS base pairs. The TM inserts both proteins into the 
mitochondrial outer membrane (tail anchored proteins) with at least two of the basic 
amino acids in the CS being necessary for the insertion (Fig. 2) (22). Bax, which is in 
the cytoplasm, sequesters its TM in its hydrophobic surface groove. Once an 
apoptotic stimuli occurs, the TM gets externalized, targets Bax to the mitochondria, 
and inserts itself into the mitochondrial outer membrane (Fig.3) (21, 23). However, 
Bak is always present at the mitochondrial outer membrane sequestered by Mcl-1 
(and Bcl-XL) (Fig. 1; 3) (19). 
As mentioned before wt p53 does not contain a MTS. Therefore, our approach is to 
achieve mitochondrial targeting of p53 by fusing the MTSs from Bak or Bax to p53. 
Murphy and colleagues have reported that wt p53 is required to be in a dimeric or 
tetrameric form in order to activate pro-apoptotic Bak (24). In addition, the DBD has 
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been reported to interact with pro-apoptotic Bak (25) and inhibit anti-apoptotic Bcl-XL 
(10) and Bcl-2 (11). Here, we show our finding that the DBD in isolation with a MTS 
from Bak or Bax is sufficient to induce apoptosis in different cancer cells. 
 
 
Fig. 1 Intrinsic mitochondrial pathway (a) Upon apoptotic stimuli, Bak homo- 
oligomerization allows pore formation and cytochrome c release. (b) Mcl-1 and Bcl-
XL sequester Bak and do not allow homo-oligomerization (c) p53-BakMTS binds 
Bak, releases Bak from both Mcl-1 and Bcl-XL, and allows homo-oligomerization and 
cytochrome c release which results in apoptosis. On the other hand, Bax is 
sequestered by Bcl-2 and Bcl-w. p53-BaxMTS binds to Bax, releases Bax from Bcl-2 
and Bcl-w and causes apoptosis (pathway for Bax not shown). 
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Fig. 2 Schematic representation of experimental constructs: Wild-type p53 is divided 
into N-terminus, DNA binding domain (DBD) and C-terminal region. The N-terminus 
consists of a transactivation domain (TA), nuclear export signal (E), MDM2 binding 
domain (M) and proline-rich domain (PRD). The C-terminus contains three nuclear 
localization signals (NLS), nuclear export signal (E) and tetramerization domain (TD). 
p53-MTS wild-type p53 was fused to the mitochondrial targeting signal (MTS) from 
Bak or Bax. DBD-MTS DNA-binding domain of p53 was fused to the MTS from Bak 
or Bax. 
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Fig. 3 Structure of the Bak and Bax mitochondrial targeting signals (MTSs) (a) The 
Bax protein is mainly found in the cytoplasm of healthy cells. Upon apoptotic stimuli, 
it translocates to the mitochondrial outer membrane. The MTS of the Bax protein, 
consisting of the transmembrane domain (TM) and the C-segment (CS), becomes 
exposed for integration into the mitochondrial outer membrane. (b) Unlike Bax, Bak 
is always present at the mitochondrial outer membrane via its TM and CS.  
 
4.3 Material and Methods 
4.3.1 Cell Lines and Transient Transfections  
1471.1 murine adenocarcinoma cells (a kind gift of G. Hager, NCI, NIH), T47D 
human ductal breast epithelial tumor cells (ATCC, Manassas, VA), H1373 human 
non-small cell lung carcinoma cells (a kind gift from Dr. Andrea Bild, University of 
Utah), SKOV-3 human ovarian adenocarcinoma cells (a kind gift from Dr. Margit 
Janat-Amsbury, University of Utah) and HeLa human epithelial cervical 
adenocarcinoma cells (ATCC) were grown as monolayers in DMEM (1471.1, SKOV-
3) or RPMI (T47D, H1373, HeLa) (Invitrogen, Carlsbad, CA) supplemented with 10% 
FBS (Invitrogen), 1% penicillin-streptomycin (Invitrogen), 1% glutamine (Invitrogen) 
and 0.1% gentamycin (Invitrogen) and maintained in a 5% CO2 incubator at 37ºC. 
T47D media was additionally supplemented with 4 mg/L insulin (Sigma, St. Louis, 
MO). For microscopy 7.5 x 104 cells for 1471.1 cells were seeded in a 2 well live cell 
chamber. For apoptosis assays 3.0 x 105 cells for T47D, 1.0 x 105 cells for HeLa, 2.0 
x 105 for H1373 and SKOV-3 were seeded in 6-well plates (Greiner Bio-One, 
Monroe, NC). To account for varying cell growth rates, different amounts of cells 
were plated in live cell chambers and 6-well plates. Following the manufacturer’s 
recommendations 24 h after seeding, transfections were performed using 1 pmol of 
DNA per well (unless otherwise indicated) and Lipofectamine 2000 (Invitrogen). 
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4.3.2 Plasmid Construction 
pEGFP-p53-BakMTS (p53-BakMTS): An oligonucleotide encoding the MTS from 
Bak (5’-
GATCCGGCAATGGTCCCATCCTGAACGTGCTGGTGGTTCTGGGTGTGGTTCTG
TTGGGCCAGTTTGTGGTACGAAGATTCTTCAAATCATGAG-3’) was annealed to 
its reverse complementary strand and fused to the C-terminus of EGFP-p53 (26) 
using the BamHI restriction sites (NEB, Ipswich, MA).  
pEGFP-BakMTS (E-BakMTS): The annealed oligonucleotide encoding the MTS from 
Bak was fused to the C-terminus of EGFP-C1 vector (Clontech, Mountain View, CA) 
(26) using the BamHI (NEB) restriction sites.  
pEGFP-DBD-BakMTS (DBD-BakMTS): The DNA encoding the DBD was amplified 
via PCR from previously subcloned pEGFP-p53 (26) using 5’- 
CCGGGCCCGCGGTCCGGAACCTACCAGGGCAGCTACG-3’ and 5’- 
CCGGGCCCGCGGGGTACCTTTCTTGCGGAGATTCTCTTCCT and cloned 
between EGFP and Bak MTS into the multiple cloning site of E-BakMTS using BspEI 
(NEB) and KpnI (NEB) sites. 
pEGFP-p53 K120A, R248A, R273A, R280A, E285A, E287A-Bak (p53m6-BakMTS) 
and pEGFP-DBD K120A, R248A, R273A, R280A, E285A, E287A-Bak (DBDm6-
BakMTS): K120A, R248A, R273A, R280A, E285A, and E287A mutations were 
introduced in p53-BakMTS and DBD-BakMTS using the QuickChange II XL Site-
Directed Mutagenesis Kit (Agilent, Santa Clara, CA). The primers listed below and 
their reverse complements were used to introduce the K120A mutation 5’-
CATTCTGGGACAGCCGCGTCTGTGACTTGCAC-3’; the R248A mutation 5’- 
CAGTTCCTGCATGGGCGGCATGAACGCGAGGCCCATCCT-3’; the R273A 
mutation 5’-GGGACGGAACAGCTTTGAGGTGGCTGTTTGTGCCTGTCCT-3’; the 
R280A mutation 5’-TTTGTGCCTGTCCTGGGGCAGACCGGCGCACA-3’; and the 
E285A, E287A mutations 5’-ACCGGCGCACAGCGGAAGCGAATCTCCGC-3’ 
(underlined sequence indicate mutation sites). 
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pEGFP-p53K120E-BakMTS (p53K120E-BakMTS ) and pEGFP-DBDK120E-
BakMTS (DBDK120E-BakMTS ): The K120E mutation was introduced into p53-
BakMTS and DBD-BakMTS via QuickChange II XL Site-Directed Mutagenesis Kit 
(Agilent) using 5’- GCATTCTGGGACAGCCGAGTCTGTGACTTGCACGTA-3’ and 
its reverse complement. 
pEGFP-p53-BaxMTS (p53-BaxMTS): An oligonucleotide encoding the MTS from 
Bax 5’-
GATCCTCCTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGG 
CGGGAGTGCTCACCGCCTCACTCACCATCTGGAAGAAGATGGGCTGAG-3’ was 
annealed to its reverse complementary strand and fused to the C-terminus of EGFP-
p53 (26) using the BamHI (NEB) restriction sites. 
pEGFP-BaxMTS (E-BaxMTS): The annealed oligonucleotide encoding the MTS from 
Bax was fused to the C-terminus of EGFP-C1 vector (Clontech) (26) using the 
BamHI (NEB) restriction sites. 
pEGFP-DBD-BaxMTS (DBD-BaxMTS): The DNA encoding the DBD was amplified 
as mentioned above and cloned between EGFP and BaxMTS into the multiple 
cloning site of E-Bax using BspEI (NEB) and KpnI (NEB) sites. 
 
4.3.3 Mitochondrial Staining and Microscopy 
Prior to microscopy, media in live cell chambers was replaced with media containing 
10% charcoal stripped fetal bovine serum (CS-FBS, Invitrogen). To stain the 
mitochondria, cells were incubated with 150 nM of MitoTracker Red FM (Invitrogen) 
for 15 min at 37°C and protected from light prior to imaging. All images of 1471.1 and 
T47D live cells were acquired as previously (26, 27) with an Olympus IX71F 
fluorescence microscope (Scientific Instrument Company, Aurora, CO) with high 
quality (HQ) narrow band GFP filter (ex, HQ480/20 nm; em, HQ510/20 nm) and 
HQ:TRITC filter (ex, HQ545/30; em, HQ620/60) from Chroma Technology 
122 
 
 
 
 
(Brattleboro, VT) with a 40× PlanApo oil immersion objective (NA 1.00) on an F-View 
Monochrome CCD camera.  
 
4.3.4 Image Analysis 
Images were analyzed by using JACoP plugin in ImageJ software (28). PCC values 
were generated using Pearson’s correlation coefficient (PCC) with post Costes’ 
automatic threshold algorithm. PCC depends on both the pixel intensity and overlap 
of signals. A PCC of +1 represents complete colocalization of EGFP constructs with 
mitochondria; a PCC of -1 represents anti-correlation, and PCC of 0 correlates to 
random distribution (29). Bolte and Cordelières defined PCC values equal to 0.6 or 
above to be colocalized (30). For images analysis, experiments were performed 
three times (n=3) with 10 cells analyzed per n and per construct.  
 
4.3.5 7- AAD Assay 
Transfected T47D, H1373, SKOV-3 and HeLa cells were pelleted and resuspended 
in 500 μL PBS (Invitrogen) containing 1 μM 7-aminoactinomycin D (7-AAD) 
(Invitrogen) for 30 min prior to analysis (26, 27). T47D and H1373 cells were 
analyzed 48 h after transfection, while SKOV-3 and HeLa cells were analyzed 24 h 
after transfection (time points optimized empirically). Only EGFP positive cells were 
assayed using the FACS Canto-II (BD- BioSciences, University of Utah Core Facility) 
with FACS Diva software as previously (26, 27). EGFP and 7-AAD were excited at 
488 nm, and detected at 507 nm and 660 nm, respectively. Independent 
transfections of each construct were assayed three times (n=3). The highest value 
(EGFP positive cells stained with 7-AAD) was set at 100%, and the lowest at 0% 
(relative 7-AAD) as previously (31). 
 
123 
 
 
 
 
4.3.6 Reporter Gene Assay 
3.5 μg of p53-BakMTS, E-BakMTS, p53-BaxMTS, E-BaxMTS, wt p53 or EGFP were 
co-transfected with 3.5 μg of p53-Luc Cis-Reporter (Agilent Technologies) encoding 
the firefly luciferase gene and 0.35 μg of pRL-SV40 plasmid encoding Renilla 
luciferase (Promega, Madison, WI) to normalize for transfection efficiency in T47D 
cells using the Dual-Glo Luciferase assay system as previously (26, 31). 
Luminescence was detected 24 h post transfection using PlateLumino (Stratec 
Biomedical Systems, Birkenfeld, Germany). Independent transfections of each 
constructs were assayed three times (n=3). The highest value was set at 100% and 
lowest value (untreated cells) was set as 0% (relative luminescence) as before (26, 
31). 
 
4.3.7 TMRE Assay 
As previously (27), 36 h after transfection T47D cells were incubated with 100 nM 
tetramethylrhodamine, ethyl ester (TMRE) (Invitrogen) for 30 min at 37ºC, pelleted 
and resuspended in 300 μL annexin-V binding buffer (1X) (Invitrogen). The FACS 
Canto-II with FACS Diva software was used to analyze only EGFP positive cells 
(excited at 488 nm with emission 530/35) stained with TMRE (excited at 561 nm 
laser with the emission 585/15). Loss in TMRE intensity represents mitochondrial 
depolarization, which correlates with an increase in mitochondrial outer membrane 
permeabilization (MOMP). Independent transfections of each construct were 
assayed three times (n=3). The highest MOMP value was set as 100% and the 
lowest as 0% (relative MOMP) as before (27). 
 
4.3.8 Caspase-9 Assay  
As previously described (27), 48 h after transfection, T47D cells were tested with SR 
FLICA Caspase-9 Assay Kit (Immunochemistry Technologies, Bloomington, MN). 
Cells were incubated with SR FLICA Caspase-9 reagent for 60 min, pelleted and 
124 
 
 
 
 
resuspended in 300 µL 1X wash buffer (Immunochemistry Technologies). The FACS 
Canto-II with FACS Diva software was used to analyzed only EGFP positive cells 
stained with caspase-9, both were excited with the 488 nm (emission filter 530/35) 
and the 561 nm laser (emission filter 585/15), respectively. Independent 
transfections of each construct were assayed three times (n=3). The highest value 
(EGFP positive cells stained with caspase-9) was set as 100% and the lowest as 0% 
(relative caspase-9) as before (27). 
 
4.3.9 Statistical Analysis 
All experiments were done in triplicate (n=3). One-way analysis of variance (ANOVA) 
with Bonferroni’s post test was used to determine statistical significance as indicated 
in figure legend. To determine the degree of colocalization odds ratio with Pearson’s 
Chi-square was applied comparing each PCC value with PCC of 0.6. A p value of < 
0.6 was considered significant (26, 27). 
 
4.4 Results 
4.4.1 Colocalization of designed constructs with the mitochondria 
Since all designed constructs are tagged to EGFP, their mitochondrial localization 
was determined using fluorescence microscopy in murine adenocarcinoma cells 
(1471.1). Figure 4a illustrates representative pictures of 1471.1 cells transfected with 
p53-BakMTS, E-BakMTS, p53-BaxMTS, E-BaxMTS and EGFP. The mitochondrial 
compartment was stained by MitoTracker red. 1471.1 cells were chosen for the 
microscopy study because their large size allows for clear distinction between 
nucleus, cytoplasm and mitochondria. Similar results have been observed for T47D 
cells (data not shown).  
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Colocalization of EGFP tagged constructs with the mitochondrial compartment was 
illustrated by graphing the generated PCC values for each construct as shown in 
Figure 4b. PCC values of 0.6 or greater represent colocalization of EGFP tagged 
constructs with mitochondria (26-28). p53-BakMTS, E-BakMTS, p53-BaxMTS and E-
BaxMTS have a significantly higher PCC value than 0.6. The negative control EGFP 
shows random distribution (PCC=0.29) (Fig. 4b). Since wt p53 is a transcription 
factor containing three nuclear localization signals (NLSs) (5), the main fraction of wt 
p53 localizes to the nucleus as we (31) and others (5) have shown before. However, 
MTSs derived from the pro-apoptotic Bak or Bax protein are capable of overcoming 
the three NLSs. These Bak and Bax MTSs are capable of targeting EGFP fused to 
p53 to the mitochondria (Fig. 4).  
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Fig. 4 Mitochondrial localization. (a) Representative images of 1471.1 cells 
transfected with p53-BakMTS, E-BakMTS, p53-BaxMTS, E-BaxMTS and EGFP. Left 
column shows EGFP tagged constructs, middle column mitochondria stained with 
MitoTracker red and right column depicts colocalization color map. Warm colors 
(red) are considered highly colocalized versus cold colors (blue) which represent 
anti-correlation (see color bars). White scale bars are all 10 μm (b) PCC values were 
graphed for each construct. PCC value equal to 0.6 and above is considered to be 
colocalized. Statistical analysis was performed using odds ratio with Pearson’s Chi-
square. The adjusted odds ratio for PCC value of 0.6 was compared with each 
sample (**p < 0.01). 
 
4.4.2 p53-BakMTS and p53-BaxMTS induce late stage apoptosis 
The ability of p53-BakMTS and p53-BaxMTS to induce apoptosis was tested via 7-
AAD assay in T47D breast cancer cells. The 7-AAD dye intercalates into double-
stranded DNA of apoptotic/necrotic cells which have a disrupted cell membrane. 
However, it is not capable of penetrating the intact cell membrane of living cells (32). 
p53-BakMTS, p53-BaxMTS and wt p53 (Fig. 5; compare 1st, 3rd, and 5th bars) 
show a significant apoptotic effect compared to their corresponding negative controls 
E-BakMTS, E-BaxMTS and EGFP respectively (Fig. 5; compare 2nd,4th, and 6th 
bars). 
The apoptotic response induced by p53-BakMTS and p53-BaxMTS is similar to wt 
p53 (Fig. 5; compare 1st, 3rd, and 5th bars). Additionally, MTS negative controls, E-
BakMTS and E-BaxMTS, show minimal activity similar to the nontoxic EGFP 
negative control (Fig 5; compare 2nd,4th, and 6th bars), which indicates no inherent 
mitochondrial toxicity for these MTSs by themselves.  
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Fig. 5 7-AAD assay in T47D cells, 48 h after transfection. Statistical analysis was 
performed using one-way ANOVA with Bonferroni’s post test; **p < 0.01, ***p < 
0.001. Error bars represent standard deviations from at least three independent 
experiments (n=3). 
 
4.4.3 p53-BakMTS and p53-BaxMTS do not trigger apoptosis through the 
nuclear but through the mitochondrial apoptotic pathway 
To validate that the apoptotic activity of p53-BakMTS and p53-BaxMTS is not due to 
transcriptional activity at the nucleus, a p53 reporter dual luciferase assay was 
conducted in T47D cells. The cis reporter system relies on a synthetic promoter 
which consists of repeats of the transcription recognition consensus for p53 
(TGCCTGGACTTGCCTGG)14 (33). Nuclear activity was represented as relative 
luminescence. Endogenous p53 is a nuclear protein and exhibits most of its tumor 
suppressor functions as a transcription factor. As expected, wt p53 shows high 
transcriptional activity (Fig. 6a; 5th bar ). p53-BakMTS, E-BakMTS, p53-BaxMTS, E-
BaxMTS (Fig. 6a; compare 1st, 2nd, 3rd, and 4th bars) show no nuclear activity 
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similar to that of  the negative control EGFP (Fig. 6a; 6th bar). This suggests that the 
induction of apoptosis of the mitochondrial constructs p53-BakMTS and p53-
BaxMTS seen in Fig. 5 (5th bar) is not due to transcriptionally active p53. 
To explore if p53-BakMTS and p53-BaxMTS initiate apoptosis through the intrinsic 
apoptotic pathway, two major hallmarks for the mitochondrial apoptotic pathway (27, 
34), mitochondrial outer membrane permeabilization (MOMP) and caspase-9 
induction, were measured.  
The TMRE assay is a direct measurement of MOMP. Homo-oligomerization of Bak 
or Bax triggers MOMP (7, 8) which results in a decrease in mitochondrial membrane 
potential (35). Cationic dyes such as TMRE accumulate in the mitochondria of 
healthy cells due to the higher negative charge seen in the mitochondria compared 
to cytoplasm (27). MOMP results in a loss of TMRE from mitochondria and can be 
measured via flow cytometry (27). Apoptotic cells are identified by a loss of TMRE 
fluorescence intensity and are represented as %MOMP induction on and y-axis (Fig. 
6b).  
The ability of caspase-9 to cleave the peptide sequence leucine-glutamic acid-
histidine-aspartic acid determines caspase-9 activity in apoptotic cells (36). When 
the mitochondrial outer membrane ruptures, cytochrome c is released from the 
intermembrane space (13). Cytochrome c and Apaf-1 form the apoptosome and 
activate caspase-9 as shown in Figure 1 (13). Caspase-9 activation was measured 
via the caspase-9 assay.  
p53-BakMTS, p53-BaxMTS and wt p53 (Fig. 6b, and c; compare 1st, 3rd, and 5th 
bars) show a significant effect on MOMP and caspase-9 activation compared to their 
corresponding controls E-BakMTS, E-BaxMTS and EGFP (Fig. 6 b, and c; compare 
2nd, 4rd, and 6th bars). The negative controls E-BakMTS and E-BaxMTS show 
higher MOMP and caspase-9 activation compared to non-toxic EGFP (Fig. 6b, and 
c; compare 2nd, 4rd, and 6th bars ).  
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Fig. 6 (a) Nuclear transcriptional activity: p53 reporter gene assay: all MTS 
constructs were tested for their ability to activate p53-Luc Cis-Reporter in T47D cells. 
Wt p53 was used as a positive control and EGFP was considered a negative control. 
(b) Mitochondrial apoptosis: TMRE assay: all constructs were assayed in T47D cells. 
Mitochondrial depolarization correlates with an increase in MOMP (measured as loss 
of TMRE fluorescence). (c) Mitochondrial apoptosis: Caspase-9 activation was 
analyzed in T47D cells. All statistical analysis for a, b, and c were performed by 
using one-way ANOVA with Bonferroni’s post test; *p< 0.05, **p < 0.01, ***p < 0.001. 
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Error bars represent standard deviations from at least three independent 
experiments (n=3). For b and c negative controls E-BakMTS and E-BaxMTS were 
compared to EGFP using one-way ANOVA with Bonferroni’s post test; #p< 0.05, ##p 
< 0.01, ###p < 0.001. p53-BakMTS and p53-BaxMTS were not significantly higher 
from wt p53. 
 
4.4.4 DBD-BakMTS and DBD-BaxMTS induce late stage apoptosis in a similar 
manner as p53-BakMTS and p53-BaxMTS 
Pietsch et al. showed that p53 must form a dimer or a tetramer to activate Bak 
oligomerization (24). Additionally, the DBD has been reported to interact with pro-
apoptotic Bak (25) and inhibit anti-apoptotic Bcl-XL (10) and Bcl-2 (11). We wanted 
to test if fusing DBD to MTS from Bak or Bax is sufficient to trigger apoptosis.  
Similar levels of 7-AAD positive staining (apoptosis) were detected between cells 
transfected with DBD-BakMTS compared to p53-BakMTS (Fig. 7a), and cells 
transfected with DBD-BaxMTS and p53-BaxMTS (Fig. 7b). Additionally, all of these 
constructs had significantly higher apoptosis compared to cells transfected with MTS 
negative controls (E-BakMTS, E-BaxMTS) (Figs. 7a and b). DBD fused to Bak or 
Bax MTS induces a similar apoptotic response as full length p53 fused to these 
MTSs (Figs. 7a and b). 
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Fig. 7 7-AAD assay in T47D cells: Apoptotic potential of DBD-BakMTS and DBD-
BaxMTS were tested. Statistical analysis was performed by using one-way ANOVA 
with Bonferroni’s post test; **p < 0.01, ***p < 0.001 compared to negative controls. 
Error bars represent standard deviations from at least three independent 
experiments (n=3). 
 
4.4.5 The activity of our re-engineered mitochondrially targeted p53 constructs 
in different cancer cell types 
To confirm that the apoptotic potential of our designed constructs causes apoptosis 
in other cell lines besides T47D breast cancer cells (which express mutant p53 with 
a L194F point mutation in the DBD of p53) (37), a 7-AAD assay was conducted in 
non-small cell lung cancer cells (H1373), ovarian cancer cells (SKOV-3) and cervical 
carcinoma cells (HeLa). H1373 (38) and SKOV-3 cells are p53 null (39) while HeLa 
cells have endogenous wt p53 (40). 
In H1373 cells, both p53-BakMTS and DBD-BakMTS apoptotic activities were 
statistically higher from their negative control E-BakMTS (Fig. 8a; compare 1st, 2nd, 
and 3rd bars). As expected, wt p53 showed significantly higher apoptosis compared 
to EGFP (Fig. 8a and b; compare 4st, and 5st bars). However, only DBD-BaxMTS 
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activity was significantly higher than E-BaxMTS (Fig. 8b; compare 2nd and 3rd bars) 
and there was no significant difference between p53-BaxMTS and E-BaxMTS (Fig. 
8b; compare 1st and 3rd bars). Additionally, DBD-BakMTS and DBD-BaxMTS had 
significantly higher activities compared to their positive controls p53-BakMTS and 
p53-BaxMTS (Fig. 8a and b; compare 1st and 2nd bars). 
In SKOV-3 cells, p53-BakMTS and DBD-BakMTS activities were significantly higher 
than their negative control E-BakMTS (Fig. 8c; compare 1st, 2nd, and 3rd bars). p53-
BaxMTS and DBD-BaxMTS activities were only significant when compared to EGFP 
but no to E-BaxMTS (Fig 8d; compare 1st, 2nd, 3rd, and 5th bars). The activity of wt 
p53 was similar to nontoxic EGFP in SKOV-3 cells (Fig. 8c and d; compare 4th and 
5th bars).  
In HeLa cells, p53-BakMTS, DBD-BakMTS (Fig. 8e; compare 1st and 2nd bars), 
p53-BaxMTS, DBD-BaxMTS (Fig. 8f; compare 1st, and 2nd bars) and wt p53 (Fig. 
8e and f; 4th bars) apoptotic activities were significant from their corresponding 
negative controls E-BakMTS (Fig. 8e; 3rd bar), E-BaxMTS (Fig. 8f; 3rd bar) and 
EGFP (Fig. 8e, and f; 5th bar) respectively. DBD-BakMTS showed a trend of higher 
apoptotic activity in HeLa cells compared to p53-BakMTS (Fig. 8e; compare 1st and 
2nd bars). In addition, DBD-BaxMTS was significantly higher than p53-BaxMTS 
(Fig.8f; compare 1st and 2nd bars). 
p53 is known to induce a conformational change in Bax that triggers its 
oligomerization and mitochondrial permeabilization through a hit-and-run type 
mechanism (7). However, this p53 interaction with Bax is transient, and the specific 
interacting residues are not known (7, 8, 12). On the other hand, it is known that p53 
interacts with the Bak protein via amino acids K120, R248, R273, R280, E285 and 
E287 in p53 (25). Therefore these residues will be mutated to determine if this is a 
Bak specific interaction. Since p53-BakMTS and DBD-BakMTS showed consistently 
higher apoptotic activities than their MTS control in all tested cell lines (Figs. 7a, 8a, 
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c, e; compare 1st, 2nd, and 3rd bars), we proceeded to examine the apoptotic 
mechanism of the Bak MTS constructs. 
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Fig. 8 7-AAD assay was conducted in (a) and (b) H1373, (c) and (d) SKOV-3, (e) 
and (f) HeLa cells. Statistical analysis was performed by using one-way ANOVA with 
Bonferroni’s post test;* p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent 
standard deviations from at least three independent experiments (n=3). 
 
4.4.6 Exploring the interaction between p53-BakMTS, DBD-BakMTS and pro-
apoptotic Bak protein 
It has been reported that p53 interacts with pro-apoptotic Bak protein via amino acids 
K120, R248, R273, R280, E285 and E287, all of which are found in the DBD of p53 
(25). To verify that the apoptotic potential of p53-BakMTS and DBD-BakMTS is 
through the p53/Bak specific pathway, all sites of p53 (K120A, R248A, R273A, 
R280A, E285A, E287A) (25) that contact the pro-apoptotic Bak protein were mutated 
to alanine. The constructs with these six mutations were named p53m6-BakMTS and 
DBDm6-BakMTS.  
Mutating all six of these residues in p53-BakMTS to eliminate binding to pro-
apoptotic Bak protein resulted in a complete loss of p53-BakMTS activity (Fig. 9a; 
4th bar). p53m6-BakMTS and DBDm6-BakMTS activities are not significantly 
different from their negative control E-BakMTS suggesting Bak dependent apoptosis 
(Fig. 9a; compare 3rd, 4th, and 5th bars). 
As mentioned above p53 interacts with Bak via its DBD (residues K120, R248, R273, 
R280, E285, E287). However, p53 also interacts with anti-apoptotic Bcl-XL through 
the following residues G117, S121, C176, H178, N239, M243, R248, G279, and 
R280 (10). Therefore, R248 and R280 localized in the DBD of p53 can interact with 
Bak and Bcl-XL. To exclude any Bcl-XL specific interaction of our designed 
constructs, only K120 was mutated in the p53-BakMTS and DBD-BakMTS plasmid 
to glutamic acid. The K120 residue only interacts with Bak not with Bcl-XL (10, 25).  
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Mutating the positively charged lysine 120 to negatively charged glutamic acid 
(K120E) in p53-BakMTS and DBD-BakMTS resulted in complete loss of apoptotic 
activity (Fig. 9b; 4th and 5th bars). p53K120E-BakMTS and DBDK120E-BakMTS 
activities are not statistically significant from the negative control E-BakMTS (Fig. 9b; 
compare 3rd, 4th, and 5th bars), suggesting a p53/Bak dependent apoptotic 
mechanism. 
 
Fig. 9 Decrease in apoptotic potential caused by (a) K120A, R248A, R273A, R280A, 
E285A, E287A (m6) mutations and (b) K120E mutation was measured via 7-AAD 
assay in T47D cells. Statistical analysis was performed by using one-way ANOVA 
with Bonferroni’s post test; **p < 0.01, ***p < 0.001 compared to E-BakMTS. Error 
bars represent standard deviations from at least three independent experiments 
(n=3). 
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4.5 Discussion 
We and others have shown that targeting p53 to the mitochondria is sufficient to 
trigger a rapid apoptotic response (4, 26, 27, 41). Previously, our focus was to target 
p53 to different mitochondrial compartments concluding that targeting it to the outer 
surface of the mitochondrial membrane is the only compartment that leads to p53-
dependent apoptosis (26), rather than non-specific mitochondrial toxicity. So far, only 
anti-apoptotic binding partners (such as Bcl-XL and Bcl-2) on the outer membrane 
have been addressed for p53 specific targeting. These constructs sequester anti-
apoptotic Bcl-2 family members and therefore indirectly activate Bak and Bax (26). 
Here, our approach is to target p53 directly to Bak and Bax proteins. To our 
knowledge, this is the first attempt to target p53 to these pro-apoptotic proteins. 
Fusing p53 to the MTSs derived from the pro-apoptotic Bak (p53-BakMTS) or Bax 
(p53-BaxMTS) proteins resulted in localization of these constructs to the 
mitochondria (Fig. 4) and induction of apoptosis (Figs. 5; 6b and c; 7). The tumor 
suppressor p53 is a nuclear protein containing three NLSs (5). When targeting p53 
to the mitochondria, the chosen MTS must counteract these NLSs. Previously, our 
lab has targeted p53 with the MTSs from ornithine transcarbamylase (OTC), 
cytochrome c oxidase (CCO), translocase of the outer membrane (TOM) and Bcl-XL 
(XL) (26). We have shown that strong MTSs from TOM and XL are capable of 
overcoming the NLSs in the p53 protein while the weak MTS from CCO and the 
medium strength MTS from OTC are not strong enough to ensure entire 
mitochondrial targeting (26). Here, we show that MTSs from Bak and Bax are 
capable of counteracting the three NLSs in wt p53 and can be considered to be 
strong MTSs (Fig. 4). Additionally, EGFP fused to MTSs from Bak (E-BakMTS) or 
Bax (E-BaxMTS) showed minimal inherent toxicity which suggests that apoptotic 
activity of p53-BakMTS and p53-BaxMTS are p53 dependent and not due to MTS 
toxicity (Fig. 5). 
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Since we confirmed mitochondrial localization and apoptotic potential of p53-
BakMTS and p53-BaxMTS, we wanted to examine if the apoptotic response occurs 
mainly through the mitochondrial pathway or through residual nuclear activity. As 
expected, wt p53 showed high nuclear activity, while p53-BakMTS and p53-BaxMTS 
showed no transcriptional activity, suggesting that the apoptotic function of p53-
BakMTS and p53-BaxMTS is transcriptionally independent (Fig. 6a). 
Further, we demonstrated that the apoptotic activity of p53-BakMTS and p53-
BaxMTS is through the intrinsic apoptotic pathway. Mitochondrial outer membrane 
permeabilization (MOMP) and caspase-9 activation can only be initiated via the 
intrinsic apoptotic pathway (13). In fact, p53-BakMTS and p53-BaxMTS triggered 
permeabilization of the mitochondrial outer membrane and induced caspase-9 
activation confirming the involvement of the intrinsic apoptotic pathway (Fig. 6b and 
c).  
Negative controls E-BakMTS and E-BaxMTS showed some MOMP and caspase-9 
activation which was higher than EGFP but still significantly lower than p53-BakMTS 
and p53-BaxMTS (Fig. 6b and c). However, this is not reflected in the more final 
apoptosis assay 7-AAD (Fig. 5) (32). It has been reported that can recover from 
mitochondrial outer membrane permeabilization (MOMP) which is measured by 
TMRE; cells can also recover from caspase-9 activation (13). Therefore, sending 
GFP to the mitochondria is slightly toxic to the cells reflected by TMRE and caspase-
9 assay (Fig. 6) but does not translate into final cell death measured by 7-AAD assay 
(Fig. 5 and 8). 
Next, we wanted to examine if a single domain of p53 (DBD) is sufficient to trigger 
apoptosis or if full length p53 is essential for cell death induction. Although the TD 
was reported to be essential for wt p53 function to exert its apoptotic effect via Bak 
oligomerization (24), we note our important discovery, that the DBD in isolation with 
a MTS from Bak or Bax is sufficient to induce apoptosis (Fig. 7). Murphy and 
colleagues reported that p53 must form a dimer or a tetramer for initiating Bak 
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oligomerization (24). However, our data is consistent with our previous finding (27) 
and other reports (10, 11) that monomeric p53 or just the DBD is sufficient to trigger 
mitochondrial dependent apoptosis. Moreover, the DBD of p53 (specifically through 
residues L120, R248, R273, R280, G285 and G287) has been shown to be the 
domain responsible for binding to Bak (25). An possible explanation to why DBD 
fused to MTS is sufficient to trigger apoptosis could be that since wt p53 does not 
have a MTS, mitochondrial import of wt p53 is only possible through dimerization 
and monoubiquitination via MDM2 (6). We postulate that forcing the DBD of p53 to 
be in close proximity to Bak via the Bak targeting signal may trigger an interaction 
with Bak via the previously reported residues in the DBD region leading to activation 
of the apoptotic pathway (25). In wt p53 the lack of a Bak MTS does not allow the 
interaction to take place. These results suggest that the Bak MTS fused to DBD can 
replace MBD and TD for mitochondrial import and is sufficient to cause Bak homo-
oligomerization and apoptosis. 
To ensure that this finding is not a T47D cell specific effect, we tested the DBD-
BakMTS and DBD-BaxMTS in three different cancer cell lines (Fig. 8; Tbl. 2). In fact, 
DBD-BakMTS showed even significantly higher (Fig. 8a) or trending higher (Figs. 7a, 
8c and e) activity compared to p53-BakMTS. A possible reason for the higher activity 
of DBD-BakMTS over full length p53-BakMTS is that DBD-BakMTS is lacking the 
MBD and C-terminus which are essential for the p53 degradation pathway. MDM2 
binds to MBD of p53 and initiates polyubiquitination of the C-terminus causing 
proteasomal degradation (42, 43). As DBD-BakMTS lacks the MBD and C-terminus, 
it may avoid polyubiquitination and subsequent proteasomal degradation, thus 
making it more stable than p53-BakMTS. 
Unlike constructs fused to Bak MTS, Bax tagged constructs showed inconsistent 
apoptotic activity profiles (Fig. 7 and 8). In SKOV-3, p53-BaxMTS and DBD-BaxMTS 
activities were not significantly different from their negative control E-BaxMTS (Fig. 
8d), and in H1373 p53-BaxMTS did not show higher activity than E-BaxMTS (Fig. 
8b). A possible explanation for this is that Bax is constantly shuttled between 
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cytoplasm and mitochondria (Fig. 3) (44, 45) . Mitochondrial p53 might lack the 
ability to activate cytoplasmic Bax while the fraction of Bax which is present at the 
mitochondria might not be sufficient to induce apoptosis in certain cell lines. This 
might offer an explanation why p53-BaxMTS and DBD-BaxMTS show inconsistent 
results (Fig. 7a; 8b,d, and f). Unlike Bax, Bak is mainly present at the mitochondria 
and sequestered by anti-apoptotic Mcl-1 and to a certain extent by Bcl-XL (19). 
As our ultimate goal is to find a construct capable of robust apoptosis, we proceeded 
with BakMTS constructs for further studies. The apoptotic mechanism of p53-
BakMTS and DBD-BakMTS was then investigated. p53-BakMTS causes apoptosis 
through a p53/Bak specific pathway, which was confirmed by mutating amino acids 
of p53 DBD (K120, R248, R273, R280, E285, E287) that are known to interact with 
the pro-apoptotic Bak protein to abolish any p53/Bak specific interactions (25). In 
fact, mutating these amino acids showed a complete loss of p53-BakMTS and DBD-
BakMTS function (Fig. 9a).  
Besides pro-apoptotic Bak, p53 also interacts with anti-apoptotic Bcl-XL through its 
DBD (residues G117, S121, C176, H178, N239, M243, R248, G279, and R280) (10). 
p53 interacts through amino acids R248 and R280 with Bak and Bax. To further 
validate that the apoptotic mechanism is mainly dependent on pro-apoptotic Bak 
protein and not Bcl-XL, the p53K120E-BakMTS and DBDK120E-BakMTS were 
created. This K120 residue is known to be significant and specific for the p53/Bak 
interaction (25). K120E mutation in p53-BakMTS and DBD-BakMTS resulted in 
dramatic loss of activity suggesting involvement of Bak/specific p53 pathway (Fig. 
9b). 
Our mitochondrially targeted p53 could potentially have additive or synergistic 
apoptotic effects with endogenous wt p53. wt p53 mainly translocates to the nucleus 
and triggers transactivation of genes responsible for the extrinsic and intrinsic 
pathway. While mitochondrial p53 might trigger the first wave of intrinsic apoptosis, 
wt p53 might additively or synergically enhance apoptosis via activation of the 
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extrinsic and intrinsic pathway. This situation would occur only if endogenous wt p53 
was activated under stress conditions such as radiation or chemotherapy treatment.  
In summary, our data shows that fusing p53 to MTSs from Bak or Bax results in 
mitochondrial localization and activation of an intrinsic apoptotic response. DBD-
BakMTS and p53-BakMTS show apoptosis in breast, non-small cell lung, ovarian 
and cervical carcinomas in a p53/Bak dependent manner. Our next step is to test 
p53-BakMTS and DBD-BakMTS using adenoviral drug delivery in orthotopic breast 
cancer and ovarian cancer models to validate this in vitro work. Ultimately, correction 
of the p53 pathway and activation of apoptosis may be a universal approach. 
Mitochondrially targeted p53, which does not dimerize nor activate genes in the 
nucleus, simply has a direct apoptotic effect. Therefore, functional, mitochondrially 
targeted monomeric p53 re-introduced into cancer cells would act as a 
"sledgehammer," effective under any circumstances regardless of genetics or the 
pathway upon which the cancer develops. 
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5. Delivery of a monomeric p53 with mitochondrial 
targeting signals from anti-apoptotic Bcl-XL to overcome 
dominant negative inhibition of mutant p53 
5.1 Abstract  
The tumor suppressor p53 is mutated in 60-88% of triple negative breast cancers, 
the most deadly form of breast cancer. Most of these mutations occur in the DNA 
binding domain (DBD) of p53 while the tetramerization domain (TD) remains active. 
This mutant p53 can heterotetramerize with exogenous wt p53 which is known as 
dominant negative inhibition. Unlike wt p53 which is only transcriptionally active as a 
tetramer, mitochondrial p53 performs its apoptotic function as a monomer. Targeting 
p53 to the mitochondria causes a rapid apoptotic response through direct interaction 
with pro-and anti-apoptotic Bcl-2 protein family members. To investigate if 
mitochondrially targeted p53 is capable of overcoming dominant negative inhibition, 
we tested p53 and its DBD tagged to the mitochondrial targeting signal (MTS) from 
anti-apoptotic Bcl-XL, in vitro and in vivo. We wanted to verify if mitochondrial p53 is 
affected by mutant p53 status in vitro, first by overexpressing R248W mutant p53 in 
p53 null non-small cell lung cancer cells (H1373 cells), and second, by conducting 
apoptosis assays in MDA-MB-468 triple negative breast cancer cells which harbor 
R273H mutant p53. While DBD fused to MTS from Bcl-XL (DBD-XL) was capable of 
overcoming dominant negative inhibition by mutant p53, it was unable to shrink 
MDA-MB-468 tumors in an orthotopic mouse model.  
 
5.2 Introduction 
The tumor suppressor p53 has been the focus of intensive cancer-based research in 
laboratories around the world for more than three decades. This resulted in 
adenovirally delivered wt p53 being approved for gene therapy in China under the 
trade names Gendicine and Oncorine (1, 2). Additionally, there are various clinical 
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trials for p53 based cancer therapy around the world (3). However, limitations of its 
use are due to dominant negative inactivation of wt p53 by endogenous mutant p53 
(4, 5). Mutations in the p53 gene typically occur in the DNA binding domain (DBD) of 
p53, while the tetramerization (TD) domain usually remains active (6, 7). Therefore, 
wt p53 can form heterotetramers with mutant p53 which abolishes the transcriptional 
activity of the wt p53/mutp53 heterotetramer complex (5, 8, 9). This is, for example, a 
problem in triple negative breast cancer (TNBC) where 60-88% of TNBC have 
mutated p53 and would exhibit dominant negative inhibition if wt p53 was 
reintroduced (10). Mitochondrial p53 could circumvent this problem, and would 
represent a major advancement in treatment of TNBC.  
We and others have shown that p53 targeted to the mitochondria interacts with pro- 
and anti-apoptotic Bcl-2 proteins at the mitochondrial outer membrane and causes a 
rapid apoptotic response (11-13). Our lab was the first to show that the DBD of p53 
delivered to the mitochondria by a mitochondrial targeting signal is sufficient to cause 
apoptosis (14). Since DBD lacks the TD which is essential for tetramer formation, 
p53 initiates apoptosis at the mitochondria likely without tetamerization (e.g., as a 
monomer). We hypothesis that monomeric p53 will evade dominant negative 
inhibition of endogenous mutant p53. Our approach is to deliver p53-XL and DBD-XL 
adenovirally and show apoptosis in vitro and in vivo. 
Since p53 delivered by adenovirus is already approved as a drug and has been used 
in various clinical trials (1, 2, 15, 16), we chose adenovirus for delivery as well. 
Nielsen et al. have already attempted to use adenovirally delivered wt p53 to treat 
xenografted triple negative breast cancer MDA-MB-468 tumors in mice (17, 18). 
However, due to the dominant negative inhibition of mutant p53, wt p53 was unable 
to cause tumor shrinkage and only resulted in tumor growth inhibition (17). Our 
approach is to use intratumorally injected adenoviral p53-XL and DBD-XL in an 
orthotopic breast cancer mouse model. We hypothesized that this would result in cell 
apoptosis and tumor shrinkage since our constructs will not be affected by dominant 
negative inhibition by mutant p53.  
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5.3 Methods 
5.3.1 Cell Lines  
H1373 human non-small cell lung carcinoma cells (a kind gift from Dr. Andrea Bild, 
University of Utah) were grown as monolayers in RPMI (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin-streptomycin-
glutamine (Invitrogen), and 0.1% gentamicin (Invitrogen). HEK293 human embryonic 
kidney (ATCC) and MDA-MB-468 human breast adenocarcinoma cells (ATCC) were 
grown as monolayers in DMEM (Invitrogen) supplemented with 10% fetal bovine 
serum, 1% penicillin-streptomycin-glutamine, and 0.1% gentamicin. MDA-MB-468 
cells were also supplemented with 1% MEM non-essential amino acids (Invitrogen). 
All cells were incubated in 5% CO2 at 37ºC. The cells were seeded for transduction 
at a density of 3.0 × 105 cells in 6-well plates (Greiner Bio-One, Monroe, NC). Viral 
transductions were carried out immediately after seeding the cells. 
 
5.3.2 Recombinant Adenovirus Production  
As previously (19), replication-deficient recombinant adenovirus serotype 5 (Ad) 
constructs were created by inserting PCR amplified p53-XL (Ad-p53-XL) or DBD-XL 
(Ad-DBD-XL) into a cassette under the control of the CMV promoter. Prior to 
insertion, these constructs were PCR amplified with primers containing 15 base pair 
homology with a linearized pAdenoX vector (Clontech) based on an In-Fusion® HD 
Cloning Kit (Clontech). Empty vector served as negative control (Ad-ZsGreen). For 
visualization the Adeno-X® Adenoviral Expression System 3 contains a separate 
CMV promoter for ZsGreen1 expression. The adenoviral vector plasmids containing 
our constructs were transformed into Stellar® competent cells (Clontech). For 
packaging and amplification, viral DNA was purified linearized and transfected into 
HEK293 cells. Viral particles were isolated from HEK293 cells by freeze-thawing, 
purified using Adeno-X® Mega Purification Kit (Clontech), and dialyzed against 
storage and proper tonicity buffer (2.5% glycerol (w/v), 25 mM NaCl, and 20 mM 
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Tris-HCl, pH 7.4). Following the manufacturer’s recommendation, flow cytometry was 
used to determine the viral titer.  
 
5.3.3 Overexpression of Mutant p53 using Lipofectamine Transfection 
H1373 cells were cotransfected with 1 pmol of the transdominant mutant pTagBFP-
mut-p53 (R248W) and 1 pmol of previously designed plasmids wt p53, p53-XL, E-XL 
or EGFP (19). To create pTagBFP-mut-p53 (R248W) the following primers were 
used 5′-CTGCATGGGCGGCATGAACTGGAGGCCCATCCTCACCA-3′ and 5′-
TGGTGAGGATGGGCCTCCAGTTCATGCCGCCCATGCAG-3′. p53-XL was 
designed by cloning wt p53 and MTS from anti-apoptotic Bcl-XL into EGFP-C1 
vector. E-XL was created by inserting MTS from XL into EGFP-C1 vector (13). 
Lipofectamine was used as the transfection reagent as before (13, 19, 20). 48 h post 
transfection, cells were stained as described in the 7-AAD assay and gated for 
EGFP and BFP using the FACSCanto-II (BD-BioSciences, University of Utah Core 
Facility) and FACSDiva software. Excitation for BFP was set at 405 nm and detected 
at 457 nm. The means from three separate experiments (n=3) were analyzed using 
two-way ANOVA with Bonferroni’s post hoc test.  
 
5.3.4 7-AAD Assay 
As previously (13, 19, 20), 48 h after transfection MDA-MB-468 cells were stained 
with 7-aminoactinomycin D (7-AAD, Invitrogen). Excitation was set at 488 nm and 
detected at 507 nm and 780 nm for ZsGreen1 and 7-AAD, respectively using the 
FACSCanto-II (BD-BioSciences, University of Utah Core Facility) and FACSDiva 
software. The means from three separate experiments (n=3) were analyzed using 
one-way ANOVA with Bonferroni’s post hoc test. 
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5.3.5 Western Blotting 
MDA-MB-468 were harvested 24 h post infection, pelleted and resuspended in 200 
μL lysis buffer (62.5 mM Tris-HCl, 2% w/v SDS, 10% glycerol, 1 % protease 
inhibitor). Standard western blotting procedures (19) were followed using primary 
antibodies to detect caspase-9, and actin as a loading control. The primary 
antibodies anti-caspase-9 (#7237P, Cell Signaling Technology) and anti-actin (rabbit, 
ab1801, Abcam) were detected with anti-rabbit (#7074S, Cell Signaling Technology) 
antibodies before the addition of SuperSignal West Pico chemiluminescent substrate 
(Thermo Scientific, Waltham, MA). The FluorChem FC2 imager and software (Alpha 
Innotech, Santa Clara, CA) was used to detect the signal. 
 
5.3.6 In Vivo Experiments  
Female nu/nu athymic mice (4-6 weeks old, Jackson Laboratories) were injected 
subcutaneously into the mammary fat pad with human MDA-MB-468 cells (1x107 
cells/mouse in 100 μl of serum-free RPMI-1640 medium). After tumors reached the 
mean size of 50 mm3, Ad-p53-XL, Ad-DBD-XL and Ad-ZsGreen1 were intratumorally 
injected on days 0-4 and 7-11. A dose of 5.0X108 pfu in 50 μL volume was 
administrated (18). Tumor volumes were measured daily using Vernier calipers 
along the longest width (W) and the corresponding perpendicular length (L) using V= 
(L x (0.5W)2) to calculate tumor volume. Mice were sacrificed and tumors and organs 
were harvested 24 h after the last injection. All procedures were approved by 
Institutional Animal Care and Use Committee (IACUC) at the University of Utah and 
performed according to established NIH and University of Utah Animal Care 
Committee guidelines.  
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5.4 Results 
5.4.1 Mitochondrial p53 can bypass dominant negative inhibition in vitro 
To determine if mitochondrial targeted p53-XL and DBD-XL can escape the 
dominant negative effect of wt p53, we first conducted a rescue experiment in 
H1373, and second, tested MDA-MB-468 cells that naturally harbor a dominant 
negative mutant p53 (R273H mutation).  
We designed a mutant p53 construct with R248W mutation (called p53R248Wmut) 
which is known to exhibit a strong dominant negative effect (21, 22). We transfected 
human non-small cell lung carcinoma cells H1373 (p53 null) (23) with our constructs 
(p53-XL, DBD-XL, E-XL, wt p53, or EGFP), with or without the p53R248Wmut, and 
conducted a 7-AAD assay on these groups. In the absence of p53R248Wmut, p53-
XL, DBD-XL and wt p53 showed significantly higher apoptosis compared to their 
negative controls E-XL and EGFP (Fig. 1A, white set of bars). When co-transfected 
with p53R248Wmut, p53-XL and DBD-XL are capable of rescuing apoptotic activity 
while the apoptotic activity of wt p53 is dramatically impaired (Fig. 1A, black set of 
bars) suggesting that mitochondrial targeting of p53 can overcome dominant 
negative inhibition of mutant p53.  
To determine if mitochondrial p53 is capable of inducing apoptosis in a cell line that 
naturally harbors a dominant negative mutation, we infected MDA-MB-468 cells with 
our designed viral constructs and conducted a 7-AAD assay and a caspase-3/7 
western blot. Triple negative breast cancer cells MDA-MB-468 harbor the R273H 
mutation which is considered to have a strong dominant negative effect on wt p53 
(24, 25). For the H1373 rescue experiment, we used lipofectamine transfection of 
plasmid DNA. However, MDA-MB-468 are resistant to lipofectamine transfection. 
Therefore, we constructed Ad-p53-XL, Ad-DBD-XL and Ad-ZsGreen1 adenoviral 
constructs. For our previous plasmids (non-viral plasmids), EGFP was directly fused 
to our construct; for adenoviral constructs, ZsGreen1 is co-expressed with our 
protein of interest.  
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When MDA-MB-468 cells were infected with Ad-p53-XL, Ad-DBD-XL and Ad-
ZsGreen1, only Ad-DBD-XL showed higher activity than Ad-ZsGreen1 in the 7-AAD 
assay (Fig. 1B). Surprisingly Ad-p53-XL was not significantly different from Ad-
ZsGreen1 control.  
To determine if the induced apoptotic effect of Ad-DBD-XL is though the 
mitochondrial/ intrinsic apoptotic pathway, caspase-9 was detected in MDA-MB-468 
cells via western blotting. Caspase-9 can only be activated via the intrinsic apoptotic 
pathway (26). A representative cropped image of the western blot is shown in figure 
1C. Ad-DBD-XL showed caspase-9 induction while Ad-p53-XL only shows a faint 
band and negative controls Ad-ZsGreen1 and untreated MDA-MB-468 cells did not 
show caspase-9 activity. 
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Figure 1: (A) rescue experiment: p53 null H1373 cells transfected either with or 
without p53R248Wmut and p53-XL, DBD-XL, E-XL, wt p53 and EGFP. 48 h post 
transfection 7-AAD assay was conducted. Statistical analysis was performed by 
using two-way ANOVA with Bonferroni’s post test; ** p < 0.01 (B) MDA-MB-468 were 
infected with Ad-p53-XL, Ad-DBD-XL and Ad-ZsGreen. 72 h post infection, 7-AAD 
assay was conducted. Statistical analysis was performed by using one-way ANOVA 
with Bonferroni’s post test; * p < 0.05 and ** p < 0.01. Error bars represent standard 
deviations from three different independent experiments (n=3). (C) Representative 
cropped western blot of MDA-MB-468 cell lysates 24 h post infection with Ad-
ZsGreen, untreated, Ad-p53-XL and Ad-DBD-XL. 
 
5.4.2 Testing the effect of mitochondrial p53 in an orthotopic breast cancer 
model, in vivo 
We injected MDA-MB-468 cells into the mouse mammary fat pad, and allowed 
tumors to grow to 50 mm3. 5.0 X 108 pfu of Ad-p53-XL, Ad-DBD-XL and Ad-ZsGreen 
were then injected intratumorally on day 0-4 and 7-11 (18). Figure 2A shows a 
representative picture of a tumor-bearing mouse (black arrow indicates tumor site). 
The tumors were harvested 24 hours after the last treatment. Excised tumors of Ad-
p53-XL, Ad-DBD-XL, untreated and Ad-ZsGreen1 are shown in figure 2B.  
Although Ad-p53-XL and Ad-DBD-XL tumors appear smaller than the controls, their 
tumor sizes were smaller to begin with. In fact, tumor size measurements in figure 
2C revealed that there were no difference between treatment groups and untreated 
showing that mitochondrial p53 is unable to evade dominant negative inhibition in 
this model. 
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Figure 2: (A) generated tumor model: SQ injection of MDA-MB-468 human breast 
cancer cells into inguinal area of female nu/nu athymic mouse. 5X108 pfu was 
injected intratumorally on days 0-4 and 7-11 (18). Black arrow indicates tumor 
location. (B) Tumors harvested from mice after treatment. (C) Tumor size reduction. 
Statistical analysis was performed by using one-way ANOVA with Bonferroni’s post 
test. Error bars represent standard deviations from at least three independent 
experiments (n=5). 
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5.5 Discussion 
Our lab and others have previously shown that targeting p53 to the mitochondria 
results in apoptosis in a variety of cancer cells (13, 20, 27). We were the first to show 
that the DBD of p53 is sufficient to cause apoptosis at the mitochondria (20). Here 
we wanted to test if mitochondrially targeted p53 is capable of overcoming dominant 
negative inhibition of endogenous mutant p53 in vitro and in vivo. 
Therefore, we first overexpressed dominant mutant p53R248W in p53 null H1373 
cells (Fig. 1A) and then conducted apoptosis assays in triple negative MDA-MB-468 
cells (Fig. 1B, C) that naturally harbor dominant negative R273H mutant (25). In 
H1373 cells, p53-XL and DBD-XL retain the same apoptotic activity with or without 
overexpressing the dominant negative mutant, while apoptotic activity of wt p53 is 
dramatically decreased (Fig 1A). However, only Ad-DBD-XL was active in the 
dominant negative MDA-MB-468 cell line while Ad-p53-XL showed the same 
inactivity as the negative control Ad-ZsGreen1 (Fig. 1B). It might be speculated that 
p53-XL is sequestered via its TD by endogenous p53 in MDA-MB-468 cells. Unlike 
p53-XL, DBD-XL does not contain a TD and is therefore not inhibited by endogenous 
p53.  
Further, we wanted to examine if apoptotic activity of DBD-XL is through the intrinsic 
apoptotic pathway. Thus, we chose to determine caspase-9 induction which can only 
be activated through the intrinsic apoptotic pathway (26). Again, Ad-DBD-XL showed 
caspase-9 activation while Ad-p53-XL only showed minimal capsase-9 activity (Fig. 
1C). In summary, these results suggest that DBD-XL can bypass dominant negative 
inhibition of mutant p53.  
Even though in vitro results looked promising, mitochondrial p53 was not capable of 
reducing MDA-MB-468 tumor size (Fig. 2C). It seems that the p53-specific intrinsic 
apoptotic response by p53-XL and DBD-XL in MDA-MB-468 cells is not sufficient to 
result in inhibition of tumor growth or tumor shrinkage in this particular mouse breast 
cancer model. The dosing regimen might be the reason for the treatment failure. At 
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day 5-6 when no drug was injected tumors started to grow again suggesting a 
transient effect of apoptosis by mitochondrial p53 (Fig. 2C). The dose used in this 
study is the same as for wt p53 therapy in MDA-MB-468 (18, 28). However, wt p53 
and mitochondrial p53 have different apoptotic profiles. While mitochondrial p53 
induces apoptosis solely through intrinsic apoptotic pathway (12, 13, 29), wt p53 
activates the intrinsic and extrinsic pathway (30). Because mitochondrial p53 only 
induces the intrinsic apoptotic pathway, the effective dose may need to be higher 
than wt p53 therapy. In addition, the R273H mutant expressed in MDA-MB-468 has 
a very aggressive cancer profile. In fact, knock-in mice harboring this mutation 
(p53R273H/-mice) develop more carcinomas and have more invasive and metastatic 
properties than p53 knock-out mice (31). Due to differences in apoptotic mechanism 
and aggressiveness of MDA-MB-468 the dose of mitochondrial p53 should be 
increased and given more frequently, or combined with another cancer therapeutic. 
It has been shown that in response to chemotherapy or radiation treatment p53-
mediated apoptosis causes tumor regression (32) and transfecting these cell lines 
with wt p53 increases the sensitivity to chemotherapy (18). The potency of 
mitochondrial p53 can be enhanced by combination with a chemotherapeutic that 
targets the nucleus and intercalates with nuclear DNA (antracycline), interferes with 
DNA replication (alkylanting agent) or abolishes DNA/RNA synthesis 
(antimetabolite). The current treatment plan of breast cancer already involves a 
variety of cytotoxic drugs such as antracycline (doxorubicin, epirubicin), alkylating 
agents (cyclophosphamide, methotrexate) and antimetabolites (fluorouracil) (35). A 
dual approach combining mitochondrial p53 with antracycline, alkylating agent or 
antimetabolite has the advantage of targeting two cellular organelles which are 
highly involved in apoptosis resulting in higher apoptosis induction (18, 33). 
However, the most promising approach is to further optimize mitochondrial targeting 
of p53 by fusing it to MTS from pro-apoptotic Bak. As previously shown, the MTS is 
responsible for directing p53 specifically to the protein where the MTS is taken from. 
We demonstrated that every protein that is tagged to XL will translocate to anti-
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apoptotic Bcl-XL (20) while p53 fused to BakMTS will translocate to pro-apoptotic 
Bak (chapter IV). When p53 is targeted to Bcl-XL, it will primary inhibit Bcl-XL and is 
less effective on other anti-apoptotic proteins such as Bcl-2 and Mcl-1. In cells 
mainly expressing Bcl-XL with low Bcl-2 and Mcl-1 levels, neutralizing Bcl-XL will 
results in Bak homooligomerization and apoptosis. However, in aggressive cancers, 
Bcl-2, Bcl-XL and Mcl-1 are often overexpressed (34-37). Therefore, the amount of 
p53-XL and DBD-XL might not be efficient enough to sequester anti-apoptotic Bcl-2 
proteins and to ensure Bak and Bax homo-oligomerization. This again suggests the 
need to increase the dose of p53-XL and DBD-XL.  
Directly targeting the pro-apoptotic Bak or Bax might be therefore superior over 
targeting Bcl-XL. Bak and Bax are directly responsible for pore formation at the 
mitochondria. While anti-apoptotic Bcl-2 proteins such as Bcl-XL need to be 
sequestered, pro-apoptotic Bak or Bax just needs to be activated by a transient 
interaction and then can form pores at mitochondrial outer membrane. We have 
shown in chapter IV that targeting p53 to the mitochondria by using the MTS from 
Bak is superior to Bax. We speculate that this is due to differences in subcellular 
localization of these proteins. Bax is constantly shuttled between mitochondria and 
cytoplasm (38, 39). Therefore the amount present at the mitochondria might be not 
sufficient to initiate apoptosis. Bak on the other hand is always present at the 
mitochondria (40) and is activated when p53 is targeted to the mitochondria with 
MTS from Bak, triggering caspase activation and apoptosis.  
In fact, we have shown that p53 or DBD fused to the MTS from pro-apoptotic Bak 
was superior over wt p53 and our chimeric p53 construct named p53-CC 
(unpublished data) in p53 null ovarian cancer cells SKOV-3 (Chapter IV). This might 
be due to a defect in the transcriptional apoptotic pathway of p53 in SKOV-3 cells. 
Targeting p53 to the mitochondria for ovarian cancer therapy will be further 
discussed in the future directions section (Chapter VII). 
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6. Re-engineered p53 avoids the dominant negative effect 
in cancer cells in vivo and in vitro 
 
The following two manuscripts have been summarize. The methods and 
figures are directly taken from the manuscripts. 
“A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells ” 
Okal A, Mossalam M, Matissek KJ, Dixon AS, Moos PJ, Lim CS, Mol Pharm. 2013 
Oct 7 
Co-Author Contribution: 
Research design: 20% 
Experimental work: 30% 
Data evaluation: 20% 
Manuscript writing: 5% 
“Re-engineered p53 activates apoptosis in vivo and causes primary tumor 
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6.1 Abstract  
The tumor suppressor p53 is mutated in more than 50% of all cancers. While most of 
the mutations occur in the DNA binding domain (DBD) of p53, the tetramerization 
domain (TD) remains intact. This allows for wtp53/mutp53 heterotetramer formation, 
abolishing the transcriptional activity of p53 and reducing its tumor suppressor 
activity. To overcome this dominant negative inhibition, we re-engineered p53. The 
TD in wt p53 was removed and replaced with the coil-coiled (CC) oligomerization 
domain from breakpoint cluster region (BCR). CC in BCR tetramerizes in similar 
fashion to the TD in p53. Our designed p53-CC translocates to the nucleus 
(fluorescence microscopy) and shows the same apoptotic potential (TUNEL-, 
Annexin V-, and 7-AAD assay) as wt p53 in breast cancer cells T47D which do not 
exhibit a strong dominant negative effect. Unlike wt p53, our p53-CC does not 
interact with endogenous mutant p53 (co-IP). p53-CC remains active when dominant 
negative mutant p53 (R175H, R248W and R273H) is overexpressed and also 
causes apoptosis in triple negative MDA-MB-468 cells which harbor the R273H all 
dominant negative mutation (7-AAD assay). In vivo, intratumorally injection of 
adenoviral p53-CC results in tumor shrinkage. Analysis of the tumor tissue showed 
that p53-CC and wt p53 were highly expressed in MDA-MB-468 tumors and wt p53 
caused more p21 expression than p53-CC (DAP staining). Additionally, p53-CC had 
higher necrotic potential (H&E staining) than wt p53 suggesting tumor shrinkage was 
due to cell death occurring through necrosis. In summary, we have shown that p53-
CC can circumvent dominant negative mutant p53 in vitro and in vivo and therefore 
can be used for cancer gene therapy.  
 
6.2 Introduction 
The TP53 gene is mutated in more than 50% of all cancers (1-4). Mutations in the 
TP53 gene occur typically by a single monoallelic missense mutation (5) frequently 
affecting the DNA binding domain (DBD) of p53 which often prevents binding of p53 
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to specific DNA-sequences, abolishing its transcriptional activity (6, 7). The amino 
terminus and the C-terminus (containing the tetramerization domain or TD) of p53 
are usually not mutated (7). Therefore, mutant p53 is capable of forming 
heterotetramers with wt p53 via its intact TD resulting in transcriptional inactivation of 
the entire p53 tetramer (8-10). This is the main disadvantage of wt p53 based gene 
therapy. While introducing wt p53 into cancers that are p53 null or harbor low levels 
of endogenous wt p53 results in apoptosis, exogenous wt p53 introduced into tumors 
with dominant negative mutant p53 face the dominant negative inhibition by 
endogenous mutant p53.  
Thus, we proposed to replace the TD in p53 by a structurally similar tetramerization 
domain. The p53 tetramer is formed via a dimeric intermediate (11). The highly 
thermodynamically stable tetramer is formed by hydrophobic helix interaction of two 
dimers (12). 
Only one other group has attempted replacing the TD before (13). Waterman et al. 
replaced the TD with an oligomerization domain which led to parallel tetramer 
formation and resulted in significant reduction in p53 transcriptional activity (13). We 
chose the oligomerization domain from breakpoint cluster region (Bcr) protein, a 72 
amino acid coiled-coil (CC) which consists of two α helices. CC tetramerizes as two 
dimers of two antiparallel oriented monomers, in a similar fashion to the TD of wt p53 
(14, 15). We hypothesized that our chimeric p53-Bcr fusion (named p53-CC) will 
solely tetramerize with itself when introduced into cancer cells harboring mutant p53. 
Therefore, our chimeric p53 is capable of escaping the dominant negative effect and 
cause apoptosis in mutant p53 cell lines.  
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6.3 Materials and methods 
6.3.1 Construction of Plasmids  
To construct pEGFP-p53-CC (p53-CC), a truncated version of wt p53 that lacks the 
tetramerization domain (amino acids 1-322) was amplified via PCR with primers 5’-
GCGCGCGCGCTCCGGAATGGAGGAGCCGCAGTCA-3’ and 5’-
GCGCGCGCGCTCCGGATGGTTTCTTCTTTGGCTGGGGAGA-3’ using the 
previously cloned pEGFP-p53 (wt p53) as the template DNA (16). The PCR product 
was then subcloned into the BspEI site of pEGFP-CC (CC). 
To design pTagBFP-mut-p53, wt p53 was amplified via PCR with primers 5’-
GCGCGCGCGCTCCGGAGCCATGGAGGAGCCGCAGT-3’, and 5’-
GCGCGCGCGCGGTACCTCAGTCTGAGTCAGGCCCTTCTGTC-3’ using pEGFP-
p53 as a template. This insert was then subcloned into the digested pTagBFP-C 
vector (Evrogen, Moscow, Russia) at the BspEI and KpnI sites. Three hot spot 
mutations (R175H, R248W, and R273H) were then introduced into pTagBFP-p53 via 
QuikChange II XL Site- Directed Mutagenesis Kit (Agilent, Santa Clara, CA). The 
following primers were used: for the R175H mutation, 5’-
TGACGGAGGTTGTGAGGCACTGCCCCCACCATGAGCGC-3’ and 5’-
GCGCTCATGGTGGGGGCAGTGCCTCACAACCTCCGTCA-3’; for R248W, 5′- 
CTGCATGGGCGGCATGAACTGGAGGCCCATCCTCACCA-3′ and 5’-
TGGTGAGGATGGGCCTCCAGTTCATGCCGCCCATGCAG-3’; and for R273H, 5’-
GGAACAGCTTTGAGGTGCATGTTTGTGCCTGTCCTGGG-3’ and 5’-
CCCAGGACAGGCACAAACATGCACCTCAAAGCTGTTCC-3’. 
 
6.3.2 Cell Lines and Transient Transfection 
T47D human ductal breast epithelial tumor cells (ATCC, Manassas, VA), (ATCC) 
and H1373 human non-small cell lung carcinoma cells (a kind gift from Dr. Andrea 
Bild, University of Utah) were grown as monolayers in RPMI (Invitrogen, Carlsbad, 
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CA) supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin-
streptomycin-glutamine (Invitrogen), 0.1% gentamicin (Invitrogen). T47D were also 
supplemented with 4 mg/L insulin (Sigma, St. Louis, MO). 1471.1 murine breast 
adenocarcinoma cells (gift of Dr. Gordon Hager, NCI, NIH), HEK293 human 
embryonic kidney (ATCC), MDA-MB-468 human breast adenocarcinoma cells 
(ATCC) were grown as monolayers in DMEM (Invitrogen) supplemented with 10% 
fetal bovine serum (Invitrogen), 1% penicillin-streptomycin-glutamine (Invitrogen), 
and 0.1% gentamicin (Invitrogen). MDA-MB-468 cells were also supplemented with 
1% MEM non-essential amino acids (Invitrogen). All cells were incubated in 5% CO2 
at 37ºC. The cells were seeded at a density of 7.5 × 104 cells (for 1471.1) and 3.0 × 
105 cells (T47D, MDA-MB-468 and H1373 cells) in 6-well plates (Greiner Bio-One, 
Monroe, NC). Transfections of 1 pmol DNA were carried out 24 h after seeding using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s recommendations. 
 
6.3.3 Microscopy 
All microscopy was performed using 1471.1 cells due to their ideal microscopic 
morphology (16). 24 h post transfection, media in 2-well live-cell chambers (Nalgene 
Nunc, Rochester, NY) was replaced with phenol red-free DMEM (Invitrogen). Cells 
were then incubated with 2 µg/mL Hoechst 33342 nuclear stain (Invitrogen) for 30 
minutes at 37ºC. Images were taken using an Olympus IX71F fluorescence 
microscope (Scientific Instrument Company, Aurora, CO) with high-quality narrow 
band GFP filter (excitation, HQ480/20 nm; emission, HQ510/ 20 nm) to detect EGFP 
and cyan GFP v2 filter (excitation HQ436/20 nm, emission HQ480/40 nm, with beam 
splitter 455dclp) to detect H33342 as previously described (17). 
 
6.3.4 TUNEL Assay 
As previously described (16), T47D cells were prepared 48 h after transfection using 
In Situ Death Detection Kit, TMR red (Roche, Mannheim, Germany). Cells were 
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EGFP gated and analyzed using FACSAria-II (BD-BioSciences, University of Utah 
Core Facility) and FACSDiva software. EGFP and TMR red were excited at 488 nm 
and 563 nm wavelengths and detected at 507 nm and 580 nm, respectively. The 
TUNEL assay was repeated three times (n=3) and analyzed using one-way ANOVA 
with Bonferroni’s post test. 
 
6.3.5 Annexin-V Assay 
The annexin-V assay was performed as before (16). Briefly, 48 h post transfection, 
T47D cells were suspended in 400 μl annexin binding buffer (Invitrogen) and 
incubated with 5 μl annexin-APC (annexin-V conjugated to allophycocyanin, 
Invitrogen) for 15 minutes. The incubated cells were EGFP gated and analyzed 
using FACSCanto-II. EGFP and APC were excited at 488 nm and 635 nm 
wavelengths and detected at 507 nm and 660 nm, respectively. Each construct was 
tested three times (n=3) and analyzed using one-way ANOVA with Bonferroni’s post 
hoc test. 
 
6.3.6 7-AAD Assay 
As before (16), following manufacturer’s instructions, T47D, H1373, and MDA-MB-
468 cells were stained with 7-aminoactinomycin D (7-AAD, Invitrogen) 48 h after 
transfection. Cells were analyzed and gated for EGFP (with same fluorescence 
intensity to ensure equal expression of proteins) using the FACSCanto-II (BD-
BioSciences, University of Utah Core Facility) and FACSDiva software. Excitation 
was set at 488 nm and detected at 507 nm and 660 nm for EGFP and 7-AAD, 
respectively. The means from three separate experiments (n=3) were analyzed using 
one-way ANOVA with Bonferroni’s post test. 
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6.3.7 Co-Immunoprecipitation (co-IP) 
The co-IP was performed using Dynabeads co-IP Kit (Invitrogen). T47D cells 
transfected with either EGFP-wt-p53 or EGFP-p53-CC were collected and weighed 
out (0.05 g) 20 h post transfection. Anti-GFP antibody (ab290, Abcam) was coupled 
to magnetic beads using Dynabeads Antibody Coupling Kit (Invitrogen). 
Approximately 0.2 g of cell pellet was lysed in 1.8 ml extraction buffer B (1x IP, 100 
mM NaCl, 2 mM MgCl2, 1 mM DTT, 1 % protease inhibitor). The lysate was 
incubated for 30 min at 4°C with 1.5 mg of the dynabeads coupled with anti-GFP 
antibody. The immune complexes were then collected by a magnet and washed 
three times with extraction buffer B and one time with last wash buffer (1x LWB, 
0.02% Tween 20). Immune complexes were then eluted using 60 µl elution buffer. 
Finally, the eluted complexes were denatured and blotted using anti-p53 antibody 
HRP-conjugated (sc-126 HRP, Santa Cruz Biotechnology, Santa Cruz, CA). 
  
6.3.8 Overexpression of Mutant p53 
H1373 cells were cotransfected with 1 pmol of the transdominant mutant pTagBFP-
mut-p53 (R175H, R248W, and R273H) and 1 pmol of wt p53, p53-CC, or CC fused 
to EGFP. 48 h post transfection, cells were stained as in the 7-AAD assay above and 
gated for EGFP and BFP using the FACSCanto-II (BD-BioSciences, University of 
Utah Core Facility) and FACSDiva software. Excitation for BFP was set at 405 nm 
and detected at 457 nm. The means from three separate experiments (n=3) were 
analyzed using one-way with Bonferroni’s post hoc test and unpaired t test. 
 
6.3.9 Recombinant Adenovirus Production 
Replication-deficient recombinant adenovirus serotype 5 (Ad) constructs were 
generated using the Adeno-X® Adenoviral Expression System 3 (Clontech). Either wt 
p53 or p53-CC was inserted into a cassette under the control of the CMV promoter. 
A separate CMV promoter controls the expression of ZsGreen1 for visualization. The 
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empty virus (vector) was used as a negative control. wt p53 and p53-CC were PCR 
amplified with primers containing 15 base pair homology with a linearized pAdenoX 
vector (Clontech) based on an In-Fusion® HD Cloning Kit (Clontech). Stellar® 
competent cells (Clontech) were transformed with the adenoviral vector plasmids 
containing our constructs. Viral DNA was then purified, linearized and transfected 
into HEK293 cells for packaging and amplification. Viral particles were isolated from 
HEK293 cells by freeze-thawing, purified using Adeno-X® Mega Purification Kit 
(Clontech), and dialyzed against storage and proper tonicity buffer (2.5% glycerol 
(w/v), 25 mM NaCl, and 20 mM Tris-HCl, pH 7.4). The viral titer was determined 
using flow cytometry per the manufacturer’s recommendation. 
 
6.3.10 In Vivo Study  
The experimental protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Utah. All experiments were performed in 
female nu/nu athymic mice (4-6 weeks old, Jackson Laboratories, Bar Harbor, ME). 
Human MDA-MB-468 cells (1x107 cells/mouse in 100ul of serum-free RPMI-1640 
medium) were injected subcutaneously into a mammary fat pad. When tumors 
reached the mean size of 50 mm3, peritumoral injections of adenoviral constructs 
(5.0X108 pfu) in a 50 μl volume were made on days 0-4 and 7-11 (18). 24 h after the 
last injection the mice were sacrificed and the organs were harvested for analyses. 
Tumor volumes were measured daily using a Vernier caliper along the longest width 
(W) and the corresponding perpendicular length (L). The tumor volume was 
calculated using V= (L x (0.5W)2). All procedures were performed according to 
established NIH and University of Utah Animal Care Committee guidelines.  
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6.3.11 Histology 
Animal tumor tissue samples and organs were fixated in 10% formalin for 24 h 
followed by dehydration in alcohol and embedded in paraffin. Embedded tissues 
were then sectioned to cut at 4 μm thick sections and mounted on plus slides. Slides 
from each tumor tissue from all mice in the three treatment groups as well as the 
untreated group were stained using hematoxylin and eosin and p21 
immunohistochemistry stain. Tissue and histological slide preparation was 
conducted by ARUP Laboratories (Salt Lake City, Utah). 
 
6.4 Results  
6.4.1 p53-CC localizes to the nucleus 
When engineering p53-CC, amino acids 323 to 393 were removed which accounts 
for most of the C-terminal domain including not only the TD, but also two of the three 
nuclear localization signals in wt p53. However, one strong NLS remains intact (aa 
305-322) in p53-CC. The two NLSs (370-376 aa and 380-386 aa) which have been 
removed in p53-CC are considered weak NLSs (16, 19). Figure 1 demonstrates that 
the one strong NLS in p53-CC is capable of targeting p53-CC to the nucleus in a 
similar manner as wt p53 in murine adenocarcinoma cells 1471.1 (Fig. 1). 1471.1 
cells were chosen for this experiment because they are larger in size, spread well, 
and are generally easier to visualize than T47D cells. However, similar results were 
observed in T47D breast cancer cells (20). 
172 
 
 
 
 
 
Figure 1: Representative images of p53-CC and wt p53 both tagged to EGFP are 
shown in the left column with images of nuclear stain H33342 in the middle column. 
The “EGFP” and “H33342 Nuclear Stain” columns have been false colored green 
and blue, respectively. The left column shows the phase contrast images. White 
scale bars on the top left corners are 10 μm.  
 
6.4.2 Exploring the apoptotic potential of p53-CC 
The apoptotic activity of p53-CC was determined via TUNEL, Annexin-V and 7-AAD 
assays in T47D human breast cancer cells. The L194F mutation which is present in 
T47D cells does not exhibit a strong transdominant effect (21). 
When cells undergo apoptosis, the nuclear DNA is cleaved by caspases. DNA 
fragments can be detected by labeling the terminal end of nucleic acids (TUNEL 
assay) (22). Another hallmark of apoptosis is the externalization of 
phosphatidylserine to the outer surface of the plasma membrane, while in healthy 
cells, phosphatidylserine is typically found on the cytosolic surface (annexin-V assay) 
(23). Additionally, rupture of the plasma membrane of dying cells can be measured 
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by 7-AAD. The 7-AAD dye enters the apoptotic/ necrotic cell (ruptured cell 
membrane) and intercalates with nuclear DNA while healthy cells, which have an 
intact plasma membrane, remain unstained (24).  
wt p53 and p53-CC have similar apoptotic activities in TUNEL (Fig. 2A), Annexin V 
(Fig. 2B) and 7-AAD (Fig. 2B) assays. Additionally, figure 2 showed that wt p53 and 
p53-CC induce significantly higher apoptosis compared to their negative controls CC 
and EGFP.  
 
Figure 2: apoptotic potential of p53-CC: (A) TUNEL, (B) Annexin-V and (C) 7-AAD 
assay was carried out 24h for (A) and 48 h for (B) and (C) after transfection. 
Statistical analysis was performed by using one-way ANOVA with Bonferroni’s post 
test; * p < 0.05, ** p < 0.01, and *** p < 0.001. Error bars represent standard 
deviations from at least three independent experiments (n=3). 
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6.4.3 p53-CC does not heterotetramerize with endogenous p53 
To explore if p53-CC solely forms homotetramers or also interacts with mutant p53, 
we conducted a co-IP. wt p53 and p53-CC (both fused to EGFP) were transfected 
into T47D cells; cells were then lysed approximately 20 h after transfection and 
incubated with anti-GFP antibody. A western blot was done using antibodies against 
EGFP and against p53. Since exogenous wt p53 and p53-CC are fused to EGFP, 
their size is different from endogenous p53. Endogenous p53 (53 kDa) was expected 
to co-immunoprecipitate with exogenous wt p53 tagged to EGFP (70 kDa) due to 
having the same TD (Fig. 3 left lane). Exogenous p53-CC tagged to EGFP (71 kDa) 
did not co-immunoprecipitate with endogenous mutant p53 (Fig. 3 right lane) due to 
their different oligomerization domains, implying that p53-CC is capable of 
overcoming dominant negative inhibition. 
 
Fig. 3: Representative cropped western blot of protein complexes co-
immunoprecipitated using anti-GFP antibody. Lane 1, exogenous wt p53 tagged to 
EGFP (70 kDa) which was transfected into T47D cells co-immunoprecipitates with 
endogenous wt p53 (53 kDa). Lane 2, exogenous p53-CC tagged to EGFP (71 kDa) 
does not co-immunoprecipitates with endogenous wt p53 (53 kDa). Unlabeled bands 
are nonspecific binding. 
 
175 
 
 
 
 
6.4.4 p53-CC evades dominant negative inhibition in vitro 
To verify if p53-CC can avoid dominant negative inhibition, we first conducted a 
rescue experiment in H1373 cells, and second infected MDA-MB-468 which harbor 
the dominant negative mutant R273H (25) with our designed constructs. 
For the rescue experiment, we transfected p53 null human non-small cell lung 
carcinoma cells H1373 (26) with wt p53, p53-CC and CC. This showed significant 
induction of apoptosis for wt p53 and p53-CC while negative control CC showed 
minimal activity (Fig. 4A first set of bars). Additionally, we designed a transdominant 
mutant p53 by combining three hotspot mutations (R175H, R248W, and R273H) that 
are known to exhibit a dominant negative effect and co-transfected this construct 
with wt p53, p53-CC or CC (27, 28). As expected, figure 4A (black set of bars) 
showed that p53-CC, but not wt p53, was still capable of inducing apoptosis in the 
presence of mutant p53 (R175H, R248W, and R273H). 
To further demonstrate that p53-CC can overcome the dominant negative effect of 
mutant p53, triple negative breast cancer cells MDA-MB-468 were infected with 
adenovirus containing wt p53, p53-CC, or Zsgreen1. Lipofectamine 2000, which was 
used for all our previous studies (Fig.1- 4A), was not capable of transfecting this cell 
line, therefore we created the Ad-wt-p53, Ad-p53-CC and Ad-Zsgreen1 adenoviral 
constructs. In our non-viral plasmids EGFP was directly fused to our constructs. For 
the adenoviral construct ZsGreen1 is co-expressed with our protein of interest. Ad-
p53-CC induces significantly higher apoptosis in MDA-MB-468 than Ad-wt-p53 and 
negative control Ad-Zsgreen1, suggesting again that p53-CC is not affected by 
dominant negative inhibition (Fig. 4B). On the other hand, Ad-wt-p53 shows the 
same minimal activity as negative control Ad-Zsgreen1 (Fig. 4B). 
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Fig. 4: p53-CC evades dominant negative inhibition: (A) rescue experiment: p53 null 
H1373 cells were transfected with wt p53, p53-CC and CC (left set of bars) or with wt 
p53, p53-CC, CC and cotransfected with mutant p53 (R175H, R248W, and R273H). 
(B) MDA-MB-468 cells were infected with Ad-wt-p53, Ad-p53-CC and Ad-Zsgreen 
and apoptotic potential was determined via 7-AAD assay. Statistical analysis was 
performed by using one-way ANOVA with Bonferroni’s post test; ** < p 0.01, and *** 
p < 0.001. Error bars represent standard deviations from three independent 
experiments (n=3). 
 
6.4.5. p53-CC bypasses dominant negative inhibition in vivo 
To verify that p53-CC can evade dominant negative inhibition in vivo, injected MDA-
MB-468 cells were injected into the mouse mammary fat pad to form orthotopic 
tumors. Once the tumors reached 50 mm3, we intratumorally injected 5.0 X 108 pfu 
of Ad-p53-CC, Ad-wt-p53 and Ad-ZsGreen1 (or no treatment) on days 0-4 and 7-11 
(18). A representative picture of the generated tumor model is shown in figure 5A. 
We harvested all the tumors from each treatment group. Figure 5B depicts images of 
representative excised tumors for Ad-p53-CC, Ad-wt-p53, Ad-ZsGreen1 and the 
untreated group. We also noticed that negative controls Ad-ZsGreen1 and untreated 
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tumors are more vascularized and bloody than tumors treated with Ad-p53-CC and 
Ad-wt-p53 (Fig. 5B). 
Ad-p53-CC had greater reduction in mean tumor size that is significant compared to 
Ad-wt-p53, Ad-ZsGreen1 and untreated (Fig. 5C). Ad-wt-p53 inhibited tumor growth 
but was not significantly different from Ad-ZsGreen1 and untreated (Fig 5C). To 
monitor overall animal health, we measured animal body weight. Figure 5D shows 
that there is no difference in the weights among the groups suggesting no toxicity 
from the virus. 
There were no abnormalities or signs of pathology for liver, kidney, spleen, heart, or 
lungs. However, metastasis of tumors were noticed in two mice of the Ad-ZsGreen1 
group and three of the mice in the untreated group. 
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Figure 5: p53-CC evades dominant negative inhibition in vivo: (A) representative 
picture of MDA-MB-468 based orthotopic mouse model. MDA-MB-468 cells were 
subcutaneously injected into the mammary fat pad. When tumors reached 50 mm3, 
they were intratumorally injected with 5 X 108 pfu per each construct on days 0-4 and 
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7-11. (B) images of represented excised tumors of different treatment groups. (C) 
tumor size reduction (D) tumor weights of different treatment groups. Statistical 
analysis was performed by using one-way ANOVA with Bonferroni’s post test † p < 
0.001. Error bars represent standard deviations from at least three independent 
experiments (n=6). 
 
6.4.6 Detection of p53 pathway specific markers 
To verify that our constructs are expressed in tumors and can induce p53-dependent 
activity, we carried out immunohistochemistry staining using hematoxylin and eosin 
staining (H&E) depicted in figure 6A left column, p21 staining in figure 6A middle 
column and ZsGreen staining figure 6A right column. ZsGreen1 is co-expressed with 
our protein of interest in vivo (Fig 6A, right column). Ad-p53-CC, Ad-wt-p53 and Ad-
ZsGreen1 showed significant expression of the construct in tumor tissue (Fig. 6 right 
column), while untreated, as expected, did not show any expression of ZsGreen1. 
Figure 6A left column shows H&E staining with solid arrows used to highlight 
necrosis while open arrows highlight non-necrotic areas. p53-CC had higher levels of 
necrosis in all tumor tissue from mice injected with Ad-p53-CC compared to Ad-wt-
p53, Ad-ZsGreen1, or untreated. Since the necrotic potential was only significantly 
higher in the Ad-p53-CC group, while Ad-wt-p53, Ad-ZsGreen1 and untreated 
showed about the same necrotic potential (Fig. 6B), detected necrosis may be due to 
tumor suppressor activity of p53-CC and not hypoxia or injection site damage. p21 
was detected using 3,3’-diaminobenzidine (DAP) staining of photomicrographs which 
stains nuclei of p21- positive cells brown. As expected Ad-ZsGreen1 and untreated 
showed no p21 expression (Fig. 6A and C). Ad-wt-p53 has significantly more p21 
expression than Ad-p53-CC (Fig 6C). This observation will further be explained in 
the discussion section.  
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Figure 6 immunohistochemistry representative pictures (A) (left column) H&E, 
(middle column) p21 and (right column) ZsGreen1 expression levels (B) and (C) 
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semi-quantitative histoscore analysis of tumor (B) necrosis and (C) p21 upregulation 
in excised tumors from all groups. Statistical analysis was performed by using one-
way ANOVA with Bonferroni’s post test; * p < 0.05, ** p < 0.01, and *** p < 0.001. 
Error bars represent standard deviations from at least three independent 
experiments (n=6). 
 
6.5. Discussion 
We are the first group to successfully re-engineer p53 by replacing its TD with the 
oligomerization domain of Bcr while still retain apoptotic activity. In the past, only one 
group has attempted swapping out the TD with a four-stranded coiled coil (13). The 
weakness of their oligomerization domain is that it forms parallel dimers of dimers 
while the TD in p53 naturally forms anti-parallel dimers of dimers (14, 15, 29). 
Therefore, Waterman et al. had limited success with p53 regulated transcriptional 
and apoptotic activity of their construct (13). 
We chose the oligomerization domain of Bcr because similar to the TD it also forms 
anti-parallel dimers of dimers (14). By constructing p53-CC, we replaced most of the 
C-terminus (starting from 322 aa) by CC and lost two out of the three NLSs. 
However, the two NLSs removed in p53-CC are considered to be weak NLSs, while 
p53-CC still harbors the strong NLS (305- 322 aa) (19). Even though p53-CC lacks 
the two weak NLSs it was still capable of translocating into the nucleus which is 
essential for its function as a transcription factor (Fig. 1).  
Since we have proven nuclear localization, we wanted to examine if p53-CC retains 
the same apoptotic potential as wt p53. p53-CC is capable of inducing apoptosis 
similar to wt p53 shown in three different apoptosis assays in breast cancer cells 
which do not contain dominant negative mutant p53 (Fig. 2). Therefore, our p53-CC 
is superior to the Waterman construct (13) which showed low activity in colony 
forming assay compared to wt p53 in osteosarcoma Saos-2 cells in which the p53 
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gene is entirely deleted (30). Thus, our CC can replace the TD of p53 and 
emphasizes that the TD has mostly a structural role in forming p53 tetramers, and its 
regulatory roles are negligible. Even though post translational modifications in the C-
terminus are important for transcriptional activity (31), we show that p53-CC has the 
same transcriptional and apoptotic activity as wt p53 although it lacks the entire C-
regulatory domain.  
Further, CC has a clear advantage over TD because unlike TD, CC does not 
heterotetramerize with endogenous wt p53 (Fig. 3). In summary, p53-CC retains wt 
p53 transcriptional and apoptotic activity (Fig. 2) and does not interact with 
endogenous wt p53 (Fig. 3) which could be beneficial in a dominant negative cell 
line. On the other hand p53-CC could potentially interact with endogenous Bcr via its 
CC. Bcr is a phosphotransferase protein that is suspected to have a role in the 
inflammatory pathway and in cell proliferation (32). However, this interaction is 
unlikely because Bcr is found in the cytoplasm (33) and p53-CC as shown via 
fluorescence microscopy (Fig. 1) translocates to the nucleus. We are further 
addressing p53-CC and Bcr interaction by introducing mutations in p53-CC to favor 
homotetramerization (manuscript in preparation: Towards super p53: A Re-
engineered Tumor Suppressor with Enhanced Homo-oligomerization and Increased 
Apoptotic Activity). 
Since we have verified homotetramerization, we wanted to examine if p53-CC is 
superior over wt p53 in evading the dominant negative effect first in vitro and then in 
vivo. Thus, we tested the ability of p53-CC to bypass the dominant negative effect 
with transdominant mutant p53 overexpression and by MDA-MB-468 that harbor 
dominant negative mutant p53 (Fig. 4). Both experiments verified that the apoptotic 
activity of p53-CC is unaffected by the presence of dominant negative mutant p53 
while wt p53 mostly loses its activity (Fig. 4). To further validate if this is still the case 
in vivo, we used an orthotopic mouse breast cancer model using triple negative 
dominant negative MDA-MB-468 cells (34). Remarkably, p53-CC was capable of 
shrinking tumors while wt p53 only stopped tumor growth (Fig. 5C). This finding 
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correlates with Nielsen and colleagues who showed that wt p53 introduced into a 
xenograft MDA-MB-468 model inhibits tumor growth but does not cause tumor 
shrinkage (34). Our data emphasizes that p53-CC is capable of overcoming the 
dominant negative effect of wt p53 in vivo (Fig. 5C). 
Next, we wanted to determine if tumor size reduction was due to p53-specific 
induction or due to p53-independent response. First, we verified that all our 
adenoviral constructs were highly expressed in tumor tissue (Fig. 6A right column). 
Second, we observed that p53-CC showed higher levels of necrosis compared to wt 
p53 (Fig. 6A left column; Fig. 6B) and negative controls ZsGreen1 and untreated, 
implying that the detected necrosis is due to p53-CC specific activity causing cell 
death which contributes to tumor reduction.  
Finally, p21 is one of the best characterized p53 cell cycle genes (35). Ad-ZsGreen1 
and untreated showed no p21 expression verifying that p21 expression was due to 
p53 specific response (Fig. 6A middle column; Fig. 6C). Ad-wt-p53 showed higher 
expression of p21 than Ad-p53-CC (Fig. 6A middle column; Fig. 6C). This might be 
due to structural and stability differences in p53-CC and wt p53. The melting 
temperature (Tm) for CC is about 83ºC (36) while Tm for TD is about 75ºC at 
physiological pH (37). Therefore, p53-CC can form more stable tetramers than wt 
p53. Additionally, it is known that mutant p53 sequesters wt p53 and forces it to form 
inactive hetero-oligomers with endogenous mutant p53 (9). The lower stability of wt 
p53 tetramers and sequestration of wt p53 results in low levels of wt p53 tetramers 
compared to high levels of p53-CC homotetramers. Basal or low levels of 
endogenous p53 typically turns on pro-arrest genes such as p21, while higher levels 
of p53 protein usually turn on pro-apoptotic genes such as Bax (38, 39). In breast 
cancer p53 activity has been linked to p21-dependent and-independent growth arrest 
and cellular senescence instead of cell death, resulting in minimal tumor regression 
and early relapse of breast cancer patients (40). Since Ad-wt-p53 induces more p21 
than Ad-p53-CC this might provide an explanation to why Ad-wt-p53 only inhibits 
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tumor growth while Ad-p53-CC shrinks the tumors. Further testing needs to be done 
to verify how exactly p53 causes tumor shrinking.  
In summary, we re-engineered p53 by replacing its TD with the CC from Bcr to 
bypass dominant negative inhibition by mutant p53. Our p53-CC has been shown to 
overcome dominant negative inhibition in vitro and in vivo. Therefore, our p53-CC 
which still remains its function in a dominant negative cancer is clearly superior over 
wt p53 gene therapy and can be used for a variety of cancers aside from breast 
cancer that currently have no cure.  
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7. Conclusions and Future Directions 
7.1 Conclusions 
7.1.1 Activity of mitochondrially targeted p53 is dependent on the 
mitochondrial targeting signal (Chapters 2 and 4) 
Targeting p53 to the mitochondria results in a rapid apoptotic response due to the 
direct interaction between p53 and pro-and anti-apoptotic Bcl-2 protein family 
members (1, 2). We attached p53 to different mitochondrial targeting signals (MTSs) 
from the mitochondrial matrix (ornithine transcarbomylase: OTC), inner membrane 
(cytochrome c oxidase: CCO), outer membrane (TOM20 complex: TOM) and outer 
surface of the outer membrane (anti-apoptotic Bcl-XL: XL; pro-apoptotic Bak: 
BakMTS; pro-apoptotic Bax: BaxMTS).  
To function as a transcription factor nuclear localization is required. p53 contains 
three nuclear localization signals (NLS) one strong NLS and two weak NLSs to 
ensure nuclear translocation (3). However, mitochondrial translocation only occurs 
upon severe stress induction. Since it is known that monoubiquitinated p53 is 
shuttled out of the nucleus into the cytoplasm, Moll and colleagues speculated that 
monoubiquitinated p53 can be shuttled into the mitochondrial through HAUSP (4, 5).  
To ensure mitochondrial localization of p53, different mitochondrial targeting signals 
were used. We showed that all the MTSs tested taken from proteins embedded in 
the mitochondrial outer membrane (XL, BakMTS, BaxMTS) are capable of targeting 
p53 to the mitochondria despite the three NLSs in the p53 protein. On the other 
hand, inner membrane (CCO) and matrix (OTC) MTSs were not capable of 
completely overcoming the NLSs. The mitochondrial localization of our p53-MTS 
constructs was determined using fluorescence microscopy and the degree of 
colocalization with the mitochondrial compartment was determined by Pearson’s 
correlation coefficient following Coste’s approach (6-8). As expected, all constructs 
that colocalized with the mitochondria, showed minimum transcriptional activity (p53 
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fused to XLMTS, BakMTS, BaxMTS). On the other hand constructs showing low 
mitochondrial localization (CCO-p53, OTC-p53) showed transcription activity. In fact, 
CCO-p53 showed the same and OTC-p53 showed half the transcription activity 
compared to wt p53. Further, mutating the strong NLS in p53 dramatically improved 
mitochondrial localization of the weak MTS CCO, and decreased its transcriptional 
activity.  
When conducting various apoptosis assays (TUNEL, Annexin V, 7-AAD assay), we 
discovered the inherent toxicity of some MTSs. The matrix signal OTC, inner 
membrane signal CCO and the outer membrane signal TOM all caused p53-
indepenten apoptosis when fused to non-toxic EGFP. We speculate that, EGFP 
fused to OTC or CCO could cause an imbalance in the sensitive mitochondrial 
system possibly interfering with proteins involved in the TCA cycle or other energy 
mechanism. On the other hand, TOM-EGFP could be interfering with the TOM 
complex which is the main import machinery for proteins into the mitochondria as 
discussed previously in the introduction section (Chapter 1) and might affect the 
sensitive import machinery (9). However, only the outer membrane signals from Bcl-
XL, Bak and Bax which are thought to localize to the outer surface of the 
mitochondrial outer membrane, do not contain inherent MTS toxicity.  
Furthermore, it is important that the pro (Bak, Bax)- or anti (Bcl-XL)- Bcl-2 protein 
from which the MTS is used is always present at the mitochondrial outer membrane. 
Bax is constantly shuttled between cytoplasm and mitochondria (10, 11). 
Mitochondrially targeted p53 which is fused to BaxMTS is not capable of activating 
cytoplasmic Bax, and the amount of mitochondrial Bax might not be sufficient for 
apoptosis induction. This results in unpredictable activity profiles varying from cell 
line to cell line for Bax. However, Bak is always present at the mitochondria and 
therefore consistent in its induction of apoptosis (12). 
As discussed above, only MTSs from the mitochondrial outer membrane lack 
inherent toxicity to the mitochondria and therefore offer specific mitochondrial 
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apoptosis that is p53 dependent. Targeting p53 to the mitochondria via MTS from its 
anti- (Bcl-XL) and pro- (Bak) binding partners results in p53 dependent apoptosis. 
p53 fused to the mitochondrial targeting signal from anti-apoptotic Bcl-XL has been 
shown to interact with anti-apoptotic Bcl-2 proteins, in particular anti-apoptotic Bcl-XL 
at the mitochondria. On the other hand, targeting p53 with the MTS from the pro-
apoptotic Bak protein verified Bak mediated apoptosis.  
Therefore, mitochondrial targeting of p53 is highly dependent on the MTS used. The 
optimal MTS for p53 specific mitochondrial targeting is a MTS from a p53 interacting 
partner which is always present at the mitochondrial outer membrane (Bcl-XL, Bak) 
and is strong enough to ensure mitochondrial localization while overcoming the 
NLSs in p53 (XL, BakMTS). 
 
7.1.2 Solely the DNA binding domain of p53 fused to a specific MTS is 
sufficient to trigger apoptosis (Chapter 3 and 4) 
We are the first group to discover that the DNA binding domain (DBD) when fused to 
a MTS from anti- apoptotic Bcl-XL or pro-apoptotic Bak or Bax is sufficient to activate 
the intrinsic apoptotic pathway. 
The MDM2 binding domain (MBD), the proline rich domain (PRD) and the DBD have 
been reported to play an important role for Bcl-XL interaction. We verified that solely 
the DBD fused to MTS from Bcl-XL (XL) is necessary for apoptosis induction while 
MBD, PRD, TD or combinations of these domains have the same impact on cell 
death as non-toxic EGFP fused to XL. Further, we showed that DBD-XL and p53-XL 
cause disruption of the mitochondrial membrane (TMRE assay) and activation of the 
intrinsic apoptotic pathway (caspase-9 assay). The initiation of the intrinsic apoptotic 
pathway is due to p53 or DBD interacting with anti-apoptotic Bcl-XL protein at the 
mitochondrial outer membrane (Bcl-XL rescue experiment).  
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For pro-apoptotic Bak, Murphy and colleagues reported that p53 must form a dimer 
or a tetramer to trigger Bak homo-oligomerization. On the other hand residues 
localized in the DBD (K120, R248, R273, R280, E285, E287) have been outlined to 
interact with pro-apoptotic Bak protein. We confirmed that DBD targeted with the 
MTS from Bak is capable of inducing the intrinsic apoptotic pathway. To illustrate 
that p53-BakMTS and DBD-BakMTS apoptotic activity is Bak protein specific, we 
mutated residues mentioned above in both constructs. Indeed, p53-BakMTS and 
DBD-BakMTS activity is completely lost when these residues are mutated, therefore 
indicating that p53-BakMTS and DBD-BakMTS cause Bak-specific apoptosis.  
The potential of DBD fused to the different MTSs to cause apoptosis in different cell 
and cancer lines was examined using a late stage apoptosis assay, 7-AAD, in 
mammary ductal carcinoma (T47D), breast adenocarcinoma (MDA-MB-231), non-
small lung carcinoma (H1373), ovarian adenocarcinoma (SKOV-3) and cervical 
carcinoma (HeLa) cells. In all tested cell lines, DBD fused to MTS from Bcl-XL or Bak 
had the same or even higher apoptotic potential than full length p53 fused to this 
MTSs. The p53/MDM2 degradation pathway as discussed earlier in the introduction 
could provide a valid explanation to why DBD shows higher activity than full length 
p53. The E-3 ligase MDM2 binds to the MBD of p53 and along with E4 factors, E like 
molecules or MDMX facilitates its polyubiquitination and proteasomal degradation 
(13). Unlike p53, DBD does not contain the MBD or the C-terminus and is therefore 
more stable than full length p53. This possible lack of degradation may explain the 
higher apoptotic activity of DBD-XL. 
In summary, we demonstrate that the DBD when fused to MTSs from Bcl-XL or Bak 
is sufficient to trigger a rapid apoptotic respond at the mitochondria. Therefore, we 
decided to test our constructs delivered by adenovirus in an orthotropic breast 
cancer model.  
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7.1.3 Targeting monomeric p53 or its DBD fused to the MTS from Bcl-XL in 
vivo (Chapter 5) 
We wanted to investigate if p53 or DBD targeted to the mitochondria is capable of 
overcoming dominant negative inhibition by mutant p53. In cancer cells, most of the 
mutations in p53 occur in its DNA binding domain while the TD remains active. 
Therefore, mutant p53 can heterotetramerize with wt p53 via their TD (dominant 
negative effect). While wild type p53 has to form a tetramer in order to be 
transcriptionally active and transactivate pro-apoptotic genes, mitochondrial p53 as 
we and others have demonstrated before (1, 14, 15) causes apoptosis at the 
mitochondria as a monomer.  
To investigate if p53 and DBD both fused to the MTS from Bcl-XL (p53-XL, DBD-XL) 
can bypass dominant negative inhibition, we overexpressed dominant mutant p53 
containing the R248W mutant (called p53R248Wmut) in p53 null H1373 non-small 
cell lung cancer cell. p53-XL and DBD-XL maintained the same apoptotic activity 
with or without overexpressing the p53R248Wmut, while wt p53 activity dramatically 
decreased when p53R248Wmut was present suggesting that p53-XL and DBD-XL 
have the potential to overcome dominant negative inhibition. Further, we tested if this 
is also true in MDA-MB-468 cells which naturally harbor dominant negative mutant 
p53 (R273H). However, only DBD-XL was active in MDA-MB-468 cells, while p53-XL 
remains the same low activity as negative control. p53-XL might be sequestered by 
mutant p53 because both harbor the same TD and could potentially 
heterotetramerize. Unlike p53-XL, DBD-XL does not contain a TD and is its activity is 
therefore not impaired by dominant mutant p53 in MDA-MB-468 cells. 
DBD fused to XL can overcome dominant negative inhibition in vitro, but it was 
unable to shrink MDA-MB-468 tumors in an orthotopic mouse mode. The dosing 
regimen might offer an explanation for the treatment failure. While transcriptionally 
active wt p53 can trigger both the extrinsic and intrinsic pathway, mitochondrial DBD 
solely initiates the intrinsic apoptotic pathway. Due to the different apoptotic profiles, 
the dose for DBD-XL has to be higher than for wt p53. Additionally, we further 
194 
 
 
 
 
optimized mitochondrial targeting of DBD by fusing it to MTS from pro-apoptotic Bak. 
Anti-apoptotic Bcl-XL needs to be sequestered to release pro-apoptotic Bak or Bax 
from the inhibitory heterodimer, and allow for pore formation at the mitochondria. 
However, pro-apoptotic Bak only needs to be activated and not sequestered in order 
to form pores. In aggressive cancers, anti-apoptotic Bcl-2 protein members such as 
Bcl-XL, Bcl-2 and Mcl-1 are overexpressed. Therefore, the amount of DBD-XL might 
not be sufficient to sequester anti-apoptotic Bak, but DBD targeted to Bak might be 
sufficient to transiently interact with Bak and facilitate its activation and apoptosis.  
 
7.1.4 Chimeric p53 can bypass dominant negative inhibition (Chapter 6) 
To bypass dominant negative inhibition of mutant p53, we substituted the 
tetramerization domain (TD) of p53 with the coiled-coil (CC) domain from BCR. Both 
oligomerization domains contain a main α- helix that orients in an anti-parallel 
fashion and a forms dimer of dimers (16, 17). Aside from us, Waterman et al. have 
substituted the TD with a four-stranded coiled coil. However, their oligomerization 
domain forms parallel tetramers, instead of anti-parallel as TD, which might explain 
its low transcriptional and apoptotic activity (18).  
To create p53-CC, we replaced most of the C-terminal domain (amino acids 
323−393) of wt p53 with CC. Thereby we removed two out three nuclear localization 
signals (3). However, p53-CC still translocates to the nucleus in the same manner as 
wt p53. Next we tested transcriptional and apoptotic activity of p53-CC and 
demonstrated that p53-CC shows the same apoptosis as wt p53 in T47D breast 
cancer cells which do not exhibit a strong dominant negative effect. Further, we 
revealed that revealed that p53-CC solely tetramerizes with itself while exogenous wt 
p53 interacts with endogenous p53. To tested apoptotic activity of p53-CC, we 
overexpressed dominant negative mutant p53 (R175H, R248W, R273H) in p53 null 
H1373 cells and then in MDA-MB-468 harboring R274H mutant p53. Both 
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experiments illustrated that p53-CC, unlike wt p53, is capable of initiating apoptosis 
and is therefore not inhibited by mutant p53.  
To examine this finding in vivo we used an orthotopic xenograft tumor bearing 
mouse model. Tumors were derived from triple negative MDA-MB-468 cells with 
dominant negative p53 (19, 20). p53-CC was capable to shrink tumors while wt p53 
only inhibited tumor growth. We further determined expression levels of adenoviral 
constructs, measured p21 expression and conducted H&E staining of tumor tissue. 
Adenovirally delivered p53-CC, wt p53 and negative control ZsGreen were highly 
expressed in tumor tissue. wt p53 had higher p21 expression while p53-CC showed 
higher necrosis (H&E staining). Necrotic potential of p53-CC might contribute to 
tumor size reduction. p21 is known to cause cell cycle arrest and p21 expression has 
been linked to minimal tumor regression and early relapse in breast cancer patients 
(21). Since wt p53 initiates p21 expression this might provide an explanation to why 
wt causes inhibition of tumor growth while p53-CC causes tumor shrinking. However, 
this needs further investigation. We anticipate that p53-CC can be used as an 
alternative to wt p53 for cancer gene therapy, especially in tumors with dominant 
mutant p53, where wt p53 has shown to be inactive.  
 
7.2 Future directions 
7.2.1 DBD fused to mitochondrial targeting signal from Bak for ovarian cancer 
targeting  
Previously, we have discovered the minimal domain of p53, its DNA binding domain 
(DBD), needed for apoptosis (22) and a rationally selected MTS with optimal activity 
(Chapter 4). We have highlighted that MTSs from the mitochondrial outer membrane 
(MOM) are optimal for p53-specific activation (14). Using MTSs from pro-apoptotic 
Bcl-2 family members Bak (23-25) will trigger mitochondrial outer membrane 
permeabilization (MOMP), resulting in activation of the intrinsic apoptotic pathway. 
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Previously, we have shown that Bak MTS may be optimal for DBD targeting and 
apoptosis.  
As mentioned in the introduction (Chapter 1), mitochondrial p53 inhibits anti-
apoptotic (Bcl-2, Bcl-XL, Mcl-1) (26-28) and activates pro-apoptotic (Bak, Bax) (24, 
25) Bcl-2 family members leading to mitochondrial outer membrane permeabilization 
(MOMP) and resulting in apoptosis. In cancer cells, overexpression of Bcl-2, Bcl-XL 
and Mcl-1 correlates with more aggressive phenotypes and leads to chemotherapy 
resistance (29-32). Many agents have been identified to target the anti-apoptotic Bcl-
2 family members. These therapeutics cause apoptosis through neutralizing anti-
apoptotic proteins at the mitochondria allowing the pro-apoptotic Bcl-2 family 
members Bak or Bax to homo-oligmomerize initiating apoptosis (33). However, these 
inhibitors do not target all anti-apoptotic Bcl-2 proteins; in fact most of them 
(Navitoclax, ABT-199) are selective to Bcl-2 (34). This limits its use since many 
cancers overexpress Bcl-XL and Mcl-1 (29-32). Therefore, our approach is to directly 
activate pro-apoptotic Bak by targeting p53 to the mitochondria using Bak’s own 
MTS. p53 activates Bak by disrupting Bak/Mcl-1 and Bak/Bcl-XL complexes (25, 26, 
35). We hypothesize that DBD-BakMTS can trigger apoptosis in cancer cells by 
preferential interaction with Bak (over Mcl-1 or Bcl-XL). 
Our data indicate a robust apoptosis from DBD-BakMTS that is entirely dependent 
on residues in the DBD that directly interact with cellular Bak. We have shown that 
the minimal domain of p53 (DBD) fused to MTS from pro-apoptotic Bak which is 
localized at the mitochondrial outer membrane results in apoptosis in a variety of 
cancer cell lines. Further, we have reported that DBD-BakMTS triggers apoptosis in 
ovarian cancer cells SKOV-3 while wt p53 and p53-CC are incapable of inducing 
apoptosis in this cell line. Since wt p53 and p53-CC mainly cause cell death through 
transactivating apoptotic genes (36), SKOV-3 might have a defect in p53 
transcription machinery. However the exact mechanism why wt p53 and p53-CC are 
inactive in SKOV-3 still needs to be investigated.  
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Further studies will test DBD-BakMTS for ovarian cancer therapy. Ovarian cancer 
has shown lack of progress in treatment, since mortality rates of ovarian cancer have 
not improved over 40 years (37-39). The Cancer Genome Atlas Research network 
identified a variety of genomic changes in ovarian cancer. While p53 gene mutations 
occur in more than 96% of ovarian serous tumors, recurrence in mutations in other 
genes were not noted, or only had a low prevalence (40). Therefore, p53 is an 
excellent target for ovarian cancer therapy.  
The apoptotic activity of DBD-BakMTS will be further tested in ovarian cancer cells, 
various ovarian cancer cell lines. We hypothesize that ovarian cancer cells with 
different p53 status will highlight that apoptotic activity of DBD-BakMTS is not 
dependent on p53 status. Since we already tested SKOV-3 ovarian adenocarcinoma 
cells from metastatic ascites which are p53 null (41), ovarian cancer cells harboring 
mutant p53 (OVCAR-3 and Caov-4) (42) and wt p53 (A2780) (43) will be tested. 
Apoptotic activity will be determined by using previously described TMRE-, caspase-
9, annexin V and 7-AAD assays.  
To explore the effect of DBD-BakMTS on normal cells, BJ normal fibroblasts and 
immortalized ovarian epithelial cells (IHOEC) will be tested (44). Since DBD-BakMTS 
is lacking the MBD and C-terminus the DBD-BakMTS is not subject to the p53/MDM-
2 degradation pathway. In wt p53, E-3 ligase MDM2 binds to the MBD of wt p53 
which triggers monoubiquitations (45). Then, MDM2 and cofactors (E4 factors, E like 
molecules) or other E-3 ligases promote polyubiquitination of C-terminal lysines 
resulting in proteasomal degradation (13). While wt p53 is known to be non-toxic to 
normal cells (46-49), DBD-BakMTS might show some toxicity to normal cells due to 
the lack of MBD and C-terminus and hence, lack of degradation. If normal cells 
undergo apoptosis with DBD-BakMTS, cancer specific promoters can be used to 
prevent this. Cancer specific promoters include survivin (50), unmodified HTERT 
(51) or ovarian cell-specific OSP-1 promoter (52), which will prevent expression in 
normal cells and hence apoptosis in these cells. Therefore, the use of these 
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promoters will ensure expression of DBD-BakMTS mainly in cancer cells and 
minimize death in normal cells. 
Further, the activity of DBD-BakMTS will be tested in a syngeneic orthotopic 
metastatic mouse model (53). The metastatic ovarian cancer model will be 
generated by injecting ID8 cells into left ovarian bursa. Prior to initiating treatment, 
tumors will be grown to approximately a size of 2-2.5cm3. This animal model closely 
replicates characteristics and hallmarks seen in human ovarian cancer by primary 
epithelial ovarian tumors, secondary peritoneal metastases and ascites production 
(53). DBD-BakMTS will be delivered by water soluble lipopolymer (WSLP). 
Heterogeneity or lack of expression of CAR and integrin co-receptors in ovarian 
tumors and adenovirus-neutralizing antibodies are major limitations to ovarian 
cancer adenoviral drug delivery (54). WSLP completed a Phase I clinical trial for 
ovarian cancer (55). We will intraperitoneal (I.P.) inject plasmid DNA encoding DBD-
BakMTS with WSLP into our new syngeneic orthotopic metastatic mouse ovarian 
cancer model, alone or in combination with carboplatin and paclitaxel. Various 
studies indicate that I.P. is superior over intravenous (I.V.) delivery (56-58). Higher 
concentrations of cytotoxic agents can be infused into the peritoneal cavity than 
would be tolerated systemically. Since the dosing could have been a problem in our 
breast cancer study with our previously designed mitochondrial construct, we chose 
I.P. to be able to increase the dosing in the ovarian cancer model. Additionally, I.P. 
allowed for sustained exposure of tumor implants to antitumor agents while normal 
tissues, such as bone marrow, are significantly less exposed. Fewell et al. used 10-
250ug of WSLP-IL-12 plasmids per injection when using an IP ovarian tumor mouse 
model (59). Due to the difference in mechanism of action between IL-12 (takes time 
to induce IFN-α) and p53-MTS (rapid apoptosis expected), we anticipate frequent 
dosing but a greater effect. Plasmid amount of DBD-BakMTS will be determined first 
in vitro by conducting apoptosis assays in ID8 mouse ovarian cancer cells after that 
concentration and dosing regime will be optimized in a preliminary animal study. 
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For future studies we are planning to combine DBD-BakMTS with standard ovarian 
chemotherapeutics. The combination of carboplatin and paclitaxel are both first line 
therapy for ovarian cancer but both not completely effective. Platinum resistant 
cancer recurs in 25% of patients within 6 months (60); platinum requires functional 
p53 protein for efficient induction of apoptosis, and loss of p53 function enhances 
resistance to cytotoxic agents (61). We anticipate that DBD delivered to the 
mitochondria via MTS from Bak will enhance/synergize with standard chemotherapy.  
If the animal study is successful for DBD-BakMTS with or without carboplatin and 
paclitaxel, this work could be beneficial for women diagnosed with late stage (>III) or 
recurrent high grade serous ovarian cancer and may result in a new clinical trial 
potent enough to prevent metastatic disease recurrence.  
 
7.2.1 Targeting DBD-Bak for lung cancer therapy 
Our p53-based therapeutic approaches may be applicable to other types of cancers 
as well, including lung cancer which is the leading cause of cancer in the United 
States. In fact, the overall 5-year survival rate is only about 15% (62). Studies have 
shown that p53 is mutated in up to 70% of lung cancers (63, 64). Therefore, p53 is 
an excellent target for lung cancer therapy. 
Recently we identified that targeting the DNA binding domain (DBD) of p53 is 
sufficient (and sometimes more efficient that wt p53) in inducing a direct apoptotic 
effect at the mitochondria in H1373 human non-small cell lung carcinoma cells 
(Chapter 4). In the future, re-engineered, mitochondrially targeted p53 may be 
effective against lung cancer. A potential way to deliver mitochondrially targeted p53 
would be as a protein formulated as a dry powder for inhalation (65, 66). 
wt p53 has been delivered as a protein for oral cancer therapy before and showed 
inhibition in cancer cell proliferation (67). However, therapeutic levels of wt p53 were 
not maintained for >36 h. This stability problem was mainly due to high degradation 
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of wt p53 via MDM-2/proteasomal pathway (67, 68). Since DBD-Bak does not 
contain MBD nor the C-terminus, we expected it to be more stable than wt p53. 
The lung is a good target for drug delivery because drugs can be delivered via 
inhalation (69, 70). It is wildly known that proteins can be absorbed through the 
lungs. One example is insulin which was the first peptide approved for inhalation 
therapy by the U.S. Food and Drug Administration in January 2006 (71). However, 
Exubera was discontinued in October 2007. The reason for the discontinuation was 
mainly the high price and insulin related safety concerns. Other insulin delivery 
alternatives (injectable, pen, etc.) are less costly (72). Potential pulmonary toxicity 
might occur because of immunogenic and growth-promoting properties of insulin and 
long-term insulin administration (73). Since DBD-Bak will be only administrate short-
term and has completely different pharmacological characteristics than insulin, 
therefore we do not expect this effect with DBD-Bak protein. One approach is to 
deliver DBD-Bak as a dry power protein in a similar manner as Exubera using the 
AERx Pulmonary Drug Delivery System. This system converts large particles 
(protein agglomerates) into a fine particle aerosol (65). If the lung dysfunction as a 
result of lung cancer is too severe and the AERx cannot be used, we will deliver the 
DBD-Bak gene via polymeric non-viral vectors (PEI-PEG, PLL) using jet nebulizers 
which can be used even when lung function is decreased (74). These vectors can 
overcome the shear forces created during nebulization while viral vectors and 
proteins lose their biological activity (75-77). By delivering DBD-Bak specifically to 
lung cancer cells, side effects will be minimized (78). 
Lung cancer is only one other possible type of cancer to target with our 
mitochondrially targeted p53. Other types of cancers could be targeted as well. This 
approach highlights mitochondrial targeted DBD again as a "sledgehammer," 
effective under any circumstances, regardless of genetics or the pathway upon 
which the cancer develops.  
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8. Appendix 
8.1 Abbreviations 
7-AAD 7-Aminoactinomycin D 
APAF 1 Apoptotic protease-activating factor 1 
BAD  BCL-2 antagonist of cell death 
Bak  Bcl-2 antagonist or killer 
BakMTS MTS from Bak 
Bax  Bcl-2-associated X protein 
BaxMTS MTS from Bax 
Bcl-2  B cell lymphoma 2 
Bcr  Breakpoint cluster region 
BH  Bcl-2 homology 
BID  BH3-interacting domain death agonist 
BIK  BCL-2-interacting killer 
BIM  BCL-2-interacting mediator of cell death 
BMF  BCL-2-interacting mediator of cell death 
BNIP3  adenovirus E1B 19 kDa protein-interacting protein 3 
CCO  MTS from cytochrome c oxidase 
CS  C-segment 
DBD  DNA binding domain 
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E  Nuclear export signal 
EMA  European Medicine Agency 
FDA  Food and Drug Administration 
HAUSP Herpes virus-associated ubiquitin-specific protease 
IMS  Intermembrane space 
MBD  MDM2 binding domain 
MDM2 Murine double minute 2 
MIRA  Mutant p53-dependent induction of rapid apoptosis 
MOMP Mitochondrial outer membrane permeabilization 
MTS  Mitochondrial targeting signal 
NLS  Nuclear localization signal 
OTC  MTS from ornithine transcarbamylase  
PAM  Presequence-translocase-associated import-motor 
PCC  Pearson’s correlation coefficient 
PRD  Proline-rich domain 
PRIMA p53 reactivation and induction of massive apoptosis 
REs  p53 response elements 
RETRA Reactivation of transcriptional reporter activity 
SFDA  China’s State Food and Drug Administration 
SMAC  Second mitochondrial derived activator of caspase 
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TA  Transactivation domain 
TCA  Tricarboxylic acid 
TD  Tetramerization domain 
TIGAR TP53-induced glycolysis and apoptosis regulator 
TIM  Translocase of the inner membrane 
TM  Transmembrane 
TMRE  Tetramethylrhodamine, ethyl ester 
TOM  MTS from translocase of the outer membrane (TOM20) 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
XIAP  X-linked inhibitor of apoptosis protein 
XL  MTS from Bcl-XL 
 
 
 
 
 
 
 
213 
 
 
 
 
8.2 Acknowledgments 
I am particularly thankful for doing my PhD in Professor Carol Lim’s lab. Professor 
Lim is an incredible mentor, she is extremely smart, kind and carrying. She finds the 
best in you and inspires those around you. Professor Lim constantly encourages me 
to become better and she gave me complete creative and intellectual freedom so 
that I can do things I never thought I can do. I want to thank her so much for all the 
hours that she spent reviewing my papers and my thesis, for helping me to improve 
my presentations and for discussing new scientific ideas. On a personal level, 
Professor Lim always took a personal interest in my well-being. When I first arrived 
to Salt Lake, she let me stay in her house for a week and even gave me her car for a 
couple of months. When I am around her, I want to become a better scientist and a 
better person. She had a major impact in shaping my scientific career, and every 
single day I am grateful that I am in her lab. All of my scientific accomplishments are 
due to her support and the collaborative lab environment that she creates. I am 
proud to know her. 
I am very grateful for having Professor Thomas Kissel as my supervisor. He was the 
one who initially introduced me to the University of Utah and encouraged me to apply 
for the GPEN program. When preparing for my GPEN time, I spend numerous hours 
in his office asking for his help and support. And despite his busy schedule, he never 
turned me down. He was always there to offer his wisdom and input. I am extremely 
grateful that he agreed to supervise my external dissertation at the University of 
Utah. I would not have done my PhD without him. 
I would like to thank my supervisory committee members, Professor Roland 
Hartmann, Professor Maike Petersen and Professor Carsten Culmsee for scientific 
discussion and for reading my thesis. I would like to specifically thank Professor 
Hartmann for writing the evaluation of my thesis. I would like to thank especially 
Professor Culmsee for agreeing to be the chair of my committee and for taking time 
to discuss carrier development planes and my research. I am grateful to Gabriele 
214 
 
 
 
 
Lins for taking the time and effort to help me with all my graduation related questions 
and problems. 
I also would like to thank Professor Margit Janat- Amsbury for training me on animal 
work and for allowing me to use her equipment in the beginning of our animal 
studies. A special thanks also to her students Aliyah Almomen and Chieh-Hsiang 
Yang for their support. I would also like to thank Robert Price for his help with the 
animal studies.  
I would like to thank former and present members of the Lim Lab especially 
Mohanad Mossalam and Abood Okal for working with me as a team on the p53 
project. Mohanad is one of the best teachers I ever had, special thanks to him for his 
patience and the time he spent with me discussing experiments. Abood and I 
developed the animal studies together. I am grateful that I got to work with him. His 
fearless and encouraging attitude made me complete scientific accomplishments I 
thought I might never be able to do. He was always there reviewing my papers, 
thesis, for scientific discussion and as a friend. I would also like to thank Ben Bruno, 
Johathan Constance, Rian Davis, David Woessner, Mudith Kakar, Geoff Miller and 
Shams Reaz for an amazing time in the Lim Lab with a lot of science talk and a tone 
of fun. A special thanks to Ben and Abood for all the fun we had during 
snowboarding. I am filled with joy that we get to work and live together. 
I would also like to thank my friends Maren Thomas and Maha Mossalam for their 
support. Maren for answering all my questions concerning my graduation, for printing 
and reviewing my thesis and for always being an amazing friend. Maha for listening 
to my problems, for being the best roommate I can imagine and for giving me a lot of 
advice. 
Foremost, I would like to thank my family, especially my mother. I dedicate this 
thesis to her. She always puts her children first. I would never be where I am today if 
it were not for the sacrifices she made, for her constant encouragement, for her 
positive and stabilizing influence and for her self-less support. I hope that I can 
215 
 
 
 
 
become half as good as a mother that she is to us. I am grateful for my grand-father, 
who always defended me even when I was wrong, for my grand-mother who was 
and is an excellent role model for independence and my father who is the most hard-
working person I know. My sister Astrid for her countless visits in Salt Lake which 
made me feel less homesick and for making me travel with her to different places in 
the US. My brother Stephan who gave me emotional support through the last few 
months of my PhD and was always able to put a smile on my face. I am incredibly 
blessed by my family standing behind me every step of the way. I am thankful to God 
for surrounding me with all these amazing people and giving me the chance to be 
part of cancer research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
216 
 
 
 
 
8.3 Declaration/Erklärung 
 
 
 
 
Hiermit versichere ich, dass die vorgelegte Dissertation 
 
“Targeting p53 and its domains for cancer therapy” 
 
von mir selbstständig und ohne unerlaubte Hilfe angefertigt wurde und ich mich 
keener anderen als der von mir ausdrücklich bezeichneten Quellen und Hilfen 
bedient habe. Die Dissertation wurde in der jetzigen oder in ähnlicher Form noch an 
keiner anderen Hochschule eingereicht und hat noch keinen sonstigen 
Prüfungszwecken gedient. 
 
 
Salt Lake City, 12. Februar 2014 
 
 
 
Karina Matissek 
 
 
 
Karina Julia Matissek 
30 S 2000E, Suite 105 
Salt Lake City, UT 84112 
Phone: 801-875-7947 
E-mail: Karina.Matissek@utah.edu 
 
Education 
 
Defense date 
April 7, 2014 
 
 
 
 
Oct 2009 
 
 
April 2009 
 
 
 
Experience 
 
Oct 2010-Present 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
July 2009- Oct 2010 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. rer. nat. (PhD): “Targeting p53 and its Domains to the Mitochondria for 
Cancer Gene Therapy” 
Matriculating out of Department of Pharmaceutics and Biopharmacy, Philipps 
University, Marburg, Germany 
Conducting research at University of Utah, Salt Lake City, Utah 
 
Master’s Degree: “Nuclear Translocation of Survivin in Breast Cancer Cells’’ 
Martin Luther University Halle-Wittenberg, Halle, Germany 
 
Pharmacy Degree 
Philipps University, Marburg, Germany 
 
 
 
 
Laboratory of Dr. Carol Lim, University of Utah 
Salt Lake City, Utah 
Ph.D. Candidate/ Research Assistant 
 Extensive experience with recombinant DNA technology, mammalian 
cell transfection, adenovirus cloning and production, apoptotic assays, 
immunohistochemistry, flow cytometry, confocal and fluorescence 
microscopy 
 Cell death assay expertise (7-AAD, Annexin V, TUNEL, Colony 
forming Assay, DNA segmentation, caspase-9 and TMRE assay) 
 Human and animal cell culture proficiency (in vitro) 
 Biosafety Level II certification pathogens (adenovirus and lentivirus) 
 IUCAC animal certification to handle and work with mice (in vivo): 
orthotopic tumor generation, tumor size measurement, intratumoral 
injection and organ harvesting  
 
Stadt-Apotheke Schoemberg 
Schoemberg b.B., Germany  
Pharmacist 
 Dispensed medications to patients 
 Patient consultation (drug interactions, side effects and applications) 
 Advised physicians about drug interactions, dosing recommendations 
and side effects 
 Compounded and optimized specialty medications  
 Trained pharmacy personnel and managed scheduling
 
Karina Julia Matissek 
 
Publications 
 
Peer-Reviewed Publications 
 
First Author Publications 
 
 Matissek K.J., Okal, A., Mossalam M., Lim C.S. Delivery of a monomeric p53 subdomain with 
mitochondrial targeting signals from pro-apoptotic Bak or Bax, Pharm Res., minor revisions. 
 
 Matissek K.J., Mossalam M., Okal A., Lim C.S. The DNA binding domain of p53 is sufficient 
to trigger a potent apoptotic response at the mitochondria. Mol Pharm. 2013 Oct 7;10(10):3592-
602. 
 
 Matissek K.J.*, Mossalam M.* (*co-first authors) Okal A., Constance J.E., Lim C.S. Direct 
induction of apoptosis using an optimal mitochondrially targeted p53. Mol Pharm. 2012 May 
7;9(5):1449-58. 
 
 Matissek K.J., Bender R.R., Davis J.R., Lim C.S. Choosing Targets for Gene Therapy in the 
book Targets for Gene Therapy. Intech Open Access Publisher, 2011 July, ISBN 978-953-307-
540-2. 
 
 
Co-Author Publications 
 
 Okal A., Mossalam M., Matissek K.J., Dixon A.S., Moos P.J., Lim C.S. A chimeric p53 evades 
mutant p53 transdominant inhibition in cancer cells. Mol Pharm. 2013 Oct 7;10(10):3922-33. 
 
 Constance J.E., Woessner D.W., Matissek K.J., Mossalam M., Lim C.S. Enhanced and selective 
killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein 
and imatinib. Mol Pharm. 2012 Nov 5;9(11):3318-29. 
 
 Okal A., Matissek, K.J., Matissek S.J., Price R., Salama M., Janát-Amsbury M.M., Lim C.S.  
Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a 
dominant negative breast cancer xenograft model. submitted to Gene Ther. 2014 Feb 5. 
 
 Okal A., Matissek S.J., Matissek K.J., Cornillie S., Cheatham T. E. III, Lim C.S. Towards Super 
p53: A Re-engineered Tumor Suppressor with Enhanced Homo-oligomerization and Increased 
Apoptotic Activity. In preparation, 2014. 
 
 
 
 
 
 
 
 
 
Karina Julia Matissek 
 
Poster Presentations 
 
 Matissek K.J., Mossalam M., Okal A, Lim C.S. Targeting Small Domains of p53 to 
Mitochondrial Bcl-XL for Cancer Therapy. American Association for Pharmaceutical Science 
Rocky Mountain Discussion Group: Perspectives in Translational and Clinical Research; Salt 
Lake City, UT, Aug 5, 2013 
 
 Matissek K.J., Mossalam M., Okal A, Lim C.S. Targeting Small Domains of p53 to 
Mitochondrial Bcl-XL for Cancer Therapy. American Association for Cancer Research Annual 
Meeting; Washington, DC, Apr 6-Apr 10, 2013 
 
 Okal A., Mossalam M., Matissek K.J., Lim C.S. An alternative tetramerization domain of p53 
for exclusive homo-oligomerization and potent tumor suppression. American Association for 
Cancer Research Annual Meeting; Washington, DC, Apr 6-Apr 10, 2013 
 
 Matissek K.J., Mossalam M., Okal A., Constance J.E., Lim C.S. Targeting p53 to Mitochondrial 
Outer Memberane Using the Bcl-XL Signal Causes p53-Specific Apoptosis. Bioscience 
Symposium, Salt Lake City, UT, Sep 25, 2012 
 
 Matissek K.J., Mossalam M., Okal A., Constance J.E., Lim, C.S. Targeting p53 to 
Mitochondrial Outer Memberane Using the Bcl-XL Signal Causes p53-Specific Apoptosis. 
American Association for Cancer Research Annual Meeting; Chicago, IL, Mar 31-Apr 4, 2012 
 
 Okal A., Mossalam M., Matissek K.J., Lim C.S. Bypassing the Dominant-Negative Effect of 
Mutant p53 in Breast Cancer Cells. American Association for Cancer Research Annual Meeting; 
Chicago, IL, Mar 31-Apr 4, 2012 
 
 Matissek K.J., Mossalam M., Okal A., and Lim C.S. Direct Induction of Apoptosis Using an 
Optimal Mitochondrially Targeted p53. American Association for Pharmaceutical Science; 
Washington, DC, Oct 23-27, 2011. Research featured in AAPS Today: "Apoptosis of Cancer 
Cells Achieved by Targeting Mitochondria?" 
 
 
Invited Talks 
 
June 27, 2013 
 
 
May 15, 2013 
 
 
Aug 27, 2012 
 
 
Oct 26, 2009 
 
 
 
 
 
 
Grand Rounds Lecture to the Department of Obstetrics and Gynecology  
University of Utah, School of Medicine, Salt Lake City, UT 
“Re-Engineering p53 for Effective Treatment of Ovarian Cancer” 
Juan Diego High School Summer Research Program 
Juan Diego High School, Salt Lake City, UT 
“Targeting p53 to Pro-Apoptotic Bak Causes Cell Death in Cancer Cells” 
PHCEU Fall 2012 Seminar Series 
University of Utah, College of Pharmacy, Salt Lake City, UT 
“Mitochondrial Targeting of p53 for Cancer Therapy” 
Master’s Thesis Defense 
Martin Luther University Halle-Wittenberg, Halle, Germany 
“Nuclear Translocation of Survivin in Breast Cancer Cells’’ 
Karina Julia Matissek 
 
Mentoring 
 
Nov- Dec 2013 
 
 
Aug- Oct 2013 
 
 
 
June-July 2013 
 
 
Oct 2012- April 2013 
 
 
 
April- Aug 2012 
 
 
Jan - April 2012 
 
 
June -July 2011 
 
 
Jan - April 2011 
 
 
 
 
Memberships 
 
Jan 2012- present 
 
Oct 2010- present 
 
Oct 201- present 
 
 
Internships 
 
Nov 2008- April 2009 
 
April- Oct 2008 
 
 
 
 
 
Phong Lu, graduate student  
Biological Chemistry Program, University of Utah  
“Introducing E34K and R55E mutations in p53-CC for breast cancer therapy” 
Jennifer Gläsel, pharmacy student  
Globalization of Pharmaceutics Education Network (GPEN) Program, Philipps 
University of Marburg  
“Targeted Mutations in p53-CC for Ovarian Cancer Therapy’’ 
Connor Helgeson, high school student  
Juan Diego High School Summer Research Program, Juan Diego High School 
“Targeting p53 to Pro-Apoptotic Bak Causes Cell Death in Cancer Cells’’ 
Christian Raab, pharmacy student 
Globalization of Pharmaceutics Education Network (GPEN) Program, Philipps 
University of Marburg  
“Targeting p53 to Bak and Bax’’ 
Russell Scow, pharmacy student  
PSURF Program University of Utah College of Pharmacy 
“Targeted Mutations in p53 Enhance Cancer Cell Apoptosis’’ 
Karen Johnson, undergraduate researcher  
ACCESS Program for Women in Science and Mathematics, University of Utah 
“Residues C176 and N239 are essential for mitochondrial activity of p53’’ 
Alex Ikeda, high school student  
Juan Diego High School Summer Research Program, Juan Diego High School 
“Targeting Domains of p53 to the Mitochondria for Cancer Therapy’’ 
Maha Mossalam, undergraduate researcher 
Department of Biology, University of Utah 
“Targeted Mutations in Mitochondrial p53’’ 
 
 
 
 
Cofounder and member of GSO/GAIN German Table Salt Lake City, Utah  
 
Associate member of American Association of Pharmaceutical Scientists 
 
Associate member of American Association for Cancer Research 
 
 
 
 
Pharmacy Intern 
Eyach Apotheke (pharmacy), Balingen, Germany 
Research Assistant  
Department of Pharmaceutics and Pharmaceutical Chemistry, University of 
Utah, Salt Lake City, Utah 
 
Karina Julia Matissek 
 
March 2005 
 
August 2004 
 
 
 
Language 
 
 
 
 
 
 
References  
 
Carol Sunai Lim,  
Ph.D. 
 
 
 
 
Prof. Dr. Thomas 
Kissel 
 
 
 
 
Margit-Maria Janat-
Amsbury, M.D.,  
Ph.D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacy Intern 
Klinikum am Steinenberg (hospital), Reutlingen, Germany 
Pharmacy Intern 
Eyach-Apotheke (pharmacy), Balingen, Germany 
 
 
 
English, full professional proficiency 
German, native 
Polish, native 
French, basic 
 
 
 
 
Associate Professor 
University of Utah, College of Pharmacy 
Department of Pharmaceutics and Pharmaceutical Chemistry 
30S 2000E Rm 2916, Salt Lake City, 84112, Utah, USA 
carol.lim@pharm.utah.edu 
 
Professor 
Philipps-Universität Marburg, Faculty of Pharmacy 
Department of Pharmaceutics and Biopharmacy,  
Ketzerbach 63, 35037 Marburg, Germany 
kissel@mailer.uni-marburg.de 
 
Assistant Professor 
University of Utah, School of Medicine 
Department of Obstetrics and Gynecology 
30 North 1900 East, Suite 2A200, Office 2A242, Salt Lake City,  
Utah, 84132, USA 
margit.janat-amsbury@hsc.utah.edu 
 
 
1 
Choosing Targets for Gene Therapy 
Karina J. Matissek, Ruben R. Bender, 
James R. Davis and Carol S. Lim 
University of Utah 
USA 
1. Introduction 
Gene therapy is often attempted in fatal diseases with no known cure, or after standard 
therapies have failed. Targeting gene defects includes addressing a single mutation, 
multiple mutations in several genes, or even addressing missing or extra copies in a 
particular disease. A defect in one specific gene may impair normal function of the 
corresponding expressed protein. For example, in X-linked severe combined 
immunodeficiency (X-SCID), there is a mutation in the IL2 receptor Ǆ gene. Another classic 
example occurs in thalassemia propagated by a defect in the ǃ-globulin gene. Some diseases 
are caused by multiple mutations in several genes. For example, some cardiovascular 
diseases may manifest due to mutations in different chromosomes which are a result of 
inherited or environmental factors. Before approaching a disease using gene therapy, the 
key protein(s) and pathways involved in the disease should first be identified. However, in 
some cases an abnormal gene is formed that results in disease; such is the case for the Bcr-
Abl gene. The oncogenic Bcr-Abl protein is the causative agent of chronic myelogenous 
leukemia (CML) which could be blocked for CML treatment. Genomic sequencing 
information, microarrays, and biochemical assays can be used to determine up- or down-
regulated proteins involved in disease, and will help determine the function of these 
proteins. In the case of some cancers, the signal transduction pathways for oncogenesis have 
been mapped out, allowing hub proteins to be identified. Hub proteins are essential proteins 
that interact with multiple other proteins in signaling cascades. If selected properly, adding 
back a tumor-suppressing hub protein (such as p53), or blocking an oncogenic hub protein 
(such as survivin) could halt cancer or alter disease progression. Gene mutations can result 
in mislocalization of these key proteins which can cause cancer; this mislocalization can be 
exploited with gene therapy approaches. Further, new types of gene therapy are being 
developed in our lab to direct proteins to other cellular compartments where their function 
is altered. This chapter will summarize these and other known targets and also focus on 
choosing newer targets for gene therapy. 
2. Known targets for gene therapy 
The general aim of gene therapy is to introduce a well-defined DNA sequence into specific 
cells. Almost any disease can be targeted with gene therapy by replacing defective genes or 
imparting a new function. In fact, 85% of clinical trials in gene therapy have been conducted 
for cancer, cardiovascular diseases and for inherited monogenic diseases. In addition, 6.5% 
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of clinical trials have been conducted for infectious diseases (mainly HIV). Cancer, 
cardiovascular diseases and HIV are ideal gene therapy targets because of their enormous 
prevalence and the associated fatal consequences of these diseases, whereas monogenic 
disorders reflect the original idea of gene therapy which is replacement of a defective gene. 
Gene therapy offers a unique opportunity to cure patients with monogenic disorders. One 
third of clinical trials for monogenic disorders are for cystic fibrosis while about 20% are for 
SCID (Edelstein et al. 2004). This section highlights the advantages of gene therapy for 
multifactorial diseases such as cancer, vascular diseases, and HIV and describes the utility of 
gene therapy for monogenic diseases such as cystic fibrosis, SCID and ǃ-thalassemia. 
2.1 Cancer 
Cancer was responsible for 7.6 million deaths in 2008 (WHO 2011) and is the largest target 
for gene therapy clinical trials. The complexity of cancer may make it difficult to bring a 
product to the market due to the number of genes involved compared to monogenetic 
disorders. However, gene therapeutics are not designed to correct these mutations by 
adding an enormous amount of DNA to the cells. Instead, they target critical proteins 
involved in signaling cascades such as the tumor suppressor p53. For example, the first gene 
therapy product was GendicineTM, an adenovirus containing the tumor suppressor p53. 
The tumor suppressor p53 is mutated in 40% of many types of cancers, and malfunction of 
p53 is the major contributor for chemotherapy resistance (Goh et al. 2011). Apoptosis can be 
triggered by transcriptionally active p53 in the nucleus (Taha et al. 2004) as well as by p53-
mediated transcriptionally independent mechanisms in the mitochondria (Vaseva et al. 
2009). Various animal studies have shown that p53 induces apoptosis even in advanced 
tumors such as lymphoma and hepatocellular carcinoma (Ventura et al. 2007; Palacios & 
Moll 2006; Xue et al. 2007).  
The first p53 based gene therapy in humans was conducted in 1996. This trial used a 
retroviral vector containing wild type p53 with an actin promoter for the treatment of non-
small cell lung carcinoma. In this study three patients showed tumor regression and three 
other patients showed tumor growth stabilization (Roth et al. 1996). China was the first 
country which approved a p53 adenovirus for gene therapy, GendicineTM SiBiono, in 
combination with radiotherapy for head and neck squamous cell cancer in 2004 (Shi & 
Zheng 2009). GendicineTM is a recombinant serotype 5 adenovirus with the E1 region 
replaced by the p53 expressing cassette (with a Rous sarcoma virus promoter). The 
adenovirus particles infect tumor target cells carrying therapeutic p53 (Peng 2005). Clinical 
trials for GendicineTM showed that in combination with radiation therapy it caused partial 
or complete tumor regression (Peng 2005; Xin 2006). There were also some clinical trials for 
GendicineTM in advanced liver cancer, lung cancer and other advanced solid tumors (Peng 
2005). It should be kept in mind that China’s State Food and Drug Administration (SFDA) 
has different standards for the approval of a cancer drug compared to the U.S. FDA and the 
European Medicine Agency (EMA). GendicineTM was approved in China on the basis of 
tumor shrinkage. The U.S. FDA and the EMA require novel cancer drugs to extend the 
lifetime of the treated patients (Guo & Xin 2006).  
Another p53 product is OncorineTM from Shanghai SunwayBiotech, an oncolytic virus. 
OncorineTM was approved for the treatment of head and neck cancer in China in 2006 (Yu & 
Fang 2007). It is a replicative adenovirus 2/adenovirus 5 hybrid with deletion in E1B55K 
and E3B (Raty et al. 2008). This oncolytic virus was expected to infect and lyse cancer cells 
only and not affect normal cells (Guo et al. 2008). Even though clinical studies showed that it 
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was not specific for cancer cells, it did, however, kill tumor cells preferentially (Garber 2006). 
Phase I/II trials showed little dose-limiting toxicity (Lockley et al. 2006) and the 
combination of OncorineTM with chemotherapy showed greater tumor shrinkage in patients 
with head and neck cancer, compared to chemotherapy alone. It should be kept in mind that 
like GendicineTM, OncorineTM was also approved by the SFDA based on objective response 
rate, not on survival (Garber 2006). Nevertheless, all the available data concerning p53 and 
its proven function as tumor suppressor qualifies it as an adjuvant treatment with 
radiotherapy or chemotherapy.  
Another approach to cancer gene therapy is gene-directed enzyme prodrug therapy 
(GDEPT).  GDEPT transfers an activating transgene into tumor cells followed by systemic 
treatment with a non-toxic drug which becomes activated only in cells expressing the 
transgene. CereproR is an adenovirus containing a herpes simplex type-1 thymidine kinase 
transgene under the cytomegalovirus promoter. CereproR is under phase I, II and III clinical 
trials in Europe for malignant glioma, a fatal form of brain cancer. In these clinical trials 
CereproR was injected multiple times into healthy brain tissues of patients following 
surgical removal of the solid tumor mass. Then the patients were treated with the prodrug 
ganciclovir, which is converted to its toxic form, deoxyguanosine, by thymidine kinase. This 
toxic metabolite affects newly dividing cells, thus it prevents new tumors from growing. In 
phase I and II trials, patients given CereproR showed a significant increase in survival. 
However, after phase III studies, the EMA rejected the marketing application for CereproR 
due to inadequate efficacy (van Putten et al. 2010; Cerepro 2009; Mitchell 2010; Raty et al. 
2008). Despite this particular failure, systemic side effects are avoided with the GDEPT 
concept. The general goal of GDEPT is the improvement of chemotherapy in terms of safety 
and efficiency using concomitant gene therapy (Edelstein et al. 2004).  
2.2 Cardiovascular diseases 
Cardiovascular diseases (CVD) encompass disorders of the heart and blood vessels and 
include hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular 
disease, heart failure, rheumatic heart disease, congenital heart disease and 
cardiomyopathies (Chiuve et al. 2006). Cardiovascular diseases are the largest health 
problem worldwide, claiming 17.1 million lives per year. Despite the complexity of 
cardiovascular disease, there is great potential for gene therapy especially in ischemia, 
angiogenesis, hypertension and hypercholesterolemia. Currently there is no gene therapy 
product on the market for CVD. Nevertheless, several clinical trials have been conducted 
(Edelstein et al. 2004; Edelstein et al. 2007). Most gene therapies for CVD aim to increase 
angiogenesis which is a mechanism to overcome ischemia. Ischemia is a condition in which 
the flow of blood is restricted to parts of the body. The response of the body is to form new 
blood vessels around the blockage, called angiogenesis, and is triggered by angiogenic 
proteins such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 
and hepatocyte growth factor (HGF) (Abo-Auda & Benza 2003; Kass et al. 1992). The goal of 
introducing genes coding for these growth factors is to increase the local concentration of 
these factors to stimulate angiogenesis (Edelstein et al. 2004). Two companies are conducting 
phase III clinical trials using FGF. Bayer Schering Pharm AG has developed alferminogene 
tadenovec, which is a replication-deficient human adenovirus serotype 5 which encodes 
human FGF4. Since myocardial ischemia is linked to coronary artery disease, the therapeutic 
goal is to improve the reperfusion of ischemic myocardium. Phase IIb/III clinical trials 
showed that it is well-tolerated; a phase III trial is ongoing to prove its efficacy (Flynn & 
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O'Brien 2008; CardioVascular BioTherapeutics). Sanofi-Aventis is developing a FGF gene 
therapy product called riferminogene pecaplasmide or NV1FGF (Riferminogene 
pecaplasmide  2010). It is a novel pCOR (conditional origin of replication) plasmid-based 
gene delivery system (Maulik 2009). NV1FGF is injected into muscle cells, and expresses 
FGF-1. The therapeutic goal is to treat chronic/critical limb ischemia since limb ischemia is 
linked to peripheral artery disease (Baumgartner et al. 2009). Phase III clinical trials are 
ongoing in 32 countries (Riferminogene pecaplasmide  2010). 
Another gene therapy approach to treat limb ischemia uses HGF. There are several animal 
studies showing that HGF can trigger formation of new blood vessels (Shigematsu et al. 
2010). The injection of the naked HGF gene is well-tolerated as shown in the first clinical 
trial conducted in Japan (Morishita et al. 2004). Another clinical trial in the U.S. showed that 
HGF injection increased tissue perfusion compared to placebo (Powell et al. 2008). Lastly, 
there is also a clinical trial to prove efficacy of HGF gene therapy, using reduction of ulcer 
size and decrease in rest pain (pain occurring during sleep) as objectives (Shigematsu et al. 
2010). 
2.3 HIV 
The human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome 
(AIDS), a severe disease characterized by profound negative effects on the immune system 
leading to life-threatening opportunistic infections. Although antiretroviral drugs have 
decreased the morbidity and mortality of HIV infected patients, currently there is no cure. 
However, new developments in gene therapy have focused on introducing genes encoding 
RNA or proteins which are capable of interfering with intracellular replication of HIV, so-
called intracellular immunization. So far, the approaches range from protein-based 
strategies such as fusion inhibitors or zinc finger nucleases to RNA-based approaches such 
as ribozymes, antisense or short hairpin RNA. Currently, a promising target is the 
chemokine receptor 5 (CCR5) which is needed for fusion of HIV with immune cells. Studies 
have shown that patients with mutated CCR5 have a higher long-term survival and slower 
progression of the disease. A homozygous defect in the CCR5 gene, a Δ32 deletion, resulting 
in a lack of functional CCR5 protein and confers resistance to HIV infection (Liu et al. 1996). 
An allogeneic stem-cell transplantation of CCR5 defective cells in a patient with HIV 
infection and acute myeloid leukemia resulted in both a negative HIV plasma viral load and 
no detection of HIV proviral DNA for more than 3.5 years after treatment (without the use 
of antiviral drugs). This result has been classified as a cure of HIV (Kitchen et al. 2011, and 
references therein; Symonds et al. 2010, and references therein). 
2.4 Monogenic diseases 
Monogenic diseases are prime targets for gene therapy due to their simple single gene 
mutations. Their disease causing mechanisms are easier to elucidate which is advantageous 
for choosing a target for gene therapy. In addition, the execution of therapy is more 
straightforward, since it is easier to transfer single genes into cells instead of several genes. 
Other important factors are the location and the type of cell in which the gene has to be 
transferred. Is the cell reachable with existing delivery systems? Is the cell already 
differentiated or is it a still dividing stem cell? Does gene transfer need to be repeated or is a 
one-time transfer sufficient? All these questions have to be considered in order to choose the 
right target for gene therapy, and it must be noted that not every disease caused by single 
gene mutations can be targeted. Three examples of well-studied diseases and attempts to 
treat these diseases using gene therapy will be discussed. 
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2.4.1 Cystic fibrosis 
Cystic fibrosis (CF) is a complex inherited disease affecting the lungs and digestive system. 
The cause of this disease is a defect in the cystic fibrosis transmembrane conductance 
regulator (CFTR), which is a chloride channel on the apical membrane of respiratory 
epithelia. This leads to reduced Cl- and increased Na+ permeability (Boucher et al. 1988). CF 
is caused by several different mutations in the CFTR gene located on chromosome 7 
(Knowlton et al. 1985). Of the hundreds of mutations that cause CF, the most common 
mutation, which occurs in approximately 70% of all cases, is the deletion of a phenylalanine 
residue at amino acid position 508 (ΔF508) (Kerem et al. 1989). CF results in decreased 
production of pancreatic enzymes leading to malnutrition, and also blocks the lung with 
unusually viscous mucus leading to life-threatening infections (Cystic Fibrosis Foundation; 
Wood 1997). It is possible to treat symptoms of CF to improve quality of life but there is no 
current cure for this disease. Mainstays for symptomatic treatment include enzymatic 
therapies (pancreatic enzymes and DNAse I) (McPhail et al. 2008), airway clearance and 
hypertonic saline for improved lung function, use of drugs that enhance Cl- secretion in 
airway epithelium (Cloutier et al. 1990) and anti-inflammatories involving ibuprofen or 
corticosteroids (Flume et al. 2010, and references therein). Despite a clear understanding of 
genetic links, gene therapy is not yet a standard treatment for CF, as recent attempts to cure 
patients with CF have not been successful. Moss et al. showed improvement in pulmonary 
function in a phase II clinical trial with 42 CF patients, of whom 20 received at least one dose 
of aerosolized adeno-associated serotype 2 virus carrying the CFTR gene. A significant 
enhancement in FEV1 (forced expiratory volume per second) was noted after 30 days 
compared to placebo. Furthermore, this study showed no adverse events demonstrating the 
safety of adeno-associated vectors (Moss et al. 2004). However, when this same group 
performed a second, larger phase IIb trial with 102 subjects, there was no significant 
improvement in FEV1 seen after 30 days compared with placebo (Moss et al. 2007). 
Expression of CFTR was noted in airway epithelium of 7 individuals with CF after the first 
administration but the effect lasted only 30 days. The second administration showed 
decreased expression. Finally, at the third administration, the expression fell to zero (Harvey 
et al. 1999). In conclusion, there is some indication that gene therapy could be used to cure 
CF, but no method has shown to be universally applicable. Further research is needed to 
find the right vector with repeatable administration and subsequent high expression while 
simultaneously being safe. Gene therapy for CF targets epithelial cells which have a limited 
life span and do not divide. Because of that, the gene has to be transferred repeatedly into 
new growing cells, which is problematic since repeated transfections have been ineffective.   
2.4.2 Severe combined immunodeficiency 
Severe combined immunodeficiency (SCID) is a rare, fatal syndrome with an incidence of 
24.3 cases per million live births (Ryser et al. 1988). The disease is characterized clinically by 
defects in humoral and cellular immunity due to profound deficiencies of T-and B-cell 
function, and if left untreated usually leads to death in infancy (Buckley et al. 1997). 
Mutations leading to SCID appear in various genes including Jak-3, adenosine deaminase, 
IL-7 receptor (Puel et al. 1998), tyrosine phosphatase CD45 (Kung et al. 2000), the 
interleukin-2 (IL-2) receptor Ǆ chain (IL2-RǄ), the Artemis gene (Kobayashi et al. 2003) and 
recombinase activating genes 1 or 2 (Schwarz et al. 1996; Buckley et al. 1997, and references 
therein). The most frequently diagnosed form of SCID is X-SCID, which is characterized by 
a mutation in the IL2-RǄ gene located on the X chromosome. This disease shows a male 
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predominance, with a mean age of diagnosis of 6.6 months. The IL2-RǄ chain is a critical 
component of many cytokine receptors including those for IL-2, -4, -7, -9, -15 and 21, where 
defects may result in greatly decreased numbers of T and NK cells. The number of B cells is 
generally normal but their activity is abnormal (Buckley et al. 1997). After maternal 
antibodies have vanished, the extreme susceptibility to infection due to opportunistic 
microbes, persistent diarrhea and failure to thrive usually lead to death in the first year of 
life unless immunologic reconstruction can be achieved. 
Hematopoietic stem cell transplantation is the standard of care for all genetic types of SCID 
with a survival rate of nearly 80% with HLA-identical parental marrow (Antoine et al. 2003). 
Even with a matched donor, stem cell transplantation may lead to long-term clinical 
complications (De Ravin & Malech 2009). Thus, other treatments for SCID are needed. An ex 
vivo gene therapy trial with two X-SCID patients, aged 8 and 11 months, demonstrated that 
gene therapy has curative potential. Administration of a retroviral vector containing the 
correct IL2-RǄ gene resulted in T cell counts similar to that of age-matched controls after 105 
days. Furthermore, the immune system responded to tetanus toxin and polioviruses within 
the normal range after primary vaccination. Both patients later showed normal growth and 
psychomotor development (Cavazzana-Calvo et al. 2000). Other studies confirmed these 
results (Hacein-Bey-Abina et al. 2002; Thrasher et al. 2005). A separate study of gene therapy 
for X-SCID with children aged 2.5, 4 and 8 years old showed mixed results. Only the 
youngest patient experienced benefit from the treatment (Chinen et al. 2007). Another trial 
with two patients, aged 15 and 20 years old also failed (Thrasher et al. 2005). Despite the 
variable outcome from these studies, gene therapy may still potentially cure X-SCID and 
other SCIDs, in particular for younger patients. It is already possible to cure newborn 
children with this modern technique, if traditional methods like BMT fail. If the safety of 
gene therapy vectors can be improved to lower the risk of insertional mutagenesis, gene 
therapy will likely become first-line therapy for to the treatment of X-SCID. In contrast to 
CF, the presence of accessible stem cells in which the functional gene could be transferred 
would allow continuous expression of this gene, making X-SCID a good candidate for gene 
therapy. 
2.4.3 β–thalassemia 
ǃ–thalassemia syndromes are a group of inherited blood disorders. Thalassemia major is 
the only transfusion-dependent type of ǃ-thalassemia and manifests itself clinically 
between 6 and 24 months of life by paleness and failure to thrive. It is marked by reduced 
(ǃ+) or absent (ǃ0) beta globin chain synthesis caused by several different single gene 
mutations, resulting in reduced hemoglobin in red blood cells (Weatherall 1976). If left 
untreated, this disease results in growth retardation, pallor, jaundice, poorly developed 
musculature, skeletal changes and other consequences leading to death during infancy 
(Cao & Galanello 2010). Blood transfusion is the current standard therapy for ǃ–
thalassamia and aims to correct the anemia from reduced hemoglobin (Cao & Galanello 
2010). This treatment, however, carries the risk of infection from blood borne diseases 
such as HIV and hepatitis and as well as the serious side effect of transfusional iron 
overload which is fatal if untreated. Currently, BMT offers the best chance for curing ǃ-
thalassemia in both in children and adults if a HLA identical donor is found, but is limited 
by complications like graft-versus-host disease or finding suitable donors (Lucarelli & 
Gaziev 2008). 
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Gene therapy of human ǃ-thalassemia is still in its infancy and requires the development of 
efficient, safe and high level gene transfer into target hematopoietic stem cells. It also 
requires regulation of erythroid lineage-specific expression and therapeutic levels of ǃ-
globin expression (Malik & Arumugam 2005). Meeting these requirements may be difficult, 
but a successful gene therapy trial was achieved in 2007 when an 18 year-old patient was 
effectively treated using a ǃ-globin-expressing lentiviral vector. The vector was transfected 
ex vivo into harvested CD34+ cells and then transplanted back into the patient’s bone 
marrow. The patient, who had no HLA-matched donors (making BMT impossible), was 
treated with high dose chemotherapy with intravenous busulfan to eliminate defective 
hematopoetic stem cells (HSC) prior to transplantation. This step was critical for the success 
of this treatment to prevent the defective HSC from diluting the corrected HSC. Three years 
post-transplant this patient no longer required blood transfusions and showed stable 
hemoglobin levels. However, mild anemia, compensatory expansion of red-blood-cell 
precursors in bone marrow, and other safety concerns have been raised (including 
development of cancers) (Cavazzana-Calvo et al. 2010). Although the long-term prognosis 
and outcome of gene therapy for ǃ-thalassemia is currently unclear, it still has the same 
advantage of the presence of accessible stem cells as X-SCID. With this in mind, targeting 
stem cells may be more successful than differentiated cells, and may be sufficient to cure the 
disease. 
3. Identifying novel targets for gene therapy 
Before targeting a disease with gene therapy, the genetic basis of that disease should be 
identified. Strategies for finding disease genes have greatly improved in the last few years 
due to the Human Genome Project and the Hap Map Project. The Hap Map Project 
identifies and catalogs genetic similarities and differences in humans (Human Genome 
Project; The International Hap Map Consortium 2003) and supplies computerized databases 
to search through and identify new gene therapy targets (Hap Map Project 2003). To find 
genes the two most common options are candidate-gene studies and genome-wide studies. 
Candidate-gene association studies are based on prior biological knowledge of gene 
function or on significant findings in linkage studies. This method is based on a single 
polymorphism and haplotypes and compares allele or haplotype frequencies between the 
case and the control group. Genome-wide studies can be divided into linkage mapping and 
genome-wide association studies. Genetic linkage mapping studies are used to discover and 
identify new genes by using genetic and phenotypic data from families. The analysis is 
conducted without any prior knowledge about genetic basis of disease. Linkage analysis 
functions by comparing genotype polymorphic markers at known locations in the genome. 
Genome-wide association studies are the most recent technology. They search the whole 
genome for single nucleotide polymorphisms (SNPs). Each study can look at hundreds or 
thousands of SNPs at the same time (for an excellent review see (Hirschhorn & Daly 2005)). 
The results are plotted into biostatistics algorithms (Nakamura 2009; Hirschhorn & Daly 
2005). The proteins identified by genomic methods can be further characterized by standard 
molecular and biochemical assays. In addition, protein targets have been identified by 
individual labs using standard molecular and biochemical methods without a priori use of 
genomic information. With the growing understanding of genes associated with many 
diseases the future for new gene therapeutics shows promise.  
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Fig. 1. Finding Novel Gene Therapy Targets. Integration of standard and modern 
technologies for disease-causing targets for gene therapy. 
3.1 Methods to find gene therapy targets 
Microarrays lay the groundwork for the methods mentioned above. The two most important 
advantages of microarrays are their small scale (multi-well plate formats) and ability to 
detect thousands of different immobilized genes simultaneously (Duggan et al. 1999; 
Siegmund et al. 2003; NCBI 2007). There are three types of microarray technologies: 
comparative genomic hybridization, expression analysis and mutation/polymorphism 
analysis, though the principle remains the same for all. First, the DNA chip corresponding 
to the DNA of interest is selected. Then, isolated messenger RNA (mRNA) is used as a 
template to generate complementary DNA (cDNA), with a fluorescent tag. This mixture is 
incubated with the DNA chip. During this incubation, tagged cDNA can specifically bind to 
the complementary DNA template on the chip. Afterwards, the hybridized cDNA can be 
detected with lasers specific to different fluorophores followed by analysis using 
computational methods (NCBI 2007). 
The Human Genome Project and the HapMap project have provided the foundation for 
candidate gene and genome-wide studies. Using these methods may allow us to draw 
conclusions between gene abnormalities and diseases. For example, many different studies 
have been conducted to determine the genes associated with cardiovascular diseases. In fact 
many CVDs are linked to mutated genes. For example, there is evidence based on genetic 
linkage analysis that chromosomes 1, 2, 3, 13, 14, 16 and X are involved in myocardial 
infarction, which is the major killer world-wide. Additionally, myocardial infarction and 
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stroke are associated with mutations in chromosome 13q12-13 containing the ALOX5AP 
gene encoding arachidonate 5-lipoxygenase-activating protein. Furthermore, high LDL, low 
HDL and high triglycerides values are high risk factors for cardiovascular disease, with 
linkage results located in all autosomes except for 2 and 14 (Arnett et al. 2007, and references 
therein). 
Finding disease-causing genes may not only help to better understand the pathophysiology 
of the disease, but may improve the diagnosis of the disease by discovery of disease-specific 
marker genes. Importantly, identification of disease-causing genes will lead to new targets 
for improved therapeutics. Genome-wide association studies which scan markers across the 
entire genome can find single mutations causing monogenic disorders as well as different 
mutations in several genes, which may lead to more gene therapy-based cures for these 
diseases.  
3.2 Hub proteins 
Genomic sequencing information, microarrays, and molecular/biochemical assays are tools 
that can help determine which proteins are responsible for disease. This information can be 
analyzed to identify hub proteins involved in disease progression. Hub proteins are key 
proteins that signal to multiple other proteins in transduction cascades. They are highly 
connected to other proteins with multiple interaction partners. Hub proteins bind with 
several distinct binding sites to other proteins. Studying the binding interface of cancer-
related proteins maybe useful for better understanding of cellular function and biological 
processes (Keskin & Nussinov 2007; Kim et al. 2006).  
3.2.1 Tumor suppressor hub proteins   
3.2.1.1 p53 
The tumor suppressor p53 is an example of a hub protein involved in cancer which loses the 
ability to bind different other proteins due to mutations (Shiraishi et al. 2004). It induces 
transactivation of target genes which are responsible for cell cycle arrest, DNA repair and 
apoptosis. p53 is mutated in 40% of cancers (Goh et al. 2010). In normal, healthy cells p53 is 
rapidly degraded via the MDM2 pathway, but when stress signals occur, p53 accumulates 
dramatically in the cell, allowing it to accomplish its apoptotic functions. p53 stimulates 
multiple signaling mechanisms which lead to apoptosis: the extrinsic pathway through 
death receptors and the intrinsic pathway through the mitochondria (Haupt et al. 2003). As 
a transcription factor it binds to p53-responsive genes, and the expressed proteins trigger 
apoptosis, G1 arrest, as well as DNA repair through different mechanisms. In addition, p53 
translocates to the mitochondria and induces a rapid apoptotic response (Erster et al. 2004; 
Haupt et al. 2003). Consequently, p53 fulfills the requirements for an ideal hub protein for 
gene therapy. Indeed, p53 adenovirus has been used for cancer therapy, and was the first 
gene therapeutic on the market.  
3.2.1.2 BRCA1 and BRCA2 
Breast cancer susceptibility protein (BRCA)1 and BRCA2 are highly associated with breast 
and ovarian cancer. The lifetime risk of developing breast cancer for a person carrying 
mutations in both genes is 82%; mutations in BRCA1 account for 52% and BRCA2 for 23% of 
all cases. Furthermore, the risk for ovarian cancer is dramatically increased due to mutations 
in BRCA1 and/or BRCA2. Thus, it is important to identify patients with a probability of 
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having mutations in these proteins. BRCA1 and BRCA2 regulate cell cycle progression, 
DNA repair and gene transcription (Metcalfe et al. 2005).  Their export into the cytoplasm is 
associated with apoptosis. In cooperation with cellular partner BARD1 (BRCA1-associated 
RING domain protein), BRCA1 is able to enter the nucleus and accomplish its role in DNA 
repair, centrosome regulation and RNA processing (Henderson 2005; Rodriguez et al. 2004). 
When the sensitive balance between BARD1 and BRCA1 is defective due to cancer-
promoting mutations in both, they remain as a dimer which results in nuclear 
compartmentalization leading to dramatic reduction of their apoptotic activity (Davis et al. 
2007; Rodriguez et al. 2004). Silencing BRCA1 expression using RNA-mediated interference, 
results in increased cytoplasmic levels of BARD1 and causes apoptosis in breast cancer cell 
lines (Rodriguez et al. 2004). BARD1 translocates to the mitochondria and causes 
oligomerization of Bax which results in apoptosis (Tembe & Henderson 2007). Therefore, 
targeting BRCA1 is a viable gene therapy-based approach.  
3.2.2 Hub proteins that promote cancer 
3.2.2.1 Survivin 
In addition to adding back hub tumor suppressors for gene therapy, oncogenic hub proteins 
can be blocked as well. The oncogene survivin is nearly universally expressed in various 
types of cancer and is almost undetectable in most adult tissue. Survivin is a unique member 
of the inhibitor of apoptosis protein (IAP) family and plays a major role as a mitotic 
regulator (Altieri 2001, and references therein). It is involved in multiple cancer-promoting 
mechanisms, particularly inhibition of apoptosis. Various parallel pathways, such as 
intervention in mitochondrial function, inhibition of caspases, and influence on gene 
expression are responsible for survivin’s anti-apoptotic function (Altieri 2008, and references 
therein). For example,  survivin and its binding partners act to prevent caspase activation; 
activated caspase 9 is required to activate effector caspase 3 and caspase 7, which execute 
mitochondrial-induced apoptosis (Li & Yuan 2008). Also, a splice variant of survivin, 
survivin ΔEx-3, translocates to the mitochondria where it interacts with proteins from the 
Bcl-2 family. These proteins are inhibitors of permeabilization of the mitochondrial outer 
membrane which is essential for cytochrome c release. Stabilization of Bcl-2 proteins 
prevents cytochrome c release, thus resulting in the inhibition of caspase 9 and caspase 3 
(Altieri 2008, and references therein). Furthermore, survivin’s role as a mitotic regulator is 
related to its inhibition of apoptosis. Survivin expression is upregulated at the G2/M phase 
to localize to the mitotic apparatus and is downregulated in interphase via ubiquitin-
dependent destruction (Li, Ambrosini, et al. 1998; Zhao et al. 2000). High survivin 
expression was detected in various types of cancers including breast, lung, colon, stomach, 
esophagus, pancreas, uterus, ovary and liver (Altieri 2008, and references therein). Dramatic 
overexpression of survivin correlates with more aggressive and invasive clinical phenotypes 
which means a poor prognosis compared to survivin-negative tumors, an increased rate of 
recurrence and chemotherapy resistance (Kato et al. 2001; Grossman & Altieri 2001). The 
differential expression and function of survivin make it an excellent target for cancer 
therapy (Altieri 2003). There are many gene-based strategies to inhibit survivin in cancer 
cells, with some in phase I and II clinical trials. One gene-based method uses survivin 
antisense oligonucleotides to prevent expression in cancer cells. Two phase II trials and one 
phase I trial by Eli Lilly and Co. are ongoing for relapsed or refractory acute myeloid 
leukemia, hormone refractory prostate cancer and advanced hepatocellular carcinoma (Ryan 
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et al. 2009). Furthermore, Alteri et al. created a replication-deficient adenovirus containing a 
dominant negative survivin mutant where threonine 34 is mutated to alanine. This mutation 
abrogates phosphorylation of threonine which impairs survivin’s ability act as a mitotic 
regulator, as only phosphorylated survivin is able to localize to the mitotic apparatus 
(O'Connor et al. 2000). Injection of adenovirus containing survivin mutant triggers apoptosis 
by cytochrome c release which leads to caspase 3 activation. Alteri et al. demonstrated in 
several cancer cell lines that this mutant causes apoptosis and confirmed these results in 
three xenograft breast cancer mice models. Interestingly, this survivin mutant was not able 
to cause apoptosis in proliferating normal human cells (Mesri et al. 2001). 
3.2.2.2 Ras 
The RAS supergene family is divided into six subfamilies RAS, RHO, RAB, ARF, RAN and 
RAD which code for more than 50 structurally related proteins. Their main function is to 
transmit signals from cell-surface receptors to the cell interior. All proteins have a guanosine 
triphosphate (GTP) binding motif in common and participate in signaling cascades. The 
RAS subfamily functions in proliferation and differentiation which makes it a prime target 
for anti-cancer therapy. The localization of Ras on the cell membrane, and binding to GTP 
are essential for its function. When Ras binds to GTP, it initiates the signaling pathway for 
cell proliferation and differentiation. However, when Ras-GTP is hydrolyzed to Ras-GDP by 
GTPase-activating proteins (GAPs), it is unable to activate its signal transduction pathway. 
This sensitive regulation process is out of balance in cancer cells due to different mutations 
in the RAS gene. Most of these mutations occur in the Ras gene itself and in the regulatory 
proteins of the Ras pathway. These mutations cause Ras to stay in the active Ras-GTP form 
and prevent conversion into the inactive Ras-GDP form. Mutated Ras protein is hyperactive 
and triggers cancer development. Hyperactive Ras is associated with different types of solid 
tumors such as pancreatic, cervical, thyroid, colon, skin, and lung tumors as well as with 
hematopoietic malignancies such as chronic myelomonocytic leukemia, acute myelogenous 
leukemia and multiple myeloma to list a few. Ras is an excellent gene therapy target due to 
its involvement in various cancers (Beaupre & Kurzrock 1999, and references therein). 
Recently it has been shown that knocking out Ras with an anti-Ras mRNA plasmid-
mediated short-hairpin RNA in combination with clinical drug vincristine resulted in 
inhibition of the growth of human hepatoma HepG2 in vivo (Sun et al. 2009). This illustrates 
once again that the combination of gene therapy with standard chemotherapy is a promising 
approach for treatment of cancer.  
3.2.2.3 AKT 
AKT, a serine/threonine kinase, plays an essential role in oncogenesis. The AKT family 
consists of three cellular homologues AKT1, AKT2 and AKT3. The encoded proteins have a 
similar structure consisting of an amino-terminal pleckstrin homology domain, a short ǂ-
helical linker and a carboxy-terminal kinase domain. Tissues have different expression 
levels of the three homologues AKT1, AKT2 and AKT3, which is why it is not surprising 
that the three different variants of AKT are overexpressed in different types of cancers. For 
example, AKT1 is overexpressed in gastric cancer and is associated with poor prognosis in 
breast and prostate cancer; AKT2 is overexpressed in ovarian and pancreatic cancer. AKT3 
is overexpressed in estrogen receptor-deficient breast cancer and in androgen-insensitive 
prostate cancer which implies that AKT3 contributes to aggressive steroid hormone-
insensitive cancer. AKT acquires growth signal autonomy and inhibits apoptosis in cancer 
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cells. It promotes cell survival through its phosphorylation of MDM2, which enhances 
nuclear accumulation of MDM2. MDM2 inhibits the transcriptional activity of p53 and 
promotes its degradation by the proteasome (Testa & Bellacosa 2001). AKT gene therapy has 
been conducted with an aerosol delivery system consisting of nano-sized glucosylated 
polyethylenimine (GPEI). It has been shown that this aerosol is capable of delivering AKT 
wild-type and kinase deficient genes into the lung of mice (Tehrani et al. 2007). Dominant 
negative alleles of AKT directly injected into lung carcinoma cells have also been shown to 
block cell survival and proliferation (Li, Simpson, et al. 1998). 
3.3 Protein-protein interactions 
A protein dimer or oligomer is a macromolecular structure formed by two (dimer) or 
several (oligomer) proteins of either same origin (homo-oligomers) or different origins 
(hetero-oligomers). For several proteins the formation of oligomers or dimers is essential in 
order to form functional systems. Both Bcr-Abl and p53 proteins function in the homo-
oligomeric form. On the other hand, hemoglobin forms hetero-oligomers consisting of two ǂ 
and two ǃ subunits to form a functional structure. If one of these subunits is defective or 
missing, the protein cannot master its tasks leading to diseases such as the previously 
described ǃ-thalassemia. Mutations in the oligomerization domain can lead to loss of 
function. Dimer or oligomer formation is governed by non-covalent interactions, including 
salt bridges, hydrogen bonds and hydrophobic interactions. A common structural motif for 
dimerization is a coiled coil consisting of usually two to five ǂ-helices that wind around one 
another like strands of a rope, meshed together like “knobs-into-holes.” They contain a 
characteristic seven-residue sequence repeat (Mason & Arndt 2004; Crick 1952). Coiled coil 
motifs play an important role in the function of several different proteins ranging from 
transcription factors such as Jun and Fos which are responsible for cell growth and 
proliferation (Glover & Harrison 1995) to the oncoprotein Bcr-Abl which leads to cancer 
(McWhirter et al. 1993). A subgroup of the coiled coil motif is represented by the “leucine 
zipper”, an unusually long ǂ-helix with protruding leucine residues in periodic repetition. 
The leucine residues from one peptide interact with leucine residues from a second peptide, 
forming a molecular zipper (Landschulz et al. 1988). Another important dimerization 
interface for proteins is the helix-loop-helix (HLH) motif. Characterized by two ǂ-helices 
connected by a short loop, this structure is highly conserved in many diverse organisms. 
Proteins containing this structure are transcription factors that are only functional as homo- 
or hetero-dimers (Murre et al. 1994, and references therein). Important HLH family 
members are myc proteins which play an essential role in cell proliferation, differentiation, 
cell growth, and apoptosis, but are also involved in development of numerous kinds of 
cancer (Vita & Henriksson 2006). Finally, another interaction motif is the zinc finger motif, 
containing several subgroups such as C2H2, Gag knuckle, treble clef, zinc ribbon, 
Zn2/Cys6, TAZ2 domain like, zinc binding loops and metallothionein (Krishna et al. 2003). 
The C2H2 zinc finger represents the most prevalent motif and contains a zinc ion 
coordinated by cysteines and histidines (Wolfe et al. 2000). Although most C2H2 fingers 
apparently contribute to protein-DNA or protein-RNA interactions, examples for protein-
protein interactions also exist. One example is Ikaros, a transcription factor participating in 
gene silencing and activation in hematopoietic cells. In this protein, dimerization is 
important for its activity and affinity to DNA (McCarty et al. 2003, and references therein). 
In addition, more complex oligomerization structures exist. For example, p53 forms a dimer 
with an antiparallel ǃ-sheet and an antiparallel helix-helix interface. Two dimers associate as 
a parallel helix-helix to form a tetramer (Jeffrey et al. 1995). 
www.intechopen.com
 
Choosing Targets for Gene Therapy 
 
15 
Gene therapy may be used to enhance or inhibit dimerization interfaces. Currently, small 
molecule drugs are unable to re-establish the ability of proteins to form dimers with the aim 
of restoring their natural function. In contrast, gene therapy can supply dimerization-
capable and functional proteins. On the other hand, if the formation of a dimer is unwanted, 
it is possible to disrupt the dimerization interface of a disease-causing protein by 
introducing proteins into the cell which compete for dimerization. Normal dimerization of 
the disease-causing protein is then blocked, hence stopping the disease. 
3.3.1 Homo-oligomerization for apoptotic activity 
The classic example of a protein that is only functional as a homo-oligomer is p53. The 
protein p53 is 393 amino acids long and contains a transactivation domain (amino acids 1-
43) and a proline-rich domain (amino acids 61-94), a DNA-binding domain (amino acids 
110-286), a tetramerization domain (amino acids 326-355) and a regulatory region (amino 
acids 363-393) (Chene 2001). As already mentioned, mutations of TP53, the gene encoding 
for p53, occur in a large proportion of human cancers. Some of these mutations may prevent 
the formation of tetramers, which lead to loss of p53 function (Vogelstein et al. 2000). Not 
only does the site-specific binding to DNA depend on oligomerization , but so do a number 
of post-translational modifications of p53 which are believed to be important regulators of 
p53 activity (Chene 2001, and references therein). Reintroducing tetramerization-capable 
p53 using gene therapy may allow treatment of cancers which are caused by mutations in 
this region of TP53. So far 49 mutations in the tetramerization domain of p53 have been 
described, even though not all mutations prevent dimerization or tetramerization. Most of 
these occurring mutants still form tetrameric structures like wild-type p53 but with reduced 
stability (Kamada et al. 2011).  
Another example where protein oligomerization yields functionality occurs with DJ-1. This 
protein bears cytoprotective functions within cells and protects neurons from stressful 
stimulants. A L166P mutation in the DJ-1 gene may prevent its ability to homodimerize, and 
it has been speculated that this can lead to neurodegeneration in autosomal recessive early 
onset Parkinsonism (Gorner et al. 2007, and references therein). Re-introduction of 
dimerization-capable DJ-1 with gene therapy is therefore a possible treatment option. 
3.3.2 Disruption of disease-causing homo-oligomerization  
Like p53, Bcr-Abl is also a protein that functions as a homo-oligomer (dimer of dimers). 
However, Bcr-Abl derives oncogenic function rather than tumor suppression from 
oligomerization. Bcr-Abl results from the fusion of the breakpoint cluster region (Bcr) gene 
on chromosome 22 and the Abelson leukemia oncogene (Abl) on chromosome 9. This results 
in an abnormal shortened chromosome called the Philadelphia chromosome. Bcr-Abl 
functions as an oncoprotein leading to increased cell proliferation and inhibition of 
apoptosis due to the constitutive activation of tyrosine kinase activity and causes 95% of all 
cases of chronic myeloid leukemia (CML) (Sawyers 1999, and references therein). The 
oligomerization of Bcr-Abl is essential for the activation of the tyrosine kinase activity of 
Bcr-Abl (McWhirter et al. 1993). Destroying the ability of Bcr-Abl to form tetramers or using 
the dimerization domain to disrupt Bcr-Abl activity would be a possible gene therapy 
approach for CML (Dixon et al. 2009). 
Finally, serpins (serine protease inhibitors) such as serpin ǂ1-antitrypsin function aberrantly 
as oligomers/polymers (Silverman et al. 2001; Lomas & Mahadeva 2002). In fact, the 
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polymerization of serpin ǂ1-antitrypsin is known to cause hepatocellular carcinoma and 
liver cirrhosis due to accumulation in the endoplasmatic reticulum of the liver (Lomas & 
Mahadeva 2002). Disruption of polymerization could also be targeted for gene therapy, 
using an exogenously added polymerization domain that could compete for binding to 
serpin ǂ1-antitrypsin. 
3.4 Cell compartments 
Targeting a gene therapy product to a specific subcellular compartment is another way to 
overcome disease. There are many diseases associated with protein malfunction in different 
organelles of the cell (Davis et al. 2007). For example, certain cancers can arise when a 
protein localizes to the wrong compartment. The typical example is cytoplasmically 
mislocalized p53. When p53 is in the cytoplasm, it cannot act as tumor suppressor since it is 
a transcription factor that needs to be in the nucleus in order to function (Kau et al. 2004; 
Wurzer et al. 2001). In addition to mislocation from the nucleus, the incorrect localization of 
proteins normally destined for lysosomes, peroxisomes, Golgi apparatus, endoplasmic 
reticulum (ER) or mitochondria can also lead to disease. Directing gene therapy products to 
specific subcellular compartments represents not only novel targets but a new way to 
approach gene therapy (Mossalam et al. 2010).  
3.4.1 Lysosomes 
Lysosomes degrade unused cellular constituents, receptors and release active enzymes 
extracellularly and are involved in post-translational maturation of proteins. Dysfunction of 
lysosomal hydrolases leads to loss of cell growth control and results in chemotherapy 
resistance as well as high metastatic potential (Castino et al. 2003). Furthermore, lysosome 
and lysosome-related organelles are associated with Lysosomal Storage Disease (LSD), 
Alzheimer’s disease and development of several types of tumors. LSD is collective term for 
40 genetic disorders due to single or multi enzyme deficiency which results in 
neurodegenerative disorders. Therapy options are limited to BMT and enzyme replacement. 
The disadvantages of BMT are morbidity and mortality as well as incomplete response to 
therapy. Enzyme replacement fails because of fast degradation of the enzyme from 
bloodstream. Due to these limitations, gene therapy represents a potential alternative. 
Currently, gene therapy is focused on using cargo proteins that deliver proteins to the 
lysosome. Since clathrin-dependent receptor-mediated endocytosis (RME) is the main 
transport mechanism for delivery to the lysosome, it is thought that all forms of LSDs can be 
treated with gene therapy (Bareford & Swaan 2007, and references therein).  
3.4.2 Peroxisomes 
Peroxisomes are multifunctional organelles which are involved in biochemical and 
metabolic processes such as oxidation of fatty acids, plasmalogen biosynthesis and 
glyoxylate detoxification. Malfunction of or defects in peroxisomes are associated with a 
variety of diseases which can be classified as Zellweger spectrum peroxisome biogenesis 
disorders or rhizomelic chondrodysplasia punctate. Defects in peroxisome biogenesis 
proteins (peroxins, encoded by PEX genes) can lead to eye anomalies, extreme hypotension, 
and hepatomegaly (to name a few), and usually are fatal by age 1-2. In general deficiencies 
in a single peroxisomal enzyme (PEX) are associated with a variety of diseases. The therapy 
approaches are focused on protein therapeutics, peroxisomal enzymes and gene therapy. 
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One possible gene therapy target is the antioxidant enzyme, catalase. A modified catalase 
molecule was transduced into hypocatalasemic fibroblasts and reduced hydrogen peroxide 
levels dramatically. This resulted in the restoration of oxidative balance, which may have 
cytoprotective effects (Terlecky & Koepke 2007). The cytoprotective role of catalase makes it 
an excellent gene therapy target, because many diseases such as cardiovascular diseases are 
linked to high hydrogen peroxide levels (Gong et al. 2010). 
3.4.3 Proteasome 
Targeting the proteasome, the cell’s degradation machinery, represents another possible 
target for gene therapy. The general inhibition of the proteasome is already used for 
treatment of inflammatory disease and cancer (Nalepa et al. 2006) while the activation of the 
proteasome can be used for neurodegenerative diseases and cardiac diseases (Dahlmann 
2007). Targeting disease-specific components of the ubiquitin-proteasome system provides 
the possibility for directed therapy approaches (Nalepa et al. 2006). The E3 ubiqitin ligases 
are important for specificity of proteasomal degradation because they recognize the proteins 
which should be destroyed (Nalepa et al. 2006). More classical drug targets are the 
ubiquitin-activation and the actual degradation step which occurs in the proteasome. A new 
approach suggested by our lab involves capturing oncogenic proteins such as survivin and 
sending them to the proteasome for degradation. This could be achieved by including a 
gene therapy construct that has a survivin dimerization domain and a proteasomal 
degradation domain, capable of capturing endogenous survivin and sending it to the 
proteasome (Mossalam et al. 2010). 
3.4.4 Mitochondria 
Mitochondria are essential for production of cellular ATP. The mitochondria consist of the 
outer membrane, the inner membrane, intermembrane space, cristae and mitochondrial 
DNA. Mutations in mitochondrial DNA are associated with muscle and central nervous 
system dysfunction, but only if most of the DNA is mutated. An interesting gene therapy 
approach is to tag mitochondria targeting signals to endonucleases which are able to 
degrade the mutated mitochondrial DNA. This mutant DNA contains the T8399G mutation 
which creates a unique restriction site and allows the restriction enzyme to distinguish 
between normal DNA and mutated DNA. It provides new therapy options for neuropathy, 
ataxia and retinitis pigmentosa (Srivastava & Moraes 2001). In addition, the mitochondrion 
is also essential in cellular apoptosis. Proteins such as p53 can be sent to the mitochondria, 
eventually resulting in cytochrome c release and apoptosis. Indeed, p53 targeted to the 
mitochondria has shown to cause apoptosis in different cancer cell lines (Palacios & Moll 
2006).  
3.4.5 Endoplasmic reticulum 
The endoplasmic reticulum (ER) produces almost all cellular lipids, and the majority of 
proteins are synthesized on the cytosolic surface of the ER. A wide range of diseases occur 
due to mistakes in protein folding/assembly in the ER such as CF and neurodegenerative 
diseases. CF is a classic gene therapy target with one single mutation which can be targeted 
by replacing the defect gene. Unfortunately, all gene therapy approaches for CF have failed 
thus far. Certain neurodegenerative diseases are affected by mutations in proteins involved 
in ER assembly. Mutations in Parkin, which is an E3 ligase responsible for ubiquitinylation 
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and regulation of proteasomal degradation, is associated with juvenile Parkinsonism. The 
Parkin proteasomal pathway normally degrades Pael-R in dopaminergic neurons. Pael-R 
accumulates in brain cells when Parkin is mutated (Aridor et al. 2004, and references 
therein). Adding back functional Parkin would then be a possible gene therapy approach for 
juvenile Parkinsonism.  
3.4.6 Golgi apparatus 
In addition to the synthesis of carbohydrates, the Golgi apparatus (GA) sorts as well as 
dispatch proteins to the ER. SPCA1 is a protein found in the trans-Golgi. When mutations 
occur in the gene (ATP2C1) encoding SPCA1, a genetic disorder results called Hailey-Hailey 
disease. These various mutations result in skin lesions which are usually benign and lead 
only in a few cases into squamous cell carcinoma (Pizzo et al. 2011). Replacing mutated 
SPCA1 would be a possible gene therapy approach to treat Hailey-Hailey disease.  
3.4.7 Nucleus 
Many diseases are associated with problems in nuclear import and export. For example, 
various types of cancers are associated with p53 and FOXO mislocalization in the cytoplasm, 
while their normal localization is the nucleus. There are several examples of proteins that 
when mislocalized to different compartments lose their function or may become oncogenic. 
The control of compartmentalization of key proteins can be used to overcome disease. 
Besides, tumor suppressors such as p53, cell cycle inhibitors, G-protein coupled receptors 
and transcription factors can also lose their function when mislocalized (Chinen et al. 2007). 
p21WAF-1 is localized in the nucleus where it accomplishes its function as cell cycle inhibitor. 
When moved to the cytoplasm, it is associated with tumor progression (Davis et al. 2007; 
Keeshan et al. 2003). G-protein coupled receptors like rhodopsin, vasopressin V2, LDL and 
CFTR all require proper localization for function. For example, rhodopsin is found in the 
membrane sacs within the rods, and when mislocalized it is confined in the plasma 
membrane of photoreceptor cell body and causes retinitis pigmentosa (Edwards et al. 2000). 
Additional transcription factors such as NF-κB and FOXO are both associated with various 
types of cancer when mislocalized to different compartments. NF-κB is located in the 
cytoplasm of normal cells whereas nuclear accumulation causes cancer. In contrast FOXO is 
found in the nucleus of normal cells and cytoplasmic localization results in cancer (Davis et 
al. 2007, and references therein).  
There are several different gene therapy approaches for targeting mislocalized proteins. The 
standard method is to add back the protein which contains functional localization signals, 
such as the adenoviral p53 vectors GendicineTM and OncorineTM. On the other hand, 
blocking general nuclear import or export machinery has been attempted, but due to the 
non-specific blockage of import/export, these methods suffer from toxicity. Instead of 
general inhibition of import/export, the protein itself can be modified. Adding nuclear 
localization signals (NLS) or nuclear export signals (NES) to the genes encoding 
mislocalized proteins allows targeting of proteins directly to the desired compartments.  
The localization of proteins can be changed by using a protein switch developed in our 
laboratory (Kakar et al. 2007; Davis et al. 2007). The protein switch is a plasmid encoding a 
NES, a NLS and a ligand binding domain (LBD) from steroid hormone receptor. The LBD 
serves as a ligand-inducible nuclear localization switch. The protein switch is cytoplasm in 
the absence of ligand and translocates to the nucleus when ligand is added. The protein 
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switch has also been designed to contain dimerization domain that allows capture of an 
endogenous protein of interest. Upon ligand addition, the protein switch-endogenous 
protein complex will then translocate to the nucleus. Removal of the endogenous protein 
from the cytoplasm can result in decrease cytoplasmic signaling or increased apoptotic 
signaling in the nucleus, with potential use in cancer therapy (Kakar et al. 2007). 
4. Conclusions 
Some of the major diseases currently targeted by gene therapy include cancer, 
cardiovascular disease, HIV, and monogenic diseases. Despite many decades of gene 
therapy research on these diseases, there currently are very few products that have made it 
to market. The search for new gene therapy targets and improved methods are therefore 
warranted. The integration of new and standard technologies (genome sequencing, 
microarrays, improved analysis, and linkage to molecular and biochemical assays) recently 
have yielded methods to uncover new drivers of cancer (Akavia et al. 2010). In 2008, the 
NIH started its Undiagnosed Diseases Program. These NIH investigators first try to 
diagnose an illness by first looking at known genetic markers, followed by standard 
molecular and biochemical assays. If no candidate genes are revealed, they then use state-of-
the-art genetic analyses that can sequence the entire exome (all exons in the human genome) 
of a patient and their family; high resolution microarrays can genotype the rest of the 
genome to "bring genomics to the clinic." After comparison to family data and a reference 
sequence (from the Human Genome Project), the gene causing a particular rare disease may 
be discovered (Maxmen 2011). Currently patients enrolled in this program are not cured; the 
candidate gene and corresponding protein are only identified. Small molecule inhibitors of 
these proteins can take years or decades to screen, therefore making replacement of these 
defective or mutant genes prime candidates for gene therapy treatment in patients with a 
rare disease.  
Further analysis of the protein can uncover the molecular basis of the disease. Is this protein 
a hub protein which interacts with many other proteins? What are the protein-protein 
interactions that govern its activity? Are there any cell compartmentalization abnormalities 
that promote disease? With this information in mind, more modern gene therapy 
approaches can be developed. In our laboratory, we have designed a protein switch 
designed to capture and change location of a harmful protein in a cell. This altered location 
could be exploited for disease therapy. For example, the Bcr-Abl protein is oncogenic in the 
cytoplasm, but causes apoptosis when moved to the nucleus (Dixon et al. 2009). A protein 
switch against Bcr-Abl is being developed in our laboratory that can dimerize to wild type 
(wt) Bcr-Abl by virtue of a coiled-coil dimerization domain (Mossalam et al. 2010). The 
protein switch also contains a ligand-inducible domain that can move the protein from the 
cytoplasm to the nucleus upon the addition of ligand (Kakar et al. 2007). Therefore, after 
capture, wt Bcr-Abl is dragged to the nucleus, where apoptosis ensues. Understanding the 
molecular mechanisms that govern protein activity can therefore be used as the next phase 
in gene therapy, where altered protein location can completely change the function of a 
protein. Other emerging modern gene therapy-based approaches including anti-gene 
therapies (antisense, siRNA, ribozymes) and immunotherapy are desired to have a 
significant impact on disease treatment. 
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ABSTRACT: Targeting the tumor suppressor p53 to the
mitochondria triggers a rapid apoptotic response as efficiently
as transcription-dependent p53.1,2 p53 forms a complex with
the antiapoptotic Bcl-XL, which leads to Bak and Bax
oligomerization resulting in apoptosis via mitochondrial outer
membrane permeabilization.3,4 Although p53 performs its main
role in the mitochondrial outer membrane, it also interacts with
different proteins in the mitochondrial inner membrane and
matrix.5,6 To further investigate mitochondrial activity of p53,
EGFP-p53 was fused to different mitochondrial targeting
signals (MTSs) directing it to the mitochondrial outer membrane (“XL-MTS” from Bcl-XL; “TOM-MTS” from TOM20), the
inner membrane (“CCO-MTS” from cytochrome c oxidase), or matrix (“OTC-MTS” from ornithine transcarbamylase).
Fluorescence microscopy and a p53 reporter dual luciferase assay demonstrated that fusing MTSs to p53 increased mitochondrial
localization and nuclear exclusion depending on which MTS was used. To examine if the MTSs initiate mitochondrial damage, we
fused each individual MTS to EGFP (a nontoxic protein) as negative controls. We performed caspase-9, TUNEL, annexin-V, and
7-AAD apoptosis assays on T47D breast cancer cells transfected with mitochondrial constructs. Except for EGFP-XL, apoptotic
potential was observed in all MTS-EGFP-p53 and MTS-EGFP constructs. In addition, EGFP-p53-XL showed the greatest
significant increase in programmed cell death compared to its nontoxic MTS control (EGFP-XL). The apoptotic mechanism for
each construct was further investigated using pifithrin-α (an inhibitor of p53 transcriptional activity), pifithrin-μ (a small molecule
that reduces binding of p53 to Bcl-2 and Bcl-XL), and overexpressing the antiapoptotic Bcl-XL. Unlike the MTSs from TOM,
CCO, and OTC, which showed different apoptotic mechanisms, we conclude that p53 fused to the MTS from Bcl-XL performs its
apoptotic potential exclusively through the p53/Bcl-XL specific pathway.
KEYWORDS: p53, mitochondria, Bcl-XL, apoptosis, pifithrin, T47D
■ INTRODUCTION
The tumor suppressor p53 stimulates a wide network of signals
involved in DNA repair, cell cycle arrest, senescence, and
apoptosis.7−9 Although most of these effects can be linked to its
role as a transcription factor, recent work has clearly
demonstrated that p53 can cause apoptosis through its
transcription-independent mitochondrial pathway.3,10 A small
but highly reproducible fraction of p53 translocates to the
mitochondria at the onset of p53-dependent apoptosis.10
Translocation of p53 to the mitochondrial outer membrane
triggers the release of cytochrome c and activation of procaspase-3.
The DNA binding domain of p53 (DBD, residues 239−248)
forms inhibitory complexes with antiapoptotic Bcl-XL and Bcl-2
proteins (Figure 1), which are located in the mitochondrial outer
membrane.11 This induces oligomerization of Bak and Bax,
allowing them to form supramolecular pores.4,12,13 In addition,
p53 activates, directly binds to, and induces oligomerization of
Bak and Bax.4,13,14 The formation of permeability transition
pores causes outer membrane rupture and releases cytochrome c
from the intramembranous space into the cytosol triggering
apoptosis via the apoptosome (Figure 1).15−17 In addition,
targeting p53 to the mitochondria triggers apoptosis faster than
the transcription-dependent nuclear pathway.1,2 In most cancer
cells, p53 is not able to bind to Bcl-2 proteins due to missense
mutations in the DBD of p53, demonstrating the importance of
the DBD in mitochondrial apoptosis.11
The therapeutic effect of pharmaceutical agents such as p53
may differ depending on their intracellular delivery.18 Precise
compartmentalization and subcompartmentalization of proteins
are essential for their biological activity. The majority of
endogenous mitochondrial p53 localizes to the outer surface of
the mitochondria,19 which occurs after either DNA damage or
hypoxic stress.10 A detailed mechanism on how p53 translocates
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into the mitochondria is still under investigation since it is a
nuclear protein due to its nuclear localization signals.20 A study
has shown that Bad (Bcl-2 antagonist of cell death) physically
interacts with cytoplasmic p53 directing it to the surface of the
mitochondria.21,22 Moll has suggested that p53 is imported via
mtHsp70 targeting the membranous compartments.10 The
interaction with mtHsp70 and Hsp60 is increased with the
R72P polymorphism in p53 due to elevation in nuclear export of
p53.23 MDM2 protein is responsible for the nuclear exclusion
and ubiquitylation of p53. The monoubiquitylated p53 is
targeted to the mitochondria under stress, which disrupts the
p53/MDM2 complex.24
Despite what is known, exogenous mitochondrial targeting of
p53 is still under investigation. To improve apoptosis via the
p53/Bcl-XL pathway, p53 was delivered to different mitochon-
drial compartments. In this study, p53 was fused to different
mitochondrial targeting signals (MTSs) targeting the mito-
chondrial outer membrane [MTS from Bcl-XL or MTS from
the translocase of the outer membrane (TOM 20)], inner
membrane (MTS from cytochrome c oxidase subunit VIII), and
matrix (MTS from ornithine transcarbamylase) (Figure 1).
MTSs (Table 1) are generally thought to form α-helices
and are important for their recognition by translocation
machineries in the mitochondrial outer (TOM complex) and
inner (TIM complex) membranes.25−28 Since MTSs are mainly
found on the amino terminus of mitochondrial proteins,25 all
MTSs used were cloned on the amino terminus except for XL,
which is inherently found on the carboxy terminus.29 XL targets
the outer surface of the mitochondria29−32 while TOM is inserted
into the outer membrane;29 CCO translocates the outer
membrane and then becomes imbedded into the inner
membrane33,34 while the OTC crosses both membranes and
translocates to the matrix.3,35 The purpose of this work is to
determine the ideal MTS for p53 mitochondrial targeting to
induce the intrinsic apoptotic pathway.
■ MATERIALS AND METHODS
EGFP-p53 Plasmid (pEGFP-p53). The DNA encoding p53
was amplified through PCR from pCMV-p53 wt (a generous gift
from Dr. S. J. Baker, Addgene, Cambridge, MA) using the primers
5 ′-GCGCGCGCGCTCCGGAGCCATGGAGGAGCCG-
CAGT-3′ and 5′-GCGCGCGCGCGGTACCTCAGTCTGAGT-
CAGGCCCTTCTGTC-3′. This was subcloned into the BspEI
and KpnI restriction enzyme sites in pEGFP-C1 (Clontech,
Mountain View, CA).
pOTC-EGFP-p53 Plasmid. An oligonucleotide encoding
the mitochondrial targeting signal from OTC (including the
Kozak region), 5′-CCGGTCGCCACCATGCTGTTTAATCT-
GAGGATCCTGTTAAACAATGCAGCTTTTAGAAATGGT-
CACAACTTCATGGTTCGAAATTTTCGGTGTGGA-
CAACCACTACAAAATAAAGTGCAGCGA-3′ was annealed
to its complementary strand. This was then cloned at the
amino terminus of EGFP-p53 at the AgeI site.
pTOM-EGFP-p53 and pCCO-EGFP-p53 Plasmids. The
OTC region from pOTC-EGFP-p53 was replaced with an-
nealed oligonucleotides encoding the mitochondrial target-
ing signal from the TOM20 complex (TOM) at the AgeI site,
5 ′-GATCCCCGGTCGCCACCATGGTGGGTCGGAA-
CAGCGCCATCGCCGCCGGTGTATGCGGGGCCCTTTT-
CATTGGGTACTGCATCTACTTCGACCGCAAAAGAC-
GAAGTGACCCCAACCGA-3′ and its reverse complement, or
with oligonucleotides encoding the mitochondrial targeting
signal from the cytochrome c oxidase (CCO) at the AgeI site,
5′-CCGGTCGCCACCATGTCCGTCCTGACGCCGCTGCT-
GCTGCGGGGCTTGACAGGCTCGGCCCGGCGGCTCC-
CAGTGCCGCGCGCCAAGATCCATTCGTTGA-3′ and its
reverse complement.
pEGFP-p53-XL Plasmid. The mitochondrial signal from
Bcl-XL was fused to the carboxy terminus of EGFP-p53 using
the BamHI restriction site as follows. The XL oligonucleotide 5′-
AGAAAGGGCCAGGAGAGATTCAACAGATGGTTCCT-
GACCGGCATGACCGTGGCCGGCGTGGTGCTGCTGGG-
CAGCCTGTTCAGCAGAAAGTGA-3′ was annealed to its
complementary strand (with BamHI sticky ends). The p53
stop codon was then mutated (TGA to TTA) in pEGFP-p53-XL
using the primers 5′-GAAGGGCCTGACTCAGACTTAGG-
TACCGCGGGCCCGGGAT-3′ and the reverse complement.
Figure 1. The mitochondrial apoptotic pathway of p53. When p53 is
targeted to the mitochondria, it interacts with antiapoptotic Bcl-XL,
enables Bax and Bak oligomerization, and activates the intrinsic
apoptotic pathway. The apoptosome (cytochrome c, APAF-1, and
caspase-9) is triggered, leading to apoptosis via activation of caspases-3,
-6, and -7. The left side of the diagram indicates the mitochondrial
signals (MTSs) used and the different subsections of the mitochondria
targeted, including the outer membrane (“XL-MTS” from Bcl-XL;
“TOM-MTS” from TOM20), the inner membrane (“CCO-MTS”
from cytochrome c oxidase), and the matrix (“OTC-MTS” from
ornithine transcarbamylase).
Table 1. A List of the Mitochondrial Targeting Signals Used in This Papera
protein compartment MTS sequence
XL outer membrane RKGQERFNRWFLTGMTVAGVVLLGSLFSRK
TOM outer membrane MVGRNSAIAAGVCGALFIGYCIYFDRKRRSDPN
CCO inner membrane MSVLTPLLLRGLTGSARRLPVPRAKIHSL
OTC matrix MLFNLRILLNNAAFRNGHNFMVRNFRCGQPLQNKVQ
aTOM and XL target the mitochondrial outer membrane, CCO translocates to the mitochondrial inner membrane, and the OTC localizes to the
mitochondrial matrix.
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pEGFP Constructs with MTSs. Plasmids encoding OTC-
EGFP, TOM-EGFP, CCO-EGFP, and EGFP-XL were constructed
using the same oligonucleotides and restriction sites mentioned
above but inserted in pEGFP-C1 instead of pEGFP-p53.
pMTS-EGFP-p53NLSmut. Mutations (K319T and K320T)
in the nuclear localization signal (NLS) of p53 were introduced
in all mitochondrial p53 constructs via QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent, Santa Clara, CA) using the
primers 5′-CTCTCCCCAGCCAACGACGAAACCACTGG-3′
and its reverse complement.
Cell Lines and Transient Transfections. 1471.1 murine
adenocarcinoma cells (gift of G. Hager, NCI, NIH), MCF-7
human breast adenocarcinoma cells (ATCC, Manassas, VA), and
T47D human ductal breast epithelial tumor cells (ATCC) were
grown as monolayers in DMEM (1471.1) or RPMI (MCF-7 and
T47D) (Invitrogen, Carlsbad, CA), supplemented with 10% fetal
bovine serum (Invitrogen), 1% penicillin−streptomycin−
glutamine (Invitrogen), and 0.1% gentamicin (Invitrogen). In
addition, T47D and MCF-7 medium was supplemented with
4 mg/L insulin (Sigma, St. Louis, MO). The cells were maintained
in a 5% CO2 incubator at 37 °C. 7.5 × 10
4 cells for 1471.1 and
3.0 × 105 cells for MCF-7 and T47D were seeded in 6-well plates
(Greiner Bio-One, Monroe, NC) or 2-well live cell chambers
(Nalgene Nunc, Rochester, NY). Transfections were carried out
24 h after seeding using Lipofectamine 2000 (Invitrogen)
following the manufacturer’s recommendations. Unless otherwise
indicated, 1 pmol of DNA was transfected per well for all assays.
Mitochondrial Staining, Microscopy, and Image
Analysis. Prior to live-cell imaging and mitochondrial staining,
medium in live cell chambers was replaced with phenol red-free
DMEM (Invitrogen) for 1471.1 cells or phenol red-free RPMI
(Invitrogen) for T47D and MCF-7 cells containing 10% charcoal-
stripped fetal bovine serum (CS-FBS, Invitrogen). Cells were
incubated with 250 nM MitoTracker Red FM (Invitrogen) for
15 min at 37 °C and protected from light. Images were acquired
as previously,36 using an Olympus IX71F fluorescence micro-
scope (Scientific Instrument Company, Aurora, CO) with high-
quality narrow band GFP filter (ex, HQ480/20 nm; em, HQ510/
20 nm) and HQ:TRITC filter (ex, HQ545/30; em, HQ620/60)
from Chroma Technology (Brattleboro, VT) with a 40× PlanApo
oil immersion objective (NA 1.00) on an F-View Monochrome
CCD camera. Images were analyzed for mitochondrial stain
overlap with EGFP fusion constructs using ImageJ software and
the JACoP plugin.37 JACoP was used to generate the colocali-
zation statistic [i.e., Pearson’s correlation coefficient (PCC) post
Costes’ automatic threshold algorithm],38,39 as we have done
before.40 PCC evaluates correlation between pairs of individual
pixels from EGFP and MitoTracker stained cells. The higher the
PCC value, the higher the correlation. For increased visual clarity
of mitochondrial localization of the EGFP-fused constructs,
spatial representations of pixel intensity correlation have been
generated using Colocalization Colormap (ImageJ).41 Microscopy
was repeated in triplicate (n = 3), and 10 cells were analyzed for
each construct.
Luciferase Assay. All constructs (3.5 μg of DNA) were
cotransfected with 3.5 μg of p53-Luc Cis-Reporter (encoding for
firefly luciferase, Agilent) in T47D and MCF-7 cells. To
normalize for transfection efficiency, 0.35 μg of pRL-SV40
plasmid (encoding for renilla luciferase, gift from Dr. Philip Moos,
University of Utah) was cotransfected. The Dual-Glo Luciferase
Assay System (Promega, Madison, WI) was used to determine
firefly luciferase activity and renilla luciferase per manufacturer’s
instructions. Luciferase activity was detected 24 h after transfection
using PlateLumino (Stratec Biomedical Systems, Birkenfeld,
Germany). Firefly luciferase values were normalized for renilla
luciferase. EGFP-p53 served as a positive control and EGFP
as a negative control. The Dual-Glo Luciferase Assay was run
three times independently, each in triplicate.
Caspase-9 Assay. T47D cells were probed 19 h after
transfection using CaspaLux9-M2D2 kit (OncoImmunin, Inc.,
Gaithersburg, MD) per manufacturer’s recommendations.
The cells were then suspended in flow cytometry buffer
(OncoImmunin, Inc.) and analyzed via the FACSAria-II (BD-
BioSciences, University of Utah Core Facility) utilizing 488 nm
(for EGFP) and 563 nm (for cleaved caspase 9 substrate)
lasers. FACSDiva software was used as an evaluation tool. Only
EGFP transfected cells at 507 nm emission were analyzed. All
constructs were gated at the same EGFP intensity levels to
ensure equal expression of proteins. The samples were detected
in the PE (phycoerythrin) channel with the 580 nm emission
peak. Each construct was assayed three times (n = 3).
TUNEL Assay. T47D cells were prepared 48 h after transfec-
tion using In Situ Death Detection Kit, TMR red (Roche,
Mannheim, Germany) per the company’s protocol. The kit labels
the DNA single strand breaks (TUNEL reaction) in apoptotic
cells. The FACSAria-II was used to analyze the cells suspended
in PBS (Invitrogen). The same FACS settings mentioned above
with the caspase-9 assay were used. Only EGFP-positive cells
were analyzed for DNA segmentation. Each construct was
analyzed three times (n = 3).
Annexin-V Assay. At 48 h post transfection, T47D cells
were assayed for annexin-V binding. The cells were suspended
in 100 μL of annexin binding buffer (Invitrogen) and incubated
with 5 μL of annexin−APC (annexin-V conjugated to allophy-
cocyanin, Invitrogen) for 15 min. The incubated cells were then
diluted in 400 μL of annexin binding buffer and analyzed using
the FACSCanto-II (BD-BioSciences, University of Utah Core
Facility) with FACSDiva software. EGFP was excited at 488 nm
wavelength and detected at 507 nm. APC was excited with
635 nm laser and detected at 660 nm. Analysis was based on
EGFP positive cells. All constructs were gated at the same EGFP
intensity levels. Each construct was tested three times (n = 3).
7-AAD Assay. T47D and MCF-7 cells were stained with
7-aminoactinomycin D (7-AAD, Invitrogen) according to manu-
facturer’s instructions 48 h after transfection. The samples were
analyzed using the FACSCanto-II (BD-BioSciences). Analyzed
cells were gated for EGFP (as mentioned in Annexin-V Assay). In
addition, EGFP and 7-AAD were excited with the 488 nm laser.
EGFP and 7-AAD were detected at 507 and 660 nm, respectively.
Each construct was assayed three times (n = 3).
Rescue Experiment Using Pifithrin-α. Six hours after
transfection, T47D cells were incubated with a previously
optimized concentration of 40 μM pifithrin-α (Cayman
Chemical, Ann Arbor, MI) for 42 h and compared to transfected
cells without pifithrin-α. At the 48 h time point, the 7-AAD assay
was performed as above.
Rescue Experiment Using Pifithrin-μ. Six hours after
transfection, T47D cells were incubated with a previously
optimized concentration of 5 nM pifithrin-μ (Tocris Bioscience,
Ellisville, MO) for 42 h and compared to transfected cells
without pifithrin-μ. At the 48 h time point, the 7-AAD assay was
performed as detailed above.
Rescue Experiment Using Bcl-XL. T47D cells were
cotransfected with 1 pmol of MTS constructs and 1 pmol of
pBcl-XL (Addgene). After 48 h, cells were pelleted and assayed
with 7-AAD as described above.
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Statistical Analysis. All experiments were repeated in
triplicate (n = 3). The data were presented as the mean ±
standard error. Statistical differences between each MTS-EGFP-
p53 and its MTS-EGFP were resolved via unpaired t test using
GraphPad Prism software. The MTS-EGFP controls were
compared to EGFP by one-way ANOVA with Tukey’s post test.
The degree of colocalization was analyzed using odds ratio
with Pearson’s Chi-square. A p value <0.05 was considered
significant.
■ RESULTS
Mitochondrial Localization of MTS-EGFP-p53. Mito-
chondrial targeting of all constructs was verified using fluore-
scence microscopy. Figure 2A shows representative 1471.1
cells, which are larger in size, spread well, and are generally
easier to visualize versus T47D or MCF-7 cells. However,
irrespective of the cell line, similar microscopy results were
observed in T47D and MCF-7 cells (data not shown). To
better illustrate the colocalization of the EGFP fused constructs,
PCC values were generated and graphed for each construct
(Figure 2B). PCC values range from +1 to −1; perfect
correlation is represented by +1, anticorrelation by −1, and a
PCC value of zero denotes random distribution.37 Following
the example of Bolte and Cordelier̀es, a PCC of 0.6 or
greater will define colocalization, or cocompartmentalization
(Figure 2B).37,40 Fusing different MTSs to EGFP and p53
showed a high degree of colocalization with the mitochondria.
EGFP-C1 served as negative control for colocalization anal-
ysis, and as expected, there was no colocalization between EGFP
alone and the mitochondria. EGFP and p53 tagged to TOM
and XL targeted the mitochondria better than CCO-EGFP-p53
and OTC-EGFP-p53. CCO and OTC were the “weakest”
MTSs since there was some nuclear targeting of both CCO-
EGFP-p53 and OTC-EGFP-p53. Therefore we mutated K319T
and K320T in the nuclear localization signal (NLS) of p53,20 which
resulted in increased mitochondrial targeting for CCO-EGFP-p53
and OTC-EGFP-p53. For easier visualization of colocali-
zation among constructs, a spatial depiction of pixel overlap and
intensity correlation are provided in the “Color Map” column
(Figure 2A). The Color Map spectrum moves from cold to warm
colors as pixel correlation increases.41
Testing the Transcriptional Activity of MTS-EGFP-p53.
To demonstrate the lack of transcriptional activity of these p53
constructs, a p53 reporter dual luciferase assay was performed in
T47D (Figure 3A) and MCF-7 cells (Figure 3B). T47D cells
contain a mutation in p53 (in the DBD which renders it inactive)
that is also localized in the cytoplasm42,43 while MCF-7 cells
express wild-type p53 mislocalized to the cytoplasm.44 TOM and
XL fused to EGFP-p53 showed no nuclear activity in either cell
line. CCO-EGFP-p53 expressed similar transcriptional activity
to EGFP-p53 (positive control) in T47D (Figure 3A) and
significant activity in MCF-7 (Figure 3B) compared to the EGFP
negative control. Introducing NLS mutations (K3319T and
K320T) in CCO-EGFP-p53 resulted in major reduction of
nuclear activity in both cell lines. OTC-EGFP-p53 showed low
transcriptional activity in MCF-7 (Figure 3B) and a significant
activation in T47D cells (Figure 3A). Surprisingly, introduction
of NLS mutations into OTC-EGFP-p53 did not result in any
changes in nuclear activity in either cell line (Figures 3A and 3B).
The Effect of MTS-EGFP-p53 on Early Apoptosis
(Caspase-9). In this paper we focused on T47D cells because
they are more resistant to apoptosis compared to MCF-7 cells.45
The apoptotic potential of p53 fused to different MTSs targeting
the mitochondrial matrix, outer, and inner membranes was
Figure 2. Colocalization of MTS constructs and MitoTracker Red mitochondrial stain in 1471.1 cells. (A) Representative images of MTS-EGFP-
p53, MTS-EGFP-p53 NLS mutation, MTS-EGFP, and EGFP-C1 are shown in the left column with images of MitoTracker Red distribution in the
middle column. The “EGFP” and “MitoTracker” columns have been false colored green and red, respectively. Enhanced visualization of colocalized
pixels is rendered in the “Color Map” column. Warm colors depict pixels with highly correlated intensity and spatial overlap while cool colors are
indicative of anticorrelation or random correlation (colorbar for interpretation is shown below column). Corresponding PCC values are shown in the
right column. White scale bars are all 10 μm. (B) The degree of colocalization is represented by PCC following Costes’ approach.38,39 All constructs
with values higher than 0.6 are considered highly colocalized with mitochondrial stain MitoTracker Red. Statistical analysis was performed by using
odds ratio with Pearson’s Chi-square. The adjusted odds ratio for PCC value of 0.6 was compared with each sample. *p < 0.05, and **p < 0.01
comparing odds ratio of lowest value for samples with odds ratio of 1 for PCC of 0.6.
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evaluated via caspase-9, TUNEL, annexin-V, and 7-AAD assays.
Caspases are a group of proteolytic enzymes that are directly
involved in apoptosis by cleaving proteins such as lamin and
PARP. Its inactive form procaspase-9 is activated through
cytochrome c release and APAF-1 which occurs after mito-
chondrial outer membrane disruption (known as the intrinsic
apoptotic pathway).46 Caspase-9 itself cleaves the peptide
sequence LEHD, which was used in the caspase-9 assay to
measure the intrinsic apoptotic pathway.47 Only EGFP-p53-XL
(p < 0.05) and OTC-EGFP-p53 (p < 0.05) were significantly
different from their corresponding MTS-EGFP controls as shown
in Figure 4.
The Effect of MTS-EGFP-p53 on DNA Fragmentation.
Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) was measured to detect DNA fragmentation by
labeling the terminal end of nucleic acids. DNA fragmentation is
a hallmark of apoptosis and is generated by caspase cleavage.48
Figure 5 illustrates that EGFP-p53-XL and CCO-EGFP-p53
are the only constructs that were statistically significant from
their control MTS-EGFP. Constructs with mutations in the
NLS of p53 did not differ from constructs without mutation
(see the Supporting Information: S1). Staurosporine, which
activates caspase-3/7 and leads to DNA fragmentation,45 served
as a positive control.
The Effect of MTS-EGFP-p53 on Plasma Membrane.
The effects of the mitochondrial constructs were further
explored by analyzing externalization of phosphatidylserine and cell
membrane rupture. Annexin-V was used to detect the externali-
zation of phosphatidylserine on the cell surface of apoptotic cells
via flow cytometry.49,50 In the majority of healthy cells, the
plasma membrane expresses phosphatidylserine on the cytosolic
surface while in apoptotic cells, the phosphatidylserine is
transported to the outer surface, which allows labeled annexin-
V to bind.51 All MTS-EGFP-p53 constructs showed a significant
effect on inducing apoptosis compared to their corresponding
MTS-EGFP controls in T47D cells (Figure 6). In addition,
EGFP-XL was the only construct that showed minimal activity
similar to the nontoxic EGFP negative control (Figure 6).
To further validate the effect of mitochondrial p53 on late
apoptosis, the 7-AAD assay was performed via flow cytometry
(Figure 7). The 7-AAD fluorescent marker cannot stain the
DNA in healthy cells due to inability to penetrate an intact cell
membrane.52 However, it is able to stain the DNA in apoptotic
and necrotic cells because of their disrupted membrane.53
Similar to annexin-V results, all mitochondrial p53 constructs
showed significant 7-AAD intercalation with DNA compared to
their MTS-EGFP controls (Figure 7A). In addition, EGFP-XL
was the only construct that showed similar activity to EGFP
alone (Figure 7A). In a cell line that is less resistant to apoptosis
such as MCF-7,45 EGFP-p53-XL is the only construct that was
Figure 3. Luciferase assay: All MTS-EGFP-p53 and MTS-EGFP-p53
NLS mutation constructs were tested for their ability to activate a p53
reporter in (A) T47D cells and (B) MCF-7 cells. EGFP-p53 serves as
a positive control and EGFP as a negative control. All constructs were
corrected to EGFP-p53 control, which is set at 100%. Statistical
analysis was performed by using one-way ANOVA with Tukey’s post
test. **p < 0.005 and ***p < 0.0005 compared to EGFP-p53.
Figure 4. The activation of caspase-9 was analyzed 19 h following
transfection of T47D cells. All constructs were corrected to untreated
control, which is set at 100%. Statistical analysis was performed by
using unpaired t test. *p < 0.05 for MTS-EGFP-p53 compared to its
MTS-EGFP.
Figure 5. T47D cells were tested 48 h following transfection. DNA
fragmentation was analyzed with the TUNEL assay. All constructs
were corrected to staurosporine positive control, which is set at 100%.
Statistical analysis was performed by unpaired t test. *p < 0.05 for
MTS-EGFP-p53 compared to its MTS-EGFP.
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significantly different from its MTS-EGFP control (Figure 7B).
In MCF-7 cells, there was no statistical difference between p53
fused to TOM, CCO, or OTC and their respective MTS-EGFP
controls (Figure 7B). Mutating the NLS of p53 in MTS-EGFP-
p53 had no effect on 7-AAD permeation in both cell lines
except with CCO-EGFP-p53 in T47D (see the Supporting
Information: S2). In addition, EGFP-XL showed no activity
similar to EGFP alone in MCF-7 (Figure 7B). Similar to annexin-V,
EGFP-XL was also the only construct with minimum activity as
EGFP alone in T47D cells (Figure 7A).
Investigating the Apoptotic Mechanism. Apoptosis
resulting from p53 transcriptional activity of our mitochondrial
p53 constructs was examined via a pifithrin-α rescue experiment.
Pifithrin-α is a small molecule that inhibits p53-mediated
transcriptional activity.54,55 The effect of pifithrin-α was
measured in a 7-AAD assay (Figure 8A). As expected from the
Figure 6. Annexin-V assay was conducted in T47D cells 48 h after
transfection. Statistical analysis was performed by one-way ANOVA
with Tukey’s post test. **p < 0.005 and ***p < 0.0005 comparing
MTS-EGFP-p53 to their MTS-EGFP controls. The negative controls
(MTS-EGFP) were compared to EGFP-C1 using one-way ANOVA
with Tukey’s post test ##p < 0.005.
Figure 7. The 7-AAD assay was tested in (A) T47D and (B) MCF-7
cells 48 h after transfection. Statistical analysis was performed by one-
way ANOVA with Tukey’s post test. *p < 0.05, **p < 0.005
comparing MTS-EGFP-p53 to their MTS-EGFP controls. The
controls (MTS-EGFP) were compared to EGFP-C1 using one-way
ANOVA with Tukey’s post test ##p < 0.005. Figure 8. Rescue experiments using (A) pifithrin-α, (B) pifithrin-μ, or
(C) Bcl-XL. 7-AAD assay was performed 48 h after transfection in
T47D cells. All constructs were fused to EGFP. Statistical analysis was
performed by unpaired t test. *p < 0.05, **p < 0.005, ***p < 0.0005
comparing treated (with pifithrin-α, pifithrin-μ, or Bcl-XL) to
untreated (no drug or Bcl-XL added).
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transcriptional activity data, the apoptotic effect of EGFP-p53
fused to either CCO or OTC was reduced significantly after
pifithrin-α treatment. In addition, there was no impact on the
apoptotic potential of EGFP-p53 fused to either XL or TOM
(Figure 8A).
In order to investigate p53’s apoptotic mechanism in the
mitochondria, pifithrin-μ was used in a rescue experiment in
the 7-AAD assay. Pifithrin-μ is a compound that reduces the
binding affinity of p53 to the antiapoptotic proteins, Bcl-2 and
Bcl-XL.56,57 Pifithrin-μ had a significant impact on the apoptotic
potential of p53 fused to both XL and OTC (Figure 8B).
However, apoptosis caused by p53 fused to either TOM or
CCO was not rescued by pifithrin-μ. In addition, all the MTS-
EGFP controls were not altered in this rescue experiment (see
the Supporting Information: S3A).
The apoptotic mechanism was further explored by over-
expression of the antiapoptotic protein, Bcl-XL. The cells were
then analyzed in the 7-AAD assay via flow cytometry. Bcl-XL had
a significant effect on reducing 7-AAD positive cells treated with
EGFP-p53 fused to TOM, XL, and OTC (Figure 8C). Cells
treated with EGFP-p53-XL showed the most significant
reduction in 7-AAD when cotransfected with Bcl-XL. Meanwhile,
Bcl-XL had no effect on cells transfected with CCO-EGFP-p53.
In addition, all the MTS-EGFP controls were not altered in this
rescue experiment (see the Supporting Information: S3B).
■ DISCUSSION
The tumor suppressor p53 was targeted with different MTSs in
order to investigate its optimal mitochondrially triggered
apoptotic pathway. We hypothesized that it might be possible
that sending any protein (even EGFP) to mitochondria could be
“toxic” to cells by disruption of mitochondrial function. Fusing
p53 to MTSs targeting the mitochondrial outer membrane, inner
membrane, and matrix did indeed result in apoptosis. However,
sending even EGFP to the mitochondrial matrix (OTC), the
inner membrane (CCO), or the TOM complex (TOM)
perturbed mitochondrial stability as evidenced by the apoptotic
assays. Only p53-XL was capable of inducing mitochondrial
apoptosis exclusively via mitochondrial p53/Bcl-XL pathway.
Directing EGFP to the matrix and inner membrane via OTC
and CCO, respectively, resulted in late stage apoptosis. This
shows that fusing EGFP to OTC or CCO has a toxic effect on
the mitochondria. We speculate that sending EGFP to the
mitochondrial matrix and inner membrane could cause an
imbalance in the sensitive mitochondrial system due to import
through mitochondrial membranes. On the other hand, targeting
EGFP to the mitochondrial outer membrane using TOM and XL
shows minimal toxicity with XL but significant toxicity with
TOM. Since EGFP-XL is directed toward Bcl-XL58 on the surface
of the outer membrane,29−31 it is not expected to become
imbedded into the mitochondrial membrane. Conversely, the
TOM-EGFP may interfere with TOM20 involved in mitochon-
drial import machinery.18,59 The TOM complex is responsible for
importing proteins across the mitochondrial outer membrane.
TOM20 is one of the receptor subunits in the TOM complex.60,61
Perhaps fusing any protein to the MTS from TOM20 might
affect the sensitive import mechanism.
As p53 is a nuclear protein, the MTS fused to it will compete
with the protein’s nuclear localization signals (NLSs). p53
contains three NLSs; the most active of them is located at
residues 305−322.20 The nuclear import of large proteins is
dependent on the availability of a NLS.62−64 To prevent the
nuclear targeting of our constructs, we introduced mutations
(K319T and K320T) in the strongest NLS of p53.20
Colocalization data and p53 transcriptional activity assay showed
an increase in mitochondrial targeting and a decrease in p53
nuclear activity after the introduction of the NLS mutations in
CCO-p53. According to our colocalization data, CCO-EGFP
showed the lowest mitochondrial targeting compared to the
other MTS-EGFP (Figure 2). The weak mitochondrial CCO
signal explains the high transcriptional activity when fused to p53
without NLS mutations (Figure 3). The strong NLS in p53
competes with the relatively weak MTS from CCO and shifts the
distribution to the nucleus. After mutating the strong NLS, the
CCO MTS was also in competition with the other weak NLSs
in p53,20 which may explain why the CCO-p53 NLS mutation
still showed transcriptional activity (Figure 3). However, the
mutations did not have any effect on the mitochondrial targeting
or nuclear activity of the TOM, XL, and OTC constructs. EGFP-
p53 fused to TOM and XL showed minimal nuclear p53 activity
presumably due to their strong mitochondrial signals. Introduc-
ing NLS mutations to p53 fused to TOM or XL did not show
any reduction on the already low transcriptional activity (Figure 3).
On the other hand, OTC-p53 showed significant p53 nuclear
activity but was not reduced upon NLS mutation (Figure 3).
In addition, the nuclear activity of MTS-p53 differed between
MCF-7 and T47D. These differences might be due to
variability in proteins involved with p53 transcriptional activity,
mitochondrial shuttling, or number of mitochondria in each cell
line. In MCF-7, all MTS-p53 constructs (with or without NLS
mutations) showed minimum transcriptional activity except for
the CCO-p53, which had half the activity of wild type p53
(Figure 3B). However, in T47D cells all MTS-p53 constructs
showed generally higher nuclear activity than in MCF-7,
especially CCO-p53, which showed the same nuclear activity as
wild type p53. CCO-p53 NLS mutation and OTC-p53 (with
and without NLS mutation) showed fifty percent transcrip-
tional activity in T47D (Figure 3A).
Even though the NLS mutations increased mitochondrial
targeting of the CCO-p53 construct, it did not have any effect
on increasing the apoptotic potential. This was also the case for
NLS mutations in all other constructs (see the Supporting
Information: S1 and S2). CCO-p53 was significant compared
to its CCO-EGFP control in TUNEL, annexin-V, and 7-AAD
assays. Since CCO-EGFP showed cytotoxicity, the increase in
apoptosis when attached to p53 was likely due to nuclear p53
activity. This is reflected in our luciferase assay (Figure 3) and
the rescue experiments with pifithrin-α, pifithrin-μ, and Bcl-XL
(Figure 8). The apoptotic activity of CCO-p53 was reduced in
the pifithrin-α (an inhibitor of p53 transcriptional activity)
rescue experiment. However, it was not rescued by either over-
expression with the antiapoptotic Bcl-XL or incubation with
pifithrin-μ (an inhibitor of p53 binding to Bcl-2 and Bcl-XL).56,57
This demonstrates that CCO-p53 does not initiate p53/Bcl-XL
specific apoptosis.
OTC-p53 also showed transcriptional activity. In addition,
OTC-p53 exhibited significant caspase-9 induction, and late
stage apoptosis compared to its cytotoxic OTC-EGFP control.
To examine if the increase of activity was due to nuclear or
mitochondrial p53, the rescue experiments (with pifithrin-μ and
Bcl-XL) were conducted and showed reduction in programmed
cell death (Figure 8). This indicates that apoptosis was likely
initiated through p53 binding to Bcl-XL and Bcl-2. In addition,
the transcriptional activity data demonstrates that OTC-p53
has activity in both the nucleus (rescued by pifithrin-α) and the
mitochondria (rescued by pifithrin-μ and Bcl-XL). Even though
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OTC directs p53 to the mitochondrial matrix, p53 is still able to
interact with Bcl-XL and Bcl-2 proteins on the outer membrane.
This could be due to cleavage of the MTS by endopeptidase,
which enables p53 to target the outer membrane.3,10
Instead of targeting the protein to the matrix and then
translocating it to the outer membrane, as was the case for
OTC, we fused EGFP-p53 to TOM to directly target the outer
membrane. Direct targeting of the outer membrane with TOM-
p53 was able to initiate apoptosis (annexin-V and 7-AAD)
robustly compared to its TOM-EGFP control. Interestingly this
increase in apoptosis was only rescued when Bcl-XL was
cotransfected but not when pifithrin-α or pifithrin-μ was added
(Figure 8). The pifithrin-α rescue experiment indicates that
TOM-p53 has no transcriptional activity. We speculate that
TOM-EGFP-p53 is binding to proapoptotic Bak and enhancing
its oligomerization, which disrupts the mitochondrial outer
membrane.13,14 Bcl-XL forms a heterodimer with Bak and
prevents Bak homodimerization.14,65,66 Therefore, when Bcl-XL
is overexpressed, it competes with TOM-p53 in binding with
Bak and hence reduces apoptosis. Since pifithrin-μ reduces
the binding of p53 to antiapoptotic Bcl-XL and Bcl-2 and has
no effect on binding to Bak, it did not show reduction in
programmed cell death for TOM-p53.
In an effort to directly target the p53/Bcl-XL pathway, we
fused XL to EGFP-p53. Directing p53 to the mitochondria via
XL showed significant caspase-9, TUNEL, 7-AAD, and annexin-
V activity compared to its EGFP-XL control. This apoptotic
response was not due to transcriptional activity of p53 as shown
in the luciferase assay data (Figure 3) and the pifithrin-α rescue
experiment (Figure 8A). However, the apoptotic response was
due to the p53/Bcl-XL pathway. To confirm this interaction,
rescue experiments using pifithrin-μ and Bcl-XL were conducted
and showed reduction in apoptosis (Figures 8B and 8C). In
addition, the EGFP-XL control showed no toxicity compared
to the other MTS-EGFP controls especially in MCF-7 cells
(Figures 6 and 7). This data demonstrates that sending p53 to a
specific protein (Bcl-XL) in the mitochondrial outer membrane
causes p53-specific apoptosis. Table 2 is a summary of the
results and speculation from this work.
In summary, efficiency in targeting the mitochondria depends
on the strength of the MTS. In the case of targeting proteins
containing relatively strong NLSs such as p53 (residues 305−
322),20 mitochondrial targeting can best be achieved by using
strong MTSs to counter the NLS. In this study, relatively weaker
MTSs are not efficient enough to compete with the strong
NLS in p53. In addition, protein targeting to the mitochondria
disrupts the sensitive balance in the mitochondria, which
initiates intrinsic apoptosis. Except for EGFP-XL, all mitochon-
drial constructs had apoptotic effects. We conclude that p53-XL
was the most specific to the p53/Bcl-XL mitochondrial pathway.
Our data shows that not all mitochondrial targeting signals are
optimal for mitochondrial induction of apoptosis with p53.
In conclusion, specific binding of p53 to mitochondrial Bcl-XL
(and hence apoptotic activity) is best achieved by directly
targeting p53 to Bcl-XL via the XL MTS. This work therefore
provides a mechanistic explanation and provides additional
speculation toward the understanding of mitochondrial p53
apoptosis. Our future goal is to employ the p53-XL construct as
a therapeutic in vivo using viral delivery. Ultimately, p53-XL
gene therapy is expected to be beneficial for other types of
progressive cancers that currently have no effective therapy.
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response of MTS-p53 compared to MTS-EGFP, and speculated apoptotic mechanism.
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ABSTRACT: The tumor suppressor p53 is one of the most studied proteins in
human cancer.1−3 While nuclear p53 has been utilized for cancer gene therapy,
mitochondrial targeting of p53 has not been fully exploited to date.4,5 In
response to cellular stress, p53 translocates to the mitochondria and directly
interacts with Bcl-2 family proteins including antiapoptotic Bcl-XL and Bcl-2 and
proapoptotic Bak and Bax.6 Antiapoptotic Bcl-XL forms inhibitory complexes
with proapoptotic Bak and Bax preventing their homo-oligomerization.7 Upon
translocation to the mitochondria, p53 binds to Bcl-XL, releases Bak and Bax
from the inhibitory complex and enhances their homo-oligomerization.8 Bak and
Bax homotetramer formation disrupts the mitochondrial outer membrane,
releases antiapoptotic factors such as cytochrome c and triggers a rapid apoptotic
response mediated by caspase induction.9 It is still unclear if the MDM2 binding
domain (MBD), the proline-rich domain (PRD) and/or DNA binding domain
(DBD) of p53 are the domains responsible for interaction with Bcl-XL.10−17 The purpose of this work is to determine if a smaller
functional domain of p53 is capable of inducing apoptosis similarly to full length p53. To explore this question, different domains
of p53 (MBD, PRD, DBD) were fused to the mitochondrial targeting signal (MTS) from Bcl-XL to ensure Bcl-XL specific
targeting.18 The designed constructs were tested for apoptotic activity (TUNEL, Annexin-V, and 7-AAD) in 3 different breast
cancer cell lines (T47D, MCF-7, MDA-MB-231), in a cervical cancer cell line (HeLa) and in non-small cell lung adenocarcinoma
cells H1373. Our results indicate that DBD-XL (p53 DBD fused to the Bcl-XL MTS) reproduces (in T47D cells) or
demonstrates increased apoptotic activity (in MCF-7, MDA-MB-231, and HeLa cells) compared to p53-XL (full length p53
fused to Bcl-XL MTS). Additionally, mitochondrial dependent apoptosis assays (TMRE, caspase-9), co-IP and overexpression of
Bcl-XL in T47D cells suggest that DBD fused to XL MTS may bind to and inhibit Bcl-XL. Taken together, our data
demonstrates for the first time that the DBD of p53 may be the minimally necessary domain for achieving apoptosis at the
mitochondria in multiple cell lines. This work highlights the role of small functional domains of p53 as a novel cancer biologic
therapy.
KEYWORDS: p53, mitochondria, Bcl-XL, apoptosis, DBD, MBD, cancer
■ INTRODUCTION
The tumor suppressor p53 is one of the most commonly
mutated genes in all cancers.1−3 Although nuclear-mediated
transcriptional activity has been extensively characterized,
mitochondrial targeting of p53 has yet to be fully exploited as
a therapeutic approach.4,5 The main advantage of targeting p53
to the mitochondria is its ability to trigger a rapid apoptotic
response, while in the nucleus p53 first has to form a tetramer,
bind to DNA, and initiate transcription of various apoptotic
genes. As a consequence of stress, p53 translocates to the
mitochondria and initiates apoptosis through mitochondrial
outer membrane permeabilization (MOMP).6 Mitochondrial
p53 directly interacts with anti- and proapoptotic members of
the Bcl-2 family of proteins located in the mitochondrial outer
membrane. In apoptosis resistant cells, the antiapoptotic
members, Bcl-XL, Bcl-2 and Mcl-1 form heterodimers with
proapoptotic proteins Bak and Bax, preventing apoptosis.7 To
trigger MOMP, p53 binds to Bcl-XL, Bcl-2 and Mcl-1 and frees
proapoptotic Bak and Bax allowing them to oligomerize.8
Homotetramer formation of Bak and Bax in the mitochondrial
outer membrane triggers the release of various proapoptotic
proteins such as cytochrome c. APAF-1 and cytochrome c form
the apoptosome and activate caspase-9 that can initiate the
caspase cascade resulting in programmed cell death.9
It is unclear which domains of p53 are directly responsible
for triggering apoptosis at the mitochondria, presumably by
interacting with antiapoptotic Bcl-XL.11−15 The structure of
p53 can be divided into amino terminus, DNA binding domain
(DBD) and C-terminal region (Figure 1A).10 The amino
terminus consists of the MDM2 binding domain (MBD) and
the proline-rich domain (PRD). The C-terminal region
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encloses the tetramerization domain (TD) and three nuclear
localization signals (NLS) (Figure 1A).10 It has been reported
that the DBD binds to antiapoptotic Bcl-XL in the
mitochondrial outer membrane and the PRD functions as an
enhancer that improves this binding.11−13 However, the MBD
has been also proposed as a binding partner for Bcl-XL which is
enhanced by the PRD.14−17
To our knowledge, no one has attempted to target different
domains of p53 to the mitochondria. Therefore, the purpose of
this study is to determine if a smaller domain of p53 is capable
of inducing apoptosis similar to full length p53 when targeted
to the mitochondria. This will be achieved by fusing different
domains of p53 (MBD, PRD, DBD, TD) to the mitochondrial
targeting signal (MTS) from Bcl-XL (abbreviated XL) to
ensure mitochondrial targeting (Figure 1B).18 This information
will provide details on which domain is responsible for the
rapid apoptotic response at the mitochondria. In addition to
answering this mechanistic question, an overall goal is to
decrease the size of the p53 construct for gene therapy
purposes.
■ MATERIALS AND METHODS
Cell Lines and Transient Transfections. 1471.1 murine
adenocarcinoma cells (gift of G. Hager, NCI, NIH), T47D
human ductal breast epithelial tumor cells (ATCC, Manassas,
VA), MCF-7 human breast adenocarcinoma cells (ATCC),18
MDA-MB-231 human breast adenocarcinoma cells (a generous
gift from Dr. David Bearss, University of Utah), HeLa human
epithelial cervical adenocarcinoma cells (ATCC), and H1373
human non-small lung carcinoma cells (a kind gift from Dr.
Andrea Bild, University of Utah) were grown as monolayers in
DMEM (1471.1) and RPMI (T47D, MCF-7, MDA-MB-231,
HeLa, H1373) (Invitrogen, Carlsbad, CA) supplemented with
10% FBS (Invitrogen), 1% penicillin−streptomycin (Invitro-
gen), 1% glutamine (Invitrogen) and 0.1% gentamycin
(Invitrogen). T47D and MCF-7 cells were additionally
supplemented with 4 mg/L insulin (Sigma, St. Louis, MO).
Cells were maintained in a 5% CO2 incubator at 37 °C. 3.0 ×
105 cells for T47D and MCF-7 cells, 1.0 × 105 cells for MDA-
MB-231 and HeLa, and 2.0 × 105 for H1373 were seeded in 6-
well plates (Greiner Bio-One, Monroe, NC). Different amounts
of cells were plated to account for varying cell growth rates in
order to maximize transfection efficiency. Approximately 24 h
after seeding, transfection was performed using 1 pmol of DNA
per well and Lipofectamine 2000 (Invitrogen) following the
manufacturer’s recommendations.
Plasmid Construction. The main plasmids used in this
work are depicted in Figure 1B.
pEGFP-p53ΔC-XL (p53ΔC-XL). The DNA encoding p53ΔC
(amino acids 1−322), a truncated version of wt-p53 that lacks
the C-terminus, was amplified via PCR with the primers 5′-
GCGCGCGCGCTCCGGAATGGAGGAGCCGCAGTCA-3′
and 5′-GCGCGCGCGCGGTACCTCATGGTTTCTTC-
TTTGGCTGGGG-3′ using previously subcloned pEGFP-
p5318 as the template DNA. p53ΔC was cloned into pEGFP-
XL (E-XL)18 using BspEI and KpnI sites.
pEGFP-DBD-XL (DBD-XL). The DNA encoding the DBD was
amplified via PCR from pEGFP-p53-XL (p53-XL)18 using 5′-
CCGGGCCCGCGGTCCGGAACCTACCAGGGCAGCTA-
CG-3′ and 5′-CCGGGCCCGCGGGGTACCTTTCTTGC-
GGAGATTCTCTTCCT and cloned into E-XL18 using
BspEI and KpnI sites.
pEGFP-PRD-DBD-XL (PRD-DBD-XL). The DNA encoding
the PRD-DBD was amplified using PCR from p53-XL18 with
the primers 5′-GCGCGCGCGCGGTACCGCTCCCAGAA-
TGCCAGAGGC-3′ and 5′-GCGCGCGCGCGGATCCT-
TTCTTGCGGAGATTCTCTT and cloned into E-XL18 at
the KpnI and BamHI sites.
pEGFP-TD-XL (TD-XL). The DNA encoding the TD was
amplified via PCR from previously subcloned p53-XL18 using
5′-GCGCGCGCGCGGGATCCGGCTGGATGGAGAAT-
ATTTCACCCTTCA-3′ and 5′-GCGCGCGCGCGGGAtCC-
Figure 1. (A) Schematic representation of wild type p53 (wt-p53). The 393 amino acids of p53 are divided into amino terminus, DNA binding
domain (DBD), and C-terminal region. The MDM2 binding domain (MBD) and proline-rich domain (PRD) are located in the amino terminus.
The tetramerization (TD) domain and the nuclear localization signals (NLSs) are located in the C-terminus. (B) Schematic representation of the
main experimental constructs and controls including the rationale for design. p53-XL shows the structure of full length p53 with enhanced green
fluorescence protein EGFP on the amino terminus and the MTS from Bcl-XL (XL) on the C-terminus. All the other constructs contain various
combinations of the different domains of p53, in addition to EGFP and XL. The negative control (E-XL) consists of only EGFP and XL.
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TCACCCAGCCTGGGCATCCTT-3′ and cloned into E-XL18
at the BamHI site.
pEGFP-MBD-PRD-XL (MBD-PRD-XL). Previously subcloned
p53-XL18 was mutated via site-directed mutagenesis using the
QuikChange II XL Site directed Mutagenesis Kit (Agilent,
Santa Clara, CA) using 5′-TCCCTTCCCAGAAAAGGTAC-
CAGGGCAGCTACGGT-3′ and its reverse complement to
introduce an additional KpnI site (mutations underlined). Then
the DBD and C-terminus were digested out using KpnI.
Additionally, a frame shift mutation was corrected (one base
pair deletion) by mutating the cloned plasmid using 5′-
TCGAGCTATGGAAACATTTTCAGACCTATGGAAAC-
TACTTCCTGAACGGAATTCTG-3′ and its complementary
strand via site-directed mutagenesis.
pEGFP-PRD-XL (PRD-XL). MBD-PRD-XL was mutated via
site-directed mutagenesis using 5′-TTCACTGAAGACCC-
AGGTCCATCCGGAGCTCCCAGAATGCCAGA-3′ and its
complementary strand to introduce an additional BspEI site.
The MBD was cut out with BspEI to create PRD-XL
pEGFP-CC (E-CC). pEGFP-CC was subcloned as before.19
pBFP-Bcl-XL (BFP-Bcl-XL). Bcl-XL was digested out from
pSFFV-neo-Bcl-XL (gift from Dr. S. Korsmeyer, Addgene,
Cambridge, MA) with EcoRI and cloned into the EcoRI site of
the pTagBFP-C vector (Evrogen, Moscow, Russia). A frame
shift mutation was conducted (one base pair addition) by
mutating the cloned plasmid using 5′-TCTCGAGCTCAAGC-
TTCGAATTCATTGGACAATGG-3′ and its complementary
strand via site-directed mutagenesis.
Mitochondrial Staining, Microscopy, and Image
Analysis. Before live-cell imaging and mitochondrial staining
of transfected cells was performed, medium in live cell
chambers was replaced with phenol red-free DMEM (In-
vitrogen) for 1471.1 cells or phenol red-free RPMI (Invitrogen)
for T47D and MCF-7 cells containing 10% charcoal stripped
fetal bovine serum (CS-FBS, Invitrogen). Cells were incubated
with 150 nM MitoTracker Red FM (Invitrogen) for 15 min at
37 °C and protected from light. As previously, images were
acquired using an Olympus IX71F fluorescence microscope
(Scientific Instrument Company, Aurora, CO) with high
quality (HQ) narrow band GFP filter (ex, HQ480/20 nm;
em, HQ510/20 nm) and HQ:TRITC filter (ex, HQ545/30;
em, HQ620/60) from Chroma Technology (Brattleboro, VT)
with a 40× PlanApo oil immersion objective (NA 1.00) on an
F-View Monochrome CCD camera.19−21
ImageJ software and JACoP plugin were used to analyze
images for mitochondrial stain overlap with EGFP fusion
constructs.18,22−24 As previously, JACoP was used to generate
the colocalization statistic [i.e., Pearson’s correlation coefficient
(PCC) with Costes’s automatic threshold algorithm].23−27
PCC evaluates correlation between pairs of individual pixels
from EGFP and MitoTracker stained cells. The higher the PCC
value, the higher the correlation. According to Costes a PCC
value of 0.6 or greater determines colocalization between a
cellular compartment and the designed protein.25 Spatial
representations of pixel intensity correlation have been
generated using Colocalization Colormap (ImageJ) for
increased visual clarity of mitochondrial localization of the
EGFP-fused constructs.28 Microscopy was repeated in triplicate
(n = 3), and 10 cells were analyzed for each construct.
7- AAD Assay. Transfected T47D, MCF-7, MDA-MB-231,
HeLa and H1373 cells were pelleted and resuspended in 500
μL of PBS (Invitrogen) containing 1 μM 7-aminoactinomycin
D (7-AAD) (Invitrogen) for 30 min prior to analysis following
the recommended protocol from the manufacturer. The assay
was performed 48 h after transfection for T47D,18 MCF-718
and H1373 and 24 h after transfection for MDA-MB-231 and
HeLa. Only EGFP positive cells were analyzed by using the
FACS Canto-II (BD BioSciences, University of Utah Core
Facility) with FACS Diva software. EGFP and 7-AAD were
excited with the 488 nm laser, and were detected at 507 and
660 nm, respectively. Independent transfections of each
construct were tested three times (n = 3).
Annexin V Assay. 48 h after transfection, T47D cells were
pelleted and resuspended in 400 μL of annexin-V binding
buffer (Invitrogen) and incubated with 5 μL of annexin-APC
(annexin-V conjugated to allophycocyanin, Invitrogen) for 15
min as before.18 Only transfected cells were analyzed as
mentioned in 7-AAD assay. EGFP and APC were excited at 488
and 635 nm wavelengths, respectively, and detected at their
corresponding 507 and 660 nm wavelengths. Independent
transfections of each construct were tested three times (n = 3).
TUNEL Assay. T47D cells were harvested 48 h after
transfection. In situ Death Detection Kit, TMR red (Roche,
Mannheim, Germany) was used following the manufacturer’s
recommendations as before.18,24 Cells were resuspended in
PBS (Invitrogen) and analyzed via the FACSAria-II (BD-
Biosciences, University of Utah Core Facility). EGFP and TMR
red were excited at 488 and 563 nm, respectively, and
FACSDiva software was used to analyze the data. Independent
transfections of each construct were tested three times (n = 3).
Colony Forming Assay (CFA). Transfected T47D cells
were harvested 24 h post transfection and resuspended in
RPMI (Invitrogen) at a concentration of 3.0 × 105 cells/mL.
The Cytoselect 96-well Cell Transformation Assay (Cell
Biolabs, San Diego, CA) was used following the manufacturer’s
recommendations. Equal amounts of 1.2% agar solution, 2×
DMEM/20% FBS media, and cell suspension (1:1:1) were
mixed, and 75 μL of the mixture was added to a 96-well plate
containing a solidified base agar layer (50 μL of previously
solidified 1.2% agar solution), and allowed to solidify at 4 °C
for 15 min. The following steps were performed according to
the manufacturer’s recommendations. A Spectra Max M2 plate
reader (Molecular Devices, Sunnyvale, CA) was used to detect
fluorescence using a 485/520 nm filter set. Independent
transfections of each construct were tested three times (n = 3).
TMRE Assay. 36 h after transfection T47D cells were
incubated with 100 nM tetramethylrhodamine ethyl ester
(TMRE) (Invitrogen) for 30 min at 37 °C.29 T47D cells were
pelleted and resuspended in 300 μL of annexin-V binding
buffer (1×) (Invitrogen). Only EGFP positive cells were
analyzed by using the FACS Canto-II (BD BioSciences,
University of Utah Core Facility) with FACS Diva software.
EGFP was excited with the 488 nm laser with emission filter
530/35, and TMRE was excited with the 561 nm laser with the
emission filter 585/15. Mitochondrial depolarization (loss in
TMRE intensity) correlates with an increase in MOMP.
Independent transfections of each construct were tested three
times (n = 3).
Caspase-9 Assay. T47D cells were probed 48 h after
transfection using SR FLICA Caspase-9 Assay Kit (Immuno-
chemistry Technologies, Bloomington, MN).30,31 Cells were
incubated with SR FLICA Caspase-9 reagent for 60 min per the
manufacturer’s recommendations, pelleted and resuspended in
300 μL of 1× wash buffer (Immunochemistry Technologies).
Only EGFP positive cells were analyzed using the FACS Canto-
II (BD BioSciences, University of Utah Core Facility) with
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FACS Diva software. EGFP and FLICA were excited with the
488 nm (emission filter 530/35) and the 561 laser (emission
filter 585/15), respectively. Independent transfections of each
construct were tested three times (n = 3).
Co-Immunoprecipitation (Co-IP). Anti-GFP antibody
(ab290, Abcam) was coupled to Dynabeads using Dynabeads
Antibody Coupling Kit (Invitrogen). 24 h post transfection,
T47D cells were prepared using the Dynabeads Co-
Immunoprecipitation Kit (Invitrogen). Cell pellets were lysed
using extraction buffer B (1 × IP, 100 nM NaCl, 2 mM MgCl2,
1 mM DTT, 1% protease inhibitor). The lysate was incubated
for 30 min at 4 °C with 1.5 mg of Dynabeads coupled with anti-
GFP antibody, and co-IP was performed per the company’s
protocol. The final protein complex was denatured, and
Western blot was performed19 by using Bcl-XL antibody (ab
2568, Abcam).
Rescue Experiment Using BFP-Bcl-XL. T47D cells were
cotransfected with 1 pmol of EGFP constructs and 1 pmol of
Figure 2. Colocalization of EGFP constructs and MitoTracker Red mitochondrial stain in 1471.1 cells. (A) Representative green fluorescence images
of MBD-XL, PRD-XL, DBD-XL, TD-XL, p53-XL, E-XL and EGFP are shown in the left column with images of MitoTracker Red distribution in the
middle column. The “EGFP” and “MitoTracker” columns have been false colored green and red, respectively. Enhanced visualization of colocalized
pixels is rendered in the “Color Map” column. Warm colors depict pixels with highly correlated intensity and spatial overlap while cool colors are
indicative of anticorrelation or random correlation (colorbar for interpretation is shown below column). Corresponding PCC values are shown in the
right column. White scale bars are all 10 μm. (B) The degree of colocalization is represented by PCC following Costes’s approach. All constructs
with values higher than 0.6 are considered highly colocalized with mitochondrial stain MitoTracker Red. Statistical analysis was performed by using
odds ratio with Pearson’s Chi-square. The adjusted odds ratio for PCC value of 0.6 was compared with each sample. *p < 0.05, and **p <
0.01comparing odds ratio of lowest value for samples with odds ratio of 1 for PCC of 0.6.
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BFP-Bcl-XL (BFP tag is necessary for gating Bcl-XL transfected
cells). 48 h after transfection the 7-AAD assay was performed as
described above. FACSCanto-II (BD BioSciences, University of
Utah Core Facility) and FACSDiva software were used for
EGFP and BFP gating. Excitation was set at 488 nm, and
detected at 507 and 660 nm for EGFP and 7-AAD, respectively.
BFP was excited at 405 nm and detected at 457 nm.
Independent transfections of each construct were tested three
times (n = 3).
Statistical Analysis. All experiments were conducted in
triplicate (n = 3). Statistical significance was determined by
one-way analysis of variance (ANOVA) with Tukey’s or
Bonferroni’s post test as indicated in figure legends; Student’s
t test was used to analyze the rescue experiment data. The
degree of colocalization was analyzed using odds ratio with
Pearson’s Chi-square test. A p value <0.05 was considered
significant.
■ RESULTS
Mitochondrial Localization of Single Domain Con-
structs. Different domains of p53 (Figure 1B) were fused to
the MTS from Bcl-XL (abbreviated XL)18 and tested for their
mitochondrial localization. Mitochondrial targeting of these
constructs (Figure 1) was determined by fluorescence
microscopy as previously.18,23,24 Figure 2A illustrates repre-
sentative 1471.1 cells, which are large in size, spread well, and
are optimal for microscopy. However, similar microscopy
results were observed in T47D cells (data not shown). Figure
2B shows colocalization of the EGFP fused constructs with
mitochondria which were generated using Pearson’s correlation
coefficient (PCC) following the example of Bolte and
Cordelier̀es and graphed for each construct.22,25,26 PCC values
range from +1 (perfect correlation) to −1 (anticorrelation),
and a PCC value of zero represents random distribution.22
Costes et al. have shown that a PCC of 0.6 or greater defines
colocalization, or cocompartmentalization (Figure 2B).25
Figure 2 shows that all designed single domain constructs
translocate into the mitochondria, as expected. EGFP served as
negative control for colocalization analysis, and there was no
colocalization between EGFP alone and the mitochondria.
Even though p53 is a nuclear protein containing three nuclear
localization signals (NLSs), the XL MTS is strong enough to
overcome nuclear targeting and directs p53-XL to the
mitochondria (Figure 1 and ref 18).
Screening the Mitochondrial Activity of Different p53
Domains via 7-AAD. To determine if a subdomain of p53 was
capable of evoking a similar apoptotic activity as wild type p53,
different domains of p53 (Figure 1B) fused to XL and
combinations of domains were tested for apoptosis using the 7-
AAD viability assay in T47D human breast cancer cells. 7-AAD
is a late apoptosis/necrosis assay which allows for distinguishing
between apoptotic/necrotic (ruptured plasma membrane) and
healthy (intact plasma membrane) cells. If the plasma
membrane is disrupted, the 7-AAD dye intercalates with
nuclear DNA of apoptotic/necrotic cells.32,33 Figure 3
demonstrates that all constructs containing DBD (PRD-DBD-
XL, DBD-XL, and p53ΔC-XL) are statistically higher than the
negative control E-XL. Additionally, these three constructs are
not statistically different from p53-XL (positive control),
indicating that all constructs containing the DBD show similar
apoptotic potential to p53-XL (Figure 3). Further, MBD-XL,
MBD-PRD-XL, and PRD-XL are not statistically significant
from the negative control E-XL suggesting no apoptotic activity
(Figure 3). Interestingly, TD-XL is statistically different from
the negative controls but is also significantly lower than p53-XL
(Figure 3).
Data from Figure 3 illustrate that there is no difference in
activity between the single domains (MBD-, PRD-, DBD-, TD;
first, third, fifth, sixth bars, respectively) versus combinations of
the domains (MBD-PRD, PRD-DBD, p53ΔC; second, fourth,
seventh bars, respectively) when fused to XL. Therefore, we
proceeded with the single domain constructs (i.e., MBD-XL,
PRD-XL, DBD-XL, and TD-XL) for the remaining experi-
ments.
Exploring the Apoptotic Potential of Designed
Constructs. To test the apoptotic potential of our designed
single domain constructs (Figure 1B), the externalization of
phoshatidylserine on the cell surface of apoptotic cells was
measured via annexin V staining 48 h after transfection.18,34
DBD-XL showed a significantly higher apoptotic response than
p53-XL (Figure 4A). Additionally, both constructs were
significantly higher than the negative control E-XL whereas
MBD-XL, PRD-XL and TD-XL were not statistically
significantly different from the negative control (Figure 4A).
Further, the fragmentation of nuclear DNA was measured
utilizing terminal deoxynucleotidyl transferase dUTP labeling
(TUNEL) which tags the terminal end of nucleic acids. DNA
fragmentation occurs when a cell is undergoing apoptosis, and
the cellular DNA is cleaved by caspases.35 The TUNEL assay
was conducted 48 h after transfection. Figure 4B shows that
both p53-XL and DBD-XL have similar activities and are
significantly higher than E-XL while MBD-XL, PRD-XL and
TD-XL are not statistically different from the negative control.
Testing the Oncogenic Potential. To test the potential of
designed constructs to inhibit the transforming ability of cancer
cells, a colony forming assay was carried out in T47D cells eight
days after treatment. As expected, p53-XL and DBD-XL
showed significant decrease in transformative ability of T47D
cells represented by fewer colonies (reduction in relative
fluorescence units) compared to E-XL (Figure 5). All the other
small domain constructs failed to reduce cell proliferation
similar to the negative control E-XL.
The Ability of DBD-XL To Induce Late Stage
Apoptosis Is Not Cell Line Specific. To ensure that the
Figure 3. The 7-AAD assay was analyzed in T47D cells 48 h after
transfection. Statistical analysis were conducted by one-way ANOVA
with Tukey’s post test. ***p < 0.001. PRD-DBD-XL, DBD-XL,
p53ΔC-XL and p53-XL were not statistically significantly different
from each other. MBD-XL, MBD-PRD-XL, PRD-XL, and TD-XL are
statistically significantly lower than p53-XL.
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ability of DBD-XL to induce apoptosis is not cell line or cancer
cell type specific, a 7-AAD assay was conducted in breast cancer
cells (MCF-7, MDA-MB-231), cervical adenocarcinoma cells
(HeLa) and human non-small cell lung adenocarcinoma cells
(H1373). T47D and MDA-MB-231 both express mutant p53,
with the mutations restricted to the DBD (L194F in T47D36
and R280L in MDA-MB-23137). These mutations reduce the
activity of tumor suppressor activity substantially and cause
these cells to be more resistant to apoptosis than MCF-7 and
HeLa.38 Additionally, MCF-7 harbor mislocalized p53 in the
cytoplasm,38 HeLa have endogenous wt-p5339 and H1373 are
p53 null.40
Since MDA-MB-231 and HeLa are highly proliferating cells,
both cell lines were assayed 24 h after transfection while T47D,
MCF-7 and H1373 cells were assayed 48 h post transfection
(optimal time points determined empirically).
Interestingly, DBD-XL showed significantly higher apoptotic
activity compared to p53-XL in MCF-7 (Figure 6A), MDA-
MB-231(Figure 6B) and H1373 (Figure 6D). In HeLa cells,
DBD-XL (and PRD-XL) were both statistically significantly
different from p53-XL (Figure 5C). These results are consistent
with the apoptosis data from T47D cells (Figures 3, 4A, and
4B) and show that DBD-XL is capable of inducing late stage
apoptosis in four cell lines which differ in their endogenous p53
status.
The Apoptotic Activity of DBD-XL Is Triggered via the
Mitochondrial/Intrinsic Pathway. To determine that
construct-induced apoptotic effects are through the mitochon-
dria, TMRE and caspase-9 assays were performed. The DBD-
XL was the only single domain construct that showed apoptotic
potential the same as or higher than p53-XL consistently in all
tested cell lines. Therefore, we proceeded to investigate only
the mechanism for DBD-XL compared to p53-XL for our
further studies.
To ensure that DBD-XL causes MOMP in the same manner
as p53-XL, the TMRE assay (analogous to the JC-1 assay) was
used.41 TMRE is a cell-permeant, cationic, red-orange
fluorescent dye that rapidly accumulates in mitochondria of
living cells due to the negative mitochondrial membrane
potential (ΔΨm) of intact mitochondria compared to
cytosol.29,42,43 Mitochondrial depolarization results in a loss
of TMRE from mitochondria and a decrease in mitochondrial
fluorescence intensity (FI).42 The mitochondrial membrane
permeabilization (loss of FI) was illustrated as % MOMP
induction on the y-axis. DBD-XL and p53-XL have similar
activity and are significantly higher than E-XL (Figure 7A).
Further, the activation of caspase-9 was measured. Caspase-9
is only triggered through the intrinsic apoptotic pathway. Once
cytochrome c is released from the mitochondria, caspase-9 is
the first effector caspase downstream of cytochrome c.44
Caspase-9 itself cleaves the peptide sequence leucine-glutamic
acid-histidine-aspartic acid (LEHD) which is used in the
caspase-9 assay to measure the intrinsic apoptotic pathway.45
DBD-XL and p53-XL show higher caspase-9 activation than E-
XL (Figure 7B). However, p53-XL triggers caspase-9 activation
significantly more than DBD-XL (Figure 7B). A proposed
explanation for this effect will be explained further in the
discussion.
Investigating the Apoptotic Mechanism via Co-IP and
Overexpression of Bcl-XL. To explore the apoptotic
mechanism of our constructs, a co-IP was conducted (Figure
Figure 4. (A) Apoptotic potential was tested in T47D cells 48 h after
transfection via annexin V assay. Statistical analysis was performed
using one-way ANOVA with Tukey’s post test with *p < 0.05. (B)
Apoptotic potential was tested in T47D cells 48 h after transfection via
TUNEL assay. Statistical analysis was performed using one-way
ANOVA with Tukey’s post test with *p < 0.05, ***p < 0.001. p53-XL
and DBD-XL were not statistically significantly different from each
other. MBD-XL, PRD-XL, and TD-XL are statistically significantly
lower than p53-XL.
Figure 5. Transformative ability of T47D cells was determined 8 days
after transfection of T47D cells via colony forming assay. Statistical
analysis was accompanied using one-way ANOVA with Tukey’s post
test; ***p < 0.001.
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8A). p53-XL, E-XL and E-CC (a negative control that does not
contain the XL signal19) were transfected into T47D cells.
T47D cells express the highest amount of endogenous Bcl-XL
protein compared to MCF-7, MDA-MB-231 and HeLa (see
Figure S1 in the Supporting Information). Approximately 24 h
after transfection, cells were lysed and incubated with anti-GFP
antibody. A Western blot was performed against EGFP (which
is fused to all the constructs) and against Bcl-XL. Endogenous
Bcl-XL (26 kDa) was expected to co-immunoprecipitate with
exogenous p53-XL (75 kDa) due to its ability to induce
apoptosis, while Bcl-XL should not co-immunoprecipitate with
the negative control E-XL. Surprisingly, Bcl-XL co-immuno-
precipitated with E-XL (32 kDa) just as p53-XL did (Figure 8A,
lane 1 and 2). To address if the binding is due to the
mitochondrial targeting signal which was originally taken from
the Bcl-XL protein, another negative control E-CC was used,
which does not contain a MTS. EGFP (27 kDa) could not be
used as a negative control because it is too close in size to Bcl-
XL (26 kDa) and would not be distinguishable on the gel. Bcl-
XL did not co-immunoprecipitate with E-CC (Figure 8A, lane
3) implying that the binding of E-XL to Bcl-XL was due to the
XL mitochondrial targeting signal.
To further explore the apoptotic mechanism of DBD-XL and
p53-XL at the mitochondria, Bcl-XL was overexpressed in
T47D cells. The apoptotic activity was measured by 7-AAD.
Cells transfected with just p53-, DBD-, or E-XL were compared
to cells cotransfected with either of these constructs and with
BFP-Bcl-XL. It was expected that the apoptotic potential of the
constructs that are undergoing apoptosis through the p53/Bcl-
XL pathway would be rescued by Bcl-XL overexpression.
Indeed, DBD-XL and p53-XL apoptotic activities were
significantly reduced when BFP-Bcl-XL was cotransfected
(Figure 8B). However, E-XL was not rescued by cotransfection
of BFP-Bcl-XL (Figure 8B).
■ DISCUSSION
Our laboratory has previously shown that targeting p53 to
antiapoptotic Bcl-XL is best achieved by using the MTS from
Bcl-XL.18 Additionally, we validated that the XL signal is the
only MTS that has no inherent toxicity by itself since it is
targeting the outer surface of the mitochondrial outer
membrane.18 Mitochondrial targeting of proteins to this region
does not disrupt the sensitive balance of the mitochondria as
reported with other MTSs.46−49 As an approach to determine
which domain of p53 is capable of inducing apoptosis similar to
p53-XL, different domains of p53 were fused to XL. To our
knowledge, this is the first attempt to target different domains
of p53 to the mitochondria.
Here, we have shown that our designed constructs
translocate to the mitochondria (Figure 2) and that any
Figure 6. 7-AAD assay was conducted in (A) MCF-7, (B) MDA-MB-231, (C) HeLa and (D) H1373. Statistical analysis was performed using one-
way ANOVA with Tukey’s post test; **p < 0.01 and ***p < 0.001.
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construct that contains the DBD of p53 is capable of inducing
apoptosis similar to wt-p53 (Figure 3). It has been suggested
that a combination of different domains of p53 is necessary for
its apoptotic function and interaction with Bcl-XL at the
mitochondria.11−13 For instance, the PRD is thought to
enhance the binding of p53 to Bcl-XL.17 However, our data
(Figure 3) clearly validates that the DBD region without the
PRD region of p53 is sufficient to induce the full mitochondrial
apoptotic function of p53. Even though the PRD was reported
to enhance the binding of MBD and DBD to Bcl-XL, it did not
have any effect on increasing the apoptotic potential. Hence,
individual domains of p53 (Figure 1B) instead of combinations
of domains were used in the remaining apoptotic assays.
Since the 7-AAD assay (Figure 3) does not distinguish
between apoptotic and necrotic cells, early apoptosis assays
(annexin V and TUNEL) were conducted to verify that our
designed constructs are causing cell death via apoptosis and not
necrosis. Indeed, DBD-XL showed the same (Figure 4B) or
higher (Figure 4A) apoptotic activity compared to p53-XL in
human breast cancer cells (T47D). To further validate the
tumor suppressor function of our constructs and their ability to
inhibit proliferation, a colony forming assay was conducted. As
expected, DBD-XL showed similar reduction in transformative
ability as p53-XL in T47D breast carcinoma cells (Figure 5).
To ensure that the increase in apoptotic activity is not cell
line, cancer type or p53 status dependent, four different cancer
cell lines (MCF-7, MDA-MB-231, HeLa, H1373) were tested.
Surprisingly, DBD-XL induces late stage apoptosis significantly
higher than p53-XL in all tested cell lines except T47D (Figure
6). The p53/MDM2 pathway might offer an explanation to
why DBD-XL shows higher apoptotic activity compared to
p53-XL. MDM2, a ubiquitin ligase (E3), binds to the MBD
Figure 7. (A) Mitochondrial depolarization correlates with an increase
in MOMP (as measured by TMRE). T47D cells were transfected with
mitochondrial constructs and assayed using TMRE 36 h post
transfection. (B) The activation of caspase-9 was analyzed 48 h
following transfection of T47D cells. Statistical analysis was performed
by using one-way ANOVA with Bonferroni’s post test; **p < 0.01 and
***p < 0.001.
Figure 8. (A) Representative cropped Western blot of protein
complexes co-immunoprecipitated using anti-GFP antibody. Lane 1,
exogenous p53-XL (75 kDa) which was transfected into T47D cells
co-immunoprecipitates with endogenous Bcl-XL (26 kDa). Lane 2,
exogenous E-XL (32 kDa) co-immunoprecipitates with exogenous Bcl-
XL (26 kDa). Lane 3 exogenous E-CC (35 kDa) fails to co-
immunoprecipitate with endogenous Bcl-XL. Unlabeled bands are
nonspecific binding. (B) Rescue experiment using Bcl-XL. 7-AAD
assay was conducted 48 h post transfection in T47D cells. Statistical
analysis was tested via unpaired t test; **p < 0.01 and ***p < 0.001.
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domain of p53 and helps to transfer ubiquitin from E2 to lysine
residues on the carboxy terminus of p53. Ubiquinated p53 is
dragged to the proteasome for degradation.50,51 DBD-XL may
evade degradation by MDM2 since it lacks the MBD and C-
terminal domain, allowing for higher stability and consequently
increased apoptotic activity. Hagn et al. showed that the amino
acids of p53 responsible for interacting with Bcl-XL are located
in the DBD of p53 (Gly117, Ser121, Cys176, His178, Asn239,
Met243, Arg248, Gly279, and Arg280) and the contact sites on
Bcl-XL are residues Ser18, Tyr22, Ser23, Gln26, and Ser28 in
helix 1 and 2, Ile114 between helix 3 and 4, and Val155,
Asp156, and Glu158 in helix 5.11 Consequently, DBD-XL
contains the residues important for interaction with Bcl-XL
while lacking the domains responsible for degradation.
Alternatively, the antioxidative role of p53 might offer an
explanation to why p53-XL shows lower apoptotic activity
compared to DBD-XL. In healthy cells, basal p53 expression
limits oxidative stress and promotes cell survival.52 p53
upregulates the expression of genes involved in the oxidative
stress survival pathways such as GPX1,53 SOD2,53
ALDH4A1,54 INP1,55 TIGAR,56 Hi9557 and PA26.57 Even
though all designed constructs translocate into the mitochon-
dria (Figure 2), a small fraction could still enter the nucleus.
Our previous publication shows that p53-XL retains some
residual transcriptional activity.18 Unlike p53-XL, which
contains full length p53, DBD-XL is not capable of transcribing
genes because it lacks the TD to form the transcriptionally
active tetrameric p53 and the PRD which enhances tran-
scription of various genes. This could provide another
explanation why DBD-XL (which does not activate gene
expression) shows higher apoptosis than p53-XL (which could
upregulate the expression of genes involved in preventing
oxidative stress).
Furthermore, the “mitochondrial priming theory” suggests
that some cancer cells such as MCF-7 cells are inherently more
sensitive to cytotoxic drugs than other cells.38,58,59 This
response correlates with the sensitive balance of anti- and
proapoptotic Bcl-2 family members at the mitochondrial outer
membrane.58,59 It is known that T47D,60 MCF-7,61,62 MDA-
MB-23162 and HeLa61 express antiapoptotic Bcl-XL. Therefore,
we compared the expression levels of Bcl-XL in T47D,60 MCF-
7,61,62 MDA-MB-23162 and HeLa61 (see Figure S1 in the
Supporting Information). Indeed, T47D cells had the highest
expression level of Bcl-XL confirming that they are “less
primed” and more resistant to apoptosis.
Since the DBD-XL shows similar or higher apoptotic activity
(measured by TUNEL, annexin V and 7-AAD) compared to
p53-XL consistently in every tested cell line (Figures 3, 4, and
6), we wanted to examine if the effect on cell death is due to a
mitochondrial dependent mechanism. DBD-XL triggers more
caspase-9 activation than the negative control E-XL (Figure 7B)
but surprisingly less caspase-9 induction than p53-XL (Figure
7B). Even though p53-XL caspase activity is higher, this is a
transient effect that is not reflected in the more “final” apoptotic
assays (Figures 3, 4, and 6). Additionally, a certain threshold of
caspase 9 activation achieved by DBD-XL may be sufficient to
induce cell death. Furthermore, DBD-XL induces MOMP to
the same extent as p53-XL, suggesting that DBD-XL dependent
apoptosis occurs through the intrinsic apoptotic pathway and
might be through a direct interaction with Bcl-XL (Figure 7A).
As described above, p53-XL could possibly be degraded via the
proteasome. Once MDM-2, a ubiquitin ligase, binds to the
MBD of p53, the C-terminal region of p53 becomes
ubiquitinated and p53 is dragged into the proteasome for
degradation.50,51 This could explain why initially p53-XL causes
more caspase-9 activation (Figure 7A), but this difference in
activity is not reflected in the more “final” apoptosis assays
where DBD-XL shows even higher apoptosis activity compared
to p53-XL (Figure 6).
In an effort to determine if the apoptotic potential of our
designed constructs is due to their interaction with Bcl-XL or if
it is independent of the p53/Bcl-XL pathway, we conducted a
co-IP and a rescue experiment achieved by overexpressing Bcl-
XL. Interestingly, Bcl-XL co-immunoprecipitated with the
“negative control” E-XL in the same manner as p53-XL (Figure
8A). We hypothesize that the interaction with Bcl-XL is
independent of p53 and it is mainly due to the XL MTS which
will directly target every protein that contains XL to Bcl-XL. To
investigate this hypothesis, E-CC (a negative control lacking
the XL signal) was created. As expected, E-CC did not bind to
Bcl-XL (Figure 8A), confirming that the XL signal is
responsible for the interaction with Bcl-XL.
To prove indirectly that the apoptotic mechanisms of p53-
and DBD-XL are through direct interaction of p53 and DBD
with Bcl-XL, a rescue experiment using overexpressed Bcl-XL
was conducted. As expected, the apoptotic activity of MBD-,
PRD- and E-XL was not altered by Bcl-XL overexpression (see
Figure S2 in the Supporting Information). However, DBD-XL
and p53-XL (and even TD-XL) demonstrated reduction in
apoptotic potential, further demonstrating the necessity of Bcl-
XL for apoptosis initiation (Figure 8B; Figure S2 in the
Supporting Information). Even though TD-XL showed
significantly lower cell death compared to p53-XL, it was still
significantly higher than the negative control E-XL, and it was
still rescued by Bcl-XL (Figure S2 in the Supporting
Information). It could be speculated that TD-XL binds to
endogenous, mutant p53 through its TD and drags it to the
mitochondria where it potentially interacts with Bcl-XL and
triggers marginal apoptosis.63 Even though endogenous, mutant
p53 is transcriptionally inactive in T47D cells due to the
presence of the L194F mutation, this mutant p53 could still be
active at the mitochondria, since the L194 residue is not
involved in the interaction between p53 and Bcl-XL.11
In summary, DBD-XL shows the same (T47D) or higher
(MCF-7, MDA-MB-231, HeLa, H1373) apoptotic activity
compared to p53-XL. Mechanistic studies suggest that DBD-XL
may bind and trigger apoptosis similar to p53 through the Bcl-
XL dependent pathway. Our data highlights that DBD (about
half the size of full length p53) can be used instead of p53 for
achieving apoptosis at the mitochondria when fused to the
MTS from Bcl-XL. The benefit of decreasing the overall size of
p53 by half while still maintaining full apoptotic activity allows
for better drug delivery options. The next goal is to use DBD-
XL as a therapeutic in vivo using adenoviral drug delivery.
In conclusion, we show for the first time that DBD-XL can
be used to trigger a potent, rapid apoptotic response in various
cancer cell lines (including breast, cervical and lung
carcinomas) with different p53 status, and is an alternative to
wt-p53 gene therapy. Importantly, the mechanism of DBD-XL-
mediated apoptosis is distinctly different from conventional
wild type p53 and represents a novel approach for cancer
therapy.
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ABSTRACT: Because of the dominant negative effect of mutant p53, there has been
limited success with wild-type (wt) p53 cancer gene therapy. Therefore, an alternative
oligomerization domain for p53 was investigated to enhance the utility of p53 for gene
therapy. The tetramerization domain of p53 was substituted with the coiled-coil (CC)
domain from Bcr (breakpoint cluster region). Our p53 variant (p53-CC) maintains
proper nuclear localization in breast cancer cells detected via fluorescence microscopy and
shows a similar expression profile of p53 target genes as wt-p53. Additionally, similar
tumor suppressor activities of p53-CC and wt-p53 were detected by terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), annexin-V, 7-
aminoactinomycin D (7-AAD), and colony-forming assays. Furthermore, p53-CC was
found to cause apoptosis in four different cancer cell lines, regardless of endogenous p53 status. Interestingly, the transcriptional
activity of p53-CC was higher than wt-p53 in 3 different reporter gene assays. We hypothesized that the higher transcriptional
activity of p53-CC over wt-p53 was due to the sequestration of wt-p53 by endogenous mutant p53 found in cancer cells. Co-
immunoprecipitation revealed that wt-p53 does indeed interact with endogenous mutant p53 via its tetramerization domain,
while p53-CC escapes this interaction. Therefore, we investigated the impact of the presence of a transdominant mutant p53 on
tumor suppressor activities of wt-p53 and p53-CC. Overexpression of a potent mutant p53 along with wt-p53 or p53-CC
revealed that, unlike wt-p53, p53-CC retains the same level of tumor suppressor activity. Finally, viral transduction of wt-p53 and
p53-CC into a breast cancer cell line that harbors a tumor derived transdominant mutant p53 validated that p53-CC indeed
evades sequestration and consequent transdominant inhibition by endogenous mutant p53.
KEYWORDS: p53, dominant-negative effect, tetramerization domain, coiled-coil, Bcr, breast cancer, tumor suppressor
■ INTRODUCTION
The tumor suppressor p53, a 393 amino acid sequence-specific
transcription factor, stimulates a wide network of signals
including cell cycle arrest, DNA repair, and apoptosis. p53-
dependent apoptosis is achieved through two distinct apoptotic
signaling pathways: the extrinsic pathway through death
receptors and the intrinsic pathway through the mitochondria.1
While p53 is able to induce apoptosis when targeted to the
mitochondria,2−4 its tumor suppressor function mainly depends
on localization to the nucleus and formation of p53 tetramers
leading to its function as a transcription factor of several target
genes.5 The p53 protein is commonly divided into three
regions: an acidic N-terminal region (codons 1−101), a DNA
binding domain (DBD, codons 102−292), and a basic C-
terminal region (codons 293−393).6 The C-terminus contains
three nuclear localization signals (NLSs), a nuclear export
signal (E), and a tetramerization domain (TD) (Figure 2A). In
response to cellular stimuli such as DNA damage and oncogene
activation,7 the murine double minute 2 (MDM2)-p53
degradation pathway is inactivated leading to increased
concentration of p53 followed by rapid accumulation in the
nucleus, which is essential for regulating cell cycle arrest, DNA
repair, senescence, and apoptosis.8,9
Current strategies to enhance the anticancer/tumor-
suppressor function of p53 are focused on introducing
additional wt-p53 to the affected cells or tumor. This treatment
modality introduces wt-p53 as a gene into cancer cells using
various delivery vehicles. Wild-type p53 is a currently approved
gene therapeutic for head and neck cancer in China.10 While a
promising approach, there are significant limitations to the
efficacy of this method, namely, the presence of mutations in
the endogenous p53 molecule.
The tumor suppressor p53 is inactivated in more than half of
all human tumors.11 Acquisition of missense mutations in the
TP53 gene results in aberrant p53 that is transcriptionally
inactive.12−14 Mutant p53 can also contribute to cancer drug
resistance due to its inhibition of wild-type (wt) p53 via a
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dominant negative effect and the acquisition of gain of function
properties.15 Since p53 binds DNA as a tetramer consisting of a
dimer of dimers,16 when endogenous mutant p53 oligomerizes
with exogenous wt-p53, the resulting tetramer is inactive.17−19
Such heterotetramerization is possible as the TD retains
functionality in mutant p53. This dominant negative effect,
wherein mutant p53 inactivates therapeutic wt-p53, represents a
key problem with using wt-p53 for gene therapy. The dominant
negative effect of p53 has shown to be operative in vivo using
knock-in mice expressing mutant p53.20
Because sequestration of wt-p53 into inactive heterote-
tramers with mutant p53 forms a critical barrier to the efficacy
of utilizing p53 for cancer therapy, improvements to advance
the efficacy of this therapy even in the presence of p53 mutants
is needed.11 Our approach to bypass the dominant negative
effect of tumor-derived p53 is to engineer a p53 variant that
relies on a different oligomerization motif to prevent hetero-
oligomer formation. To our knowledge, only one attempt has
been made to eliminate the dominant negative effect of mutant
p53 in heterotetramers via substituting its TD, with marginal
success.21 Whereas the native TD of p53 drives the formation
of antiparallel tetramers,21−23 this previous work utilized an
oligomerization domain that led to parallel tetramer formation
which resulted in a significant reduction in p53 function. We
recognized that the oligomerization domain from breakpoint
cluster region (Bcr) protein, a 72 amino acid coiled-coil (CC),
tetramerizes as two dimers of two antiparallel-oriented
monomers,24 in a similar fashion to the TD of wt-p53. This
would be a suitable candidate for TD substitution,22 forming a
chimeric p53-Bcr fusion. Table 1 depicts the oligomerization
domains for p53 (TD) and the CC domain from Bcr.
This report demonstrates that our p53 variant, namely, p53-
CC, shows higher levels of transcriptional activity in reporter
gene assays and exhibits similar tumor suppressor activity
compared to wt-p53 in cell lines with varying p53 status. Lastly,
we show the ability of p53-CC to circumvent the dominant
negative effect in cancer cells harboring a strong transdominant
mutant p53. Figure 1 illustrates our hypothesis of bypassing the
dominant negative effect with p53-CC (right side), which
maintains functional tumor suppressor activity.
■ MATERIALS AND METHODS
Construction of Plasmids (Figure 2A). To construct
pEGFP-p53-CC (p53-CC), a truncated version of wt-p53 that
lacks the tetramerization domain (amino acids 1−322) was
amplified via PCR with primers 5′-GCGCGCGCGCTCCG-
GAATGGAGGAGCCGCAGTCA-3′ and 5′-GCGCGCGCG-
CTCCGGATGGTTTCTTCTTTGGCTGGGGAGA-3′ using
the previously cloned pEGFP-p53 (wt-p53) as the template
DNA.4 The PCR product was then subcloned into the BspEI
site of pEGFP-CC (CC).26
To create pEGFP-p53-ΔTDC (p53-ΔTDC), the same
truncated version of wt-p53 (amino acids 1−322) was amplified
via PCR with primers 5′-GCGCGCGCGCTCCGGAATG-
GAGGAGCCGCAGTCA-3′ and 5′-GCGCGCGCGCGGTA-
CCTCATGGTTTCTTCTTTGGCTGGGG-3′ using pEGFP-
p53 as the template DNA.4 The PCR product (insert) was then
subcloned into the digested pEGFP-C1 vector (Clontech,
Mountain View, CA) at the BspEI and KpnI sites.
To design pTagBFP-mut-p53, wt-p53 was amplified via PCR
with primers 5′-GCGCGCGCGCTCCGGAGCCATGGAG-
GAGCCGCAGT-3′, and 5′-GCGCGCGCGCGGTAC-
CTCAGTCTGAGTCAGGCCCTTCTGTC-3′ using pEGFP-
p53 as a template. This insert was then subcloned into the
digested pTagBFP-C vector (Evrogen, Moscow, Russia) at the
BspEI and KpnI sites. Three hot spot mutations (R175H,
R248W, and R273H)27,28 were then introduced into pTagBFP-
p53 via QuikChange II XL Site- Directed Mutagenesis Kit
(Agilent, Santa Clara, CA). The following primers were used:
for the R175H mutation, 5′-TGACGGAGGTTGTGA-
GGCACTGCCCCCACCATGAGCGC-3′ and 5′-GCGCT-
CATGGTGGGGGCAGTGCCTCACAACCTCCGTCA-3′;
for R248W, 5′-CTGCATGGGCGGCATGAACTGGAGG-
CCCATCCTCACCA-3′ and 5′-TGGTGAGGATGGGCC-
TCCAGTTCATGCCGCCCATGCAG-3′; and for R273H,
5′-GGAACAGCTTTGAGGTGCATGTTTGTGCCTGTCC-
TGGG-3′ and 5′-CCCAGGACAGGCACAAACATGCACC-
TCAAAGCTGTTCC-3′.
Cell Lines and Transient Transfection. T47D human
ductal breast epithelial tumor cells (ATCC, Manassas, VA),
MCF-7 human breast adenocarcinoma cells (ATCC), HeLa
human epithelial cervical adenocarcinoma cells (ATCC),
H1373 human non-small cell lung carcinoma cells (a kind
gift from Dr. Andrea Bild, University of Utah), and MDA-MB-
231 human breast adenocarcinoma cells (ATCC) were grown
as monolayers in RPMI (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Invitrogen), 1%
penicillin−streptomycin−glutamine (Invitrogen), and 0.1%
gentamicin (Invitrogen). T47D and MCF-7 were also
supplemented with 4 mg/L insulin (Sigma, St. Louis, MO).
1471.1 murine breast adenocarcinoma cells (gift of Dr. Gordon
Hager, NCI, NIH), HEK293 human embryonic kidney cells
(ATCC), MDA-MB-468 human breast adenocarcinoma cells
(ATCC), and 4T1 murine breast carcinoma cells were grown as
monolayers in DMEM (Invitrogen) supplemented with 10%
fetal bovine serum, 1% penicillin-streptomycin−glutamine, and
0.1% gentamicin. MDA-MB-468 cells were also supplemented
with 1% MEM nonessential amino acids (Invitrogen). All cells
were incubated in 5% CO2 at 37 °C. The cells were seeded at a
density of 7.5 × 104 cells (for 1471.1, MDA-MB-231, HeLa,
and 4T1 cells) and 3.0 × 105 cells (for MCF-7, T47D,
Table 1. Comparison of the Native TD from wt-p53 to the
CC Domain from Bcra
aSnapshots were taken with molecular visualization software PyMOL
(PyMOL Molecular Graphics System Version 1.5.0.4, Schrödinger,
LLC) initiated from the1C26 for p53 TD22 and 1K1F for Bcr CC25
PDB structures.
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HEK293, MDA-MB-468, and H1373 cells) in 6-well plates
(Greiner Bio-One, Monroe, NC). Transfections of 1 pmol
DNA were carried out 24 h after seeding using Lipofectamine
2000 (Invitrogen) following the manufacturer’s recommenda-
tions.4
Microscopy. All microscopy was performed using 1471.1
cells due to their ideal microscopic morphology.4 Twenty-four
hours post transfection, media in 2-well live-cell chambers
(Nalgene Nunc, Rochester, NY) was replaced with phenol red-
free DMEM (Invitrogen). Cells were then incubated with 2 μg/
mL Hoechst 33342 nuclear stain (Invitrogen) for 30 min at 37
°C. Images were taken using an Olympus IX71F fluorescence
microscope (Scientific Instrument Company, Aurora, CO) with
a high-quality narrow band GFP filter (excitation, HQ480/20
nm; emission, HQ510/20 nm) to detect EGFP and cyan GFP
v2 filter (excitation HQ436/20 nm, emission HQ480/40 nm,
with beam splitter 455dclp) to detect H33342 as previously
described.29
RT-PCR. Twenty-four hours following transfection of T47D
cells, mRNA from cell lysates was isolated using RNeasy Mini
Kit (Qiagen, Valencia, CA). cDNA was then obtained using
RT2 First Strand Kit (Qiagen) and mixed with RT SYBR Green
qPCR Mastermix (Qiagen). Equal volumes were then aliquoted
into a 384-well p53 Signaling Pathway PCR Array (Qiagen).
Roche LightCycler 480 was used for real-time PCR cycling.
Analysis of the PCR array was performed using the
manufacturer’s web-based analysis software (http://
pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
Genes outside of a 2-fold range were considered to be
statistically different per the manufacturer. The PCR array was
performed once and used as a screening tool as before.30−32
Western Blotting. Twenty-four hours following trans-
fection of T47D cells, EGFP-positive cells were sorted using the
FACSAria-II (BD-BioSciences). The 3 × 105 cells were pelleted
and resuspended in 200 μL of lysis buffer (62.5 mM Tris-HCl,
2% w/v SDS, 10% glycerol, 1% protease inhibitor). Standard
Western blotting procedures33 were followed using primary
antibodies to detect p21/WAF1, Bax, and actin as a loading
control. The primary antibodies anti-p21 (ab16767, Abcam,
Cambridge, MA), anti-Bax (ab7977, Abcam), antiactin (mouse,
ab3280, Abcam), and antiactin (rabbit, ab1801, Abcam) were
detected with antirabbit (no. 7074S, Cell Signaling Technology,
Danvers, MA) or antimouse (ab6814, Abcam) HRP-conjugated
antibodies before the addition of SuperSignal West Pico
chemiluminescent substrate (Thermo Scientific, Waltham,
MA). Signals were detected using a FluorChem FC2 imager
and software (Alpha Innotech, Sanata Clara, CA). Each
Western blot was repeated at least three times.
TUNEL Assay. As previously described,4 T47D cells were
prepared 48 h after transfection using an In Situ Death
Detection Kit, TMR red (Roche, Mannheim, Germany). Cells
were EGFP gated and analyzed using FACSAria-II (BD-
BioSciences, University of Utah Core Facility) and FACSDiva
software. EGFP and TMR red were excited at 488 and 563 nm
wavelengths and detected at 507 and 580 nm, respectively. The
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay was repeated three times (n = 3) and analyzed
using one-way analysis of variance (ANOVA) with Bonferroni’s
post hoc test.
Annexin-V Assay. The annexin-V assay was performed as
before.4 Briefly, 48 h post transfection, T47D cells were
suspended in 400 μL annexin binding buffer (Invitrogen) and
incubated with 5 μL of annexin-APC (annexin-V conjugated to
allophycocyanin, Invitrogen) for 15 min. The incubated cells
were EGFP gated and analyzed using FACSCanto-II. EGFP
and APC were excited at 488 and 635 nm wavelengths and
detected at 507 and 660 nm, respectively. Each construct was
tested three times (n = 3) and analyzed using one-way ANOVA
with Bonferroni’s post hoc test.4
Figure 1. Proposed mechanism of p53-CC activity. Left side of figure: exogenously added wt-p53 can still form heterotetramers with mutant p53 due
to the presence of the TD and becomes inactivated. Right side of figure: p53-CC can bypass transdominant inhibition by mutant p53 in cancer cells
and still exhibit tumor suppressor activity.
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7-AAD Assay. As before,4 following manufacturer’s
instructions, T47D, MCF-7, H1373, and MDA-MB-468 cells
were stained with 7-aminoactinomycin D (7-AAD, Invitrogen)
48 h after transfection. Since HeLa, MDA-MB-231, and 4T1
cells are highly proliferating cells, these cell lines were assayed
24 h post transfection. Cells were analyzed and gated for EGFP
(with same fluorescence intensity to ensure equal expression of
proteins) using the FACSCanto-II (BD-BioSciences, University
of Utah Core Facility) and FACSDiva software. Excitation was
set at 488 nm and detected at 507 and 660 nm for EGFP and 7-
AAD, respectively. The means from three separate experiments
(n = 3) were analyzed using one-way ANOVA with
Bonferroni’s post hoc test.
Colony Forming Assay (CFA). CFA was carried out using
the Cytoselect 96-well cell transformation assay (Cell Biolabs,
San Diego, CA). A base agar layer was prepared per
manufacturer’s directions, and 50 μL was transferred to each
well of a clear-bottom 96-well plate. T47D cells were
transfected as described above with wt-p53, p53-CC, or CC
and harvested 24 h post transfection. The cells were
resuspended in RPMI medium (Invitrogen) at a concentration
of 3.0 × 105 cells/mL per the manufacturer’s instructions. A cell
agar layer was then prepared as recommended, and 75 μL of
the mixture was transferred to each well of the 96-well plate
containing the base agar layer. A portion of 100 μL of complete
culture medium was added to each well; plates were then
incubated at 37 °C and 5% CO2 for 7 days. The culture
medium was removed, solubilized, and lysed. A sample of 10 μL
of cell lysates were then transferred to a new black-bottom 96-
well plate. 90 μL of CyQuant GR dye working solution (1:400
in PBS) was added to each well and incubated for 10 min at
RT. A Spectra Max M2 plate reader (Molecular Devices,
Sunnyvale, CA) was used to detect fluorescence using a 485/
520 nm filter set. Independent transfections of each construct
were tested three times (n = 3) and analyzed using one-way
ANOVA with Bonferroni’s post hoc test.
Reporter Gene Assay. A sample of 3.5 μg of construct (wt-
p53, p53-CC, CC, or EGFP) was cotransfected with 0.35 μg of
pRL-SV40 plasmid encoding for Renilla luciferase (Promega,
Madison, WI) to normalize for transfection efficiency in T47D
cells. In addition to Renilla luciferase, constructs were
cotransfected with 3.5 μg of p53-Luc Cis-Reporter (Agilent
Technologies, Santa Clara, CA),4 p21/WAF1 reporter (a
generous gift from Dr. Bert Vogelstein, Addgene plasmid
16451, Cambridge, MA)34 or PUMA reporter (from Dr.
Vogelstein, Addgene plasmid 16591);35 all three reporters
Figure 2. (A) Schematic representation of the experimental constructs and controls. Full length p53 (wt-p53) contains a MDM2 binding domain
(MBD), a transactivation domain (TA) in the amino terminus, a proline-rich domain (PRD), a DNA binding domain (DBD), a strong nuclear
localization signal (NLS), a tetramerization domain (TD) that also contains a nuclear export signal (E), and a carboxy terminus (C-terminus) that
includes two weak NLS’s. For p53-CC, the TD and C-terminus were replaced by the coiled-coil (CC) from Bcr. p53-ΔTDC lacks both the TD and
the C-terminus. All constructs were fused to EGFP on the N-terminus (not shown in diagram). (B) Representative fluorescence microscopy images
of 1471.1 cells confirm exclusive nuclear accumulation of EGFP-p53-CC similar to EGFP-wt-p53. EGFP fluorescence, nuclear staining with H33342,
and phase contrast images are shown, left to right. 1471.1 breast cancer cells were chosen for this study due to their optimal microscopy
characteristics (elongated morphology and distinguishable subcellular compartments).4 White scale bars on the top left corners are 10 μm.
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encode the firefly luciferase gene. The Dual-Glo Luciferase
Assay System (Promega) was used to determine firefly
luciferase activity and Renilla luciferase per manufacturer’s
instructions. Luminescence from active luciferase was then
detected using PlateLumino (Stratec Biomedical Systems,
Birkenfeld, Germany) as previously.4 Renilla luciferase activity
was used to normalize the firefly luciferase values. The highest
relative luminescence value was set at 100%, and untreated cells
were set at 0%. The means from triplicate samples were taken
from three independent experiments and analyzed using one-
way ANOVA with Bonferroni’s post hoc test.
Co-immunoprecipitation (co-IP). The co-IP was per-
formed using Dynabeads co-IP Kit (Invitrogen). T47D cells
transfected with either EGFP-wt-p53 or EGFP-p53-CC were
collected and weighed out (0.05 g) 20 h post transfection. Anti-
GFP antibody (ab290, Abcam) was coupled to magnetic beads
using Dynabeads Antibody Coupling Kit (Invitrogen).
Approximately 0.2 g of cell pellet was lysed in 1.8 mL of
extraction buffer B (1× IP, 100 mM NaCl, 2 mM MgCl2, 1 mM
DTT, 1% protease inhibitor). The lysate was incubated for 30
min at 4 °C with 1.5 mg of the Dynabeads coupled with anti-
GFP antibody. The immune complexes were then collected by
a magnet and washed three times with extraction buffer B and
one time with last wash buffer (1× LWB, 0.02% Tween 20).
Immune complexes were then eluted using 60 μL of elution
buffer. Finally, the eluted complexes were denatured and
blotted using anti-p53 antibody HRP-conjugated (sc-126 HRP,
Santa Cruz Biotechnology, Santa Cruz, CA).
Overexpression of Mutant p53. H1373 cells were
cotransfected with 1 pmol of the transdominant mutant
pTagBFP-mut-p53 (R175H, R248W, and R273H)27,28 and 1
pmol of wt-p53, p53-CC, or CC fused to EGFP. Forty-eight
hours post transfection, cells were stained as in the 7-AAD
assay above and gated for EGFP and BFP using the
FACSCanto-II (BD-BioSciences, University of Utah Core
Facility) and FACSDiva software. Excitation for BFP was set
Figure 3. p53-CC is capable of transactivating several p53 target genes. (A) Scatter plot representation of mRNA levels of 84 p53 target genes in
T47D cells transfected with wt-p53 or p53-CC. Each dot represents one of the 84 genes assayed in this PCR array. The two magenta lines represent
a boundary of 2-fold upregulation or downregulation in mRNA levels. Cells treated with wt-p53 or p53-CC showed similar levels of mRNA for all 84
genes except for one, p53AIP1, which is circled on the scatter plot. (B) Representative cropped Western blots of T47D cell lysates 24 h post
transfection with wt-p53, p53-CC, p53-ΔTDC, or CC. Similar levels of Bax and p21/WAF1 protein expression were detected from cells treated with
wt-p53 or p53-CC. Each Western blot was repeated at least three times.
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at 405 nm and detected at 457 nm. The means from three
separate experiments (n = 3) were analyzed using one-way
ANOVA with Bonferroni’s post hoc test.
Recombinant Adenovirus Production. Replication-
deficient recombinant adenovirus serotype 5 (Ad) constructs
were generated using the Adeno-X Adenoviral Expression
System 3 (Clontech). Either wt-p53 or p53-CC was inserted
into a cassette under the control of the CMV promoter. A
separate CMV promoter controls the expression of ZsGreen1
for visualization. The empty virus (vector) was used as a
negative control. Wt-p53 and p53-CC were PCR amplified with
primers containing 15 base pair homology with a linearized
pAdenoX vector (Clontech) based on an In-Fusion HD
Cloning Kit (Clontech). Stellar competent cells (Clontech)
were transformed with the adenoviral vector plasmids
containing our constructs. Viral DNA was then purified,
linearized and transfected into HEK293 cells for packaging
and amplification. Viral particles were isolated from HEK293
cells by freeze−thawing, purified using an Adeno-X Mega
Purification Kit (Clontech), and dialyzed against storage and
proper tonicity buffer (2.5% glycerol (w/v), 25 mM NaCl, and
20 mM Tris-HCl, pH 7.4). The viral titer was determined using
flow cytometry per the manufacturer’s recommendation.
■ RESULTS
p53-CC Localizes to the Nucleus. Because the nuclear
localization of p53 is important for antiapoptotic function, we
first chose to investigate if p53-CC also localized to the nucleus.
Full length wt-p53 contains three NLSs encoded by amino
acids 305−322, 370−376, and 380−386 (Figure 2A, top).
Given that p53-CC (illustrated in Figure 2A) lacks most of the
C-terminal domain (amino acids 323−393), which contains
two NLSs, nuclear accumulation of p53-CC was verified using
fluorescence microscopy (Figure 2B). Both wt-p53 and p53-CC
were fused to EGFP to enable visualization of the subcellular
localization of each protein. Figure 2B shows similar nuclear
accumulation of p53-CC and wt-p53 in 1471.1 murine
adenocarcinoma cells. CC alone fused to EGFP showed mostly
cytoplasmic localization (data not shown). Similar results were
obtained in T47D and MCF-7 breast cancer cells (data not
shown).
Wt-p53 and p53-CC Show Similar Gene Expression
Profiles. After verifying the nuclear localization of p53-CC via
fluorescence microscopy, the activity of p53-CC was inves-
tigated next. The Human p53 Signaling Pathway RT2 Profiler
PCR Array (Qiagen, Valencia, CA)32 was used to compare the
transcription profiles between wt-p53 and p53-CC in T47D
human breast cancer cells. T47D cells contain mutant p53 (a
L194F mutation) that does not exhibit a strong transdominant
effect.36 Exogenously added wt-p53 has been shown to be
functional in this cell line,4,33 and hence these cells can be used
for comparing wt-p53 activity with p53-CC. The PCR array
uses real-time PCR to measure the expression profiles of 84
genes directly related to p53-mediated signal transduction,
including genes involved in apoptosis, cell cycle, DNA repair,
cell proliferation, and differentiation. Analysis of the PCR array
indicated that p53-CC showed a similar expression profile for
83 out of 84 genes compared to wt-p53 (Figure 3A), with the
exception of the p53AIP1 gene (circled in black), whose
protein product is one of many involved in the intrinsic
Figure 4. Apoptotic and cell proliferation assays were performed in T47D cells 48 h after transfection. (A) TUNEL assay shows similar apoptotic
activity of p53-CC compared to wt-p53. Both p53-CC and wt-p53 demonstrate a significantly higher activity compared to CC negative control.
Similar results were obtained from (B) annexin V staining and (C) 7-AAD staining. (D) The colony forming assay shows the transformative ability
of T47D cells post treatment with wt-p53, p53-CC, and CC. Cells treated with wt-p53 and p53-CC show significant reduction in transformative
ability (oncogenic potential) of T47D cells compared to untreated cells or cells treated with CC. Mean values were analyzed using one-way ANOVA
with Bonferroni’s post test; * p < 0.05, ** p < 0.01, and *** p < 0.001. Error bars represent standard deviations from at least three independent
experiments (n = 3).
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apoptotic pathway. A tetramerization-deficient form of p53
(p53-ΔTDC) was included as a negative control in these assays
to validate that the activity of p53-CC is due to proper tetramer
formation, along with CC (also a negative control). As
expected, both p53-ΔTDC and CC had significantly different
expression profiles from wt-p53 (Supplementary Figures 1 and
2) in the p53 signaling pathway PCR array.
To verify the array results, the protein expression of two
typical genes involved in two different pathways that are
directly regulated by p53, Bax and p21/WAF1, were examined
by Western blotting. Bax is involved in the p53-dependent
intrinsic apoptosis pathway,1 while p21/WAF1 is involved in
cell cycle arrest.37 Figure 3B shows that T47D cells transfected
with wt-p53 (first lane) or p53-CC (second lane) demonstrated
overexpression of Bax and p21, while the monomeric form of
p53 (p53-ΔTDC, third lane) and the CC (fourth lane)
negative controls did not significantly induce expression of the
Bax and p21/WAF1. Faint p21/WAF1 bands are observed with
negative controls and represent background levels of this
protein. Due to its inactivity, p53-ΔTDC was not included in
the remaining apoptotic assays.
p53-CC Exhibits Tumor Suppressor Activity. To
determine if the similar gene expression profiles between
p53-CC and wt-p53 correlate with comparable tumor
suppressor activity, the apoptotic potential (TUNEL, annexin
V, 7-AAD) and transformative ability (colony formation) were
tested in T47D cells. As mentioned before, T47D cells were
chosen to compare the activity of p53-CC and wt-p53, since we
have shown before that wt-p53 is active in these cells.4,33
The TUNEL assay, which measures DNA fragmentation into
nucleosomal segments, is a hallmark of apoptosis.38 Figure 4A
shows that p53-CC has a similar ability to induce DNA
fragmentation as wt-p53 compared to CC control. Next, the
apoptotic potential of p53-CC was also validated in the
annexin-V assay, which evaluates the externalization of
phosphatidylserine on the cell surface of apoptotic cells.39,40
Similar levels of annexin-V positive staining were detected
between cells transfected with p53-CC and wt-p53 (Figure 4B),
and had significantly higher positive staining in cells transfected
with CC negative control. The last apoptotic assay tested was
the 7-AAD viability assay. In apoptotic or necrotic cells, the
plasma membrane is disrupted, allowing intercalation of the 7-
AAD stain into DNA in the nucleus of these damaged cells.41,42
In this assay (Figure 4C), p53-CC maintains the same level of
apoptotic activity as wt-p53 and is able to induce higher levels
of cell death compared to the control (CC). Finally, the
decrease in transformative ability (or oncogenic potential) of
cells treated with p53-CC or wt-p53 were tested via a colony
forming assay. In this assay, treatment with a tumor suppressor
would be expected to reduce the number of cell colonies
formed in an agar matrix. Indeed, as shown in Figure 4D, both
p53-CC (second bar) and wt-p53 (first bar) significantly
reduced the number of colonies formed compared to the
negative controls (CC and untreated cells, third and fourth
bars, respectively). Overall, these results indicate that p53-CC
shows a similar ability to induce statistically significant levels of
apoptosis and to reduce oncogenic potential as wt-p53.
To ensure that the potential for p53-CC to induce apoptosis
is neither dependent on endogenous p53 status nor cancer cell
line specific, p53-CC was tested in several different cell lines.
Human epithelial cervical adenocarcinoma cells (HeLa), which
express endogenous wt-p53,43 MDA-MB-231 metastatic triple-
negative breast cancer cells harboring mutant p53,44 MCF-7
breast cancer cells with wild type but mislocalized p53,45 and
H1373 non-small cell lung carcinoma cells that are p53 null46
(Table 2), were tested in the 7-AAD assay. In all four cell lines,
p53-CC and wt-p53 were able to induce similar levels of
apoptosis and were higher than the negative control (CC), as
shown in Figure 5A−D.
p53-CC Maintains Transcriptional Activity of p53
Target Genes. While p53-CC exhibited similar apoptotic
activity as wt-p53, we wanted to determine if p53-CC was
capable of activating promoters of p53-dependent target genes.
Tetramerization of p53 is a prerequisite to transcriptional
activity, thus transcriptional activation will indicate tetrameriza-
tion ability (of both wt-p53 and p53-CC).47 The transcriptional
activity of p53-CC was tested in T47D cells using three
different reporter gene assays. The first was the p53 cis-reporter
system, a common reporter for measuring p53 activity, which
relies on a synthetic promoter consisting of repeats of the
transcription recognition consensus for p53 (TGCCTGGACT-
TGCCTGG)14.
48 The second and third reporter systems
utilized the binding consensus sequences from p21/WAF1
and PUMA promoters, respectively. p21/WAF1 is a cyclin-
dependent kinase inhibitor that mediates p53-dependent G1
cell cycle arrest,34,37 while PUMA translocates to the
mitochondria, deactivates antiapoptotic Bcl-2 and Bcl-XL
proteins and induces p53-dependent apoptosis.49 In all three
reporter gene assays, p53-CC showed higher transcriptional
activity compared to wt-p53, and both were higher than the
negative controls CC and EGFP (Figure 6A−C) in T47D cells.
p53-CC Avoids Interaction with Endogenous p53. We
hypothesized that the higher level of transcriptional activity of
p53-CC over wt-p53 was due to the possible hetero-
oligomerization of wt-p53 with endogenous mutant p53 in
this cell line. Therefore, a co-IP assay was performed to
determine if exogenously added wt-p53 interacts with mutant
p53 present in these cells. To this end, mutant p53 in T47D
cells would not be expected to coimmunoprecipitate with p53-
CC. Cell lysates transfected with either EGFP-wt-p53 or EGFP-
p53-CC were incubated with anti-GFP antibody to selectively
immunoprecipitate our fusion EGFP proteins (Figure 6D).
Endogenous p53 that could potentially coimmunoprecipitate
with either exogenous EGFP-wt-p53 or EGFP-p53-CC was
probed using anti-p53 antibody. Figure 6D shows that
endogenous p53 (53 kDa) coimmunoprecipitates with
exogenous wt-p53 (left lane, 70 kDa) but fails to
immunoprecipitate with p53-CC (right lane, 71 kDa). These
findings indicate that endogenous p53 interacts directly with
exogenous wt-p53, which is presumably due to hetero-
oligomerization via their TDs. As expected, p53-CC, which
lacks the native TD, evaded binding to endogenous p53. It
should be noted that a prominent secondary band is normally
Table 2. Comparison of the Four Different Cell Lines
(HeLa, MDA-MB-231, MCF-7, and H1373) in Terms of p53
Status and Cancer Type
cell line p53 Status cancer type ref
HeLa wild-type cervical adenocarcinoma 40
MDA-MB-231 mutated (R280K) triple-negative breast
cancer
41
MCF-7 mislocalized to
cytoplasm
breast cancer 42
H1373 null non-small cell lung
carcinoma
43
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detected by this anti-p53 antibody at about 69 kDa (per Santa
Cruz Biotechnology).
Bypassing the Dominant Negative Effect. Since p53-
CC did not interact with endogenous wt-p53 in the co-IP assay,
the ability of p53-CC to bypass the dominant negative effect
was tested, first using overexpression of a dominant negative
mutant p53 in H1373 cells (p53 null), and second, in MDA-
MB-468 cells that harbor a strong dominant negative p53
mutant.50 The ability of p53-CC to “rescue” the loss of
apoptotic activity induced by an inactive mutant p53 in H1373
(p53 null) cells was tested; Figure 7A shows that, in the
absence of the inactive mutant p53 (first three sets of bars),
both p53-CC and wt-p53 can similarly induce apoptosis
(measured by 7-AAD) compared to the negative CC control.
However, when a transdominant mutant p53 is added (bars 4−
6), only p53-CC is able to rescue apoptotic activity, while wt-
p53 cannot. We engineered this transdominant mutant p53 by
combining three hotspot mutations (R175H, R248W, and
R273H) that are known to exhibit a dominant negative
effect.27,28 This supports the notion that p53-CC can bypass the
dominant negative effect of a transdominant mutant p53. To
further investigate this, the ability of p53-CC to induce
apoptosis was tested in a cell line known to contain an
endogenous strong transdominant mutant form of p53, MDA-
MB-468.51 The endogenous p53 in MDA-MB-468 contains the
R273H point mutation that is known to exhibit transdominant
inhibition of wt-p53, so exogenous wt-p53 in this case would be
expected to have limited activity. MDA-MB-468 cells are
resistant to transient transfection with lipofectamine (used in
the majority of these studies), so instead, they were transduced
with adenovirus (Ad) constructs carrying the wt-p53 or p53-
CC as genetic cargo. Figure 7B shows that, indeed, only Ad-
p53-CC (second bar) is able to significantly induce apoptotic
activity measured by 7-AAD compared to wt-p53 and empty Ad
vector (bars 1 and 3, respectively). This suggests that the
transdominant effect of endogenous mutant p53 found in
MDA-MB-468 cells can be circumvented by using an
oligomerization variant of p53, namely, p53-CC. Finally, we
also tested adenovirally delivered p53-CC in a p53 null cell line
(Figure 7C), where both wt-p53 and p53-CC should be active.
Indeed, as shown in Figure 7C, both constructs are active in
this cell line. Interestingly, p53-CC is more active than wt-p53
in this particular cell line.
■ DISCUSSION
To summarize, our data show that a version of p53 with an
alternative tetramerization domain localizes to the correct
subcellular compartment (the nucleus, Figure 2B), and shows a
similar gene expression profile as wt-p53 (Figure 3A). Two
genes regulated by p53, Bax, and p21/WAF1 also showed
similar protein expression levels when induced by p53-CC or
wt-p53, as demonstrated by Western blotting (Figure 3B).
Tumor suppressor activity, measured apoptotic activity (by
TUNEL, annexin V, and 7-AAD) and reduced oncogenic
potential (reduced number of colonies), Figure 4A−D, was
similar between p53-CC and wt-p53. Importantly, p53-CC was
found to induce statistically significant levels of apoptosis in
four different cell lines (Figure 5A−D), regardless of p53 status,
Figure 5. 7-AAD assay conducted in four different cell lines with varying p53 status: (A) Hela, (B) MDA-MB-231, (C) MCF-7, and (D) H1373. In
all four cases, p53-CC is capable of inducing cell death in a similar fashion compared to wt-p53, regardless of the endogenous p53 status or the
cancer cell line used. Statistical analysis was performed using one-way ANOVA with Bonferroni’s post test; **p < 0.01 and ***p < 0.001.
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indicating that p53-CC activity is not dependent on p53 status,
nor is it cell-line specific (see Table 2). The transcriptional
activity of p53-CC was tested using three reporter gene assays
in Figure 6A−C (a standard p53 reporter gene, a p21/WAF1
reporter involved in cell cycle arrest, and a PUMA reporter
involved in apoptosis) and, in all three cases, was higher than
wt-p53. In T47D cells, the transcriptional activity of p53-CC
was higher than wt-p53 in these reporter gene assays (Figure
6A−C), while the apoptotic activity of p53-CC was similar to
wt-p53 (Figure 4A−C). This is not unexpected, since
transcriptional activity does not necessarily linearly correlate
with apoptotic activity. Transcriptional activity of target genes is
a prerequisite step prior to the apoptotic cascade; if a threshold
of transcriptional activity is met, the downstream measure of
apoptosis may not change significantly. Interestingly, the
negative controls (p53ΔTDC and CC) did not have activity
in binding nor were able to express apoptotic or cell cycle arrest
genes.
A co-IP was performed and showed that p53-CC did not
interact with endogenous p53 (Figure 6D). Since there was no
interaction between p53-CC and endogenous p53, the ability of
p53-CC to bypass the dominant negative effect was tested, first
with transdominant mutant p53 overexpression (Figure 7A),
and second, in MDA-MB-468 cells that harbor a tumor-derived
endogenous transdominant negative p53 mutant (Figure 7B).
In both cases, p53-CC appears to not be effected by this
endogenous transdominant inhibition. Finally, adenovirally
delivered p53-CC was also tested in a p53 null cell line and
was active, as expected (Figure 7C).
Mutant p53 retains its tetramerization capability since its TD
remains intact and can form inactive p53 tetramers upon the
introduction of exogenous wt-p53 in cancer cells (Figure 1, left
side). These heterotetramers have a significantly reduced
transcriptional activity compared to homotetramers of p53-
CC. Such a phenomenon gives rise to a great barrier that limits
the utility of p53 for cancer therapy.11 As an approach to
prevent hetero-oligomerization, we investigated swapping the
TD with an alternative oligomerization domain (Table 1). The
CC from Bcr tetramerizes in a similar fashion as the TD; both
form dimers of two antiparallel-oriented monomers.52 To our
knowledge, only one attempt at substituting the TD of p53 to
eliminate the dominant negative effect of mutant p53 in
heterotetramers has been made, with marginal success.21 This
previous work utilized an oligomerization domain that leads to
parallel tetramer formation, whereas the native TD of p53
drives the formation of antiparallel tetramers.21−23 This might
offer an explanation to the significant reduction in p53 function
observed in their published activity assays21 compared to wt-
p53. On the other hand, our results show that p53-CC evades
hetero-oligomerization with mutant p53, allowing it to retain
the full tumor suppressor function of wt-p53.
Bcr, from which the CC was obtained, is a ubiquitous
eukaryotic phosphotransferase protein that may have a role in
general cell metabolism. Theoretically, p53-CC could interact
with Bcr via its CC domain. While this is a possibility, this may
be unlikely due to the compartmentation of Bcr (found in the
cytoplasm)53 vs p53-CC (found in the nucleus, shown in
Figure 2B). Bcr-knockout mice still survive; the major defect in
these mice was reduced intimal proliferation in low-flow carotid
Figure 6. Relative luminescence representing the activation of (A) the p53-cis reporter, (B) the p21/WAF1 reporter, and (C) the PUMA reporter in
T47D cells. The ability of p53-CC to transactivate these promoters is higher than wt-p53. In all three cases, 3.5 μg of construct (wt-p53, p53-CC,
CC, or EGFP) was cotransfected with 0.35 μg of pRL-SV40 plasmid encoding for Renilla luciferase to normalize for transfection efficiency. In
addition to Renilla luciferase, constructs were cotransfected with 3.5 μg of p53-Luc cis-reporter, p21/WAF1 reporter, or PUMA reporter encoding
for firefly luciferase. Mean values were analyzed using one-way ANOVA with Bonferroni’s post test; **p < 0.01 and ***p < 0.001. Error bars
represent standard deviations from three independent experiments (n = 3). (D) Interaction of endogenous p53 with exogenous wt-p53 or p53-CC
was investigated in T47D via co-IP. A representative cropped Western blot of protein complexes coimmunoprecipitated using anti-GFP antibody is
shown. Left lane, endogenous p53 (53 kDa) coimmunoprecipitates with exogenous EGFP-wt-p53 (70 kDa). Right lane, endogenous p53 fails to
coimmunoprecipitate with exogenous EGFP-p53-CC (71 kDa).
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arteries compared to wt mice.54 Bcr has mostly been studied in
the context of chronic myeloid leukemia (CML) where a
reciprocal chromosomal translocation with Abl results in the
fusion protein Bcr-Abl, the causative agent of CML.55 The
activity of Bcr-Abl is largely due to the constitutive activation of
the Abl portion of the molecule.56 Generally, Bcr may be
involved in inflammatory pathways and cell proliferation.54 We
have previously reported that the isolated Bcr coiled-coil does
not in itself induce apoptosis.26 Nevertheless, potential
inadvertent interaction with the CC oligomerization domain
of Bcr via any introduced p53-CC is currently being addressed
in our laboratory by introducing mutations in the CC domain
of p53-CC that will disfavor interactions with Bcr-CC.
Besides not interacting with endogenous p53, the elevation
in p53-CC transcriptional activity could also be due to a higher
stability of the p53-CC tetramer compared to wt-p53 tetramer.
We have reported that melting temperature (Tm) for CC is
about 83 °C,26 which is slightly higher than the Tm for TD
around 75 °C at physiological pH.57 In fact, our laboratory has
shown previously that CC forms homodimers in thermal
denaturation studies.26 However, further experiments would be
needed to definitively prove the biochemical tetramerization of
p53-CC.
Our results corroborate our hypothesis that, unlike wt-p53,
p53-CC can circumvent transdominant inhibition of mutant
p53, illustrating the potential of using p53-CC as an alternative
to wt-p53 for cancer gene therapy. Since the dominant negative
effect of mutant p53 in cancer cells is currently one of the
barriers limiting the use of p53 in cancer gene therapy,11 our
approach offers an alternative to overcome this barrier by
swapping the TD of p53 with an alternative oligomerization
domain while maintaining the tumor suppressor activity. Our
designed p53-CC is expected to cause apoptosis in many types
of cancers, especially in tumors with transdominant mutant
p53, where wt-p53 has proven to be ineffective. Ultimately, we
plan on utilizing the p53-CC construct as a gene therapeutic
delivered using an adenoviral vector that could replace the
current limited utility of wild-type p53 as a cancer therapeutic.
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ABSTRACT: The oncoprotein Bcr-Abl stimulates prosurvival pathways and
suppresses apoptosis from its exclusively cytoplasmic locale, but when targeted to the
mitochondrial compartment of leukemia cells, Bcr-Abl was potently cytotoxic.
Therefore, we designed a protein construct to act as a mitochondrial chaperone to
move Bcr-Abl to the mitochondria. The chaperone (i.e., the 43.6 kDa intracellular
cryptic escort (iCE)) contains an EGFP tag and two previously characterized motifs:
(1) an optimized Bcr-Abl binding motif that interacts with the coiled-coil domain of
Bcr (ccmut3; 72 residues), and (2) a cryptic mitochondrial targeting signal (cMTS;
51 residues) that selectively targets the mitochondria in oxidatively stressed cells
(i.e., Bcr-Abl positive leukemic cells) via phosphorylation at a key residue (T193) by
protein kinase C. While the iCE colocalized with Bcr-Abl, it did not relocalize to the
mitochondria. However, the iCE was selectively toxic to Bcr-Abl positive K562 cells as
compared to Bcr-Abl negative Cos-7 fibroblasts and 1471.1 murine breast cancer cells.
The toxicity of the iCE to leukemic cells was equivalent to 10 μM imatinib at 48 h and the iCE combined with imatinib potentiated cell
death beyond imatinib or the iCE alone. Substitution of either the ccmut3 or the cMTS with another Bcr-Abl binding domain (derived
from Ras/Rab interaction protein 1 (RIN1; 295 residues)) or MTS (i.e., the canonical IMS derived from Smac/Diablo; 49 residues) did
not match the cytotoxicity of the iCE. Additionally, a phosphorylation null mutant of the iCE also abolished the killing effect. The
mitochondrial toxicity of Bcr-Abl and the iCE in Bcr-Abl positive K562 leukemia cells was confirmed by flow cytometric analysis of
7-AAD, TUNEL, and annexin-V staining. DNA segmentation and cell viability were assessed by microscopy. Subcellular localization of
constructs was determined using confocal microscopy (including statistical colocalization analysis). Overall, the iCE was highly active
against K562 leukemia cells and the killing effect was dependent upon both the ccmut3 and functional cMTS domains.
KEYWORDS: cryptic MTS, Bcr-Abl, Bcr-Abl binding, coiled-coil, molecular chaperone
■ INTRODUCTION
The fusion oncoprotein, and constitutively active tyrosine
kinase, Bcr-Abl (autoinhibition of c-Abl kinase activity is lost in
Bcr-Abl fusion)1 is the central etiologic agent of chronic
myelogenous leukemia (CML) and is exclusively localized in
the cytoplasmic space at the plasma membrane primarily
through interactions with cytoskeletal actin.1 Directing a change
in Bcr-Abl’s subcellular location can change Bcr-Abl from an
oncogenic agent into a proapoptotic factor.2,3
Normal c-Abl fulfills a terminal role as a proapoptotic factor
when targeted to the mitochondria under a variety of cellular
insults.4,5 We previously demonstrated that direct targeting of
c-Abl to the mitochondria is toxic to leukemia cells.6 Therefore,
relocalizing Bcr-Abl to the mitochondria would mimic death-
directed mitochondrial c-Abl function, which is largely defunct in
CML cells.7,8 In this paper, as with c-Abl,6 the direct mito-
chondrial targeting of Bcr-Abl (by fusion to canonical MTSs
targeting the mitochondrial matrix,9 inner mitochondrial
membrane,10 and the intermitochondrial membrane space11)
was cytotoxic.
In light of this, we designed a small protein, the intracellular
cryptic escort (iCE), for the purpose of capturing and translocating
Bcr-Abl to the mitochondria. The Bcr-Abl capture motif employed
for the iCE was a previously optimized coiled-coil (i.e., the
ccmut3)12 which demonstrated both the ability to bind and, when
fused to four nuclear localization signals (NLS), move endogenous
Bcr-Abl to the nucleus.13 The ccmut3 oligomerizes with the coiled-
coil domain of the Bcr portion of Bcr-Abl while possessing a
reduced affinity for homodimer formation.12 We paired the ccmut3
with a “cryptic” mitochondrial targeting signal (cMTS) that is
activated by phosphorylation (by PKA and/or PKC) in a reactive
oxygen species dependent manner.6
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Despite the lack of iCE/Bcr-Abl mitochondrial localization
the iCE alone was selectively toxic to Bcr-Abl positive K562
cells to the same degree as 10 μM imatinib at 48 h. The killing
capacity of the iCE was ablated by substitution of either the
ccmut3 (with the Bcr-Abl binding domain of Ras and Rab
interactor 1 (RIN1-BD)14) or the cMTS (with the canonical
intermitochondrial membrane space targeting sequence (IMS)
from Smac/Diablo11) in two “mock” iCEs, the RIN-cMTS or
the IMS-ccmut3, respectively. The combination of the iCE with
imatinib was the most potent inducer of leukemic cell death.
This work demonstrates the selective killing of Bcr-Abl positive
cells by a designed Bcr-Abl coiled-coil interacting protein where
phosphorylation (via PKC and/or PKA) is coincident with the
cell death effect.
■ EXPERIMENTAL SECTION
Subcloning and Construction of Plasmids. pEGFP-Bcr-
Abl was constructed as previously described.3 Bcr-Abl DNA was
also cloned into pmCherry-C1 (Clonetech, Mountain View, CA,
USA) and pTagBFP-C (Evrogen, Moscow, Russia) at the EcoR1
site on both vectors creating pmCherry-Bcr-Abl and pBFP-Bcr-
Abl, respectively. The pOTC-EGFP-Bcr-Abl was created using an
oligonucleotide encoding the MTS from OTC (incorporating
the Kozak sequence), 5′-CCGGTCGCCACCATGCTGTTT-
AATCTGAGGATCCTGTTAAACAATGCAGCTTTTAGA-
AATGGTCACAACTTCATGGTTCGAAATTTTCGGTGT-
GGACAACCACTACAAAATAAAGTGCAGCGA-3′, which
was annealed to its complementary strand and subsequently
cloned into the AgeI site of EGFP-Bcr-Abl. The pIMS-EGFP-
Bcr-Abl, pIMS-EGFP, and pIMS-EGFP-ccmut3 were made by
annealing and ligating four oligonucleotides encoding the Kozak
sequence and IMS signal (1, (5′-phosphorylated) 5′-CCGGTG-
CCACCATGAGAAGCGTGTGCAGCCTGTTCAGATACA-
GACAGAGATTCCCCGTGCTGGCCAACAGCAA-3′; 2, 5′-
GAAGAGATGCTTCAGCGAGCTGATCAAGCCCTGGCA-
CAAGACCGTGCTGACCGGCTTCGGCATGACCCTGTG-
CGCCGTGCCCATCGGA-3′; 3, 5′-TGCCACCATGAGAA-
GCGTGTGCAGCCTGTTCAGATACAGACAGAGATTCC-
CCGTGCTGGCCAACAGCAAGAAGAG-3′; 4, (5′ phosp-
horylated) 5′-ATGCTTCAGCGAGCTGATCAAGCCCTGG-
CACAAGACCGTGCTGACCGGCTTCGGCATGACCCTG-
TGCGCCGTGCCCATCAGGACCGG-3′) followed by insertion
into the AgeI site of pEGFP-Bcr-Abl, pEGFP, or pEGFP-ccmut3,12
respectively. The inner mitochondrial membrane targeting sequence
(IMM) was incorporated into the pIMM-EGFP-Bcr-Abl and
pIMM-EGFP by annealing the 5′ phosphorylated oligonucleotide
encoding the Kozak sequence and IMM signal, 5′-CCGGTCGC-
CACCATGTCCGTCCTGACGCCGCTGCTGCTGCGGGG-
CTTGACAGGCTCGGCCCGGCGGCTCCCAGTGCCGCG-
CGCCAAGATCCATTCGTTGA-3′, with its reverse compliment
followed by ligation into the AgeI site of pEGFP-Bcr-Abl and
pEGFP-C1, respectively. The kinase dead mutant of pIMM-EGFP-
Bcr-Abl (i.e., pIMM-EGFP-Bcr-Abl-KD) was made using site
directed mutagenesis with the primer 5′-CTGACGGTGGCCGT-
GGCGACCTTGAAGGAGGAC-3′ and its reverse compliment.
The pRIN-cMTS construct was made by PCR amplifying the
binding domain of the human RIN1 gene (NM_004292, OriGene,
Rockville, MD, USA) with the primers 5′-GCGCGCGCGATCT-
ATGGAAAGCCCTGGAGAGTCAGGCGCG-3′ and 5′-GCG-
CGCGAATTCCCGTACCCCACTGAGCTCTCCCTCCGTA-
GCAGCTGGC-3′ and inserted into pEGFP-cMTS using the BglII
and EcoR1 sites. The murine glutathione S-transferase A4-4 [Swiss-
Prot: P24472.3] cMTS (N-terminal residues, 172−222)15 was
constructed by annealing four oligonucleotides encoding the cMTS
(1, (5′-phosphorylated) 5′-AATTCCGCCCCCGTGCTGAGCG-
ACTTCCCCCTGCTGCAGGCCTTCAAGACCAGAATCA-
GCAACATCCCCACCATCAAGAAGTTCCTGCAGCCC-3′; 2,
5′-CTGCCGGGCTGCAGGAACTTCTTGATGGTGGGGA-
TGTTGCTGATTCTGGTCTTGAAGGCCTGCAGCAGGG-
GGAAGTCGCTCAGCACGGGGGCGG-3′; 3, 5′-GGCAGC-
CAGAGAAAGCCCCCCCCCGACGGCCCCTACGTGGAG-
GTGGTGAGAACCGTGCTGAAGTTCGGCGCCGGCTGC-
TGCCCCGGCTGCTGCTGA-3′; 4, (5′ phosphorylated) 5′-
AATTTCAGCAGCAGCCGGGGCAGCAGCCGGCGCCGA-
ACTTCAGCACGGTTCTCACCACCTCCACGTAGGGGC-
CGTCGGGGGGGGGCTTTCTCTGG-3′) simultaneously and
then inserting the annealed product into the multiple cloning site
(MCS) of EGFP-C1 vector (Promega Biotech, Madison, WI),
with or without the ccmut3 sequence present, at the EcoRI
site creating pEGFP-cMTS6 (cMTS) and pEGFP-ccmut3-cMTS
(iCE), respectively. The pEGFP-ccmut3-cMTS null (S189A and
T193A) was created using site-directed mutagenesis using primers,
5′-GACCAGAATCGCCAACATCCCCGCCATCAAGAAGT-
TCCTGCAGCCCGGCAGCCAGAGAA-3′ and its reverse
compliment. All constructs were verified by sequence analysis.
Materials. RPMI-1640 medium, MitoTracker Red CM-
H2XRos (MitoTracker CMXros), Hoechst 33342 (cell permeable
nuclear stain), 7-aminoactinomycin D (7-AAD; DNA intercalating
dye permeable to dying or dead cells), annexin−APC (annexin-V
conjugated to allophycocyanin), staurosporine, Lipofectamine
LTX with Plus Reagent, trypan blue 0.4%, phosphate-buffered
saline (PBS), fetal bovine serum (FBS), and gentamycin were
purchased from Invitrogen (Carlsbad, CA). Penicillin−streptomy-
cin−L-glutamine (P-S-G; 100U/mL), DMEM media, and trypsin
were purchased from Gibco BRL (Grand Island, NY). The poly-
L-lysine (0.01% solution) was purchased from Sigma-Aldrich
(St. Louis, MO). Imatinib (CT-IM001) was purchased from
ChemieTek (Indianapolis, IN). QuikChange II XL Site-Directed
Mutagenesis Kit was purchased from Agilent Technologies (Santa
Clara, CA). Cell Line Nucleofector Kit V was purchased from
Lonza Group (Basel, Switzerland). Restriction enzymes (EcoRI,
AgeI, and BglII) were purchased from New England Biolabs
(Ipswich, MA).
Cell Lines and Culture Conditions. As previously
described,6 K562 cells (nonadherent human chronic myelog-
enous leukemia cell line), gift from Dr. K. Elenitoba-Johnson,
University of Michigan, and Cos-7 (monkey kidney fibroblast
adherent cell line; ATCC) were cultured in RPMI 1640
supplemented with 10% FBS, 1% P-S-G, and 0.1% gentamycin.
Murine mammary adenocarcinoma 1471.1 cells, (gift from
Gordon Hager, PhD, NCI, NIH) were grown as monolayers in
DMEM supplemented with 10% FBS, 1% P-S-G, and 0.1%
gentamycin. K562 cells were passaged at a density of 0.5 × 105/
mL every other day, for ten passages. Cos-7 and 1471.1 cells
were passaged at 80% confluency, split 1:10 in fresh media, and
discontinued after passage 15. All cells were maintained in a 5%
CO2 incubator at 37 °C.
Expression of Constructs in K562 Leukemia, Cos-7
Fibroblast, and 1471.1 Breast Cancer Cells. Constructs
were transiently transfected into K562 cells using the Amaxa
Nucleofector II, as described previously.3 Briefly, 1 × 106 K562
cells (initially seeded at a density of 0.5 × 105 cells/mL)
between passages 5 and 10, were pelleted and resuspended in
100 μL of Amaxa Solution V, combined with 2 μg of DNA, and
transfected in an Amaxa cuvette under program T-013.
Transfected cells were immediately transferred to a 25 cm2
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flask with 7 mL of prewarmed complete RPMI. Transient
transfection of 1471.1 and Cos-7 was carried out in two-well live-
cell chambers (Lab-Tek chamber slide system, Nalge NUNC
International, Naperville, IL) or sterile 6-well tissue culture plates
(Greiner CellStar, Greiner Bio-one GmbH) using Lipofectamine
LTX as per manufacturers’ instructions between passages 3 and
15 in antibiotic free media.
Cell Proliferation. Trypan blue exclusion was used to
determine cell proliferation (cell viability)16 in K562 cells 48 h
post-transfection of EGFP-C1, cMTS, ccmut3, cMTS, and iCE,
with and without the presence of imatinib (10 μM).
Western Blotting. As previously described,17 cell lysates
were prepared in lysis buffer (62.5 mM Tris-HCl, 2% w/v SDS,
10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue)
followed by standard blotting using antibodies to detect p-Bcr-
Abl, p-Crk-L, p-STAT5, and elF4E as the protein loading control.
Primary antibody labels (anti-pAbl (Y245), anti-pCrk-L (Y207),
and anti-elF4E, Cell Signaling Technology; anti-pSTAT5 (Y694),
Abcam) were detected with (#7074, Cell Signaling Technology)
secondary antibody prior to the addition of ChemiGlo
(AlphaInnotech, Cell Biosciences, Santa Clara, CA, USA)
chemiluminescent substrate and detection using a FluorChem
FC2 imager (AlphaInnotech).
Mitochondrial Staining. As previously described,6 aliquots
of transfected K562 suspension cells (400 μL) were plated into
poly-L-lysine coated 4-well live-cell chambers at least four hours
in advance of microscopy. Cells were incubated with
MitoTracker Red CM-H2XRos (K562, 100 nM; Cos-7 and
1471.1, 325 nM) for 45 min at 37 °C and protected from light
prior to imaging.
Microscopy. Fluorescent images of K562, Cos-7, and
1471.1 live cells were acquired on an Olympus IX81 FV1000-
XY spectral confocal microscope (Imaging Core Facility,
University of Utah) equipped with 405 nm diode, 488 nm
argon, and 543 nm HeNe lasers using a 60× PlanApo oil
immersion objective (NA 1.45) using Olympus FluoView software,
as previously described.6 Excitation and emission filters were as
follows: EGFP, 488 nm excitation, emission filter 500−530 nm;
MitoTracker Red CM-H2XRos, 543 nm excitation, emission filter
555−655 nm. Images were collected in sequential line mode with
exposure and gain of laser kept constant and below detected pixel
saturation for each group of cells. No channel crosstalk was
observed. Pixel resolution was kept at 1024 × 1024 (0−2.5-fold
digital zoom) with a pixel dwell time of 12.5 μs. Imaging of K562
cells for the analysis of DNA segmentation was acquired on an
Olympus IX71F fluorescence microscope (Scientific Instrument
Company, Aurora, CO) with a 60× PlanApo oil immersion
objective (NA 1.4) on an F-view monochrome CCD camera.
K562 cells were stained with the nuclear dye Hoechst 33342
(Invitrogen, Carlsbad, CA) at a concentration of 4 μM.
Image Analysis. Images were analyzed as previously
described.6 Briefly, original images were converted to 8-bit,
then stacked as separate channels, and corrected for back-
ground noise using ImageJ plugin “BG subtraction from
background” in default mode (i.e., mean background intensity
outside of cells was subtracted).18 Image and statistical analysis
was performed with JACoP plugin in ImageJ.19 Pearson’s
correlation coefficient (PCC) was generated using Costes’
automatic threshold algorithm.20,21 The PCC is dependent
upon both the pixel intensity and overlap of signal and has a
range of +1 (complete colocalization) to −1 (anticorrelation)
with zero correlating with random distribution between
comparators.19 The PCC threshold for defining colocalization
(i.e., colocalization due to cocompartmentalization) is 0.6 as
per Bolte and Cordelier̀es.19 Channels have been false-colored
(cyan and magenta) using ImageJ LUT for increased visual
clarity. Additionally, spatial representation of intensity
correlation was included using the Colocalization Colormap
ImageJ plugin. “Colormap” displays positively correlated pixels
in hot colors and negatively correlated pixels in cold colors that
can be visually interpreted using the color scale bar.22
Identification of segmented nuclei was performed using the
nuclear dye H33342 on K562 cells displaying green
fluorescence 24 h post transfection.
7-AAD Assay. Flow cytometric assay of cell death was done
as previously described.12 Briefly, K562, Cos-7, or 1471.1 cells
were resuspended in 500 μL of ice cold PBS containing 1 μM
7-aminoactinomycin D (7-AAD) for 30 min prior to analysis.
Cells that have compromised membrane integrity (late
apoptosis/necrosis) are permeable to 7-AAD.23 Medium from
adherent Cos-7 and 1471.1 cells was collected prior to
trypsinization of cell monolayer and recombined with the
enzymatically released cell population for centrifugation and
subsequent resuspension. Analysis and gating was performed on a
BD FACSCanto II (Flow Cytometry Core Facility, University of
Utah) using BD FACSDiva software (BD Biosciences, Franklin
Lakes, NJ). At least three separate experiments (n ≥ 3) in
duplicate were performed. Compensation controls were included
with each experiment.
TUNEL Assay. As previously described,24 detection of DNA
strand breaks in the K562 cell line was performed using the
In Situ Death Detection Kit, TMR red (Roche, Mannheim,
Germany), as per the manufacturers’ protocol. Terminal
deoxynucleotidyl transferase (TdT) dUTP nick-end labeling
(TUNEL) detects cells that have extensive DNA degradation in
late stage apoptosis/necrosis.25 Samples were run on a Becton-
Dickinson FACSAria-II (BD-BioSciences, University of Utah Core
Facility) using the 488 nm (for EGFP) and 563 nm (TMR red)
laser lines with FACSDiva software. Analysis was performed on
EGFP positive cells using preset gates. The TMR red positive cells
were detected in the PE (phycoerythrin) channel. Each construct
was assayed in at least triplicate (n ≥ 3).
Annexin-V Assay. Annexin-V binding was assessed, as
previously described,24 48 h post-transfection in K562 cells.
Externalized phosphatidylserine in the plasma membrane is
indicative of early apoptosis and is bound specifically by annexin
V.26 K562 cells were suspended in 100 μL of annexin binding
buffer (Invitrogen) and incubated with 5 μL of annexin-V con-
jugated to allophycocyanin (annexin−APC, Invitrogen) for 10 min.
The incubated cells were then diluted in 400 μL of annexin
binding buffer and analyzed using the FACSCanto-II (BD-
BioSciences, University of Utah Core Facility) with FACSDiva
software. EGFP (excitation 488 nm and emission 507 nm) and
APC (excitation 635 nm and emission 660 nm) fluorescence was
collected. Analysis was conducted on EGFP-positive cells using
preset EGFP gates. Each construct was tested in triplicate (n = 3).
Statistics. Data are shown as mean ± SEM, with one-way
ANOVA using Tukey’s post hoc test or two-way ANOVA using
the Bonferroni post-test (as indicated in the figure legends) to
compare measurements between experimental data with an N
of 3 or greater. Statistical significance was set at p < 0.05 (by
convention p < 0.05 is represented with *; p < 0.01 with **;
p < 0.001 with ***). GraphPad Prism Graph 4 (GraphPad, La
Jolla, CA) software was used for generating statistics.
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■ RESULTS
Targeting Bcr-Abl to the Mitochondria Induces Cell
Death in K562 Leukemia Cells. Cell death evaluated by flow
cytometric analysis of 7-AAD (DNA accessibility) and
annexin−APC (phosphatidylserine externalization) staining
(Figure 1) showed the toxic consequences of mitochondrially
targeted Bcr-Abl (Figure 1, third column) at 24 h post-transfection
in K562 cells. DNA segmentation analysis of K562 cells with
mitochondrially targeted Bcr-Abl also revealed the same pattern
(data not shown). The IMM-Bcr-Abl was created by fusing Bcr-
Abl to a canonical mitochondrial targeting signal (MTS; derived
from cytochrome c oxidase subunit VIII) that is widely used to
direct proteins to the mitochondria and the inner mitochondrial
membrane in particular (IMM; see Table 1).10 Interestingly, the
kinase dead version (i.e., mutation of a single critical lysine ablates
the capacity for kinase activity) of mitochondrially targeted Bcr-
Abl (IMM-Bcr-Abl-KD; see Table 1) yields no statistical difference
in cell death to that of IMM-Bcr-Abl (compare Figure 1, third and
fourth columns). Furthermore, mitochondrially targeted Bcr-Abl
and Bcr-Abl-KD (Figure 1, third and fourth columns) significantly
induced more cell death as compared to the gold standard of
current CML therapy, imatinib (IM; 10 μM) (Figure 1, second
column) at 24 h.
In addition to the IMM, Bcr-Abl was also targeted to the
mitochondrial matrix (OTC-Bcr-Abl) and IMS (IMS-Bcr-Abl)
(Table 1). Figure 2A shows representative images of E-Bcr-Abl
or mitochondrially targeted Bcr-Abl in K562 cells compared to
MitoTracker CMXros (MitoTracker) dye. The E-Bcr-Abl
construct was not associated with the mitochondria (Figure 2A,
compare first column with second, “MitoTracker” column), but
each of the mitochondrially targeted Bcr-Abl constructs did
Figure 1. Direct targeting of Bcr-Abl to the mitochondria causes
leukemic cell death. Flow cytometric analysis of EGFP positive K562 cells
24 h post-transfection stained with 7-AAD and annexin−APC. Both
IMM-Bcr-Abl and the kinase dead version (IMM-Bcr-Abl-KD) displayed
higher cell death than imatinib or mitochondrially targeted EGFP (IMM-
EGFP). Statistical differences were determined using a one-way ANOVA
with Tukey’s post hoc test (error bars are ±SEM, N ≥ 4).
Table 1. Canonical Mitochondrial Targeting Sequences
Used To Target Bcr-Abl to the Mitochondriaa
construct target compartment kinase reference
OTC-Bcr-Abl mitochondrial matrix active 9
IMS-Bcr-Abl mitochondrial intermembrane
space
active 11
IMM-Bcr-Abl mitochondrial inner membrane active 10
IMM-Bcr-Abl-
KD
mitochondrial inner membrane inactive 27
IMM-EGFP mitochondrial inner membrane N/A 24
E-Bcr-Abl cytoplasmic (nontargeted) active 3
aMTSs targeting different mitochondrial compartments were fused to
Bcr-Abl and tested for cellular toxicity. KD represents a kinase dead
version of Bcr-Abl where a so-called “essential lysine” residue is
mutated at the ATP binding site, abolishing all kinase activity.27
Figure 2. Submitochondrial targeting of Bcr-Abl in K562 leukemia cells.
(A) Representative images of E-Bcr-Abl or Bcr-Abl fused to a canonical
MTS in K562 cells and compared to MitoTracker CMXros staining. Each
of the MTS-Bcr-Abl constructs localizes to the mitochondria while the
nontargeted E-Bcr-Abl remains cytosolic. Channel one (EGFP) and
channel two (MitoTracker) have been false-colored, cyan and magenta.
Colocalized cyan and magenta pixels show as white in merged
(“composite” column) images. The “Colormap” (far right column) is a
visual representation of pixel correlation both in space and in intensity
with positive correlation shown as hot colors and negative correlation in
cooler colors and can be interpreted using the color scale bar (shown at
bottom of the “Colormap” column). Scale bars are 5 μm. (B) Cell death
as determined by 7-AAD staining in K562 cells 48 h post transfection.
Statistical differences were determined using a one-way ANOVA with
Tukey’s post hoc test (error bars are SEM, N ≥ 3).
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localize (Figure 2A, second through fourth rows) to the mito-
chondria. The corresponding EGFP-only constructs (i.e., IMM-
EGFP, IMS-EGFP, and OTC-EGFP) were also tested and
exhibited mitochondrial localization and low toxicity. Therefore,
only data on the IMM-EGFP is shown (Figure 1, IMM-EGFP).
We further characterized the effects of targeting Bcr-Abl to the
mitochondrial matrix with the OTC MTS in Cos-7 and 1471.1
cells (Figure S1 in the Supporting Information).
In K562 cells, the OTC and the IMM fused Bcr-Abl
constructs were significantly more toxic (7-AAD positive) than
the nontargeted E-Bcr-Abl (Figure 2B, compare fourth and fifth
columns to second column) at 48 h post-transfection. Yet, there
was no difference in toxicity between the individual MTS-Bcr-
Abl constructs (Figure 2B, compare third, fourth, and fifth
columns).
The iCE Exhibits Selective Toxicity to Bcr-Abl Positive
K562 Cells. Since Bcr-Abl targeted to the mitochondria is toxic
(Figure 1, third column), we designed a bimodal construct (intra-
cellular cryptic escort (iCE)) using a previously characterized
cMTS6 and our optimized Bcr-Abl binding domain, ccmut312
(see Figure 3 for description of constructs). The iCE and its
component parts (i.e., EGFP, ccmut3, and cMTS; Figure 3) were
transfected into Bcr-Abl positive K562 and Bcr-Abl negative
Cos-7 and 1471.1 cell lines. The cell death profiles, as measured
by flow cytometric analysis of 7-AAD staining, demonstrated a
cell type-dependent response to the constructs. The iCE was toxic
only in the K562 cell line (Figure 4A, K562, iCE column) as was
imatinib (Figure 4A, K562, IM column). There was no significant
difference in Cos-7 or 1471.1 between treatment with imatinib
or the constructs individually with the exception of 1471.1 cells
with the iCE combined with imatinib (Figure 4C, 1471.1,
iCE + IM column). This was not evidenced in Cos-7 where the
combination of imatinib and the iCE was not toxic (Figure 4B,
Cos-7, iCE + IM column). In contrast, within K562 cells imatinib
and the iCE were not different from one another (Figure 4A,
K562, compare iCE to IM columns) but both were different from
the EGFP control and the iCE components (Figure 4A, K562,
EGFP, ccmut3, and cMTS columns). The iCE when combined
with imatinib (Figure 4A, K562, iCE + IM column) had the
greatest killing effect.
Figure 5A includes the components comprising the iCE (i.e.,
EGFP, ccmut3, and cMTS) combined with imatinib. There was
no difference between imatinib alone and the individual
components of the iCE combined with imatinib (Figure 5A,
compare IM with EGFP+IM, ccmut3 + IM, and cMTS + IM).
The cMTS alone was not different from imatinib, however
when compared to the iCE alone (Figure 5A, compare cMTS
to iCE) the difference was extremely significant (P < 0.001).
Overall, the iCE + IM was significantly different (P < 0.001) in
its killing potential when compared to all constructs regardless
of imatinib treatment (Figure 5A, compare iCE + IM to EGFP
+ IM, ccmut3 + IM, and cMTS + IM).
Representative histograms (Figure 5B) from a set of K562
cells transfected and/or treated (imatinib (10 μM) or positive
control staurosporine (1 μM)) at 48 h demonstrate the dif-
ference in dead cells when the iCE and imatinib are combined
Figure 3. Domain arrangement of constructs. RIN-BD = Abl binding domain from the Ras and Rab interactor 1 (RIN1; binds the SH3/SH2
domains of Bcr-Abl), IMS = intermitochondrial membrane space, ccmut3 = coiled-coil mutation set 3, cMTS = cryptic mitochondrial translocation
sequence, Bcr = breakpoint cluster region, Abl = Abelson proto-oncogene, EGFP = enhanced green fluorescent protein. See Figure S2 in the
Supporting Information for domain residue sequences.
Figure 4. Cell death in Bcr-Abl positive (K562 leukemia) and Bcr-Abl negative (Cos-7 fibroblast and 1471.1 breast cancer) cells 48 h post-
transfection or treatment with 10 μM imatinib. Cell death was assessed by flow cytometric analysis of 7-AAD. (A, left) K562 cells. (B, middle) Bcr-
Abl negative Cos-7 cells. (C, right) 1471.1 breast cancer cells. One-way ANOVA with Tukey’s post-test performed on individual cell types (error
bars are SEM, N ≥ 3).
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(Figure 5B, compare staurosporine or imatinib to iCE +
imatinib). The vertical line within the plot is the gate for
7-AAD positive cells for which the percent is listed in the
shaded box. As expected, a similar cell death pattern was seen
using a different cell permeable nuclear stain (H33342) to
identify nuclear segmentation by microscopy3 (Figure 5C,
compare imatinib only (top right set) to iCE + imatinib (lower
right set)). The relative health of the cells was revealed by
phase contrast as well, where the cells treated with imatinib and
the iCE evidence the sequelae of apoptosis/necrosis (e.g., cell
shrinkage/swelling and membrane blebbing)3 in comparison to
the untreated control (e.g., round cells with intact membranes)
(Figure 5C, compare “Phase” of iCE, “no treatment” and
“imatinib” to control, “no treatment”). The combined treat-
ment of imatinib and the iCE increases DNA segmentation
(Figure 5C, compare the stained nuclei of the iCE, “no
treatment” and “imatinib” to iCE, with “imatinib”). The peak
time for iCE + IM killing of K562 is 48 h (Figure 5D) whereas
it is later for imatinib alone (10 μM imatinib kills most
K562 cells by approximately 72 to 96 h, our unpublished
observations).
Cell Viability Decreases and Apoptosis Increases
When the iCE Is Combined with Imatinib. Trypan blue
exclusion (cell viability), terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL), and phosphatidylserine
(PS) externalization (annexin-V binding) demonstrated the
antileukemic activity of the iCE in K562 cells (Figures 6A, 6B,
and 6C, respectively).
Cell viability was significantly decreased for the iCE compared
to EGFP and ccmut3 but not the cMTS (Figure 6A, compare
Figure 5. The iCE combined with imatinib is toxic to K562 cells. (A) This figure is an expansion of the data set seen in Figure 4A, K562 (cell death
in K562 at 48 h). Box and whisker plot showing percent 7-AAD positive cells 48 h post-transfection and/or treatment with imatinib. The darker
shaded boxes (of the box plot) represent the presence of imatinib (10 μM). Statistical differences were determined using one-way ANOVA with
Tukey’s post hoc test (error bars are SEM, N ≥ 4). (B) Representative set of flow cytometric histograms displaying cell count on the y-axis and
7-AAD intensity on the x-axis. The percent 7-AAD positive (as gated) for the sample is listed in the shaded box, and the mean (Figure 4A, K562)
and median values (Figure 5A) are listed below. (C) Phase-contrast paired with fluorescent images using the nuclear dye, H33342, at 48 h post-
transfection (iCE) or imatinib treatment. Upper left, control K562 cells; lower left, cells transfected with iCE construct; upper right, cells treated with
imatinib only; lower right, cells transfected with the iCE and treated with imatinib. White arrow in bottom, rightmost panel indicates a cell with a
segmented nucleus. Scale bar is 20 μm. (D) Evaluation of 7-AAD positive K562 cells at 8, 24, and 48 h post-transfection and/or imatinib treatment.
Statistical difference was determined for the parameters of time and treatment using two-way ANOVA with Bonferroni post test (error bars are SEM,
N ≥ 3).
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“no treatment”, iCE to EGFP and ccmut3 data points). However,
the decline in cell viability with imatinib present (Figure 6A,
“IM”) was extremely significant for the iCE when compared to
the other component constructs. The cell viability assessment
was completed 48 h post-transfection but 24 h post-addition of
imatinib (IM). Reducing the incubation time, for this assay, with
imatinib to 24 instead of 48 h allowed better discernment of
viable cells (e.g., Figure 5C, bottom row, third column, “Phase”
for iCE + imatinib demonstrates the lack of cells with intact
plasma membranes). The level of apoptosis as determined by
TUNEL and annexin−APC staining (in contrast to 7-AAD
staining which detects late-stage necrotic/apoptotic cells)28
was extremely significant for the combined iCE + IM when
compared to IM treated K562 cells (Figure 6B, iCE + IM vs IM;
or Figure 6C, compare iCE + IM to ccmut3 + IM and cMTS +
IM). Both assays were completed 48 h post-transfection and/or
imatinib (10 μM) treatment and analyzed by flow cytometry.
The iCE Colocalizes with Bcr-Abl. Figure 7A shows the
cellular localization of the EGFP-tagged iCE or its components
(see Figure 3 for domain arrangement of constructs)
coexpressed with exogenous Bcr-Abl (labeled with either blue
or mCherry fluorescent proteins) in Cos-7 cells. The iCE, like
the ccmut3 alone, colocalizes (defined as a Pearson correlation
coefficient (PCC) greater than 0.6 as established by Bolte and
Cordelier̀es)19 with Bcr-Abl (Cos-7, Figure 7A, fourth row,
PCC = 0.63 ± 0.04; and 1471.1, Figure 7B, PCC = 0.83 ±
0.05). The colocalized iCE/Bcr-Abl exhibits a punctate pattern
in both Cos-7 and 1471.1 cells which was different from the
typical diffuse pattern of colocalized ccmut3/Bcr-Abl (Figure 7A,
compare second row, first column (Bcr-Abl with ccmut3
present) to fourth row, first column (Bcr-Abl with iCE present)).
Figure 6. Assessment of cell viability and apoptotic induction in K562
cells. (A) Viability 48 h post-transfection and 24 h after addition of
imatinib. One-way ANOVA with Tukey’s post hoc test was performed
within each treatment type (i.e., “no treatment” and “IM”). (B)
Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) was assessed 48 h post-transfection and/or with imatinib
treatment by flow cytometry. (C) Phosphatidylserine externalization
detection using annexin−APC and flow cytometric analysis 48 h post-
transfection and/or imatinib treatment. Dark shaded columns indicate
imatinib treatment. Statistical differences were determined by using
one-way ANOVA with Tukey’s post hoc test (for all assays here, error
bars are SEM, N ≥ 3).
Figure 7. Representative images of exogenous Bcr-Abl coexpressed
with the iCE or its individual components and cMTS mitochondrial
localization. Scale bars are 5 μm. (A) Comparison of subcellular
localization and association between Bcr-Abl (first column, cyan) and
the iCE or iCE component parts (second column, magenta) in Cos-7
cells. The PCC values in the “Composite” column represent the
degree of colocalization between Bcr-Abl and the given construct. (B)
Coexpression of Bcr-Abl (first column, cyan) and the iCE (second
column, magenta) in 1471.1 cells with PCC value below the
“composite” image. (C) cMTS expression in K562 and 1471.1 cells
(first column, cyan) with MitoTracker staining (second column,
magenta).
Molecular Pharmaceutics Article
dx.doi.org/10.1021/mp3003539 | Mol. Pharmaceutics 2012, 9, 3318−33293324
The cMTS and EGFP, as expected, do not colocalize with
Bcr-Abl in Cos-7 cells (Cos-7: Figure 7A, third row, PCC =
0.3 ± 0.1, for cMTS and Bcr-Abl and Figure 7A, first row, PCC =
0.02 ± 0.03, for EGFP and Bcr-Abl). The cMTS alone localized
to the mitochondria (Figure 7C, cMTS in K562 (top) and
1471.1 (bottom) compared to MitoTracker) in K562 and 1471.1
cells with higher oxidative backgrounds but not in the “low ROS”
Cos-7 (Figure 7A, third row from top).6
The iCE Did Not Associate with the Mitochondria.
Unlike the cMTS alone which colocalized with the mitochon-
dria in both K562 and 1471.1 cells6 (Figure 7C), the iCE
remained cytoplasmic in its distribution across all three cell
types (Figure 8, compare “iCE” column to “MitoTracker”
column, first through third rows). In K562 cells the ccmut3
alone colocalized with Bcr-Abl and the cMTS alone colocalized
with the mitochondria (Figure 7C, top), but the iCE did not
localize to the mitochondria (Figure 8, first row).
The difference between the iCE and the iCE Null are the
S189A and T193A mutations preventing phosphorylation at
these sites in the cMTS domain of the iCE Null (Figure 3).
Incorporating S189A and T193A mutations (i.e., iCE-Null, see
Figure 3) led to a qualitative distribution difference between the
iCE (punctate looking) and the diffuse iCE Null (Figure 8,
compare “iCE” in the first row with “iCE Null” in the bottom row).
The Toxic Effect of the iCE on K562 Cells Is Lost upon
Substitution of the cMTS or the ccmut3 with Another
Canonical MTS or Bcr-Abl Binding Domain. When the
ccmut3 is substituted for another Bcr-Abl binding domain (i.e.,
RIN-BD)14 to create a mock iCE (Figure 3, RIN-cMTS), the
cytotoxic effect remains equivalent to the cMTS alone, and the
concomitant use of imatinib does not potentiate toxicity
beyond that of imatinib alone (Figure 9A, RIN-cMTS and RIN-
cMTS + IM columns). Furthermore, substituting the cMTS
with a canonical IMS MTS,11 (Figure 3, IMS-ccmut3)
diminished toxicity to that of the ccmut3 alone, or upon the
addition of imatinib, no more toxicity than imatinib alone
(Figure 9A, IMS-ccmut3 and IMS-ccmut3 + IM columns). The
mock iCEs localize to different subcellular compartments
(Figure 9B, compare top (IMS-ccmut3) and bottom (RIN-
cMTS) rows). The IMS-ccmut3 localizes to the mitochondria
(Figure 9B, top row, compare “IMS-ccmut3” to “MitoTracker”
columns) while the RIN-cMTS remains cytoplasmic (Figure 9B,
bottom row, compare “RIN-cMTS” to “MitoTracker” column).
The cellular distribution of IMS-ccmut3 (mitochondrial) and
RIN-cMTS (cytoplasmic) remained the same in the presence of
10 μM imatinib (data not shown).
The Toxic Effect of the iCE Is Dependent upon the
Key Phospho Residues in the cMTS Domain. Incorporat-
ing S189A and T193A mutations (i.e., iCE-Null, see Figure 3)
into the cMTS domain of the iCE leads to a significant
reduction in cell death (i.e., 7-AAD) and apoptosis (e.g.,
annexin−APC) in K562 cells at 48 h (Figures 10A and C,
compare iCE to iCE Null columns). However, this effect is
Figure 8. Representative images of the subcellular localization of the
iCE (or iCE Null, see Figure 3) in K562, Cos-7, and 1471.1 cells and
compared to MitoTracker. The iCE did not localize to the
mitochondria of K562, Cos-7 or 1471.1 cells. Scale bars are 5 μm.
Figure 9. Domain substitution of either the ccmut3 or the cMTS in
the iCE. (A) Flow cytometric analysis for 7-AAD was measured 48 h
post-transfection and/or treatment. IM, iCE, iCE + IM, ccmut3, and
cMTS values are also in Figure 4A. Imatinib is 10 μM. Statistical
differences were determined using one-way ANOVA with Tukey’s post
hoc test (error bars are SEM, N ≥ 3). (B) Representative images of the
subcellular localization of the mock iCE constructs (first column),
IMS-ccmut3 (top) and RIN-cMTS (bottom), in K562 cells stained
with MitoTracker (second column). Scale bars are 5 μm.
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more pronounced in combination with imatinib (Figures 10A
and 10C, compare iCE + IM to iCE Null + IM columns). The
trend is similar for TUNEL staining but did not reach statistical
significance (Figure 10B).
■ DISCUSSION
The ubiquitously expressed tyrosine kinase c-Abl has a
proapoptotic function at the mitochondria, and we have
previously demonstrated that direct targeting of c-Abl to the
mitochondria induces K562 leukemia cell death.6 Based on this
we have targeted the constitutively active and oncogenic form
of c-Abl (i.e., Bcr-Abl) to the mitochondria. Bcr-Abl is the
causative agent for the vast majority of CML cases, and was
directed to the mitochondria as a proof of concept that
mitochondrial Bcr-Abl could effectively be used to destroy
diseased cells. Yet, the mitochondrial substrates(s) and
submitochondrial localization of the proapoptotic c-Abl are
not known.5,6 Therefore, in order to investigate the potential
antileukemic activity of a “surrogate death-directed c-Abl,” in
the form of mitochondrial Bcr-Abl, we targeted exogenous Bcr-
Abl by fusion with different MTSs to three submitochondrial
regions (Table 1). Similar to mitochondrial c-Abl, Bcr-Abl
was toxic when targeted to the mitochondria of CML cells
(Figure 1, third column). Unlike c-Abl,29 Bcr-Abl’s mitochon-
drial cytotoxic effect was independent of its kinase activity
(Figure 1, fourth column). However, there are instances where
the kinase activity of c-Abl is dispensable for the induction of
apoptosis (e.g., via p38 MAPK).30 Overall, the tyrosine kinase-
independent killing of CML cells is compelling because it
suggests that the strategy of targeting Bcr-Abl to the mito-
chondria would be compatible with and complementary to
current tyrosine kinase inhibitor (TKI) therapy.
This led to an attempt to move endogenous Bcr-Abl by
means of a designed chaperone protein (Figure 3, schematic of
constructs) to exploit the toxicity of mitochondrial Bcr-Abl.
The intracellular cryptic escort (iCE) was constructed for the
purpose of binding and translocating endogenous Bcr-Abl to
the mitochondria. Both the ccmut3 and cMTS domains which
comprise the iCE have been previously characterized.6,12
The activation and mitochondrial targeting of the cMTS is
limited to cell types with an elevated ROS phenotype.6 K562
cells exhibit high basal levels of ROS, which is a common
pathophysiological feature of malignancy.31,32 The elevated
oxidative stress level leads to an increase in active PKA and
PKC which, in turn, phosphorylate (residues S189 (PKA) and/
or T193 (PKC)) and thereby “activate” the cMTS to induce
mitochondrial translocation in a Hsp70 dependent manner.6,15
Moreover, the cMTS demonstrated robust and selective
mitochondrial targeting when fused to c-Abl (i.e., Abl-cMTS)
in K562 cells.6
The ccmut3 Bcr-Abl binding protein oligomerizes in an
antiparallel orientation with the coiled-coil domain of Bcr-Abl.12
Dixon et al. demonstrated that the ccmut3 efficiently bound to
and translocated Bcr-Abl to the nucleus when fused to four strong
nuclear localization signals (NLS).13 However, cell death from
nuclear entrapment or nuclear targeting of Bcr-Abl is less when
compared to mitochondrially targeted Bcr-Abl. For instance, K562
cell death assessed by nuclear segmentation analysis 24 h post-
transfection with 4NLS-Bcr-Abl or IMM-Bcr-Abl yielded a mean
of 12%3 versus 88%, respectively (data not shown).
Consistent with the cytotoxicity (7-AAD staining) elicited by
the direct mitochondrial targeting of Bcr-Abl at 48 h (Figure 2B,
third through fifth columns), the iCE also induced cell death
(Figure 4A, iCE column) to a similar level within the same time
frame. However, subcellular compartmental analysis of confocal
images comparing between the mitochondria (stained with
MitoTracker) and fluorescent protein tagged iCE and/or Bcr-
Abl did not indicate any mitochondrial accumulation of the iCE
or iCE/Bcr-Abl (Figure 9, compare iCE column to MitoTracker
column, K562 cells). Therefore, the cytoplasmically localized
iCE and the mitochondrially targeted Bcr-Abl (MTS-Bcr-Abl)
are likely inducing cell death by different mechanisms.
Our experience with NLS (e.g., one NLS was insufficient to
move Bcr-Abl but four NLS were sufficient)3 suggested that
perhaps the “strength” of the cMTS (within the iCE) was not
sufficient to overcome the cytoplasmic interactions of Bcr-Abl
for efficient translocation to the mitochondria. Anticipating that
this could happen, we employed imatinib to better facilitate
iCE-to-mitochondrial targeting for two reasons. First, imatinib
Figure 10. Effect of phospho-residue substitution in the iCE on cell
death and apoptosis using flow cytometric analysis at 48 h in K562
cells. Imatinib is 10 μM (indicated by shaded columns). (A) 7-AAD
staining. IM, EGFP, iCE, and iCE + IM, values are also in Figure 4A.
(B) Apoptosis as measured by TUNEL staining. IM, EGFP, iCE, and
iCE + IM, values are also in Figure 6B. (C) Annexin−APC staining.
IM, EGFP, iCE, and iCE + IM, values are also in Figure 6C. Statistical
difference was determined using one-way ANOVA with Tukey’s post
hoc test (for all assays here, error bars are SEM, N ≥ 3).
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treatment increases the level of ROS/PKC activity, which in
turn stimulates increased mitochondrial localization of the
cMTS.6 Second, imatinib bound Bcr-Abl undergoes a
conformational change that decreases its association with
actin, freeing Bcr-Abl for relocalization.33 Yet, even with the
addition of 10 μM imatinib the iCE did not localize to the
mitochondria in K562 cells.
Moreover, in light of the subcellular distribution of the iCE
in Bcr-Abl negative cell types, the iCE was likely not hindered
from translocating to the mitochondria due to its interaction
with Bcr-Abl. Within the context of the Cos-7 cells (which have
low inherent ROS and therefore low mitochondrial accumu-
lation of the cMTS),6 the iCE was expected to remain
cytoplasmic. However, in the Bcr-Abl negative and high ROS
1471.1 cell line the cMTS alone strongly localizes to the
mitochondria.6 Accordingly, without Bcr-Abl to “keep” the iCE
cytoplasmic the iCE should localize to the mitochondria in this
cell line. This was not the case however, and the iCE did not
localize to the mitochondria of 1471.1 cells (Figure 8, third
row). This result revealed that the ccmut3 fusion to the cMTS
may compromise the capacity for iCE mitochondrial trans-
location.
Nonetheless, the antileukemic activity caused by the iCE
appears to be entirely dependent upon the combination of the
ccmut3 and cMTS. Mock “iCE’s” substituting either the
ccmut3 with RIN-BD (RIN-cMTS; RIN-BD binds SH3/SH2
domains of Bcr-Abl)14 or the cMTS with the canonical IMS
MTS (IMS-ccmut3; IMS targets the intermitochondrial
membrane space)11 failed to restore cell death beyond control
levels (Figure 9A). The RIN-cMTS and IMS-ccmut3 results
suggest that the toxicity of the iCE is not propagated by either
ccmut3 localization to the mitochondria (Figure 9B, top row)
or the cMTS remaining bound to Bcr-Abl (at least to the SH2/
SH3 domains via RIN-BD, which would put the cMTS domain
of the iCE on Bcr-Abl but at a different location) in the
cytoplasm (Figure 9B, bottom row). The cytotoxic effect of the
iCE is also dependent upon phosphorylation of the cMTS.
Mutating the cMTS domain key phospho residues S189A and
T193A (iCE Null; Figure 3), which are required for
mitochondrial translocation of the cMTS alone,6 ablates the
killing activity of the iCE.
The ccmut3 alone and imatinib, as expected,12 both reduced
the level of phospho-Bcr-Abl and Bcr-Abl substrate phosphor-
ylation (i.e., p-Stat5 and p-Crk-L), but the iCE and iCE Null
were unchanged from control in K562 cells (Western blot; data
not shown). Therefore, the iCE is not acting as a dominant-
negative for Bcr-Abl kinase activity. Yet since the iCE
colocalizes with Bcr-Abl, it may be disrupting non-kinase Bcr-
Abl survival/antiapoptotic function. For instance, the iCE may
hinder (e.g., steric interference) kinase-independent signaling
from Bcr-Abl such as Src kinase Hck phosphorylation of the
Grb2 binding site on Bcr-Abl or Bcr’s RhoGEF activity.34,35
Alternatively, it may be possible that the ccmut3 (binding in
an antiparallel coiled-coil)17 positions the cMTS where the
phosphorylation of the S189 and/or T193 is central to the
mechanism for cell death induction. In K562 cells only
phosphorylation of the T193 is critical for mitochondrial
translocation function of the cMTS whereas S189 is not.6
Perhaps the cytotoxic nature of the iCE is also primarily a
function of PKC phosphorylation. Although beyond the scope
of this paper, a negative feedback coupling of PKC and Bcr-Abl
involving transient calcium influx may play a role in the
essential nature of cMTS phospho residues, and T193 in
particular. Increased transient calcium influx can stimulate
cellular proliferation while, conversely, blocking calcium influx
via PKC activation is toxic to Ph+ leukemia cells.36 Inhibition of
Bcr-Abl activity with imatinib relieves negative regulation of
PKC and thereby diminishes intracellular calcium flux.36
Perhaps increased stimulation or altered localization of PKC
(due to the presence of the iCE) could further diminish
transient calcium influx. A fascinating possibility that connects
calcium homeostasis and iCE toxicity is depicted in Figure 11.
In this report, we demonstrate that direct targeting of Bcr-
Abl to the mitochondria elicits cell death induction in a cell
Figure 11. Possible mechanisms for iCE induced toxicity to K562 leukemia cells. With imatinib (IM) present, Bcr-Abl kinase activity is eliminated1
and the iCE may be potentiating leukemic cell death by altering calcium status and/or blocking kinase-independent oncogenic functions of Bcr-Abl.
Bcr-Abl tyrosine kinase (Y kinase) activity stimulates transient calcium influx (which stimulates proliferation) while PKC activation, at the plasma
membrane, can have the opposite effect on calcium transients, which has been shown to be toxic to leukemia cells.36−38 Another cause of iCE
enhanced cell death may be through a more complete blockade of Bcr-Abl signaling by steric restriction of kinase-independent pathways.34,39 Steric
effects may be caused by the presence of PKA and/or PKC, a conformational change in the cMTS domain, and/or binding of Hsp70 to the
phosphorylated cMTS.15 iCE toxicity requires interaction with Bcr-Abl via the CC domain and the wild-type cMTS (S/T phospho residues). The
ccmut3 competes with Bcr-Abl for oligomerization at the N-terminal portion of the Bcr to Abl fusion at the CC,12 blocking Bcr-Abl
transautophosphorylation.17.
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type specific and kinase-independent manner. Additionally, we
attempted to harness Bcr-Abl’s mitochondrial death induction
activity with the use of a designed protein chaperone (i.e., iCE)
in order to restore the defunct apoptotic avenue of
“mitochondrial death-directed c-Abl” in CML cells. Though
the iCE bound to Bcr-Abl, the iCE/Bcr-Abl complex did not
translocate to the mitochondria. However, the iCE combined
with imatinib treatment was potently antileukemic as measured
by 7-AAD (late apoptosis/necrosis), TUNEL (apoptosis/necrosis),
annexin-V (apoptosis), and trypan blue exclusion assay (cell
viability).
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